0001493152-22-013346.txt : 20220513 0001493152-22-013346.hdr.sgml : 20220513 20220513163246 ACCESSION NUMBER: 0001493152-22-013346 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220513 DATE AS OF CHANGE: 20220513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 22923338 BUSINESS ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 BUSINESS PHONE: (215) 345-0919 MAIL ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 10-Q 1 form10-q.htm
0000868278 false --12-31 Q1 0000868278 2022-01-01 2022-03-31 0000868278 2022-05-13 0000868278 2022-03-31 0000868278 2021-12-31 0000868278 2021-01-01 2021-03-31 0000868278 us-gaap:CommonStockMember 2021-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000868278 us-gaap:RetainedEarningsMember 2021-12-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000868278 us-gaap:TreasuryStockMember 2021-12-31 0000868278 us-gaap:CommonStockMember 2020-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000868278 us-gaap:RetainedEarningsMember 2020-12-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000868278 us-gaap:TreasuryStockMember 2020-12-31 0000868278 2020-12-31 0000868278 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000868278 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000868278 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0000868278 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000868278 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000868278 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000868278 us-gaap:CommonStockMember 2022-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000868278 us-gaap:RetainedEarningsMember 2022-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000868278 us-gaap:TreasuryStockMember 2022-03-31 0000868278 us-gaap:CommonStockMember 2021-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000868278 us-gaap:RetainedEarningsMember 2021-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000868278 us-gaap:TreasuryStockMember 2021-03-31 0000868278 2021-03-31 0000868278 us-gaap:IPOMember 2021-01-01 2021-03-31 0000868278 PRPH:DiagnosticServicesMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesMember 2021-01-01 2021-03-31 0000868278 PRPH:InvestmentSharesMember 2021-06-25 0000868278 PRPH:InvestmentSharesMember 2021-12-31 0000868278 srt:MinimumMember 2022-01-01 2022-03-31 0000868278 srt:MaximumMember 2022-01-01 2022-03-31 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2022-01-01 2022-03-31 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2021-01-01 2021-03-31 0000868278 PRPH:USGovernmentObligationsMember 2022-03-31 0000868278 PRPH:CorporateObligationsMember 2022-03-31 0000868278 PRPH:USGovernmentObligationsMember 2021-12-31 0000868278 PRPH:CorporateObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:USGovernmentObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:USGovernmentObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:USGovernmentObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:CorporateObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:CorporateObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:CorporateObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel1Member 2022-03-31 0000868278 us-gaap:FairValueInputsLevel2Member 2022-03-31 0000868278 us-gaap:FairValueInputsLevel3Member 2022-03-31 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:USGovernmentObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:USGovernmentObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:USGovernmentObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:CorporateObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:CorporateObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:CorporateObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel1Member 2021-12-31 0000868278 us-gaap:FairValueInputsLevel2Member 2021-12-31 0000868278 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000868278 PRPH:ZeroToTwelveMonthsMember 2022-03-31 0000868278 PRPH:ZeroToTwelveMonthsMember 2021-12-31 0000868278 PRPH:ThirteenToTwentyFourMember 2022-03-31 0000868278 PRPH:ThirteenToTwentyFourMember 2021-12-31 0000868278 PRPH:OverTwentyFourMember 2022-03-31 0000868278 PRPH:OverTwentyFourMember 2021-12-31 0000868278 PRPH:DiagnosticServicesMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesMember 2021-01-01 2021-03-31 0000868278 PRPH:ContractManufacturingMember 2022-01-01 2022-03-31 0000868278 PRPH:ContractManufacturingMember 2021-01-01 2021-03-31 0000868278 PRPH:RetailAndOthersMember 2022-01-01 2022-03-31 0000868278 PRPH:RetailAndOthersMember 2021-01-01 2021-03-31 0000868278 PRPH:GenomicProductsAndServicesMember 2022-01-01 2022-03-31 0000868278 PRPH:GenomicProductsAndServicesMember 2021-01-01 2021-03-31 0000868278 PRPH:NebulaAcquisitionMember PRPH:NebulaStockPurchaseAgreementMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember PRPH:NebulaStockPurchaseAgreementMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember PRPH:CitiBankNAMember PRPH:NebulaStockPurchaseAgreementMember 2021-08-09 2021-08-10 0000868278 PRPH:MrKamalObbadMember PRPH:NebulaAcquisitionMember 2021-08-09 2021-08-10 0000868278 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:TradeNamesMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:TradeNamesMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:IntellectualPropertyMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:IntellectualPropertyMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember 2021-08-10 0000868278 us-gaap:TradeNamesMember 2022-03-31 0000868278 us-gaap:TradeNamesMember 2021-12-31 0000868278 us-gaap:TradeNamesMember 2022-01-01 2022-03-31 0000868278 us-gaap:IntellectualPropertyMember 2022-03-31 0000868278 us-gaap:IntellectualPropertyMember 2021-12-31 0000868278 us-gaap:IntellectualPropertyMember 2022-01-01 2022-03-31 0000868278 us-gaap:CustomerRelationshipsMember 2022-03-31 0000868278 us-gaap:CustomerRelationshipsMember 2021-12-31 0000868278 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-03-31 0000868278 us-gaap:LicenseMember 2022-03-31 0000868278 us-gaap:LicenseMember 2021-12-31 0000868278 us-gaap:LicenseMember 2022-01-01 2022-03-31 0000868278 us-gaap:LandMember 2022-03-31 0000868278 us-gaap:LandMember 2021-12-31 0000868278 us-gaap:BuildingImprovementsMember 2022-03-31 0000868278 us-gaap:BuildingImprovementsMember 2021-12-31 0000868278 srt:MinimumMember us-gaap:BuildingImprovementsMember 2022-01-01 2022-03-31 0000868278 srt:MaximumMember us-gaap:BuildingImprovementsMember 2022-01-01 2022-03-31 0000868278 us-gaap:MachineryAndEquipmentMember 2022-03-31 0000868278 us-gaap:MachineryAndEquipmentMember 2021-12-31 0000868278 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-03-31 0000868278 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-03-31 0000868278 us-gaap:EquipmentMember 2022-03-31 0000868278 us-gaap:EquipmentMember 2021-12-31 0000868278 srt:MinimumMember us-gaap:EquipmentMember 2022-01-01 2022-03-31 0000868278 srt:MaximumMember us-gaap:EquipmentMember 2022-01-01 2022-03-31 0000868278 us-gaap:ComputerEquipmentMember 2022-03-31 0000868278 us-gaap:ComputerEquipmentMember 2021-12-31 0000868278 srt:MinimumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-03-31 0000868278 srt:MaximumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-03-31 0000868278 us-gaap:FurnitureAndFixturesMember 2022-03-31 0000868278 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000868278 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-03-31 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-09-13 2020-09-15 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-09-15 0000868278 PRPH:LetterAgreementMember us-gaap:UnsecuredDebtMember 2022-02-28 0000868278 us-gaap:UnsecuredDebtMember 2022-02-28 0000868278 us-gaap:UnsecuredDebtMember 2022-02-28 2022-02-28 0000868278 2022-02-28 0000868278 2022-02-28 2022-02-28 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2022-01-01 2022-03-31 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2021-01-01 2021-03-31 0000868278 2021-02-14 2021-02-14 0000868278 2022-02-14 2022-02-14 0000868278 PRPH:ShareRepurchaseProgramMember 2021-09-08 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2021-05-20 0000868278 PRPH:TwoThousandTenDirectorsPlanMember us-gaap:CommonStockMember 2022-03-31 0000868278 PRPH:AmendedTwoThousandTenPlanMember 2021-05-20 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2021-12-31 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2022-03-31 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2022-01-01 2022-03-31 0000868278 srt:ChiefExecutiveOfficerMember PRPH:TwoThousandEighteenStockIncentivePlanMember 2018-04-11 2018-04-12 0000868278 PRPH:TwoThousandEighteenStockIncentivePlanMember PRPH:CEOOptionsMember 2018-09-04 2018-09-05 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2018-09-04 2018-09-05 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2018-09-04 2018-09-05 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-01-23 2019-01-24 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-01-23 2019-01-24 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-12-11 2019-12-12 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-12-11 2019-12-12 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-06-02 2021-06-03 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-06-02 2021-06-03 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2022-03-10 2022-03-10 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2022-03-10 2022-03-10 0000868278 PRPH:MrKamalObbadMember PRPH:InducementOptionAwardMember 2022-01-01 2022-03-31 0000868278 PRPH:InducementOptionAwardMember 2022-03-31 0000868278 PRPH:InducementOptionAwardMember 2022-01-01 2022-03-31 0000868278 PRPH:InducementOptionAwardMember PRPH:NextThreeYearsMember 2022-01-01 2022-03-31 0000868278 PRPH:InducementOptionAwardMember 2022-01-01 2022-03-31 0000868278 PRPH:InducementOptionAwardMember 2021-01-01 2021-12-31 0000868278 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000868278 us-gaap:WarrantMember 2022-01-01 2022-03-31 0000868278 us-gaap:WarrantMember 2021-01-01 2021-03-31 0000868278 2021-01-01 2021-12-31 0000868278 us-gaap:WarrantMember 2021-12-31 0000868278 us-gaap:WarrantMember 2022-03-31 0000868278 PRPH:PlazaMedicalLaboratoryCorpMember 2020-10-23 0000868278 PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2020-10-21 2020-10-23 0000868278 PRPH:OldBridgeNewJerseyMember 2020-12-08 0000868278 PRPH:OldBridgeNewJerseyMember 2020-12-07 2020-12-08 0000868278 PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2020-12-07 2020-12-08 0000868278 PRPH:FinalMonthsMember PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2020-12-07 2020-12-08 0000868278 PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2021-01-01 2021-12-31 0000868278 PRPH:OperatingLeaseLiabilitiesMember 2022-03-31 0000868278 PRPH:OperatingLeaseRightOfUseAssetMember 2022-03-31 0000868278 PRPH:UnrelatedThirdPartyMember srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember 2020-09-25 0000868278 PRPH:UnrelatedThirdPartyMember us-gaap:SecuredDebtMember 2020-09-25 0000868278 PRPH:UnrelatedThirdPartyMember srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember 2020-07-21 0000868278 PRPH:UnrelatedThirdPartyMember srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember 2020-07-29 0000868278 PRPH:UnrelatedThirdPartyMember srt:MinimumMember 2021-01-14 0000868278 PRPH:UnrelatedThirdPartyMember srt:MaximumMember 2021-01-14 0000868278 PRPH:TerminationAgreementMember 2021-01-15 2021-02-28 0000868278 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0000868278 us-gaap:SalesRevenueNetMember PRPH:DiagnosticServicesClientsOneMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000868278 us-gaap:SalesRevenueNetMember PRPH:DiagnosticServicesClientsTwoMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000868278 us-gaap:SalesRevenueNetMember PRPH:DiagnosticServicesClientsThreeMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000868278 us-gaap:SalesRevenueNetMember PRPH:DiagnosticServicesClientsOneMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0000868278 us-gaap:SalesRevenueNetMember PRPH:DiagnosticServicesClientsTwoMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsOneMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsTwoMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsOneMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsTwoMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsThreeMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000868278 PRPH:TradeReceivableMember PRPH:DiagnosticServicesClientsFourMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000868278 PRPH:DiagnosticServicesMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesMember 2021-01-01 2021-03-31 0000868278 PRPH:ConsumerProductsMember 2022-01-01 2022-03-31 0000868278 PRPH:ConsumerProductsMember 2021-01-01 2021-03-31 0000868278 PRPH:UnallocatedCorporateMember 2022-01-01 2022-03-31 0000868278 PRPH:UnallocatedCorporateMember 2021-01-01 2021-03-31 0000868278 PRPH:DiagnosticServicesMember 2022-03-31 0000868278 PRPH:DiagnosticServicesMember 2021-12-31 0000868278 PRPH:ConsumerProductsMember 2022-03-31 0000868278 PRPH:ConsumerProductsMember 2021-12-31 0000868278 PRPH:UnallocatedCorporateMember 2022-03-31 0000868278 PRPH:UnallocatedCorporateMember 2021-12-31 0000868278 PRPH:CommonStockPurchaseWarrantsMember 2022-01-01 2022-03-31 0000868278 PRPH:CommonStockPurchaseWarrantsMember 2021-01-01 2021-03-31 0000868278 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000868278 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000868278 PRPH:JasonKarkusMember 2022-01-01 2022-03-31 0000868278 PRPH:JasonKarkusMember 2021-01-01 2021-03-31 0000868278 us-gaap:SubsequentEventMember PRPH:MrWhiteMember 2022-05-08 2022-05-09 0000868278 us-gaap:SubsequentEventMember 2022-05-08 2022-05-09 0000868278 us-gaap:SubsequentEventMember 2022-05-09 0000868278 us-gaap:SubsequentEventMember 2022-05-25 0000868278 PRPH:CEOOptionsMember us-gaap:SubsequentEventMember 2022-05-08 2022-05-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft PRPH:Segment xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____to _____

Commission file number 000-21617

 

ProPhase Labs, Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware   23-2577138

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

711 Stewart Ave, Suite 200    
Garden City, New York   11530
(Address of principal executive office)   (Zip Code)

 

(215) 345-0919

 

(Registrant’s telephone number, including area code)

 

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0005   PRPH   Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or shorter period that the registration was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company, See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding May 13, 2022
Common Stock, $0.0005 par value   15,485,900

 

 

 

 
 

 

ProPhase Labs, Inc. and Subsidiaries

TABLE OF CONTENTS

 

  PAGE
PART I. FINANCIAL INFORMATION  
     
Item 1. Financial Statements (Unaudited) 3
     
  Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 3
     
  Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2022 and 2021 4
     
  Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2022 and 2021 5
     
  Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2022 and 2021 6
     
  Notes to Condensed Consolidated Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 33
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 41
     
Item 4. Controls and Procedures 41
     
PART II. OTHER INFORMATION  
   
Item 1. Legal Proceedings 42
Item 1A. Risk Factors 43
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 43
Item 3. Defaults Upon Senior Securities 43
Item 4. Mine Safety Disclosures 43
Item 5. Other Information 43
Item 6. Exhibits 43
     
Signatures 44

 

2
 

 

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

     March 31,     December 31, 
   March 31,   December 31, 
   2022   2021 
   (Unaudited)     
ASSETS          
Current assets          
Cash and cash equivalents  $25,807   $8,408 
Restricted cash   -    250 
Marketable debt securities, available for sale   3,543    8,779 
Marketable equity securities, at fair value   -    76 
Accounts receivable, net   36,694    37,708 
Inventory, net   4,680    4,600 
Prepaid expenses and other current assets   1,831    1,496 
Total current assets   72,555    61,317 
           
Property, plant and equipment, net   6,440    5,947 
Prepaid expenses, net of current portion   251    460 
Right-of-use asset, net   4,319    4,402 
Intangible assets, net   10,143    10,852 
Goodwill   5,709    5,709 
Other assets   248    608 
TOTAL ASSETS  $99,665   $89,295 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable  $8,204   $7,026 
Accrued diagnostic services   1,012    1,890 
Accrued advertising and other allowances   95    104 
Lease liabilities   654    663 
Deferred revenue   2,246    2,034 
Income tax payable   

4,285

    

1,312

 
Other current liabilities   3,274    2,495 
Total current liabilities   19,770    15,524 
           
Non-current liabilities:          
Deferred revenue, net of current portion   858    905 
Deferred tax liability   443    - 
Note payable   18    44 
Unsecured convertible promissory notes, net   7,997    9,996 
Lease liabilities, net of current portion   4,134    4,198 
Total non-current liabilities   13,450    15,143 
Total liabilities   33,220    30,667 
           
COMMITMENTS AND CONTINGENCIES   -     -  
           
Stockholders’ equity          
Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding   -    - 
Common stock authorized 50,000,000, $0.0005 par value, 15,485,900 and 15,485,900 shares outstanding, respectively   16    16 
Additional paid-in capital   105,634    104,552 
Retained earnings   10,490    2,642 
Treasury stock, at cost, 17,018,846 and 16,818,846 shares, respectively   (49,557)   (48,407)
Accumulated other comprehensive loss   (138)   (175)
Total stockholders’ equity   66,445    58,628 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $99,665   $89,295 

 

See accompanying notes to condensed consolidated financial statements

 

3
 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Other Comprehensive Loss

(in thousands, except per share amounts)

(unaudited)

 

     March 31, 2022     March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Revenues, net  $47,531   $15,271 
Cost of revenues   18,854    6,344 
Gross profit   28,677    8,927 
           
Operating expenses:          
Diagnostic expenses   4,672    3,809 
General and administration   7,824    3,782 
Research and development   35    115 
Total operating expenses   12,531    7,706 
Income (loss) from operations   16,146    1,221 
           
Interest income, net   73    87 
Interest expense   (233)   (251)
Change in fair value of investment securities   (76)   - 
Income from operations before income taxes   15,910    1,057 
Income tax expense   (3,416)   - 
Income from operations after income taxes   12,494    1,057 
Net income  $12,494   $1,057 
           
Other comprehensive loss:          
Unrealized gain (loss) on marketable debt securities   37    (11)
Total comprehensive income  $12,531   $1,046 
           
Earnings per share:          
Basic  $0.81   $0.07 
Diluted  $0.68   $0.06 
           
Weighted average common shares outstanding:          
Basic   15,486    14,563 
Diluted   18,740    18,200 

 

See accompanying notes to condensed consolidated financial statements

 

4
 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

(unaudited)

 

   Common Stock Shares Outstanding     Par Value     Additional Paid in Capital     Retained Earnings     Comprehensive Loss     Treasury Stock     Total 
   Common Stock Shares Outstanding   Par Value   Additional Paid in Capital   Retained Earnings   Comprehensive Loss   Treasury Stock   Total 
Balance as of January 1, 2022   15,485,900   $16   $104,552   $2,642   $(175)  $(48,407)  $58,628 
Issuance of common shares for debt conversion   200,000    -    600    -    -    -    600 
Cash dividends   -    -    -    (4,646)   -    -    (4,646)
Repurchases of common shares   (200,000)   -    -    -    -    (1,150)   (1,150)
Unrealized loss on marketable debt securities    -    -    -    -    37    -    37 
Stock-based compensation   -    -    482    -    -    -    482 
Net income   -    -    -    12,494    -    -    12,494 
Balance as of March 31, 2022   15,485,900   $16   $105,634   $10,490   $(138)  $(49,557)  $66,445 

 

   Common Stock Shares Outstanding     Par Value     Additional Paid in Capital     Retained Earnings     Comprehensive Loss     Treasury Stock     Total 
  

Common Stock

Shares Outstanding,

   Par Value   Additional Paid in Capital   Accumulated Deficit  

Accumulated

Comprehensive Income (loss)

   Treasury Stock   Total 
Balance as of January 1, 2021   11,604,253   $14   $61,674   $(3,631)  $(11)  $(47,490)  $10,556 
Issuance of common stock and warrants for cash from public offering, net of $2,365 offering cost   3,000,000    2    35,133    -    -    -    35,135 
Issuance of common stock and warrants for cash from private offering   550,000    -    5,500    -    -    -    5,500 
Unrealized loss on marketable debt securities   -    -    -    -    (11)   -    (11)
Stock-based compensation   -    -    428    -    -    -    428 
Net income   -    -    -    1,057    -    -    1,057 
Balance as of March 31, 2021   15,154,253   $16   $102,735   $(2,574)  $(22)  $(47,490)  $52,665 

  

See accompanying notes to condensed consolidated financial statements

 

5
 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

     March 31, 2022     March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Cash flows from operating activities          
Net income  $12,494   $1,057 
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Realized loss on marketable debt securities   179    2 
Depreciation and amortization   1,249    536 
Amortization of debt discount   1    2 
Amortization on right-of-use assets   83    85 
Gain on sale of assets   (23)   - 
Stock-based compensation expense   482    428 
Change in fair value of investment securities   76    - 
Accounts receivable allowances   (924)    - 
Inventory valuation reserve   25    - 
Changes in operating assets and liabilities:          
Accounts receivable   1,938   (11,178)
Inventory   (105)   (12,987)
Prepaid and other assets   (126)   2,243 
Other assets   360    (8)
Accounts payable and accrued expenses   1,178    4,009 
Accrued diagnostic services   (878)   - 
Deferred revenue   165    - 
Deferred tax liability   

443

    - 
Lease liabilities   (73)   101 
Income tax payable   

2,973

    - 
Other liabilities   770    7,818 
Net cash provided by (used in) operating activities   20,287    (7,892)
           
Cash flows from investing activities          
Issuance of secured promissory note receivable   -    (1,000)
Purchase of marketable securities   (206)   (2,005)
Proceeds from sale of marketable debt securities   5,300    100 
Proceeds from dispositions of property and other assets   85    - 
Capital expenditures   (1,095)   (3,927)
Net cash provided by (used in) investing activities   4,084    (6,832)
           
Cash flows from financing activities          
Proceeds from issuance of common stock from public offering, net   -    35,135 
Proceeds from issuance of common stock and warrants from private offering   -    5,500 
Repayment of note payable   (1,426)   - 
Repurchases of common shares   (1,150)   - 
Payment of dividends   (4,646)   - 
Net cash (used in) provided by financing activities   (7,222)   40,635 
           
Increase in cash, cash equivalents and restricted cash   17,149    25,911 
Cash, cash equivalents and restricted cash, at the beginning of the period   8,658    6,816 
Cash, cash equivalents and restricted cash, at the end of the period  $25,807   $32,727 
           
Supplemental disclosures:          
Cash paid for income taxes  $-   $- 
Interest payment on the promissory notes  $241   $250 
           
Supplemental disclosure of non-cash investing and financing activities:          
Issuance of common shares for debt conversion  $600   $- 
Net unrealized gain (loss), investments in marketable debt securities  $37   $(11)

 

See accompanying notes to condensed consolidated financial statements

 

6
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 1 - Organization and Business

 

ProPhase Labs, Inc. (“ProPhase”, “we”, “us”, “our” or the “Company”) is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. We provide traditional CLIA molecular laboratory services, including SARS-CoV-2 (“COVID-19”) testing and seek to leverage our Clinical Laboratory Improvement Amendments (“CLIA”) accredited laboratory services to provide whole genome sequencing and research direct to consumers, while building a genomics database to be used for further research. In addition, we have deep experience with over-the-counter (“OTC”) consumer healthcare products and dietary supplements. We currently conduct our operations through two operating segments: diagnostic services and consumer products. Until late Fiscal 2020, we were engaged primarily in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. However, commencing in December 2020, we also began offering COVID-19 and other Respiratory Pathogen Panel (RPP) molecular tests through our diagnostic services business, and in August 2021 we began offering personal genomics products and services.

 

Our wholly owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (“PCR”) testing for COVID-19. Critical to COVID-19 testing, we provide fast turnaround times for results. We also offer rapid antigen and antibody/immunity testing for COVID-19. On October 23, 2020, we acquired Confucius Plaza Medical Laboratory Corp. (“CPM”), which included a non-operating but certified 4,000 square foot CLIA accredited laboratory located in Old Bridge, New Jersey. In December 2020, we expanded our diagnostic service business with the build-out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in January 2021.

 

On August 10, 2021, we acquired Nebula Genomics, Inc. (“Nebula”), a privately owned personal genomics company, through our new wholly owned subsidiary, ProPhase Precision Medicine, Inc. (“ProPhase Precision”) (see Note 3, Business Acquisitions). ProPhase Precision focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

 

Our wholly owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.

 

We also develop and market dietary supplements under the TK Supplements® brand.

 

Note 2 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and other comprehensive loss and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of operating results that may be achieved over the course of the full year.

 

7
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Segments

 

In accordance with FASB ASC 280, “Segment Reporting” (“ASC 280”), the Company discloses financial and descriptive information about its reportable operating segments.

 

ASC 280 establishes standards for reporting information about operating segments in annual and interim financial statements and requires that companies report financial and descriptive information about their reportable segments based on a management approach. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and major customers.

 

Operating segments are defined as components of an enterprise that engage in business activities for which separate financial information is available and is evaluated by the Chief Operating Decision Maker (“CODM”), which for the Company is its Chief Executive Officer, in deciding how to allocate resources and assess performance. We maintain two operating segments: diagnostic services (which includes our COVID-19 and other diagnostic testing services) and consumer products (which includes our contract manufacturing, retail customers and personal genomics products and services) (see Note 15 Segment Information).

 

Business and Liquidity Risks and Uncertainties

 

We launched our diagnostic service business in December 2020 and expanded in January 2021 with the opening of our Garden City, New York CLIA accredited laboratory. Our diagnostic service business is and will continue to be influenced by the level of demand for COVID-19 and other diagnostic testing, how long this demand persists, the prices we are able to receive for performing our testing services, our ability to collect payment or reimbursement for our testing services, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.

 

While our revenues increased significantly for the year ended December 31, 2021 and the first quarter of fiscal 2022 as a result of the launch of our diagnostic services business, we will continue to be dependent on both government agency and insurance company reimbursement as well as the prevalence of COVID-19 associated strains.

 

In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), was enacted, providing for reimbursement to healthcare providers for COVID-19 tests provided to uninsured individuals, subject to continued available funding. Approximately 69% and 57% of our diagnostic services revenue for the three months ended March 31, 2022 and 2021, respectively was generated from this program for the uninsured. On March 22, 2022, the Health Resources & Services Administration (HRSA) program stopped accepting claims for COVID-19 testing and treatment due to lack of sufficient funds. Despite requests from the Acting Director of the Office of Management and Budget and the White House Coordinator for COVID-19 Response for additional emergency funding for the uninsured program, emergency funding has not been allocated to the HRSA uninsured program as of the financial statement issuance date. We continue to perform testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize any revenue related to COVID-19 testing that we performed for uninsured individuals from March 23, 2022 through March 31, 2022. If funding for the HRSA program is reinstituted in the future, we will submit eligible claims for reimbursement to HRSA and record the associated revenues. If the HRSA program remains unfunded and we are unable to submit claims for reimbursement, there could be a material adverse effect on our business and financial condition.

 

8
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

In addition, our diagnostic service business is subject to extensive federal, state, and local laws and regulations, all of which are subject to change, as well as laws and regulations governing the submission of claims for payment for our services, such as those relating to: coverage of our services under Medicare, Medicaid and other federal health care programs; the amounts that we may bill for our services; and the party to which we must submit claims. Also, reimbursement policies and requirements for some payers and procedures are ambiguous, which could lead to billing errors and related disputes. There can be no assurance that our efforts to offer and perform COVID-19 or other diagnostic testing will be successful in the future or that the revenue and operating profits from such business will increase or maintain their current level.

 

We acquired and commenced our personal genomics business in August 2021. This business is and will continue to be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.

 

Our consumer sales are and will continue to be influenced by (i) the timing of acceptance of our TK Supplements® consumer products in the marketplace, and (ii) fluctuations in the timing of purchase and the ultimate level of demand for the OTC healthcare and cold remedy products that we manufacture, which is largely a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period from September to March when the incidence of the common cold rises as a result of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net revenues from our contract manufacturing business. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.

 

For the three months ended March 31, 2022, $20.3 million was provided by operating activities. The Company had cash, cash equivalents and marketable securities of $29.4 million as of March 31, 2022. Based on management’s current business plans, the Company estimates it will have enough cash and liquidity to finance its operating requirements for at least 12 months from the date of filing these unaudited condensed consolidated financial statements. However, due to the nature of the diagnostic business and the Company’s focus thus far on COVID-19 testing, there are inherent uncertainties associated with managements’ business plan and cash flow projections, particularly if the Company is unable to grow its diagnostic testing business beyond COVID-19 testing services.

 

The Company’s future capital needs and the adequacy of its available funds will depend on the Company’s ability to achieve sustained profitability from its diagnostic services, the Company’s ability to successfully diversify its diagnostic services revenue streams and the Company’s ability to market and grow its personal genomics business. The Company may be required to raise additional funds through equity or debt securities offerings or strategic collaboration and/or licensing agreements in order to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Company’s failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition.

 

Use of Estimates

 

The preparation of condensed consolidated financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration of diagnostic test reimbursement rates, the provision for uncollectible receivables and billing errors, allowances, slow moving and/or dated inventory and associated provisions, the potential impairment of long-lived assets, stock based compensation valuations, income tax asset valuations and assumptions related to accrued advertising.

 

Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the condensed consolidated financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these securities.

 

Restricted Cash

 

Restricted cash as of December 31, 2021 includes approximately $250,000 held in escrow related to a potential purchase of an additional lab facility. The potential purchase was not consummated, and we are pursuing the return of the escrow, which is in dispute. As of March 31, 2022, we recognized an expense for this balance as the recovery of the funds was no longer considered probable.

 

9
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Marketable Debt Securities

 

We have classified our investments in marketable debt securities as available-for-sale and as a current asset. Our investments in marketable debt securities are carried at fair value, with unrealized gains and as a separate component of stockholders’ equity. Realized gains and losses from our marketable debt securities are recorded as interest income (expense). These investments in marketable debt securities carry maturity dates between one and three years from date of purchase.

 

The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (in thousands) (see fair value of financial instruments):

 

   As of March 31, 2022 
   Amortized   Unrealized   Unrealized   Fair 
   Cost   Gains   Losses   Value 
U.S. government obligations  $667   $123   $(44)  $746 
Corporate obligations   2,839    -    (42)   2,797 
   $3,506   $123   $(86)  $3,543 

 

   As of December 31, 2021 
   Amortized   Unrealized   Unrealized   Fair 
   Cost   Gains   Losses   Value 
U.S. government obligations  $650   $17   $-   $667 
Corporate obligations   8,304    -    (192)   8,112 
   $8,954   $17   $(192)  $8,779 

 

Marketable Equity Securities

 

Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within other non-operating income, net in the consolidated statements of income.

 

On June 25, 2021, we were issued 1,260,619 common shares (the “Investment Shares”) as an interest payment under our note receivable (see Note 13, Consulting Agreement and Secured Promissory Note Receivable) with a fair value of $315,000 at the time of issuance and a fair value of $76,000 at December 31, 2021. The investment was classified as a Level 1 financial instrument. We recorded a $76,000 decrease in fair value of investment securities within the statement of operations for the three months ended March 31, 2022.

 

Accounts Receivable, net

 

Accounts receivable consists primarily of amounts due from government agencies and healthcare insurers. Unbilled accounts receivable relates to the delivery of our diagnostic testing services for which the related billings will occur in a future period, after a patient’s insurance information has been validated, and represent amounts for which we have a right to receive payment. Unbilled accounts receivable is classified as accounts receivable on the consolidated balance sheet. We carry our accounts receivable at the amount of consideration for which we expect to be entitled less allowances. When estimating the allowances for our diagnostics business, the Company pools its receivables based on the following payer types: healthcare insurers and government payers. The Company principally estimates the allowances by pool based on historical collection experience, current economic conditions, government and healthcare insurer payment trends, and the period of time that the receivables have been outstanding. Should a payer’s reimbursement policy change or their credit quality deteriorate, the Company removes the payer from their respective pools and establishes allowances based on the individual risk characteristics of such payer.

 

10
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands):

 

   March 31, 2022   December 31, 2021 
Trade accounts receivable  $24,727   $18,520 
Unbilled accounts receivable   14,944    23,089 
 Accounts receivable, gross   39,671    41,609 
Less allowances   (2,977)   (3,901)
Total accounts receivable  $36,694   $37,708 

 

Inventory, net

 

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (“FIFO”), or net realizable value. Inventory items are analyzed to determine cost and the net realizable value and appropriate valuation adjustments are established.

 

At March 31, 2022 and December 31, 2021, the components of inventory are as follows (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Diagnostic services testing material  $3,103   $2,989 
Raw materials   1,238    1,514 
Work in process   476    260 
Finished goods   322    272 
Inventory  $5,139   $5,035 
Inventory valuation reserve   (459)   (435)
Inventory, net  $4,680   $4,600 

 

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years.

 

Concentration of Financial Risks

 

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.

 

We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2022, our cash and cash equivalents and restricted cash balance was $25.8 million. Of the total bank balance, $0.9 million was covered by federal depository insurance and $24.9 million was uninsured at March 31, 2022.

 

11
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection rates. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depends on information provided to the payors and meeting their requirements for reimbursement.

 

Leases

 

At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. We have elected not to recognize on the balance sheet leases with terms of 12 months or less. We typically only include an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in our assessment unless there is reasonable certainty that we will renew.

 

Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in our leases is typically not readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 12, Leases).

 

The components of a lease should be allocated between lease components (e.g., land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.

 

Goodwill and Intangible Assets

 

Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying identifiable assets and liabilities acquired in a business combination. Goodwill and intangible assets deemed to have an indefinite life are not amortized, but instead are assessed for impairment annually. Additionally, if an event or change in circumstances occurs that would more likely than not reduce the fair value of the reporting unit below its carrying value, we would evaluate goodwill at that time.

 

In testing for goodwill impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, we conclude that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If we conclude otherwise, we are required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than the carrying value, an impairment charge will be recorded to reduce the reporting unit to fair value.

 

12
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Intangible assets deemed to have finite lives are amortized on a straight-line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to our future cash flows.

 

Fair Value of Financial Instruments

 

We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
     
  Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
     
  Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, and unsecured note payable, approximate their fair values because of the short-term nature of these instruments.

 

We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity securities change in fair value reported on the condensed consolidated statement of operations. The components of marketable securities are as follows (in thousands):

 

   As of March 31, 2022 
   Level 1   Level 2   Level 3   Total 
U.S. government obligations  $-   $746   $-   $746 
Corporate obligations   -    2,797    -    2,797 
   $-   $3,543   $-   $3,543 

 

13
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

   As of December 31, 2021 
   Level 1   Level 2   Level 3   Total 
U.S. government obligations  $-   $667   $-   $667 
Corporate obligations   -    8,112    -    8,112 
Marketable equity securities   76    -    -    76 
   $76   $8,779   $-   $8,855 

 

There were no transfers of marketable debt securities between Levels 1, 2 or 3 for the three months ended March 31, 2022 and 2021.

 

Revenue Recognition

 

We recognize revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. We recognize revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

Contract with Customers and Performance Obligations

 

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Sales from product shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. Revenue from diagnostic services is recognized when the results are made available to the customer. Revenue from our personal genomics business is recognized when the genetic testing results are provided to the customer. For subscription services associated with our genomic testing, we recognize revenue ratably over the term of the subscription.

 

Transaction Price

 

For contract manufacturing and retail customers, the transaction price is fixed based upon either (i) the terms of a combined master agreement and each related purchase order, or (ii) if there is no master agreement, the price per individual purchase order received from each customer. The customers are invoiced at an agreed upon contractual price for each unit ordered and delivered by the Company.

 

Revenue from retail customers is reduced for trade promotions, estimated sales returns and other allowances in the same period as the related sales are recorded. No such allowance is applicable to our contract manufacturing customers. We estimate potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

 

14
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

We do not accept returns from our contract manufacturing customers. Our return policy for retail customers accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time during which product may be returned. All requests for product returns must be submitted to us for pre-approval. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will accept return requests only for products in their intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed.

 

For our diagnostic services business, a revenue transaction is initiated when we receive a requisition order to perform a diagnostic test. The information provided on the requisition form is used to determine the party that will be billed for the testing performed and the expected reimbursement. We provide diagnostic services to a range of customers. In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or Medicaid program and other government reimbursement programs. We bill the providers at standard price and take into consideration negotiated discounts and anticipated reimbursement remittance adjustments based on the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that vary from the listed contract price.

 

For our personal genomics business, a revenue transaction is initiated by a DNA test kit sale direct to the consumer sales via our website or through online retailers. The kit sales and subscriptions are billed at a standard price and take into consideration any discounts when revenue is recorded.

 

Recognize Revenue When the Company Satisfies a Performance Obligation

 

Recognition for contract manufacturing and retail customers is satisfied at a point in time when the goods are shipped to the customer as (i) we have transferred control of the assets to the customers upon shipping, and (ii) the customer obtains title and assumes the risks and rewards of ownership after the goods are shipped.

 

For diagnostic services, recognition occurs at the point in time that the results are made available to the customer, which is when the customer benefits from the information contained in the results and obtains control.

 

For genomic services, we satisfy our product performance obligation at a point in time when the genetic testing results are provided to the customer. For subscriptions services associated with its genomic testing, we satisfy our performance obligation ratably over the subscription period. If the customer does not return the test kit, services cannot be completed by us, potentially resulting in unexercised rights (“breakage”) revenue, including lifetime subscription services. We estimate breakage for the portion of test kits not expected to be returned using an analysis of historical data and consider other factors that could influence customer test kit return behavior. When breakage revenue is recognized on a kit, we recognize breakage on any associated subscription services ratably over the term of the subscription. The Company recognized breakage revenue from aggregate unreturned test kits and subscriptions of $0.4 million for the three months ended March 31, 2022.

 

Contract Balances

 

Deferred revenues primarily consist of amounts that have been billed to or received from customers in advance of revenue recognition and prepayments received from customers in advance of services performed for the R&D work. As of March 31, 2022 and December 31, 2021, we have deferred revenue of $3.1 million and $2.9 million, respectively. Our new personal genomics business comprised $2.9 million of the deferred revenue as of March 31, 2022. The deferred revenue balance within the personal genomics business is comprised of kits to be sequenced and subscription services, which have an average life between 12 and 36 months. The remainder of deferred revenue relates to research and development (“R&D”) stability and release testing programs recognized as contract manufacturing revenue.

 

15
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table disaggregates our deferred revenue by recognition period (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Recognition Period          
0-12 Months  $2,246   $2,034 
13-24 Months   598    530 
Over 24 Months   260    375 
Total  $3,104   $2,939 

 

Disaggregation of Revenue

 

We disaggregate revenue from contracts with customers into four categories: diagnostic services, contract manufacturing, retail and others, and genomic products and services. We determined that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

The following table disaggregates the Company’s revenue by revenue source for the three months ended March 31, 2022 and 2021 (in thousands):

 

   For the three months ended 
Revenue by Customer Type  March 31, 2022   March 31, 2021 
Diagnostic services  $44,913   $12,738 
Contract manufacturing   1,154    1,908 
Retail and others   546    625 
Genomic products and services   918    - 
Total revenue, net  $47,531   $15,271 

 

Customer Consideration

 

The Company makes payments to certain diagnostic services customers for distinct services that approximate the fair value for those services. Such services include specimen collection, the collection and delivery of insurance and patient information necessary for billing and collection, and logistics services. Consideration associated with specimen collection services is classified in cost of revenues and the remaining costs are classified as diagnostic expenses within operating expenses in the accompanying statement of operations.

 

Sales Tax Exclusion from the Transaction Price

 

We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from the customer.

 

Shipping and Handling Activities

 

We account for shipping and handling activities that we perform as activities to fulfill the promise to transfer the good.

 

16
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Advertising and Incentive Promotions

 

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of general and administrative expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net revenue, and (iii) free product, which is accounted for as part of cost of revenues. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2022 and 2021 were $60,000 and $168,000, respectively.

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation in accordance with FASB ASC 718, “Compensation - Stock Compensation.” Under the fair value recognition provision of the ASC, stock-based compensation cost is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options and warrants granted using the Black-Scholes-Merton option pricing model and stock grants at their closing reported market value. We recognize all stock-based payments to employees and directors, including grants of stock options, as compensation expense in the condensed consolidated financial statements based on their grant date fair values. The grant date fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. We account for forfeitures as they occur.

 

Stock and stock options to purchase our common stock have been granted to employees pursuant to the terms of certain agreements and stock option plans (see Note 7, Stockholders’ Equity). Stock options are exercisable during a period determined by us, but in no event later than seven years from the date granted.

 

Research and Development (“R&D”)

 

R&D costs are charged to operations in the period incurred. R&D costs incurred for the three months ended March 31, 2022 and 2021 were $35,000 and $115,000, respectively. R&D costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products, dietary supplements and validation costs in association with the diagnostic services business.

 

Income Taxes

 

The Company recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse.

 

The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. We evaluate, on a quarterly basis whether, based on all available evidence, it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740- 10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused.

 

The Company accounts for uncertainties in income taxes under the provisions of FASB ASC 740-10-05 (the “Subtopic”). The Subtopic clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The Subtopic prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Subtopic provides guidance on the de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

17
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Recently Issued Accounting Standards, Adopted

 

The Financial Accounting Standards Board (“FASB”) recently issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The adoption of ASU 2020-06 did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.

 

Recently Issued Accounting Standards, Not Yet Adopted

 

In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.

 

18
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 3 - Business Acquisition

 

Nebula Acquisition

 

On August 10, 2021 (the “Effective Date”), the Company and its wholly owned subsidiary, ProPhase Precision, entered into and closed a Stock Purchase Agreement (the “Nebula Stock Purchase Agreement”) with Nebula, each of the stockholders of Nebula (the “Seller Parties”), and Kamal Obbad, as Seller Party Representative. Pursuant to the terms of the Nebula Stock Purchase Agreement, ProPhase Precision acquired all of the issued and outstanding shares of common stock of Nebula from the Seller Parties, for an aggregate purchase price of approximately $14.3 million, subject to post-closing adjustments (the “Nebula Acquisition”). A portion of the purchase price equal to $3.6 million was paid in shares of the Company’s common stock to certain Seller Parties and noteholders of Nebula, based on their election to receive shares of the Company’s common stock in lieu of cash, which shares were valued at a price per share of $7.46, which is equal to the average closing price of the Company’s common stock on Nasdaq for the five trading days preceding the signing of the Nebula Stock Purchase Agreement. A portion of the purchase price equal to $1,080,000 (the “Escrow Amount”) is being held in escrow by Citibank, N.A. (the “Escrow Agent”) until February 23, 2023 (“Escrow Termination Date”), pursuant to the terms and conditions of an escrow agreement entered into with the Escrow Agent, as security for the indemnification obligations of the Seller Parties. At the Escrow Termination Date, the remaining amount, if any, of the Escrow Amount, less any amount reasonably necessary to pay any claim with respect to which a notice of claim has been timely and properly given, will be delivered to the Seller Parties, as applicable.

 

In connection with the Nebula Acquisition, ProPhase Precision entered into an employment agreement with Kamal Obbad, the Chief Executive Officer of Nebula, on the Effective Date, pursuant to which Mr. Obbad serves as Senior Vice President, Director of Sales and Marketing of ProPhase Precision. As a condition to the employment agreement, Mr. Obbad was awarded a stock option to purchase 250,000 shares of Company common stock at an exercise price equal to $7.67 per share, the closing price of the Company common stock on the Effective Date (see Note 7, Stockholders’ Equity).

 

Based on the valuation, the total consideration of $12.7 million, which is net of $1.6 million in cash acquired, has been allocated to assets acquired and liabilities assumed based on their respective fair values as follows (in thousands):

 

Account  Amount 
Short term investments  $1,800 
Accounts receivable   171 
Inventory   133 
Prepaid and other current assets   379 
Definite-lived intangible assets   10,990 
Total assets acquired   13,473 
Accounts payable   (805)
Accrued expenses and other current liabilities   (43)
Deferred revenue   (2,391)
Note payable   (81)
Deferred tax liability   (1,925)
Total liabilities assumed   (5,245)
Net identifiable assets acquired   8,228 
Goodwill   4,446 
Total consideration, net of cash acquired (1)  $12,674 

 

(1) Net of $1.6 million cash acquired.

 

19
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired. The Company believes the goodwill related to the acquisition was a result of the expected synergies to be realized from combining operations and is not deductible for income tax purposes. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.

 

The intangible assets identified in conjunction with the Nebula Acquisition are as follows (in thousands):

 

   Gross Carrying Value   Estimated Useful Life (in years) 
Trade names  $5,550    15 
Proprietary intellectual property   4,260    5 
Customer relationships   1,180    1 
Total  $10,990      

 

Note 4 – Goodwill and Acquired Intangible Assets

 

Goodwill

 

There were no changes in goodwill for the three months ended March 31, 2022.

 

20
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Intangible Assets, Net

 

Intangible assets as of March 31, 2022 and December 31, 2021 consisted of the following (in thousands):

 

  

March 31,

2022

  

December 31,

2021

  

Estimated Useful

Life (in years)

Trade names  $5,550   $5,550   15
Proprietary intellectual property   4,260    4,260   5
Customer relationships   1,180    1,180   1
CLIA license   1,307    1,307   3
 Total intangible assets, gross   12,297    12,297    
Less: accumulated amortization   (2,154)   (1,445)   
Total intangible assets, net  $10,143   $10,852    

 

Amortization expense for acquired intangible assets was $709,000 and $109,000 during the three months ended March 31, 2022 and 2021, respectively. The estimated future amortization expense of acquired intangible assets as of March 31, 2022 is as follows (in thousands):

 

      
Remaining periods ended December 31, 2022  $1,669 
Year ended December 31, 2023   1,585 
Year ended December 31, 2024   1,222 
Year ended December 31, 2025   1,222 
Year ended December 31, 2026   890 
Thereafter   3,555 
 Total intangible assets, net  $10,143 

 

Note 5 - Property, Plant and Equipment

 

The components of property, plant and equipment are as follows (in thousands):

 

  

March 31,

2022

  

December 31,

2021

   Estimated Useful Life
Land  $352   $352    
Building improvements   1,729    1,729   10-39 years
Machinery   4,740    4,740   3-7 years
Lab equipment   4,936    4,330   3-7 years
Computer equipment   1,589    1,211   3-5 years
Furniture and fixtures   468    468   5 years
 Property, Plant and Equipment, Gross   13,814    12,830    
Less: accumulated depreciation   (7,374)   (6,883)   
Total property, plant and equipment, net  $6,440   $5,947    

 

Depreciation expense incurred for the three months ended March 31, 2022 and 2021 was $491,000 and $428,000, respectively.

 

Note 6 -Unsecured Convertible Promissory Notes Payable

 

On September 15, 2020, we issued two unsecured, partially convertible, promissory notes (the “September 2020 Notes”) for an aggregate principal amount of $10 million to two investors (collectively, the “Lenders”).

 

On February 28, 2022, we entered into a letter agreement (the “Letter Agreement”) with one of the Lenders providing for the payoff of its September 2020 Note in the principal amount of $2,000,000.

 

Pursuant to the terms of the Letter Agreement, (i) the Lender converted $600,000 of the principal amount due to him under his September 2020 Note into 200,000 shares of Company common stock (the “Conversion Shares”) at a price of $3.00 per share as provided for under the terms of the September 2020 Note (the “Conversion”), (ii) the Company paid to the Lender $1,440,548 in cash, representing $1,400,000 of the remaining principal under the September 2020 Note following the Conversion plus $40,548 in accrued and outstanding interest under the September 2020 Note, and (iii) the Company repurchased the Conversion Shares at a price of $5.75 per share for an aggregate amount of $1,150,000 (for a total aggregate payment to the Lender of $2,590,548).

 

21
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The September 2020 Note that remains outstanding as of March 31, 2022 is due and payable on September 15, 2023 and accrues interest at a rate of 10% per year from the closing date, payable on a quarterly basis, until the September 2020 Note is repaid in full. We have the right to prepay the outstanding September 2020 Note at any time after the 13-month anniversary of the initial issuance date after providing written notice to the Lender and may prepay the September 2020 Note prior to such time with the consent of the Lender. The Lender has the right, at any time, and from time to time, on and after the 13-month anniversary of the initial issuance date to convert up to an aggregate of $3.0 million of the September 2020 Note into common stock of the Company at a conversion price of $3.00 per share. Repayment of the September 2020 Note has been guaranteed by our wholly owned subsidiary, PMI.

 

The September 2020 Note contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the September 2020 Note may be accelerated. The September 2020 Note also contain certain restrictive covenants which, among other things, restrict our ability to create, incur, assume or permit to exist, directly or indirectly, any lien (other than certain permitted liens described in the September 2020 Note) securing any indebtedness of the Company, and prohibits us from distributing or reinvesting the proceeds from any divestment of assets (other than in the ordinary course) without the prior approval of the Lender.

 

For the three months ended March 31, 2022 and 2021, we incurred $233,000 and $251,000, respectively, in interest expense related to the September 2020 Notes.

 

Note 7 - Stockholders’ Equity

 

Our authorized capital stock consists of 50 million shares of common stock, $0.0005 par value, and one million shares of preferred stock, $0.0005 par value.

 

Preferred Stock

 

The preferred stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of March 31, 2022 and December 31, 2021, no shares of preferred stock have been issued.

 

Common Stock Dividends

 

On February 14, 2022, the board of directors of the Company declared a special cash dividend of $0.30 per share on the Company’s common stock, paid on March 10, 2022, in the amount of $4.6 million to holders of record of the Company’s common stock on March 1, 2022.

 

22
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Common Stock

 

Stock Repurchase Program

 

On September 8, 2021, the board of directors (the “Board”) approved a stock repurchase program under which the Company was authorized to repurchase up to $6.0 million of its outstanding shares of common stock from time to time, over a six-month period.

 

During the three months ended March 31, 2022, the Company did not make any common shares repurchase under the stock repurchase program. The stock repurchase program expired on March 30, 2022.

 

The 2010 Directors’ Equity Compensation Plan

 

On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Directors’ Equity Compensation Plan (the “Amended 2010 Directors’ Plan”) at the 2021 Annual Meeting of Stockholders of the Company (the “2021 Annual Meeting”). The Amended 2010 Directors’ Plan authorizes the issuance of up to 775,000 shares of common stock.

 

At March 31, 2022, there were 425,126 stock options outstanding and there were no shares of common stock available to be issued under the Amended 2010 Directors’ Plan.

 

The 2010 Equity Compensation Plan

 

On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Equity Compensation Plan (the “Amended 2010 Plan”) at the 2021 Annual Meeting. The Amended 2010 Plan authorizes the issuance of up to 4,900,000 shares of common stock.

 

As of December 31, 2021 and March 31, 2022, there were 2,014,874 stock options outstanding and 295,785 stock options available to be issued under the 2010 Plan. We will recognize an aggregate of approximately $1,684,000 of remaining share-based compensation expense related to outstanding stock options over a weighted average period of 2.8 years.

 

The 2018 Stock Incentive Plan

 

On April 12, 2018, our stockholders approved the 2018 Stock Incentive Plan (the “2018 Stock Plan”). The 2018 Stock Plan provides for the grant of incentive stock options to eligible employees of the Company, and for the grant of non-statutory stock options to eligible employees, directors and consultants. The 2018 Stock Plan provides that the total number of shares that may be issued pursuant to the 2018 Stock Plan is 2,300,000 shares. At April 12, 2018, all 2,300,000 shares have been granted in the form of stock options to Ted Karkus (the “CEO Option”), our Chief Executive Officer. To date, no stock options have been exercised under the 2018 Stock Plan. No share based compensation expense will be recognized in forward periods related to the 2018 Stock Plan.

 

The 2018 Stock Plan requires certain proportionate adjustments to be made to the stock options granted under the 2018 Stock Plan upon the occurrence of certain events, including a special distribution (whether in the form of cash, shares, other securities, or other property) in order to maintain parity. Accordingly, the Compensation Committee of the board of directors, as required by the terms of the 2018 Stock Plan, adjusted the terms of the CEO Option, such that the exercise price of the CEO Option was reduced from $3.00 per share to $2.00 per share, effective as of September 5, 2018, the date the special $1.00 special cash dividend was paid to stockholders. The exercise price of the CEO Option was further reduced from $2.00 to $1.75 per share, effective as of January 24, 2019, the date the $0.25 special cash dividend was paid to stockholders. The exercise price of the CEO Option was further reduced from $1.75 to $1.50 per share, effective as of December 12, 2019, the date another $0.25 special cash dividend was paid to stockholders. The exercise price of the CEO Option was further reduced from $1.50 to $1.20 per share, effective as of June 3, 2021, the date another $0.30 special cash dividend was paid to Company’s stockholders. The exercise price of the CEO Option was further reduced from $1.20 to $0.90 per share, effective as of March 10, 2022, the date another $0.30 special cash dividend was paid to Company’s stockholders.

 

23
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Inducement Option Award

 

As part of Nebula Acquisition, the Company issued a non-qualified stock option to Kamal Obbad, the Chief Executive Officer of Nebula, as an inducement to his employment with the Company (the “Inducement Award”). The Inducement Award entitles Mr. Obbad to purchase up to 250,000 shares of the Company’s common stock at an exercise price of $7.67 per share, the closing price of the Company’s common stock on the closing date of the Nebula Acquisition. The Inducement Award was granted to Mr. Obbad on the closing date of the Nebula Acquisition. The Inducement Award vested 25% on the grant date and will vest 25% per year for the next three years subject to Mr. Obbad’s continued employment with the Company. The Inducement Award expires on the seventh anniversary of the grant date. Any portion of the Inducement Award that does not vest and become exercisable will be forfeited for no consideration. The grant date fair value of the Inducement Award was approximately $1,128,000.

 

During the year ended December 31, 2021, we issued an inducement award to a non-employee to purchase up to 100,000 shares of the Company’s common stock at an exercise price of $5.76, the closing price of the common stock on the date of grant. The award vests in four equal installments from the date of grant. The award expires on the seventh anniversary of the grant date.

 

All inducement awards have been granted outside of the Company’s equity compensation plans.

 

The following table summarizes stock options activity during the three months ended March 31, 2022 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Awards (in thousands, except per share data).

 

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
   Total Intrinsic Value 
Outstanding as of January 1, 2022   5,110   $3.27    3.4   $20,820 
Forfeited   (20)   8.99    -    - 
Outstanding as of March 31, 2022   5,090   $3.11    3.2   $20,767 
Options vested and exercisable   4,069   $2.41    2.4   $19,398 

 

As of March 31, 2022, there were 5,090,000 stock options outstanding and 295,785 stock options available to be issued. We will recognize an aggregate of approximately $2,746,000 of remaining share-based compensation expense related to outstanding stock options over a weighted average period of 2.8 years.

 

Stock Warrants

 

The following table summarizes warrant activity during the three months ended March 31, 2022 (in thousands, except per share data):

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
 
Outstanding as of January 1, 2022   855   $8.23    1.9 
Warrants granted   -    -    - 
Outstanding as of March 31, 2022   855   $8.23    1.6 
Warrants vested and exercisable   855   $8.23    1.6 

 

We recognized $0 and $105,000 of share-based compensation expense during the three months ended March 31, 2022 and 2021, respectively.

 

24
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 8 - Defined Contribution Plans

 

We maintain the ProPhase Labs, Inc. 401(k) Savings and Retirement Plan, a defined contribution plan for our employees. Our contributions to the plan are based on the amount of the employee plan contributions and compensation. Our contributions to the plan in the three months ended March 31, 2022 and 2021 were $52,000 and $13,000, respectively.

 

Note 9 – Income Taxes

 

We recognize tax assets and liabilities for the future tax consequences related to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for net operating loss carryforwards. Management evaluated the deferred tax assets for recoverability using a consistent approach that considers the relative impact of negative and positive evidence, including historical profitability and projections of future reversals of temporary differences and future taxable income. We are required to establish a valuation allowance for deferred tax assets if management determines, based on available evidence at the time the determination is made, that it is not more likely than not that some portion or all of the deferred tax assets will be realized. As of March 31, 2022 the Company has net deferred tax liabilities for federal and combined states jurisdictions compared to net deferred tax assets with a full valuation allowance as of December 31, 2021. The decrease in deferred tax assets with a corresponding decrease in valuation allowance against those assets as of March 31, 2022 is primarily due to utilization of net operating losses. The Company has net deferred tax assets in other states jurisdictions where we maintain a full valuation allowance. Judgment is required to estimate forecasted future taxable income, which may be impacted by future business developments, actual results, tax initiatives, legislative, and other economic factors. The Company will continue to monitor income levels and potential changes to its operating and tax model, and other legislative or global developments in its determination.

 

The Company’s effective tax rate for the three months ended March 31, 2022 is 21.47% and it is primarily driven by federal tax at 21%, state taxes at 7.1%, and a decrease in the valuation allowance for federal and combined states jurisdictions. The total tax expense for the three months ended March 31, 2022 is $3.4 million and it mostly relates to current federal and combined state taxes.

 

25
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 10 - Other Current Liabilities

 

The following table sets forth the components of other current liabilities at March 31, 2022 and December 31, 2021, respectively (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Accrued commissions  $1,294   $1,283 
Accrued payroll   50    514 
Accrued expenses   356    300 
Accrued returns   246    338 
Accrued benefits and vacation   50    60 
Accrued insurance reimbursement   

1,278

    

-

 
Total other current liabilities  $3,274   $2,495 

 

Note 11 - Commitments and Contingencies

 

Manufacturing Agreement

 

The Company and its wholly owned subsidiary, PMI, entered into a manufacturing agreement (the “Manufacturing Agreement”) with Mylan in connection with the asset purchase agreement we entered into with Mylan in 2017. Pursuant to the terms of the Manufacturing Agreement, Mylan (or an affiliate or designee) purchased the inventory of the Company’s Cold-EEZE® brand and product line, and PMI agreed to manufacture certain products for Mylan, as described in the Manufacturing Agreement, at prices that reflect current market conditions for such products and include an agreed upon mark-up on our costs. On May 1, 2021, the Manufacturing Agreement was assigned by Mylan to Nurya Brands, Inc. (“Nurya”) in connection with Nurya’s acquisitions of certain assets from Mylan, including the Cold-EEZE® brand and product line. Unless terminated sooner by the parties, the Manufacturing Agreement will remain in effect until March 29, 2023. Thereafter, the Manufacturing Agreement may be renewed by Nurya for up to four successive one-year periods by providing notice of its intent to renew not less than 90 days prior to the expiration of the then-current term.

 

Future Obligations

 

We have estimated future minimum obligations for an executive’s employment agreement over the next five years as of March 31, 2022, as follows (in thousands):

 

   Employment Contracts 
Remaining periods in 2022  $506 
2023   675 
2024   675 
2025   675 
2026   675 
Total  $3,206 

 

Litigation

 

In the normal course of our business, we may be named as a defendant in legal proceedings. It is our policy to vigorously defend litigation or to enter into a reasonable settlement where management deems it appropriate.

 

26
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 12 - Leases

 

On October 23, 2020, we completed the acquisition of CPM, which included the acquisition of a 4,000 square foot CLIA accredited laboratory located in Old Bridge, New Jersey, which was owned by CPM (which is now known as ProPhase Diagnostics NJ, Inc.). The lease is for a term of 24 months with a monthly base lease payment of $5,950.

 

On December 8, 2020, the Company entered into a Lease Agreement (the “NY Lease”) with BRG Office L.L.C. and Unit 2 Associates L.L.C. (the “Landlord”), pursuant to which the Company has agreed to lease certain premises located on the second floor (the “Leased Premises”) of 711 Stewart Avenue, Garden City, New York (the “Building”). The Leased Premises serve as the Company’s second location and corporate headquarters, offering a wide range of laboratory testing services for diagnosis, screening and evaluation of diseases, including COVID-19 and Respiratory Pathogen Panel Molecular tests.

 

The NY Lease was effective as of December 8, 2020, and commenced in January 2021 (the “Commencement Date”) when the facility was made available to us by the landlord. The initial term of the NY Lease is 10 years and seven months (the “Initial Term”), unless sooner terminated as provided in the NY Lease. We may extend the term of the NY Lease for one additional option period of five years. We have the option to terminate the NY Lease on the sixth anniversary of the Commencement Date, provided that we give the landlord written notice not less than nine months and not more than 12 months in advance and that we pay the landlord a termination fee.

 

For the first year of the NY Lease, we will pay a base rent of $56,963 per month (subject to a seven-month abatement period), with a gradual rental rate increase of 2.75% for each 12-month period thereafter in lieu of paying its proportionate share of common area operating expenses, culminating in a monthly base rent of $74,716 during the final months of the Initial Term. In addition to the monthly base rent, we are responsible for its proportionate share of real estate tax escalations in accordance with the terms of the NY Lease.

 

We also have a right of first refusal to lease certain additional space located on the ground floor of the Building containing 4,500 square feet and 4,600 square feet, as more particularly described in the NY Lease. We also have a right of first offer to purchase the Building during the term of the NY Lease.

 

At March 31, 2022, we had operating lease liabilities for the New York and New Jersey leases of approximately $4.8 million and right of use assets of approximately $4.3 million, which were included in the condensed consolidated balance sheet.

 

The following summarizes quantitative information about our operating leases (amounts in thousands): 

 

   March 31, 2022   March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Operating leases          
Operating lease cost  $204   $204 
Operating lease expense   204    204 
Total rent expense  $204   $204 

 

27
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Maturities of the Company’s operating leases, excluding short-term leases, are as follows (in thousands):

 

      
Remaining Periods Ended December 31, 2022  $580 
Year Ended December 31, 2023   738 
Year Ended December 31, 2024   747 
Year Ended December 31, 2025   768 
Year Ended December 31, 2026   783 
Thereafter   3,876 
Total   7,492 
Less present value discount   (2,704)
Operating lease liabilities  $4,788 

 

 

Note 13 - Consulting Agreement and Secured Promissory Note Receivable

 

Promissory Note and Security Agreement

 

On September 25, 2020 (the “Restatement Effective Date”), we entered into the Secured Note with a company consulting for us (“the Consultant”), pursuant to which we loaned $3.0 million to the Consultant (inclusive of $1.0 million in the aggregate previously loaned to the Consultant, as described below).

 

The Secured Note amended and restated in its entirety (i) that certain Promissory Note and Security Agreement, dated July 21, 2020 (the “Original July 21 Note”), pursuant to which we loaned $750,000 to the Consultant and (ii) that certain Promissory Note and Security Agreement, dated July 29, 2020 (the “Original July 29 Note”, and, together with the Original July 21 Note, the “Original Notes”), pursuant to which we loaned $250,000 to the Consultant.

 

Commencing after September 1, 2021, in addition to payments of interest, the Consultant is also required to make payments on the principal amount of the loan equal to 1/36 of the then outstanding principal amount.

 

28
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The entire remaining unpaid principal amount of the Secured Note, together with all accrued and unpaid interest thereon and all other amounts payable under the Secured Note, will be due and payable, if not sooner paid, on September 30, 2022.

 

The Secured Note contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the Secured Note may be accelerated.

 

Amendment and Termination Agreement

 

On January 14, 2021, we entered into an Amendment and Termination Agreement (the “Termination Agreement”) with the Consultant pursuant to which the parties amended the Secured Note and terminated the former consulting agreement with the Consultant (the “Consulting Agreement”). Pursuant to the terms of the Termination Agreement, the Company loaned an additional $1 million to the Consultant in consideration for the termination of the Consulting Agreement and termination of the Company’s obligation to pay any additional consulting fees. As a result, the initial principal amount due under the Secured Note was increased from $2.75 million to $3.75 million plus all accrued and unpaid interest arising under the Secured Note through and including January 14, 2021.

 

Under the terms of the Termination Agreement, the Consultant will continue to sell and process its viral test by RT-PCR (together with other viral and other types of tests). Until the Secured Note is paid in full, each COVID-19 Test Kit sold or processed from and after January 14, 2021, and for which payment of at least the specified amount as defined for the test, is received by the Consultant, the Consultant will pay us a specified amount (the “Test Fee”). We received the first payment in the amount of $95,000 with respect to the Test Fees from January 15 through February 2021. On June 25, 2021, we were issued 1,260,619 shares of common stock of the Consultant with a fair value of $315,000 as an interest payment under the Secured Note in lieu of Test Fees from March through June 2021.

 

Effective September 1, 2021, in addition to the payment of the Test Fees described above, the Consultant is also required to make payments to us in an amount equal to the greater of (x) the Test Fee, or (y) 1/36th of the then outstanding principal amount together with interest thereon. The Company did not receive any payments from the Consultant for either contractual principal or interest.

 

29
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

On October 11, 2021, the Company provided the Consultant with a Notice of Default and demanded the Secured Note be paid in full immediately. On January 25, 2022, the Company filed a complaint with the United States District Court for the District of Delaware for judgment against the Consultant for money damages consisting of principal, interest, default interest and other fees and costs. As a result, the Company considered that it is not probable that it will collect all amounts due under the Secured Note and reduced the carrying value of the Secured Note to $0 as of December 31, 2021 with a corresponding charge-off of $3.75 million during the year ended December 31, 2021.

 

Note 14 - Significant Customer Concentrations

 

Revenue for the three months ended March 31, 2022 and 2021 was $47.5 million and $15.3 million, respectively. Three diagnostic services clients accounted for 36.7%, 21.4%, and 11.0% of our revenue for the three months ended March 31, 2022. Two diagnostic services clients accounted for 46.1% and 31.6% of our revenue for the three months ended March 31, 2021. No contract manufacturing customer’s accounted for a significant portion of our revenue for the three month ended March 31, 2022 or 2021. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.

 

Two diagnostic services payers comprised 33.6% and 26.5% of our total reimbursement receivable balances from government agencies and healthcare issuers at March 31, 2022. Four diagnostic services payers comprised 43.0%, 11.6%, 10.7% and 10.7% of our total reimbursement receivable balances from government agencies and healthcare issuers at December 31, 2021.

 

Currently, we rely on a sole supplier to manufacture our saliva collection kits used by customers who purchase our personal genomics services. Change in the supplier or design of certain of the materials that we rely on, in particular the saliva collection kit, could result in a requirement for additional premarket review from the FDA before making such a change.

 

Note 15 - Segment Information

 

The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO as CODM assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.

 

30
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table is a summary of segment information for three months ended March 31, 2022 and 2021 (amounts in thousands):

 

   March 31, 2022   March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Net revenues          
Diagnostic services  $44,913   $12,737 
Consumer products   2,618    2,534 
Consolidated net revenue   47,531    15,271 
Cost of revenue          
Diagnostic services   16,702    4,345 
Consumer products   2,152    1,999 
Consolidated cost of revenue   18,854    6,344 
Depreciation and amortization expense          
Diagnostic services   576    345 
Consumer products   600    3 
Total Depreciation and amortization expense   1,176    348 
Operating and other expenses   11,591    7,522 
Income (loss) from operations, before income taxes          
Diagnostic services   20,026    2,839 
Consumer products   (1,863)   (35)
Unallocated corporate   (2,253)   (1,747)
Total income from operations, before income taxes   15,910    1,057 
Income tax expense   (3,416)   - 
Total income from operations, after income taxes   12,494    1,057 
Net income  $12,494   $1,057 

 

The following table is a summary of segment information as of March 31, 2022 and December 31, 2021 (amounts in thousands):

 

  

March 31,

2022

  

December 31,

2021

 
         
ASSETS          
Diagnostic services  $51,823   $51,150 
Consumer products   23,378    24,139 
Unallocated corporate   24,464    14,006 
Total assets  $99,665   $89,295 

 

 

Note 16 - Earnings Per Share

 

Basic earnings per share (“EPS”) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.

 

31
 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):

   March 31, 2022   March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Net income - basic  $12,494   $1,057 
Interest on unsecured convertible promissory note   232    - 
Net income - diluted  $12,726   $1,057 
           
Weighted average shares outstanding - basic   15,486    14,563 
Diluted shares- Stock Options   2,232    2,895 
Diluted shares- Stock Warrants   222    284 
Unsecured convertible promissory note   800    458 
Weighted average shares outstanding - diluted   18,740    18,200 

 

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):

 

   For the three months ended 
Anti-dilutive securities  March 31, 2022   March 31, 2021 
Common stock purchase warrants   455    455 
Stock Options   810    - 
Anti-dilutive securities   1,265    455 

 

Note 17 - Related Parties

 

Jason Karkus, Executive Vice President and Co-Chief Operations Officer of ProPhase Diagnostics, is the son of Ted Karkus, the Company’s Chairman and Chief Executive Officer. For the three months ended March 31, 2022 and 2021, Mr. Karkus received compensation of $55,000 and $30,000, respectively.

 

Note 18 – Subsequent Event

 

Appointment of Chief Financial Officer

 

On May 9, 2022, the Company announced that has appointed Bill White as Chief Financial Officer of the Company, effective May 23, 2022 (the “Effective Date”), replacing Monica Brady, who is currently serving as Chief Financial Officer of the Company. Ms. Brady will remain with the Company and continue to serve as the Company’s Chief Accounting Officer, and Chief Financial Officer of the Company’s wholly-owned subsidiary, ProPhase Diagnostics, as of the Effective Date.

 

As an inducement to his employment as Chief Financial Officer of the Company, the Compensation Committee granted Mr. White a stock option (the “Option Award”) to purchase up to 400,000 shares of the Company’s common stock. This award was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded under the Company’s stockholder approved equity plan. The option award will vest over a four year period, with 12.5% vesting every six months following the Effective Date, and contingent upon the commencement of his employment and continued service through each vesting date. The options have an exercise price of $6.74 per share, the closing price of the Company’s common stock on May 9, 2022, and will be exercisable for a period of seven years. 

 

Announcement of Cash Dividend

 

On May 9, 2022, the board of directors of the Company declared a special cash dividend of $0.30 per share for stockholders of record as of May 25, 2022, which will approximate $4.6 million. On the same date, the Compensation Committee of the board of directors approved an adjustment to the stock option granted to Mr. Karkus on February 23, 2018 (the “CEO Option”), as required under the Company’s 2018 Stock Plan, as a consequence of the special cash dividend. The board of directors has adjusted the terms of the CEO Option, such that the exercise price of the CEO Option will be reduced from $0.90 per share to $0.60 per share, effective as of June 3, 2022, the date the special cash dividend is to be paid.

 

32
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis should be read in conjunction with our interim unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q (“Quarterly Report”) and the audited financial statements and notes thereto as of and for the year ended December 31, 2021 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2022 (the “2021 Annual Report”). As used in this Quarterly Report, unless the context suggests otherwise, “we,” “us,” “our,” or “ProPhase” refer to ProPhase Labs, Inc. and its subsidiaries, unless the context otherwise requires.

 

Forward-Looking Statements

 

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements relate to future events or our future financial performance. Forward-looking statements typically are identified by use of terms such as “anticipate”, “believe”, “plan”, “expect”, “intend”, “may”, “will”, “should”, “estimate”, “predict”, “potential”, “continue” and similar words although some forward-looking statements are expressed differently. This Quarterly Report may also contain forward-looking statements attributable to third parties relating to their estimates regarding the growth of our markets.

 

You are cautioned that forward-looking statements are not guarantees of performance and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, achievements or prospects to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. Many of these factors are beyond our ability to predict.

 

Such risks and uncertainties include, but are not limited to:

 

  Our ability to generate revenue and sufficient profits from Respiratory Pathogen Panel (“RPP”) Molecular tests if and when demand for COVID-19 testing decreases or becomes no longer necessary;
     
  Our ability to collect payment for the tests we deliver;
     
  Our ability to manage our growth successfully;
     
  Our ability to compete effectively, including our ability to maintain and increase our markets and/or market share in the markets in which we do business;
     
  Our dependence on our largest diagnostic services customers;
     
  Our ability to successfully offer, perform and generate revenues from our personal genomics businesses;
     
  Our ability to secure additional capital, when needed to support our diagnostic services business, personal genomics business, manufacturing business and product development and commercialization programs;
     
  Potential disruptions to our supply chain or increases to the price of or adulteration of key raw materials or supplies;
     
  Potential disruptions in our ability to manufacture our products and those of others;
     
  Seasonal fluctuations in demand for the products and services we provide;
     
  Our ability to successfully develop and commercialize our existing products and any new products;
     
  Our ability to attract, retain and motivate our key employees;
     
  Our ability to protect our proprietary rights;

 

33
 

 

  Our ability to comply with regulatory requirements applicable to our businesses;
     
  The complexity of billing for, and collecting revenue for, testing services;
     
  Our dependence on third parties to provide services critical to our lab diagnostic services business;
     
  General economic conditions, including as a result of the ongoing COVID-19 pandemic and the war in Ukraine; and
     
  Our ability to remediate the material weakness in our internal controls over financial reporting and prevent other material weaknesses.

 

Given the risks and uncertainties surrounding forward-looking statements, you should not place undue reliance on these statements. You should also consider carefully the statements we make under other sections of this Quarterly Report and in our 2021 Annual Report, as well as in other documents we file from time to time with the SEC that address additional risks that could cause our actual results to differ from those set forth in any forward-looking statements. Our forward-looking statements speak only as the date of this Quarterly Report. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

 

General

 

We are a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. We provide traditional CLIA molecular laboratory services, including SARS-CoV-2 (“COVID-19”) testing and seek to leverage our Clinical Laboratory Improvement Amendments (“CLIA”) accredited laboratory services to provide whole genome sequencing and research direct to consumers, while building a genomics data base to be used for further research. In addition, we have deep experience with over-the-counter (“OTC”) consumer healthcare products and dietary supplements. We conduct our operations through two operating segments: diagnostic services and consumer products. Until late fiscal year 2020, we were engaged primarily in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. This includes the development and marketing of dietary supplements under the TK Supplements® brand. However, commencing in December 2020, we also began offering COVID- 19 and other RPP Molecular tests through our diagnostic service business, and in August 2021 we began offering personal genomics products and services.

 

Our wholly owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (“PCR”) testing for COVID-19. Critical to COVID-19 testing, we provide fast turnaround times for results. We also offer best-in-class rapid antigen and antibody/immunity testing for COVID-19. On October 23, 2020, we completed the acquisition of all of the issued and outstanding shares of capital stock of Confucius Plaza Medical Laboratory Corp. (“CPM”), which owned a 4,000 square foot CLIA accredited laboratory located in Old Bridge, New Jersey for approximately $2.5 million. In December 2020, we expanded our diagnostic service business with the build-out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in January 2021.

 

On August 10, 2021, we acquired Nebula Genomics, Inc. (“Nebula”), a privately owned personal genomics company, through our new wholly owned subsidiary, ProPhase Precision Medicine. We offer whole genome sequencing and related services through this new subsidiary. ProPhase Precision Medicine, Inc. focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

 

Our wholly owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.

 

Our diagnostic service business is and will continue to be influenced by the level of demand for COVID-19 and other diagnostic testing, how long this demand persists, the price we are able to receive for performing our testing services, our ability to collect payment or reimbursement for our testing services, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.

 

34
 

 

Our personal genomics business is and will continue to be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.

 

Our consumer sales are and will continue to be influenced by (i) the timing of acceptance of our TK Supplements® consumer products in the marketplace, and (ii) fluctuations in the timing of purchase and the ultimate level of demand for the OTC healthcare and cold remedy products that we manufacture, which is largely a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period from September to March when the incidence of the common cold rises as a result of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net revenues from our contract manufacturing business. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.

 

In addition, we continue to actively pursue acquisition opportunities for other companies, technologies and products within and outside the consumer products industry.

 

While our revenues have increased significantly as a result of our diagnostic services business, we will continue to be dependent on both government agency and insurance company reimbursement as well as the prevalence of COVID-19 associated strains. There can be no assurance that our efforts to offer and perform COVID-19 or other diagnostic testing will continue to be successful and the revenue and operating profits from such business will increase from or maintain their current level.

 

Results of Operations

 

Three Months Ended March 31, 2022 as Compared to the Three Months Ended March 31, 2021

 

For the three months ended March 31, 2022, net revenue was $47.5 million as compared to $15.3 million for the three months ended March 31, 2021. The increase in net revenue was the result of a $32.2 million increase in net revenue from diagnostic services and an immaterial increase in consumer products. The increase in net revenue for diagnostic services was due to increased COVID-19 testing volumes performed as a result of the Omicron variant, which emerged in early 2022. Overall diagnostic testing volume increased from 113,000 tests in the first quarter of 2021 to 377,000 tests in the first quarter of 2022, of which 60.3% and 69.0% were reimbursed by the HRSA uninsured program, respectively. The average variable consideration received was $120.14 per adjudicated test in the first quarter of 2022 versus $139.04 per adjudicated test in the first quarter of 2021. See “HRSA Funding” section in the Liquidity and Capital Resources management disclosures below for additional information.

 

Cost of revenues for the three months ended March 31, 2022 were $18.9 million, comprised of $16.7 million for diagnostic services and $2.2 million for consumer products. Cost of revenues for the three months ended March 31, 2021 were $6.3 million, comprised of $4.3 million for diagnostic services and $2.0 million for consumer products.

 

We realized a gross profit of $28.7 million for the three months ended March 31, 2022 as compared to $8.9 million for the three months ended March 31, 2021. The increase of $19.8 million was comprised of an increase of $19.8 million from diagnostic services offset by an immaterial decrease in consumer products. For the three months ended March 31, 2022 and 2021 we realized an overall gross margin of 60.3% and 58.5%, respectively. Gross margin for diagnostic services was 62.8% and 65.9% in the 2022 and 2021 comparable periods, respectively. The decrease in gross margin was principally due to increased sample collection costs and additional costs for HRSA-related testing for which revenue could not be recognized, partially offset by a decrease in cost of test materials. Gross margin for consumer products was 17.8% and 21.1% in the 2022 and 2021 comparable periods, respectively. Gross margin for consumer products have historically been influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs and timing of shipments to customers.

 

Diagnostic services costs for the three months ended March 31, 2022 were $4.7 million compared to $3.8 million for the three months ended March 31, 2021. The increase of $0.9 million was due to increased COVID-19 testing volumes performed as a result of the Omicron variant, which emerged in early 2022, partially offset by a greater proportion of costs allocated to cost of revenues as a result of the nature of agreements with network providers.

 

General and administration expenses for the three months ended March 31, 2022 were $7.8 million as compared to $3.8 million for the three months ended March 31, 2021. The increase of $4.0 million in general and administration expenses was principally related to an increase in personnel expenses and professional fees associated with our diagnostic services business.

 

Research and development costs for the three months ended March 31, 2022 were $35,000 as compared to $115,000 for the three months ended March 31, 2021. The decrease in research and development costs for the three months ended March 31, 2022 as compared to the three months ended March 31, 2021 was principally due to a decrease in personnel expenses associated with our diagnostics services business.

 

Interest and other income for the three months ended March 31, 2022 and 2021 was $73,000 and $87,000, respectively. The decrease in interest income for the three months ended March 31, 2022 as compared to the three months ended March 31, 2021 was principally due to the higher account balance of our investment account that bears interest.

 

35
 

 

Interest expense for the three months ended March 31, 2022 was $233,000 compared to $251,000 for the three months ended March 31, 2021. The decrease in interest expense for the three months ended March 31, 2022 as compared to the three months ended March 31, 2021 was principally due to the repayment during the three months ended March 31, 2022 of one of the two September 2020 unsecured convertible notes payable that accrued interest at a rate of 10% per year.

 

As a result of the effects described above, net income from operations for the three months ended March 31, 2022 was $12.5 million, or $0.81 per share, as compared to $1.1 million, or $0.07 per share, for the three months ended March 31, 2021. Diluted earnings per share for the three months ended March 31, 2022 and 2021 were $0.68 and $0.06, respectively.

 

Non-GAAP Financial Measure and Reconciliation

 

In an effort to provide investors with additional information regarding our results of operations as determined by accounting principles generally accepted in the United States of America (“GAAP”), we disclose certain non-GAAP financial measures. The primary non-GAAP financial measure we disclose are EBITDA and Adjusted EBITDA.

 

We define EBITDA as net income (loss) before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding acquisition costs, other non-cash items, and other unusual or non-recurring charges (as described in the table below).

 

We use EBITDA and Adjusted EBITDA internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s ongoing economic performance. We have chosen to provide this information to investors to enable them to perform more meaningful comparisons of operating results. The following table sets forth the reconciliations of EBITDA and Adjusted EBITDA excluding other costs to the most comparable GAAP financial measures (in thousands):

 

   For the three months ended 
   March 31, 2022   March 31, 2021 
GAAP net income (1)  $12,494   $1,057 
Interest, net   160    164 
Depreciation and amortization   1,250    457 
EBITDA   13,904    1,678 
Share-based compensation expense   482    428 
Non-cash rent expense (2)   10    186 
Bad debt expense (3)   250    - 
Adjusted EBITDA  $14,646   $2,292 

 

(1) We believe that net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most directly comparable to EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA measure the Company’s operating performance without regard to certain expenses. EBITDA and Adjusted EBITDA are not presentations made in accordance with GAAP and the Company’s computation of EBITDA and Adjusted EBITDA may vary from others in the industry. EBITDA and Adjusted EBITDA have important limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of the Company’s results as reported under GAAP.

 

36
 

 

(2) The non-cash portion of rent, which reflects the extent to which our GAAP rent expense recognized exceeds (or is less than) our cash rent payments. For newer leases, our rent expense recognized typically exceeds our cash rent payments, while for more mature leases, rent expense recognized is typically less than our cash rent payments.

 

(3) Full allowance reserved related to restricted cash.

 

Liquidity and Capital Resources

 

Our aggregate cash, cash equivalents and restricted cash as of March 31, 2022 were $25.8 million as compared to $8.7 million at December 31, 2021. Our working capital was $52.8 million and $45.8 million as of March 31, 2022 and December 31, 2021, respectively. The increase of $17.1 million in our cash, cash equivalents and restricted cash for the three months ended March 31, 2022 was principally due to our proceeds from the sale of marketable debt securities of $5.3 million and $20.3 million cash provided by operating activities, offset by (i) purchases of marketable securities of $0.3 million, (ii) cash dividend payments of $4.6 million, (iii) repayment of note payable of $1.4 million, (iv) repurchase of common shares for $1.2 million, and (v) capital expenditures of $1.1 million.

 

To date the principal sources of capital to fund our operations have been from diagnostic services, product sales, net proceeds from the offering of equity securities, and issuances of promissory notes. Based on management’s current business plans, the Company estimates it will have enough cash and liquidity to finance its operating requirements for at least 12 months from the date of filing these unaudited condensed consolidated financial statements. However, due to the nature of the diagnostic business and the Company’s focus thus far on COVID-19 testing, there are inherent uncertainties associated with managements’ business plan and cash flow projections, particularly if the Company is unable to grow its diagnostic testing business beyond COVID-19 testing services. See “HRSA Funding” below.

 

COVID-19

 

The COVID-19 pandemic has not had a material adverse impact on our business to date. We experienced higher than normal net revenue for the year ended December 31, 2021 and three months ended March 31, 2022, primarily as a result of revenue from our diagnostic services business, which offers COVID-19 testing. There can be no assurance that demand for our COVID-19 testing services will continue to exist in the future due to the widespread and effective vaccination of a majority of Americans against COVID-19 and successful containment efforts. If there is no demand for our COVID-19 testing services, and we are unable to generate sufficient profits from other RPP Molecular tests, our business could be materially adversely affected.

 

There are still numerous uncertainties associated with the COVID-19 pandemic, including the efficacy of the vaccines that have been developed to treat the virus and their ability to protect against new strains of the virus, people’s willingness to receive a vaccine, possible resurgences of the coronavirus and/or new strains of the virus, the extent and duration of protective and preventative measures that may be adopted by local, state and/or the federal government in the future as a result of future outbreaks, including business closures, the ongoing impact of COVID-19 on the U.S. and world economy and consumer confidence, and various other uncertainties all of which could negatively impact our Company as a whole.

 

The COVID-19 pandemic has had a negative impact on the global capital markets and economies worldwide and could ultimately have a material adverse impact on our ability to raise capital needed to develop and commercialize products.

 

HRSA Funding

 

In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted, providing for reimbursement to healthcare providers for COVID-19 tests provided to uninsured individuals, subject to continued available funding. Approximately 69% and 57% of our diagnostic services revenue for the three months ended March 31, 2022 and 2021, respectively was generated from this program for the uninsured. On March 22, 2022, the Health Resources & Services Administration (“HRSA”) uninsured program stopped accepting claims for COVID-19 testing and treatment due to lack of sufficient funds. Despite requests from the Acting Director of the Office of Management and Budget and the White House Coordinator for COVID-19 Response for additional emergency funding for the uninsured program, emergency funding has not been allocated to the HRSA uninsured program. We continue to perform testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize $4.3 million in revenues related to COVID-19 testing that we performed for uninsured individuals from March 23, 2022 through March 31, 2022. If funding for the HRSA program is reinstituted, we will submit eligible claims for reimbursement to HRSA and record the associated revenues. If the HRSA program remains unfunded and we are unable to submit claims for reimbursement, there could be a material adverse effect on our business and financial condition.

 

37
 

 

At-the-Market Facility

 

On December 28, 2021, we entered into a Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”), pursuant to which we may offer and sell, from time to time through the Sales Agent, shares of our common stock having an aggregate offering price of up to $100,000,000, subject to the terms and conditions of the Sales Agreement. We are not obligated to make any sales of shares under the Sales Agreement.

 

We will pay the Sales Agent a fixed commission rate of 2.0% of the aggregate gross proceeds from the sale of any shares pursuant to the Sales Agreement and have agreed to provide the Sales Agent with customary indemnification and contribution rights. We also agreed to reimburse the actual out-of-pocket accountable expenses of the Sales Agent up to $60,000 (of which a $25,000 advance was paid on December 7, 2021).

 

Additionally, we will pay to H.C. Wainwright & Co. (“Wainwright”), a fee equal to 1.0% of the gross proceeds of the sales price of all the shares sold under the Sales Agreement, pursuant to a separate financial services agreement with Wainwright. Wainwright is not a sales agent under the Sales Agreement.

 

As of March 31, 2022, we have not sold any shares under the Sales Agreement.

 

Impact of Inflation

 

We are subject to normal inflationary trends and anticipate that any increased costs for our contract manufacturing and retail operations would be passed on to our customers; however, any increased costs related to diagnostic services would be absorbed by the Company. Inflation has not had a material effect on our business.

 

Critical Accounting Policies and Estimates

 

Our significant accounting policies are described in Note 2 of the Notes to Condensed Consolidated Financial Statements included under Item 8 of this Part II. However, certain accounting policies are deemed “critical”, as they require management’s highest degree of judgment, estimates and assumptions. These accounting policies, estimates and disclosures have been discussed with the Audit Committee of our Board of Directors. A discussion of our critical accounting policies and estimates, the judgments and uncertainties affecting their application and the likelihood that materially different amounts would be reported under different conditions or using different assumptions are as follows:

 

Use of Estimates

 

The preparation of condensed consolidated financial statements and the accompanying notes thereto, in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the estimation of the variable consideration associated with the diagnostic reimbursement rates, the provision for bad debt and billing discrepancies, sales returns and allowances, inventory obsolescence, useful lives of property and equipment, impairment of goodwill, intangibles and property and equipment, income tax valuations and assumptions related to accrued advertising. The estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the condensed consolidated financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

 

38
 

 

Revenue Recognition and Accounts Receivables

 

We generate revenue principally through four types of revenue streams: diagnostic services, contract manufacturing, genomic products and services, and retail and other. The process for estimating revenues and the ultimate collection of receivables involves assumptions and judgments.

 

Revenue from our diagnostic services is recognized when the lab test is complete, and the diagnostic test result is provided to the customer. Revenue from our genomics services is recognized when the sequencing report is provided to the customer. Revenue from our consumer products is recognized when the shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. We bill the providers at standard price and take into consideration for negotiated discounts and an anticipated reimbursement remittance adjustments based on the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that may vary from the standard price.

 

We carry our accounts receivable at cost less an allowance for doubtful accounts. Allowances for doubtful accounts are based upon our judgment regarding collectability. On a periodic basis, we evaluate our receivables and establish an allowance for doubtful accounts, based on a history of past write-offs, collections, current credit conditions or generally accepted future trends in the industry and/or local economy. Accounts are written off as uncollectible at the time we determine that collections are unlikely. The reserve is not intended to address return activity or disputed balances with ongoing customers, as this should be addressed in a reserve for credit memos with a corresponding charge to revenue.

 

Goodwill and Long-lived Assets

 

We review our goodwill at least annually for impairment as well as the carrying value of goodwill and our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be fully recoverable. When it is determined that the carrying amount of long-lived assets or goodwill is impaired, impairment is measured by comparing an asset’s estimated fair value to its carrying value. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; and industry competition, general economic and business conditions, among other factors.

 

Income Taxes

 

Accounting for income taxes requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities. These deferred taxes are measured by applying the provisions of tax laws in effect at the balance sheet date, including the impact of the Tax Cuts and Jobs Act (“TCJA”) enacted on December 22, 2017. The TCJA made broad and significant changes to the U.S. tax code that affects the year ended December 31, 2017, including, but not limited to, a change in the federal rate from 35% to 21% effective January 1, 2018.

 

We recognize in income the effect of a change in tax rates on deferred tax assets and liabilities in the period that includes the TCJA enactment date. We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total net current and non-current deferred tax asset is being provided.

 

39
 

 

Inventories

 

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (“FIFO”), or net realizable value. We regularly review inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on current and anticipated customer demand, production and laboratory requirements.

 

Recently Adopted Accounting Standards

 

The Financial Accounting Standards Board (“FASB”) recently issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The adoption of ASU 2020-06 did not have a material impact on our condensed consolidated financial statements or disclosures.

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 did not have a material impact on our condensed consolidated financial statements or disclosures.

 

Recently Issued Accounting Standards, Not Yet Adopted

 

In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for us for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.

 

40
 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Like virtually all commercial enterprises, we can be exposed to the risk (“market risk”) that the cash flows to be received or paid relating to certain financial instruments could change as a result of changes in interest rate, exchange rates, commodity prices, equity prices and other market changes.

 

Our operations are not subject to risks of material foreign currency fluctuations, nor do we use derivative financial instruments in our investment practices. We place our marketable investments in instruments that meet high credit quality standards. We do not expect material losses with respect to our investment portfolio or excessive exposure to market risks associated with interest rates. The impact on our results of one percentage point change in short-term interest rates would not have a material impact on our future earnings, fair value, or cash flows related to investments in cash equivalents or interest-earning marketable securities.

 

Current economic conditions may cause a decline in business and consumer spending which could adversely affect our business and financial performance including the collection of accounts receivables, notes receivable, realization of inventory and recoverability of assets. In addition, our business and financial performance may be adversely affected by current and future economic conditions, including a reduction in the availability of credit, financial market volatility and recession.

 

Except for the broad effects of COVID-19 including its negative impact on the global economy and major financial markets, there have been no material changes to our market risk exposures since December 31, 2021.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed with or submitted to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial and accounting officer, to allow timely decisions regarding required disclosure.

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2022. This evaluation was carried out under the supervision and with the participation of our principal executive officer and principal financial and accounting officer. Based on that review, our management, including our principal executive officer and principal financial and accounting officer, concluded that due to the material weakness described below, our disclosure controls and procedures were not effective at the reasonable assurance level as of March 31, 2022.

 

41
 

 

Material Weakness

 

In connection with our 2021 Annual Report, our management conducted an evaluation of the effectiveness of our system of internal control over financial reporting based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). Based upon that review, our management, including our principal executive officer and principal financial and accounting officer, concluded that the Company’s internal controls over financial reporting were not effective as of March 31, 2022, as a material weakness exists. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements could occur but will not be prevented or detected on a timely basis.

 

The material weakness that was identified relates to the lack of appropriate standard operating procedures and billing system controls associated with the diagnostic billing and revenue process, as well as the lack of contemporaneous assessments and associated documentation of the reimbursement receivables leading to additional allowance requirements.

 

Management is committed to remediating the material weakness. We have begun the process of implementing changes to our internal control over financial reporting to remediate the control deficiencies that gave rise to the material weakness, including further improvements in our processes, the current billing system and analyses that support the estimates associated with the allowances. Further, we expect to perform a comprehensive review of our billing standard operating procedures, training and resources in our billing and accounting functions.

 

We will not consider the material weakness remediated until the remedial controls operate for a sufficient period of time and we have concluded, through testing, that these controls are effectively designed and operating effectively. We will continue to assess throughout 2022.

 

Changes in Internal Control Over Financial Reporting

 

Except as described above, no change in internal control over financial reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.

 

Part II. Other Information

 

Item 1. Legal Proceedings.

 

From time to time, we have been and may again become involved in legal proceedings arising in the ordinary course of business. We are not presently a party to any material litigation.

 

42
 

 

Item 1A. Risk Factors.

 

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on Form 10-K filed with the SEC on March 31, 2022. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. 

As of the date of this Quarterly Report on Form 10-Q, except as described below, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on March 31, 2022. However, we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC. 

 

Our ability to achieve or sustain profitability depends on our collection of payment for the tests we deliver, which we may not be able to do successfully.

 

Our customer base for our COVID-19 tests is principally comprised of governmental bodies, municipalities, and large corporations who pay us directly or through third-party payors. In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted, providing for reimbursement to healthcare providers for COVID-19 tests provided to uninsured individuals, subject to continued available funding. Approximately 60 and 57% of our diagnostic services revenue for the three months ended March 31, 2022 and 2021, respectively was generated from this program for the uninsured. On March 22, 2022, the Health Resources & Services Administrations (“HRSA”) uninsured program stopped accepting claims for COVID-19 testing and treatment due to the lack of sufficient funds. Despite requests from the Acting Director of the Office of Management and Budget and the White House Coordinator for COVID-19 Response for additional emergency funding for the uninsured program, emergency funding has not been allocated to the HRSA uninsured program. We continue to perform testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize $4.3 million of revenues related to COVID-19 testing which was performed for uninsured individuals from March 23, 2022 through March 31, 2022. If funding for the HRSA program is reinstituted, we will submit eligible claims for reimbursement to HRSA and record the associated revenues. If the HRSA program remains unfunded and we are unable to submit claims for reimbursement, there could be a material adverse effect on our business and financial condition.

 

Further, healthcare policy changes that influence the way healthcare is financed or other changes in the market that impact payment rates by institutional or non-institutional customers could also affect our collection rates. If we are unable to convince customers of the value and benefit provided by our tests, these customers may slow, or stop altogether, their purchases of these tests. Our collection risks also include the potential for default or bankruptcy by the party responsible for payment and other risks associated with payment collection generally. Any inability to maintain our past payment collection levels could cause our revenue and ability to achieve profitability to decline and adversely affect our business, prospects and financial condition.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None

 

Item 4. Mine Safety Disclosures.

 

Not applicable

 

Item 5. Other Information.

 

None

 

Item 6. Exhibits

 

Exhibit No.   Description
     
31.1   Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2   Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1   Certification by the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2   Certification by the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101. INS#   Inline XBRL Instance Document
     
101.SCH#   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL#   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF#   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB#   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE#   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

43
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ProPhase Labs, Inc.
     
  By: /s/ Ted Karkus
    Ted Karkus
    Chairman of the Board and Chief Executive Officer (Principal Executive Officer)
Date: May 13, 2022    
  By: /s/ Monica Brady
    Monica Brady
   

Chief Financial Officer

(Principal Financial Officer)

Date: May 13, 2022    

 

44

EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, Ted Karkus, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;
   
2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) for the registrant and have:

 

  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 13, 2022

 

  By: /s/ Ted Karkus
    Ted Karkus
   

Chairman of the Board and Chief Executive

Officer (Principal Executive Officer)

 

 
EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, Monica Brady, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;
   
2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) for the registrant and have:
   
  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 13, 2022

 

  By: /s/ Monica Brady
    Monica Brady
   

Chief Financial Officer

(Principal Financial Officer)

 

 
EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ted Karkus, Chief Executive Officer of ProPhase Labs, Inc., a Delaware corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

  /s/ Ted Karkus
  Ted Karkus
 

Chairman of the Board and Chief Executive Officer

(Principal Executive Officer)

  May 13, 2022

 

 
EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Monica Brady, Chief Financial Officer of ProPhase Labs, Inc., a Delaware corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

  /s/ Monica Brady
  Monica Brady
 

Chief Financial Officer

(Principal Financial Officer)

May 13, 2022

 

 

 

EX-101.SCH 6 prph-20220331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Business Acquisition link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Goodwill and Acquired Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Unsecured Convertible Promissory Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Defined Contribution Plans link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Consulting Agreement and Secured Promissory Note Receivable link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Significant Customer Concentrations link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Business Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Goodwill and Acquired Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Summary of Components of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Accounts Receivable Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Disaggregation by Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Intangible Assets Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Business Acquisition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Goodwill and Acquired Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Property, Plant and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Unsecured Convertible Promissory Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Schedule of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Summary of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Defined Contribution Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Schedule of Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Schedule of Estimated Future Minimum Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Summary of Quantitative Information About Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Schedule of Maturity of Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Consulting Agreement and Secured Promissory Note Receivable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Significant Customer Concentrations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Schedule of Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation (Details) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - Related Parties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000070 - Disclosure - Subsequent Event (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 prph-20220331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 prph-20220331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 prph-20220331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Treasury Stock [Member] Sale of Stock [Axis] IPO [Member] Product and Service [Axis] Diagnostic Services [Member] Investment Type [Axis] Investment Shares [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Cooperative Incentive Promotion Costs [Member] Financial Instrument [Axis] U.S. Government Obligations [Member] Corporate Obligations [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Scenario [Axis] 0-12 Months [Member] 13-24 Months [Member] Over 24 Months [Member] Concentration Risk Benchmark [Axis] Contract Manufacturing [Member] Retail And Others [Member] Genomic Products and Services [Member] Business Acquisition [Axis] Nebula Acquisition [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Nebula Stock Purchase Agreement [Member] Credit Facility [Axis] CitiBankm, N.A. [Member] Title of Individual [Axis] Mr. Kamal Obbad [Member] Finite-Lived Intangible Assets by Major Class [Axis] Trade Names [Member] Intellectual Property [Member] Customer Relationships [Member] License [Member] Long-Lived Tangible Asset [Axis] Land [Member] Building Improvements [Member] Machinery and Equipment [Member] Equipment [Member] Computer Equipment [Member] Furniture and Fixtures [Member] Debt Instrument [Axis] September 2020 Notes [Member] Long-Term Debt, Type [Axis] Unsecured Debt [Member] Letter Agreement [Member] Share Repurchase Program [Axis] Share Repurchase Program [Member] Plan Name [Axis] 2020 Directors Equity Compensation Plan [Member] 2010 Directors Plan [Member] Amended 2010 Plan [Member] Two Thousand Ten Equity Compensation Plan [Member] Chief Executive Officer [Member] 2018 Stock Incentive Plan [Member] Award Type [Axis] CEO Options [Member] 2018 Stock Incentive Plan [Member] Stockholders [Member] Inducement Option Award [Member] Next Three Years [Member] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Plaza Medical Laboratory Corp [Member] Confucius Labs [Member] Geographic Distribution [Axis] Old Bridge New Jersey [Member] Final Months [Member] Balance Sheet Location [Axis] Operating Lease Liabilities [Member] Operating Lease Right Of Use Asset [Member] Related Party [Axis] Unrelated Third party [Member] Revision of Prior Period [Axis] Revision of Prior Period, Adjustment [Member] Secured Debt [Member] Termination Agreement [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Revenue Benchmark [Member] Customer [Axis] Diagnostic Services Clients One [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Diagnostic Services Clients Two [Member] Diagnostic Services Clients Three [Member] Trade Receivable [Member] Diagnostic Services Clients Four [Member] Segments [Axis] Consumer Products [Member] Unallocated Corporate [Member] Antidilutive Securities [Axis] Common Stock Purchase Warrants [Member] Jason Karkus [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Mr White [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Restricted cash Marketable debt securities, available for sale Marketable equity securities, at fair value Accounts receivable, net Inventory, net Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Prepaid expenses, net of current portion Right-of-use asset, net Intangible assets, net Goodwill Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable Accrued diagnostic services Accrued advertising and other allowances Lease liabilities Deferred revenue Income tax payable Other current liabilities Total current liabilities Non-current liabilities: Deferred revenue, net of current portion Deferred tax liability Note payable Unsecured convertible promissory notes, net Lease liabilities, net of current portion Total non-current liabilities Total liabilities COMMITMENTS AND CONTINGENCIES Stockholders’ equity Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding Common stock authorized 50,000,000, $0.0005 par value, 15,485,900 and 15,485,900 shares outstanding, respectively Additional paid-in capital Retained earnings Treasury stock, at cost, 17,018,846 and 16,818,846 shares, respectively Accumulated other comprehensive loss Total stockholders’ equity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, par value Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] Revenues, net Cost of revenues Gross profit Operating expenses: Diagnostic expenses General and administration Research and development Total operating expenses Income (loss) from operations Interest income, net Interest expense Change in fair value of investment securities Income from operations before income taxes Income tax expense Income from operations after income taxes Net income Other comprehensive loss: Unrealized gain (loss) on marketable debt securities Total comprehensive income Earnings per share: Basic Diluted Weighted average common shares outstanding: Basic Diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Issuance of common shares for debt conversion Issuance of common shares for debt conversion, shares Cash dividends Repurchases of common shares Repurchases of common share, shares Unrealized loss on marketable debt securities Stock-based compensation Net income Issuance of common stock and warrants for cash from public offering, net of $2,365 offering cost Issuance of common stock and warrants for cash from public offering, shares Issuance of common stock and warrants for cash from private offering Issuance of common stock and warrants for cash from private offering, shares Ending balance, value Ending balance, shares Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Public offering costs Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Realized loss on marketable debt securities Depreciation and amortization Amortization of debt discount Amortization on right-of-use assets Gain on sale of assets Stock-based compensation expense Change in fair value of investment securities Accounts receivable allowances Inventory valuation reserve Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid and other assets Other assets Accounts payable and accrued expenses Accrued diagnostic services Deferred revenue Deferred tax liability Lease liabilities Income tax payable Other liabilities Net cash provided by (used in) operating activities Cash flows from investing activities Issuance of secured promissory note receivable Purchase of marketable securities Proceeds from sale of marketable debt securities Proceeds from dispositions of property and other assets Capital expenditures Net cash provided by (used in) investing activities Cash flows from financing activities Proceeds from issuance of common stock from public offering, net Proceeds from issuance of common stock and warrants from private offering Repayment of note payable Repurchases of common shares Payment of dividends Net cash (used in) provided by financing activities Increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash, at the beginning of the period Cash, cash equivalents and restricted cash, at the end of the period Supplemental disclosures: Cash paid for income taxes Interest payment on the promissory notes Supplemental disclosure of non-cash investing and financing activities: Issuance of common shares for debt conversion Net unrealized gain (loss), investments in marketable debt securities Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Business Combination and Asset Acquisition [Abstract] Business Acquisition Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Acquired Intangible Assets Property, Plant and Equipment [Abstract] Property, Plant and Equipment Debt Disclosure [Abstract] Unsecured Convertible Promissory Notes Payable Equity [Abstract] Stockholders’ Equity Retirement Benefits [Abstract] Defined Contribution Plans Income Tax Disclosure [Abstract] Income Taxes Other Liabilities Disclosure [Abstract] Other Current Liabilities Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Leases Leases Consulting Agreement And Secured Promissory Note Receivable Consulting Agreement and Secured Promissory Note Receivable Risks and Uncertainties [Abstract] Significant Customer Concentrations Segment Reporting [Abstract] Segment Information Earnings Per Share [Abstract] Earnings Per Share Related Party Transactions [Abstract] Related Parties Subsequent Events [Abstract] Subsequent Event Basis of Presentation Segments Business and Liquidity Risks and Uncertainties Use of Estimates Cash and Cash Equivalents Restricted Cash Marketable Debt Securities Marketable Equity Securities Accounts Receivable, net Inventory, net Property, Plant and Equipment Concentration of Financial Risks Leases Goodwill and Intangible Assets Fair Value of Financial Instruments Revenue Recognition Advertising and Incentive Promotions Stock-Based Compensation Research and Development (“R&D”) Income Taxes Recently Issued Accounting Standards, Adopted Recently Issued Accounting Standards, Not Yet Adopted Summary of Components of Marketable Securities Schedule of Accounts Receivable Net Schedule of Components of Inventory Schedule of Fair Value of Financial Instruments Schedule of Deferred Revenue Schedule of Disaggregation by Revenue Schedule of Assets Acquired and Liabilities Assumed Schedule of Intangible Assets Acquisition Schedule of Intangible Assets Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets Schedule of Property, Plant and Equipment Schedule of Stock Options Activity Summary of Warrant Activity Schedule of Other Current Liabilities Schedule of Estimated Future Minimum Obligations Summary of Quantitative Information About Operating Leases Schedule of Maturity of Operating Leases Schedule of Segment Information Schedule of Basic and Diluted Net Loss Per Share Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Amortized Cost Unrealized Gains Unrealized Losses Fair Value Trade accounts receivable Unbilled accounts receivable  Accounts receivable, gross Less allowances Total accounts receivable Diagnostic services testing material Raw materials Work in process Finished goods Inventory Inventory valuation reserve Inventory, net Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Fair value of marketable debt securities Marketable equity securities Contract with Customer, Liability Schedule of Product Information [Table] Product Information [Line Items] Total revenue, net Percentage of revenue from diagnostic services Risks and Uncertainties in Entity's Business Net cash provided by (used in) operating activities Cash Equivalents, at Carrying Value Restricted Cash Investment owned, balance shares Investment owned, at fair value Fair value of investment securities Description of property plant and equipment useful lives Cash and cash equivalents and restricted cash balance Federal depository insurance Uninsured Breakage revenue Deferred Revenue [custom:ContractWithCustomerEstimatedLife] Advertising and incentive promotion expenses R&D costs incurred Short term investments Accounts receivable Inventory Prepaid and other current assets Definite-lived intangible assets Total assets acquired Accounts payable Accrued expenses and other current liabilities Deferred revenue Note payable Deferred tax liability Total liabilities assumed Net identifiable assets acquired Total consideration, net of cash acquired Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Cash acquired from acquisition Gross carying value Estimated useful life (in years) Payments for repurchase of common stock Business acquisition, purchase price Shares issued, price per share Purchase price Escrow termination date Stock options to purchase shares Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Business combination consideration Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items]  Total intangible assets, gross Finite-Lived Intangible Asset, Useful Life Less: accumulated amortization Total intangible assets, net Remaining periods ended December 31, 2022 Year ended December 31, 2023 Year ended December 31, 2024 Year ended December 31, 2025 Year ended December 31, 2026 Thereafter Amortization of Intangible Assets Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items]  Property, Plant and Equipment, Gross Property, Plant and Equipment, Useful Life Less: accumulated depreciation Total property, plant and equipment, net Depreciation Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Debt Instrument, Maturity Date Principal amount Shares issued Debt conversion price Cash Remaining principal amount Accrued interest Conversion amount Debt instrument periodic payment Debt Instrument, Interest Rate, Stated Percentage Debt Conversion, Description Convertible Debt Interest Expense, Other Number of Shares Options Outstanding - Beginning Weighted Average Exercise Price Options Outstanding - Beginning Weighted Average Remaining Contractual Life Total Intrinsic Value - Beginning Number of Shares, Forfeited Weighted Average Exercise Price, Forfeited Total Intrinsic Value - Forfeited Number of Shares Options Outstanding - Ending Weighted Average Exercise Price Options Outstanding - Ending Total Intrinsic Value - Ending Number of Shares Options Vested and Exercisable Weighted average exercise price, vested and exercisable Weighted Average Remaining Contractual Term, vested and exercisable Total Intrinsic Value, Options Vested and Exercisable Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of Shares Warrants Outstanding - Beginning Weighted Average Exercise Price Warrants Outstanding - Beginning Weighted Average Remaining Contractual Life Warrants Outstanding - Beginning Warrants granted Weighted Average Exercise Price, Warrants Granted Weighted Average Remaining Contractual Life Warrants granted Number of Shares Warrants Outstanding - Ending Weighted Average Exercise Price Warrants Outstanding - Ending Weighted Average Remaining Contractual Life Warrants Outstanding - Ending Number of Shares Warrants Vested and Exercisable Weighted Average Exercise Price, Warrants Vested and Exercisable Weighted Average Remaining Contractual Life Warrants Vested and Exercisable Class of Treasury Stock [Table] Equity, Class of Treasury Stock [Line Items] Common stock, dividends, per share, cash paid Payments of ordinary dividends, common stock Stock Repurchase Program, Remaining Authorized Repurchase Amount Share-based compensation number of authorized shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Common Stock, Capital Shares Reserved for Future Issuance Share-Based Payment Arrangement, Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Stock Issued During Period, Shares, Employee Stock Ownership Plan Share-based compensation arrangement by share-based payment award, options, grants in period, gross Share-based payment arrangement, option, exercise price range, upper range limit Share-based payment arrangement, option, exercise price range, lower range limit Share-based compensation arrangement by share-based payment award, accelerated vesting, number Business acquisition, share price Share-based compensation arrangement by share-based payment award, award vesting rights, percentage Share-based pyment arrangement, plan modification, incremental cost Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price Defined contributions Effective income tax rate Effective income tax rate, federal Effective income tax rate, state Income tax expense Accrued commissions Accrued payroll Accrued expenses Accrued returns Accrued benefits and vacation Accrued insurance reimbursement Total other current liabilities Remaining periods in 2022 2023 2024 2025 2026 Total Summary Of Quantitative Information About Operating Leases Operating leases Operating lease cost Operating lease expense Total rent expense Schedule Of Maturity Of Operating Leases Remaining Periods Ended December 31, 2022 Year Ended December 31, 2023 Year Ended December 31, 2024 Year Ended December 31, 2025 Year Ended December 31, 2026 Thereafter Total Less present value discount Operating lease liabilities Area of land Operating lease payments Lease term of contract Operating lease description Gradual rental rate increase percentage Operating lease, liability Operating lease, right-of-use asset Debt Instrument, Face Amount Test fees received Investment Owned, Balance, Shares Secured Debt Accounts Receivable, Credit Loss Expense (Reversal) Concentration Risk [Table] Concentration Risk [Line Items] Revenues Concentration risk, percentage Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Consolidated net revenue Consolidated cost of revenue Total Depreciation and amortization expense Operating and other expenses Total income from operations, after income taxes Total income from operations, before income taxes Total assets Net income - basic Interest on unsecured convertible promissory note Net income - diluted Weighted average shares outstanding - basic Diluted shares- Stock Options Diluted shares- Stock Warrants Unsecured convertible promissory note Weighted average shares outstanding - diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Annual base salary Subsequent Event [Table] Subsequent Event [Line Items] Share-based compensation arrangement Award vesting percentage Exercise price per share Special cash dividend Dividend payable Exercise price of option Exercise price of option Issuance of common stock and warrants for cash from private offering. Issuance of common Stock and warrants Offering cost. Issuance of common Stock and warrants shares. Issuance of common stock and warrants for cash from private offering shares. September 2020 Notes [Member] Corporate Obligations [Member] U.S. Government Obligations [Member] Inventory lab material. Over 24 Months [Member] 0-12 Months [Member] 13-24 Months [Member] Diagnostic Services [Member] Retail and Other [Member] Contract Manufacturing [Member] Marketable Securities [Member] Investment Shares [Member] Amended 2010 Plan [Member] Two Thousand Ten Equity Compensation Plan [Member] Two Thousand Eighteen Stock Incentive Plan [Member] Breakage revenue. 2018 Stock Incentive Plan [Member] Cooperative Incentive Promotion Costs [Member] Nebula acquisition [Member] Nebula Stock Purchase Agreement [Member] CitiBankm, N.A. [Member] Inducement Option Award [Member] Mr. Kamal Obbad [Member] Share based compensation Arrangement by share Based payment award options forfeited in Period intrinsic value. Tax cuts and jobs act [Member] Accrued return. Diagnostic expenses Change in fair value of investment securities Issuance of common shares for debt conversion Issuance of common shares for debt conversions Inventory valuation reserve Increase decrease in accrued diagnostic services Increase decrease in lease liabilities Agreement termination date. Incremental common shares attributable to warrants.to call options Incremental common shares attributable to warrants. Common Stock Purchase Warrants [Member] Plaza Medical Laboratory Corp [Member] Confucius Labs [Member] Old Bridge New Jersey [Member] Final Months [Member] Gradual rental rate increase percentage. Jason Karkus [Member] Stock option received. Operating Lease Liabilities [Member] Unrelated Third party [Member] Operating Lease Right Of Use Asset [Member] Consulting Agreement [Member] Test fees received. Diagnostic Services Clients One [Member] Diagnostic Services Clients Two [Member] Trade Receivable [Member] Diagnostic Services Clients Four [Member] Diagnostic Services Clients Three [Member] Business combination assets and liabilities short term investments Proceeds from maturities of marketable securities Proceeds from issuance of common stock and warrants from private offering Marketable Debt Securities [Policy Text Block] Recently Issued Accounting Standards Not Yet Adopted [Policy Text Block] 02/09/2022 Note [Member] Schedule Of Warrant Activity [Table Text Block] Genomic Products and Services [Member] Share Repurchase Program [Member] 2020 Directors Equity Compensation Plan [Member] 2010 Directors Plan [Member] CEO Options [Member] Stock Holders [Member] Restricted cash allowance Purchase Price Of Escrow Amount. Escrow Maturity Date. Assumed current liabilities accrued expenses and other current liabilities Assumed current liabilities note payable Sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1. Vested and exercisable weighted average exercise price Options outstanding weighted average remaining contractual term Operating loss carry forwards expiration dates description. Percentage for utilization of taxable income. Tax credit carryforward limitation amount. Tax credit carryforward remaining amount. Note receivable Interest on unsecured convertible promissory note Secured Promissory Note Receivable And Consulting Agreement [Text Block] Termination Agreement [Member] Operating and other expenses. Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price 1. Share based compensation arrangement by share based payment award non options outstanding granted weighted average exercise price 1. Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term 1. Share based compensation arrangement by share based payment award non options granted weighted average remaining contractual term. Share based compensation arrangement by share based payment award non options vested and exercisable weighted average remaining contractual term 2. Letter Agreement [Member] Next Three Years [Member] Accrued insuance reimbursement. 2018 Stock Incentive Plan [Member] [Default Label] Assets, Current Liabilities, Current Liabilities, Noncurrent Liabilities Treasury Stock, Value Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Dividends, Common Stock, Cash Stock Repurchased During Period, Value Stock Repurchased During Period, Shares Marketable Securities, Realized Gain (Loss) Gain (Loss) on Sale of Properties Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Other Noncurrent Assets IncreaseDecreaseInAccruedDiagnosticServices Increase (Decrease) in Deferred Revenue Increase (Decrease) in Deferred Income Taxes IncreaseDecreaseInLeaseLiabilities Increase (Decrease) in Income Taxes Payable IssuanceOfSecuredPromissoryNoteReceivable Payments to Acquire Marketable Securities Payments to Acquire Productive Assets Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Payments of Dividends Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations IssuanceOfCommonSharesForDebtConversion Lessee, Operating Leases [Text Block] Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Lessee, Leases [Policy Text Block] Income Tax, Policy [Policy Text Block] Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Accounts Receivable, before Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss Accounts Receivable, after Allowance for Credit Loss Inventory, Gross Inventory Valuation Reserves Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1 Contractual Obligation Operating Lease, Expense Lease, Cost Lessee, Operating Lease, Liability, to be Paid, after Year Five Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount EX-101.PRE 10 prph-20220331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
3 Months Ended
Mar. 31, 2022
May 13, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2022  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 000-21617  
Entity Registrant Name ProPhase Labs, Inc.  
Entity Central Index Key 0000868278  
Entity Tax Identification Number 23-2577138  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 711 Stewart Ave  
Entity Address, Address Line Two Suite 200  
Entity Address, City or Town Garden City  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 11530  
City Area Code (215)  
Local Phone Number 345-0919  
Title of 12(b) Security Common Stock, par value $0.0005  
Trading Symbol PRPH  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   15,485,900
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 25,807 $ 8,408
Restricted cash 250
Marketable debt securities, available for sale 3,543 8,779
Marketable equity securities, at fair value 76
Accounts receivable, net 36,694 37,708
Inventory, net 4,680 4,600
Prepaid expenses and other current assets 1,831 1,496
Total current assets 72,555 61,317
Property, plant and equipment, net 6,440 5,947
Prepaid expenses, net of current portion 251 460
Right-of-use asset, net 4,319 4,402
Intangible assets, net 10,143 10,852
Goodwill 5,709 5,709
Other assets 248 608
TOTAL ASSETS 99,665 89,295
Current liabilities    
Accounts payable 8,204 7,026
Accrued diagnostic services 1,012 1,890
Accrued advertising and other allowances 95 104
Lease liabilities 654 663
Deferred revenue 2,246 2,034
Income tax payable 4,285 1,312
Other current liabilities 3,274 2,495
Total current liabilities 19,770 15,524
Non-current liabilities:    
Deferred revenue, net of current portion 858 905
Deferred tax liability 443
Note payable 18 44
Unsecured convertible promissory notes, net 7,997 9,996
Lease liabilities, net of current portion 4,134 4,198
Total non-current liabilities 13,450 15,143
Total liabilities 33,220 30,667
COMMITMENTS AND CONTINGENCIES
Stockholders’ equity    
Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding
Common stock authorized 50,000,000, $0.0005 par value, 15,485,900 and 15,485,900 shares outstanding, respectively 16 16
Additional paid-in capital 105,634 104,552
Retained earnings 10,490 2,642
Treasury stock, at cost, 17,018,846 and 16,818,846 shares, respectively (49,557) (48,407)
Accumulated other comprehensive loss (138) (175)
Total stockholders’ equity 66,445 58,628
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 99,665 $ 89,295
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, par value $ 0.0005 $ 0.0005
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, shares authorized 50,000,000 50,000,000
Common stock, par value $ 0.0005 $ 0.0005
Common stock, shares outstanding 15,485,900 15,485,900
Treasury stock, shares 17,018,846 16,818,846
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenues, net $ 47,531,000 $ 15,271,000
Cost of revenues 18,854,000 6,344,000
Gross profit 28,677,000 8,927,000
Operating expenses:    
Diagnostic expenses 4,672,000 3,809,000
General and administration 7,824,000 3,782,000
Research and development 35,000 115,000
Total operating expenses 12,531,000 7,706,000
Income (loss) from operations 16,146,000 1,221,000
Interest income, net 73,000 87,000
Interest expense (233,000) (251,000)
Change in fair value of investment securities (76,000)
Income from operations before income taxes 15,910,000 1,057,000
Income tax expense (3,416,000)
Income from operations after income taxes 12,494,000 1,057,000
Net income 12,494,000 1,057,000
Other comprehensive loss:    
Unrealized gain (loss) on marketable debt securities 37,000 (11,000)
Total comprehensive income $ 12,531,000 $ 1,046,000
Earnings per share:    
Basic $ 0.81 $ 0.07
Diluted $ 0.68 $ 0.06
Weighted average common shares outstanding:    
Basic 15,486 14,563
Diluted 18,740 18,200
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 14 $ 61,674 $ (3,631) $ (11) $ (47,490) $ 10,556
Beginning balance, shares at Dec. 31, 2020 11,604,253          
Unrealized loss on marketable debt securities (11) (11)
Stock-based compensation 428 428
Net income 1,057 1,057
Issuance of common stock and warrants for cash from public offering, net of $2,365 offering cost $ 2 35,133 35,135
Issuance of common stock and warrants for cash from public offering, shares 3,000,000          
Issuance of common stock and warrants for cash from private offering 5,500 5,500
Issuance of common stock and warrants for cash from private offering, shares 550,000          
Ending balance, value at Mar. 31, 2021 $ 16 102,735 (2,574) (22) (47,490) 52,665
Ending balance, shares at Mar. 31, 2021 15,154,253          
Beginning balance, value at Dec. 31, 2021 $ 16 104,552 2,642 (175) (48,407) 58,628
Beginning balance, shares at Dec. 31, 2021 15,485,900          
Issuance of common shares for debt conversion 600 600
Issuance of common shares for debt conversion, shares 200,000          
Cash dividends (4,646) (4,646)
Repurchases of common shares (1,150) (1,150)
Repurchases of common share, shares (200,000)          
Unrealized loss on marketable debt securities 37 37
Stock-based compensation 482 482
Net income 12,494 12,494
Ending balance, value at Mar. 31, 2022 $ 16 $ 105,634 $ 10,490 $ (138) $ (49,557) $ 66,445
Ending balance, shares at Mar. 31, 2022 15,485,900          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
IPO [Member]  
Subsidiary, Sale of Stock [Line Items]  
Public offering costs $ 2,365
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Cash flows from operating activities      
Net income $ 12,494,000 $ 1,057,000  
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Realized loss on marketable debt securities 179,000 2,000  
Depreciation and amortization 1,249,000 536,000  
Amortization of debt discount 1,000 2,000  
Amortization on right-of-use assets 83,000 85,000  
Gain on sale of assets (23,000)  
Stock-based compensation expense 482,000 428,000  
Change in fair value of investment securities 76,000  
Accounts receivable allowances (924,000)  
Inventory valuation reserve 25,000  
Changes in operating assets and liabilities:      
Accounts receivable 1,938,000 (11,178,000)  
Inventory (105,000) (12,987,000)  
Prepaid and other assets (126,000) 2,243,000  
Other assets 360,000 (8,000)  
Accounts payable and accrued expenses 1,178,000 4,009,000  
Accrued diagnostic services (878,000)  
Deferred revenue 165,000  
Deferred tax liability 443,000  
Lease liabilities (73,000) 101,000  
Income tax payable 2,973,000  
Other liabilities 770,000 7,818,000  
Net cash provided by (used in) operating activities 20,287,000 (7,892,000)  
Cash flows from investing activities      
Issuance of secured promissory note receivable (1,000,000)  
Purchase of marketable securities (206,000) (2,005,000)  
Proceeds from sale of marketable debt securities 5,300,000 100,000  
Proceeds from dispositions of property and other assets 85,000  
Capital expenditures (1,095,000) (3,927,000)  
Net cash provided by (used in) investing activities 4,084,000 (6,832,000)  
Cash flows from financing activities      
Proceeds from issuance of common stock from public offering, net 35,135,000  
Proceeds from issuance of common stock and warrants from private offering 5,500,000  
Repayment of note payable (1,426,000)  
Repurchases of common shares (1,150,000)  
Payment of dividends (4,646,000)  
Net cash (used in) provided by financing activities (7,222,000) 40,635,000  
Increase in cash, cash equivalents and restricted cash 17,149,000 25,911,000  
Cash, cash equivalents and restricted cash, at the beginning of the period 8,658,000 6,816,000 $ 6,816,000
Cash, cash equivalents and restricted cash, at the end of the period 25,807,000 32,727,000 $ 8,658,000
Supplemental disclosures:      
Cash paid for income taxes  
Interest payment on the promissory notes 241,000 250,000  
Supplemental disclosure of non-cash investing and financing activities:      
Issuance of common shares for debt conversion 600,000  
Net unrealized gain (loss), investments in marketable debt securities $ 37,000 $ (11,000)  
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Business
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Business

Note 1 - Organization and Business

 

ProPhase Labs, Inc. (“ProPhase”, “we”, “us”, “our” or the “Company”) is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. We provide traditional CLIA molecular laboratory services, including SARS-CoV-2 (“COVID-19”) testing and seek to leverage our Clinical Laboratory Improvement Amendments (“CLIA”) accredited laboratory services to provide whole genome sequencing and research direct to consumers, while building a genomics database to be used for further research. In addition, we have deep experience with over-the-counter (“OTC”) consumer healthcare products and dietary supplements. We currently conduct our operations through two operating segments: diagnostic services and consumer products. Until late Fiscal 2020, we were engaged primarily in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. However, commencing in December 2020, we also began offering COVID-19 and other Respiratory Pathogen Panel (RPP) molecular tests through our diagnostic services business, and in August 2021 we began offering personal genomics products and services.

 

Our wholly owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (“PCR”) testing for COVID-19. Critical to COVID-19 testing, we provide fast turnaround times for results. We also offer rapid antigen and antibody/immunity testing for COVID-19. On October 23, 2020, we acquired Confucius Plaza Medical Laboratory Corp. (“CPM”), which included a non-operating but certified 4,000 square foot CLIA accredited laboratory located in Old Bridge, New Jersey. In December 2020, we expanded our diagnostic service business with the build-out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in January 2021.

 

On August 10, 2021, we acquired Nebula Genomics, Inc. (“Nebula”), a privately owned personal genomics company, through our new wholly owned subsidiary, ProPhase Precision Medicine, Inc. (“ProPhase Precision”) (see Note 3, Business Acquisitions). ProPhase Precision focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

 

Our wholly owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.

 

We also develop and market dietary supplements under the TK Supplements® brand.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and other comprehensive loss and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of operating results that may be achieved over the course of the full year.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Segments

 

In accordance with FASB ASC 280, “Segment Reporting” (“ASC 280”), the Company discloses financial and descriptive information about its reportable operating segments.

 

ASC 280 establishes standards for reporting information about operating segments in annual and interim financial statements and requires that companies report financial and descriptive information about their reportable segments based on a management approach. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and major customers.

 

Operating segments are defined as components of an enterprise that engage in business activities for which separate financial information is available and is evaluated by the Chief Operating Decision Maker (“CODM”), which for the Company is its Chief Executive Officer, in deciding how to allocate resources and assess performance. We maintain two operating segments: diagnostic services (which includes our COVID-19 and other diagnostic testing services) and consumer products (which includes our contract manufacturing, retail customers and personal genomics products and services) (see Note 15 Segment Information).

 

Business and Liquidity Risks and Uncertainties

 

We launched our diagnostic service business in December 2020 and expanded in January 2021 with the opening of our Garden City, New York CLIA accredited laboratory. Our diagnostic service business is and will continue to be influenced by the level of demand for COVID-19 and other diagnostic testing, how long this demand persists, the prices we are able to receive for performing our testing services, our ability to collect payment or reimbursement for our testing services, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.

 

While our revenues increased significantly for the year ended December 31, 2021 and the first quarter of fiscal 2022 as a result of the launch of our diagnostic services business, we will continue to be dependent on both government agency and insurance company reimbursement as well as the prevalence of COVID-19 associated strains.

 

In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), was enacted, providing for reimbursement to healthcare providers for COVID-19 tests provided to uninsured individuals, subject to continued available funding. Approximately 69% and 57% of our diagnostic services revenue for the three months ended March 31, 2022 and 2021, respectively was generated from this program for the uninsured. On March 22, 2022, the Health Resources & Services Administration (HRSA) program stopped accepting claims for COVID-19 testing and treatment due to lack of sufficient funds. Despite requests from the Acting Director of the Office of Management and Budget and the White House Coordinator for COVID-19 Response for additional emergency funding for the uninsured program, emergency funding has not been allocated to the HRSA uninsured program as of the financial statement issuance date. We continue to perform testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize any revenue related to COVID-19 testing that we performed for uninsured individuals from March 23, 2022 through March 31, 2022. If funding for the HRSA program is reinstituted in the future, we will submit eligible claims for reimbursement to HRSA and record the associated revenues. If the HRSA program remains unfunded and we are unable to submit claims for reimbursement, there could be a material adverse effect on our business and financial condition.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

In addition, our diagnostic service business is subject to extensive federal, state, and local laws and regulations, all of which are subject to change, as well as laws and regulations governing the submission of claims for payment for our services, such as those relating to: coverage of our services under Medicare, Medicaid and other federal health care programs; the amounts that we may bill for our services; and the party to which we must submit claims. Also, reimbursement policies and requirements for some payers and procedures are ambiguous, which could lead to billing errors and related disputes. There can be no assurance that our efforts to offer and perform COVID-19 or other diagnostic testing will be successful in the future or that the revenue and operating profits from such business will increase or maintain their current level.

 

We acquired and commenced our personal genomics business in August 2021. This business is and will continue to be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.

 

Our consumer sales are and will continue to be influenced by (i) the timing of acceptance of our TK Supplements® consumer products in the marketplace, and (ii) fluctuations in the timing of purchase and the ultimate level of demand for the OTC healthcare and cold remedy products that we manufacture, which is largely a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period from September to March when the incidence of the common cold rises as a result of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net revenues from our contract manufacturing business. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.

 

For the three months ended March 31, 2022, $20.3 million was provided by operating activities. The Company had cash, cash equivalents and marketable securities of $29.4 million as of March 31, 2022. Based on management’s current business plans, the Company estimates it will have enough cash and liquidity to finance its operating requirements for at least 12 months from the date of filing these unaudited condensed consolidated financial statements. However, due to the nature of the diagnostic business and the Company’s focus thus far on COVID-19 testing, there are inherent uncertainties associated with managements’ business plan and cash flow projections, particularly if the Company is unable to grow its diagnostic testing business beyond COVID-19 testing services.

 

The Company’s future capital needs and the adequacy of its available funds will depend on the Company’s ability to achieve sustained profitability from its diagnostic services, the Company’s ability to successfully diversify its diagnostic services revenue streams and the Company’s ability to market and grow its personal genomics business. The Company may be required to raise additional funds through equity or debt securities offerings or strategic collaboration and/or licensing agreements in order to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Company’s failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition.

 

Use of Estimates

 

The preparation of condensed consolidated financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration of diagnostic test reimbursement rates, the provision for uncollectible receivables and billing errors, allowances, slow moving and/or dated inventory and associated provisions, the potential impairment of long-lived assets, stock based compensation valuations, income tax asset valuations and assumptions related to accrued advertising.

 

Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the condensed consolidated financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these securities.

 

Restricted Cash

 

Restricted cash as of December 31, 2021 includes approximately $250,000 held in escrow related to a potential purchase of an additional lab facility. The potential purchase was not consummated, and we are pursuing the return of the escrow, which is in dispute. As of March 31, 2022, we recognized an expense for this balance as the recovery of the funds was no longer considered probable.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Marketable Debt Securities

 

We have classified our investments in marketable debt securities as available-for-sale and as a current asset. Our investments in marketable debt securities are carried at fair value, with unrealized gains and as a separate component of stockholders’ equity. Realized gains and losses from our marketable debt securities are recorded as interest income (expense). These investments in marketable debt securities carry maturity dates between one and three years from date of purchase.

 

The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (in thousands) (see fair value of financial instruments):

 

   As of March 31, 2022 
   Amortized   Unrealized   Unrealized   Fair 
   Cost   Gains   Losses   Value 
U.S. government obligations  $667   $123   $(44)  $746 
Corporate obligations   2,839    -    (42)   2,797 
   $3,506   $123   $(86)  $3,543 

 

   As of December 31, 2021 
   Amortized   Unrealized   Unrealized   Fair 
   Cost   Gains   Losses   Value 
U.S. government obligations  $650   $17   $-   $667 
Corporate obligations   8,304    -    (192)   8,112 
   $8,954   $17   $(192)  $8,779 

 

Marketable Equity Securities

 

Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within other non-operating income, net in the consolidated statements of income.

 

On June 25, 2021, we were issued 1,260,619 common shares (the “Investment Shares”) as an interest payment under our note receivable (see Note 13, Consulting Agreement and Secured Promissory Note Receivable) with a fair value of $315,000 at the time of issuance and a fair value of $76,000 at December 31, 2021. The investment was classified as a Level 1 financial instrument. We recorded a $76,000 decrease in fair value of investment securities within the statement of operations for the three months ended March 31, 2022.

 

Accounts Receivable, net

 

Accounts receivable consists primarily of amounts due from government agencies and healthcare insurers. Unbilled accounts receivable relates to the delivery of our diagnostic testing services for which the related billings will occur in a future period, after a patient’s insurance information has been validated, and represent amounts for which we have a right to receive payment. Unbilled accounts receivable is classified as accounts receivable on the consolidated balance sheet. We carry our accounts receivable at the amount of consideration for which we expect to be entitled less allowances. When estimating the allowances for our diagnostics business, the Company pools its receivables based on the following payer types: healthcare insurers and government payers. The Company principally estimates the allowances by pool based on historical collection experience, current economic conditions, government and healthcare insurer payment trends, and the period of time that the receivables have been outstanding. Should a payer’s reimbursement policy change or their credit quality deteriorate, the Company removes the payer from their respective pools and establishes allowances based on the individual risk characteristics of such payer.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands):

 

   March 31, 2022   December 31, 2021 
Trade accounts receivable  $24,727   $18,520 
Unbilled accounts receivable   14,944    23,089 
 Accounts receivable, gross   39,671    41,609 
Less allowances   (2,977)   (3,901)
Total accounts receivable  $36,694   $37,708 

 

Inventory, net

 

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (“FIFO”), or net realizable value. Inventory items are analyzed to determine cost and the net realizable value and appropriate valuation adjustments are established.

 

At March 31, 2022 and December 31, 2021, the components of inventory are as follows (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Diagnostic services testing material  $3,103   $2,989 
Raw materials   1,238    1,514 
Work in process   476    260 
Finished goods   322    272 
Inventory  $5,139   $5,035 
Inventory valuation reserve   (459)   (435)
Inventory, net  $4,680   $4,600 

 

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years.

 

Concentration of Financial Risks

 

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.

 

We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2022, our cash and cash equivalents and restricted cash balance was $25.8 million. Of the total bank balance, $0.9 million was covered by federal depository insurance and $24.9 million was uninsured at March 31, 2022.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection rates. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depends on information provided to the payors and meeting their requirements for reimbursement.

 

Leases

 

At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. We have elected not to recognize on the balance sheet leases with terms of 12 months or less. We typically only include an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in our assessment unless there is reasonable certainty that we will renew.

 

Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in our leases is typically not readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 12, Leases).

 

The components of a lease should be allocated between lease components (e.g., land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.

 

Goodwill and Intangible Assets

 

Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying identifiable assets and liabilities acquired in a business combination. Goodwill and intangible assets deemed to have an indefinite life are not amortized, but instead are assessed for impairment annually. Additionally, if an event or change in circumstances occurs that would more likely than not reduce the fair value of the reporting unit below its carrying value, we would evaluate goodwill at that time.

 

In testing for goodwill impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, we conclude that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If we conclude otherwise, we are required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than the carrying value, an impairment charge will be recorded to reduce the reporting unit to fair value.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Intangible assets deemed to have finite lives are amortized on a straight-line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to our future cash flows.

 

Fair Value of Financial Instruments

 

We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
     
  Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
     
  Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, and unsecured note payable, approximate their fair values because of the short-term nature of these instruments.

 

We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity securities change in fair value reported on the condensed consolidated statement of operations. The components of marketable securities are as follows (in thousands):

 

   As of March 31, 2022 
   Level 1   Level 2   Level 3   Total 
U.S. government obligations  $-   $746   $-   $746 
Corporate obligations   -    2,797    -    2,797 
   $-   $3,543   $-   $3,543 

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

   As of December 31, 2021 
   Level 1   Level 2   Level 3   Total 
U.S. government obligations  $-   $667   $-   $667 
Corporate obligations   -    8,112    -    8,112 
Marketable equity securities   76    -    -    76 
   $76   $8,779   $-   $8,855 

 

There were no transfers of marketable debt securities between Levels 1, 2 or 3 for the three months ended March 31, 2022 and 2021.

 

Revenue Recognition

 

We recognize revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. We recognize revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

Contract with Customers and Performance Obligations

 

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Sales from product shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. Revenue from diagnostic services is recognized when the results are made available to the customer. Revenue from our personal genomics business is recognized when the genetic testing results are provided to the customer. For subscription services associated with our genomic testing, we recognize revenue ratably over the term of the subscription.

 

Transaction Price

 

For contract manufacturing and retail customers, the transaction price is fixed based upon either (i) the terms of a combined master agreement and each related purchase order, or (ii) if there is no master agreement, the price per individual purchase order received from each customer. The customers are invoiced at an agreed upon contractual price for each unit ordered and delivered by the Company.

 

Revenue from retail customers is reduced for trade promotions, estimated sales returns and other allowances in the same period as the related sales are recorded. No such allowance is applicable to our contract manufacturing customers. We estimate potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

We do not accept returns from our contract manufacturing customers. Our return policy for retail customers accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time during which product may be returned. All requests for product returns must be submitted to us for pre-approval. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will accept return requests only for products in their intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed.

 

For our diagnostic services business, a revenue transaction is initiated when we receive a requisition order to perform a diagnostic test. The information provided on the requisition form is used to determine the party that will be billed for the testing performed and the expected reimbursement. We provide diagnostic services to a range of customers. In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or Medicaid program and other government reimbursement programs. We bill the providers at standard price and take into consideration negotiated discounts and anticipated reimbursement remittance adjustments based on the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that vary from the listed contract price.

 

For our personal genomics business, a revenue transaction is initiated by a DNA test kit sale direct to the consumer sales via our website or through online retailers. The kit sales and subscriptions are billed at a standard price and take into consideration any discounts when revenue is recorded.

 

Recognize Revenue When the Company Satisfies a Performance Obligation

 

Recognition for contract manufacturing and retail customers is satisfied at a point in time when the goods are shipped to the customer as (i) we have transferred control of the assets to the customers upon shipping, and (ii) the customer obtains title and assumes the risks and rewards of ownership after the goods are shipped.

 

For diagnostic services, recognition occurs at the point in time that the results are made available to the customer, which is when the customer benefits from the information contained in the results and obtains control.

 

For genomic services, we satisfy our product performance obligation at a point in time when the genetic testing results are provided to the customer. For subscriptions services associated with its genomic testing, we satisfy our performance obligation ratably over the subscription period. If the customer does not return the test kit, services cannot be completed by us, potentially resulting in unexercised rights (“breakage”) revenue, including lifetime subscription services. We estimate breakage for the portion of test kits not expected to be returned using an analysis of historical data and consider other factors that could influence customer test kit return behavior. When breakage revenue is recognized on a kit, we recognize breakage on any associated subscription services ratably over the term of the subscription. The Company recognized breakage revenue from aggregate unreturned test kits and subscriptions of $0.4 million for the three months ended March 31, 2022.

 

Contract Balances

 

Deferred revenues primarily consist of amounts that have been billed to or received from customers in advance of revenue recognition and prepayments received from customers in advance of services performed for the R&D work. As of March 31, 2022 and December 31, 2021, we have deferred revenue of $3.1 million and $2.9 million, respectively. Our new personal genomics business comprised $2.9 million of the deferred revenue as of March 31, 2022. The deferred revenue balance within the personal genomics business is comprised of kits to be sequenced and subscription services, which have an average life between 12 and 36 months. The remainder of deferred revenue relates to research and development (“R&D”) stability and release testing programs recognized as contract manufacturing revenue.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table disaggregates our deferred revenue by recognition period (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Recognition Period          
0-12 Months  $2,246   $2,034 
13-24 Months   598    530 
Over 24 Months   260    375 
Total  $3,104   $2,939 

 

Disaggregation of Revenue

 

We disaggregate revenue from contracts with customers into four categories: diagnostic services, contract manufacturing, retail and others, and genomic products and services. We determined that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

The following table disaggregates the Company’s revenue by revenue source for the three months ended March 31, 2022 and 2021 (in thousands):

 

   For the three months ended 
Revenue by Customer Type  March 31, 2022   March 31, 2021 
Diagnostic services  $44,913   $12,738 
Contract manufacturing   1,154    1,908 
Retail and others   546    625 
Genomic products and services   918    - 
Total revenue, net  $47,531   $15,271 

 

Customer Consideration

 

The Company makes payments to certain diagnostic services customers for distinct services that approximate the fair value for those services. Such services include specimen collection, the collection and delivery of insurance and patient information necessary for billing and collection, and logistics services. Consideration associated with specimen collection services is classified in cost of revenues and the remaining costs are classified as diagnostic expenses within operating expenses in the accompanying statement of operations.

 

Sales Tax Exclusion from the Transaction Price

 

We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from the customer.

 

Shipping and Handling Activities

 

We account for shipping and handling activities that we perform as activities to fulfill the promise to transfer the good.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Advertising and Incentive Promotions

 

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of general and administrative expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net revenue, and (iii) free product, which is accounted for as part of cost of revenues. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2022 and 2021 were $60,000 and $168,000, respectively.

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation in accordance with FASB ASC 718, “Compensation - Stock Compensation.” Under the fair value recognition provision of the ASC, stock-based compensation cost is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options and warrants granted using the Black-Scholes-Merton option pricing model and stock grants at their closing reported market value. We recognize all stock-based payments to employees and directors, including grants of stock options, as compensation expense in the condensed consolidated financial statements based on their grant date fair values. The grant date fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. We account for forfeitures as they occur.

 

Stock and stock options to purchase our common stock have been granted to employees pursuant to the terms of certain agreements and stock option plans (see Note 7, Stockholders’ Equity). Stock options are exercisable during a period determined by us, but in no event later than seven years from the date granted.

 

Research and Development (“R&D”)

 

R&D costs are charged to operations in the period incurred. R&D costs incurred for the three months ended March 31, 2022 and 2021 were $35,000 and $115,000, respectively. R&D costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products, dietary supplements and validation costs in association with the diagnostic services business.

 

Income Taxes

 

The Company recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse.

 

The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. We evaluate, on a quarterly basis whether, based on all available evidence, it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740- 10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused.

 

The Company accounts for uncertainties in income taxes under the provisions of FASB ASC 740-10-05 (the “Subtopic”). The Subtopic clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The Subtopic prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Subtopic provides guidance on the de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Recently Issued Accounting Standards, Adopted

 

The Financial Accounting Standards Board (“FASB”) recently issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The adoption of ASU 2020-06 did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.

 

Recently Issued Accounting Standards, Not Yet Adopted

 

In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Business Acquisition
3 Months Ended
Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Business Acquisition

Note 3 - Business Acquisition

 

Nebula Acquisition

 

On August 10, 2021 (the “Effective Date”), the Company and its wholly owned subsidiary, ProPhase Precision, entered into and closed a Stock Purchase Agreement (the “Nebula Stock Purchase Agreement”) with Nebula, each of the stockholders of Nebula (the “Seller Parties”), and Kamal Obbad, as Seller Party Representative. Pursuant to the terms of the Nebula Stock Purchase Agreement, ProPhase Precision acquired all of the issued and outstanding shares of common stock of Nebula from the Seller Parties, for an aggregate purchase price of approximately $14.3 million, subject to post-closing adjustments (the “Nebula Acquisition”). A portion of the purchase price equal to $3.6 million was paid in shares of the Company’s common stock to certain Seller Parties and noteholders of Nebula, based on their election to receive shares of the Company’s common stock in lieu of cash, which shares were valued at a price per share of $7.46, which is equal to the average closing price of the Company’s common stock on Nasdaq for the five trading days preceding the signing of the Nebula Stock Purchase Agreement. A portion of the purchase price equal to $1,080,000 (the “Escrow Amount”) is being held in escrow by Citibank, N.A. (the “Escrow Agent”) until February 23, 2023 (“Escrow Termination Date”), pursuant to the terms and conditions of an escrow agreement entered into with the Escrow Agent, as security for the indemnification obligations of the Seller Parties. At the Escrow Termination Date, the remaining amount, if any, of the Escrow Amount, less any amount reasonably necessary to pay any claim with respect to which a notice of claim has been timely and properly given, will be delivered to the Seller Parties, as applicable.

 

In connection with the Nebula Acquisition, ProPhase Precision entered into an employment agreement with Kamal Obbad, the Chief Executive Officer of Nebula, on the Effective Date, pursuant to which Mr. Obbad serves as Senior Vice President, Director of Sales and Marketing of ProPhase Precision. As a condition to the employment agreement, Mr. Obbad was awarded a stock option to purchase 250,000 shares of Company common stock at an exercise price equal to $7.67 per share, the closing price of the Company common stock on the Effective Date (see Note 7, Stockholders’ Equity).

 

Based on the valuation, the total consideration of $12.7 million, which is net of $1.6 million in cash acquired, has been allocated to assets acquired and liabilities assumed based on their respective fair values as follows (in thousands):

 

Account  Amount 
Short term investments  $1,800 
Accounts receivable   171 
Inventory   133 
Prepaid and other current assets   379 
Definite-lived intangible assets   10,990 
Total assets acquired   13,473 
Accounts payable   (805)
Accrued expenses and other current liabilities   (43)
Deferred revenue   (2,391)
Note payable   (81)
Deferred tax liability   (1,925)
Total liabilities assumed   (5,245)
Net identifiable assets acquired   8,228 
Goodwill   4,446 
Total consideration, net of cash acquired (1)  $12,674 

 

(1) Net of $1.6 million cash acquired.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired. The Company believes the goodwill related to the acquisition was a result of the expected synergies to be realized from combining operations and is not deductible for income tax purposes. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.

 

The intangible assets identified in conjunction with the Nebula Acquisition are as follows (in thousands):

 

   Gross Carrying Value   Estimated Useful Life (in years) 
Trade names  $5,550    15 
Proprietary intellectual property   4,260    5 
Customer relationships   1,180    1 
Total  $10,990      

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Acquired Intangible Assets
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Acquired Intangible Assets

Note 4 – Goodwill and Acquired Intangible Assets

 

Goodwill

 

There were no changes in goodwill for the three months ended March 31, 2022.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Intangible Assets, Net

 

Intangible assets as of March 31, 2022 and December 31, 2021 consisted of the following (in thousands):

 

  

March 31,

2022

  

December 31,

2021

  

Estimated Useful

Life (in years)

Trade names  $5,550   $5,550   15
Proprietary intellectual property   4,260    4,260   5
Customer relationships   1,180    1,180   1
CLIA license   1,307    1,307   3
 Total intangible assets, gross   12,297    12,297    
Less: accumulated amortization   (2,154)   (1,445)   
Total intangible assets, net  $10,143   $10,852    

 

Amortization expense for acquired intangible assets was $709,000 and $109,000 during the three months ended March 31, 2022 and 2021, respectively. The estimated future amortization expense of acquired intangible assets as of March 31, 2022 is as follows (in thousands):

 

      
Remaining periods ended December 31, 2022  $1,669 
Year ended December 31, 2023   1,585 
Year ended December 31, 2024   1,222 
Year ended December 31, 2025   1,222 
Year ended December 31, 2026   890 
Thereafter   3,555 
 Total intangible assets, net  $10,143 

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant and Equipment
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment

Note 5 - Property, Plant and Equipment

 

The components of property, plant and equipment are as follows (in thousands):

 

  

March 31,

2022

  

December 31,

2021

   Estimated Useful Life
Land  $352   $352    
Building improvements   1,729    1,729   10-39 years
Machinery   4,740    4,740   3-7 years
Lab equipment   4,936    4,330   3-7 years
Computer equipment   1,589    1,211   3-5 years
Furniture and fixtures   468    468   5 years
 Property, Plant and Equipment, Gross   13,814    12,830    
Less: accumulated depreciation   (7,374)   (6,883)   
Total property, plant and equipment, net  $6,440   $5,947    

 

Depreciation expense incurred for the three months ended March 31, 2022 and 2021 was $491,000 and $428,000, respectively.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Unsecured Convertible Promissory Notes Payable
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Unsecured Convertible Promissory Notes Payable

Note 6 -Unsecured Convertible Promissory Notes Payable

 

On September 15, 2020, we issued two unsecured, partially convertible, promissory notes (the “September 2020 Notes”) for an aggregate principal amount of $10 million to two investors (collectively, the “Lenders”).

 

On February 28, 2022, we entered into a letter agreement (the “Letter Agreement”) with one of the Lenders providing for the payoff of its September 2020 Note in the principal amount of $2,000,000.

 

Pursuant to the terms of the Letter Agreement, (i) the Lender converted $600,000 of the principal amount due to him under his September 2020 Note into 200,000 shares of Company common stock (the “Conversion Shares”) at a price of $3.00 per share as provided for under the terms of the September 2020 Note (the “Conversion”), (ii) the Company paid to the Lender $1,440,548 in cash, representing $1,400,000 of the remaining principal under the September 2020 Note following the Conversion plus $40,548 in accrued and outstanding interest under the September 2020 Note, and (iii) the Company repurchased the Conversion Shares at a price of $5.75 per share for an aggregate amount of $1,150,000 (for a total aggregate payment to the Lender of $2,590,548).

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The September 2020 Note that remains outstanding as of March 31, 2022 is due and payable on September 15, 2023 and accrues interest at a rate of 10% per year from the closing date, payable on a quarterly basis, until the September 2020 Note is repaid in full. We have the right to prepay the outstanding September 2020 Note at any time after the 13-month anniversary of the initial issuance date after providing written notice to the Lender and may prepay the September 2020 Note prior to such time with the consent of the Lender. The Lender has the right, at any time, and from time to time, on and after the 13-month anniversary of the initial issuance date to convert up to an aggregate of $3.0 million of the September 2020 Note into common stock of the Company at a conversion price of $3.00 per share. Repayment of the September 2020 Note has been guaranteed by our wholly owned subsidiary, PMI.

 

The September 2020 Note contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the September 2020 Note may be accelerated. The September 2020 Note also contain certain restrictive covenants which, among other things, restrict our ability to create, incur, assume or permit to exist, directly or indirectly, any lien (other than certain permitted liens described in the September 2020 Note) securing any indebtedness of the Company, and prohibits us from distributing or reinvesting the proceeds from any divestment of assets (other than in the ordinary course) without the prior approval of the Lender.

 

For the three months ended March 31, 2022 and 2021, we incurred $233,000 and $251,000, respectively, in interest expense related to the September 2020 Notes.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Stockholders’ Equity

Note 7 - Stockholders’ Equity

 

Our authorized capital stock consists of 50 million shares of common stock, $0.0005 par value, and one million shares of preferred stock, $0.0005 par value.

 

Preferred Stock

 

The preferred stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of March 31, 2022 and December 31, 2021, no shares of preferred stock have been issued.

 

Common Stock Dividends

 

On February 14, 2022, the board of directors of the Company declared a special cash dividend of $0.30 per share on the Company’s common stock, paid on March 10, 2022, in the amount of $4.6 million to holders of record of the Company’s common stock on March 1, 2022.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Common Stock

 

Stock Repurchase Program

 

On September 8, 2021, the board of directors (the “Board”) approved a stock repurchase program under which the Company was authorized to repurchase up to $6.0 million of its outstanding shares of common stock from time to time, over a six-month period.

 

During the three months ended March 31, 2022, the Company did not make any common shares repurchase under the stock repurchase program. The stock repurchase program expired on March 30, 2022.

 

The 2010 Directors’ Equity Compensation Plan

 

On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Directors’ Equity Compensation Plan (the “Amended 2010 Directors’ Plan”) at the 2021 Annual Meeting of Stockholders of the Company (the “2021 Annual Meeting”). The Amended 2010 Directors’ Plan authorizes the issuance of up to 775,000 shares of common stock.

 

At March 31, 2022, there were 425,126 stock options outstanding and there were no shares of common stock available to be issued under the Amended 2010 Directors’ Plan.

 

The 2010 Equity Compensation Plan

 

On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Equity Compensation Plan (the “Amended 2010 Plan”) at the 2021 Annual Meeting. The Amended 2010 Plan authorizes the issuance of up to 4,900,000 shares of common stock.

 

As of December 31, 2021 and March 31, 2022, there were 2,014,874 stock options outstanding and 295,785 stock options available to be issued under the 2010 Plan. We will recognize an aggregate of approximately $1,684,000 of remaining share-based compensation expense related to outstanding stock options over a weighted average period of 2.8 years.

 

The 2018 Stock Incentive Plan

 

On April 12, 2018, our stockholders approved the 2018 Stock Incentive Plan (the “2018 Stock Plan”). The 2018 Stock Plan provides for the grant of incentive stock options to eligible employees of the Company, and for the grant of non-statutory stock options to eligible employees, directors and consultants. The 2018 Stock Plan provides that the total number of shares that may be issued pursuant to the 2018 Stock Plan is 2,300,000 shares. At April 12, 2018, all 2,300,000 shares have been granted in the form of stock options to Ted Karkus (the “CEO Option”), our Chief Executive Officer. To date, no stock options have been exercised under the 2018 Stock Plan. No share based compensation expense will be recognized in forward periods related to the 2018 Stock Plan.

 

The 2018 Stock Plan requires certain proportionate adjustments to be made to the stock options granted under the 2018 Stock Plan upon the occurrence of certain events, including a special distribution (whether in the form of cash, shares, other securities, or other property) in order to maintain parity. Accordingly, the Compensation Committee of the board of directors, as required by the terms of the 2018 Stock Plan, adjusted the terms of the CEO Option, such that the exercise price of the CEO Option was reduced from $3.00 per share to $2.00 per share, effective as of September 5, 2018, the date the special $1.00 special cash dividend was paid to stockholders. The exercise price of the CEO Option was further reduced from $2.00 to $1.75 per share, effective as of January 24, 2019, the date the $0.25 special cash dividend was paid to stockholders. The exercise price of the CEO Option was further reduced from $1.75 to $1.50 per share, effective as of December 12, 2019, the date another $0.25 special cash dividend was paid to stockholders. The exercise price of the CEO Option was further reduced from $1.50 to $1.20 per share, effective as of June 3, 2021, the date another $0.30 special cash dividend was paid to Company’s stockholders. The exercise price of the CEO Option was further reduced from $1.20 to $0.90 per share, effective as of March 10, 2022, the date another $0.30 special cash dividend was paid to Company’s stockholders.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Inducement Option Award

 

As part of Nebula Acquisition, the Company issued a non-qualified stock option to Kamal Obbad, the Chief Executive Officer of Nebula, as an inducement to his employment with the Company (the “Inducement Award”). The Inducement Award entitles Mr. Obbad to purchase up to 250,000 shares of the Company’s common stock at an exercise price of $7.67 per share, the closing price of the Company’s common stock on the closing date of the Nebula Acquisition. The Inducement Award was granted to Mr. Obbad on the closing date of the Nebula Acquisition. The Inducement Award vested 25% on the grant date and will vest 25% per year for the next three years subject to Mr. Obbad’s continued employment with the Company. The Inducement Award expires on the seventh anniversary of the grant date. Any portion of the Inducement Award that does not vest and become exercisable will be forfeited for no consideration. The grant date fair value of the Inducement Award was approximately $1,128,000.

 

During the year ended December 31, 2021, we issued an inducement award to a non-employee to purchase up to 100,000 shares of the Company’s common stock at an exercise price of $5.76, the closing price of the common stock on the date of grant. The award vests in four equal installments from the date of grant. The award expires on the seventh anniversary of the grant date.

 

All inducement awards have been granted outside of the Company’s equity compensation plans.

 

The following table summarizes stock options activity during the three months ended March 31, 2022 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Awards (in thousands, except per share data).

 

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
   Total Intrinsic Value 
Outstanding as of January 1, 2022   5,110   $3.27    3.4   $20,820 
Forfeited   (20)   8.99    -    - 
Outstanding as of March 31, 2022   5,090   $3.11    3.2   $20,767 
Options vested and exercisable   4,069   $2.41    2.4   $19,398 

 

As of March 31, 2022, there were 5,090,000 stock options outstanding and 295,785 stock options available to be issued. We will recognize an aggregate of approximately $2,746,000 of remaining share-based compensation expense related to outstanding stock options over a weighted average period of 2.8 years.

 

Stock Warrants

 

The following table summarizes warrant activity during the three months ended March 31, 2022 (in thousands, except per share data):

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
 
Outstanding as of January 1, 2022   855   $8.23    1.9 
Warrants granted   -    -    - 
Outstanding as of March 31, 2022   855   $8.23    1.6 
Warrants vested and exercisable   855   $8.23    1.6 

 

We recognized $0 and $105,000 of share-based compensation expense during the three months ended March 31, 2022 and 2021, respectively.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Defined Contribution Plans
3 Months Ended
Mar. 31, 2022
Retirement Benefits [Abstract]  
Defined Contribution Plans

Note 8 - Defined Contribution Plans

 

We maintain the ProPhase Labs, Inc. 401(k) Savings and Retirement Plan, a defined contribution plan for our employees. Our contributions to the plan are based on the amount of the employee plan contributions and compensation. Our contributions to the plan in the three months ended March 31, 2022 and 2021 were $52,000 and $13,000, respectively.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

Note 9 – Income Taxes

 

We recognize tax assets and liabilities for the future tax consequences related to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for net operating loss carryforwards. Management evaluated the deferred tax assets for recoverability using a consistent approach that considers the relative impact of negative and positive evidence, including historical profitability and projections of future reversals of temporary differences and future taxable income. We are required to establish a valuation allowance for deferred tax assets if management determines, based on available evidence at the time the determination is made, that it is not more likely than not that some portion or all of the deferred tax assets will be realized. As of March 31, 2022 the Company has net deferred tax liabilities for federal and combined states jurisdictions compared to net deferred tax assets with a full valuation allowance as of December 31, 2021. The decrease in deferred tax assets with a corresponding decrease in valuation allowance against those assets as of March 31, 2022 is primarily due to utilization of net operating losses. The Company has net deferred tax assets in other states jurisdictions where we maintain a full valuation allowance. Judgment is required to estimate forecasted future taxable income, which may be impacted by future business developments, actual results, tax initiatives, legislative, and other economic factors. The Company will continue to monitor income levels and potential changes to its operating and tax model, and other legislative or global developments in its determination.

 

The Company’s effective tax rate for the three months ended March 31, 2022 is 21.47% and it is primarily driven by federal tax at 21%, state taxes at 7.1%, and a decrease in the valuation allowance for federal and combined states jurisdictions. The total tax expense for the three months ended March 31, 2022 is $3.4 million and it mostly relates to current federal and combined state taxes.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Other Current Liabilities
3 Months Ended
Mar. 31, 2022
Other Liabilities Disclosure [Abstract]  
Other Current Liabilities

Note 10 - Other Current Liabilities

 

The following table sets forth the components of other current liabilities at March 31, 2022 and December 31, 2021, respectively (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Accrued commissions  $1,294   $1,283 
Accrued payroll   50    514 
Accrued expenses   356    300 
Accrued returns   246    338 
Accrued benefits and vacation   50    60 
Accrued insurance reimbursement   

1,278

    

-

 
Total other current liabilities  $3,274   $2,495 

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 11 - Commitments and Contingencies

 

Manufacturing Agreement

 

The Company and its wholly owned subsidiary, PMI, entered into a manufacturing agreement (the “Manufacturing Agreement”) with Mylan in connection with the asset purchase agreement we entered into with Mylan in 2017. Pursuant to the terms of the Manufacturing Agreement, Mylan (or an affiliate or designee) purchased the inventory of the Company’s Cold-EEZE® brand and product line, and PMI agreed to manufacture certain products for Mylan, as described in the Manufacturing Agreement, at prices that reflect current market conditions for such products and include an agreed upon mark-up on our costs. On May 1, 2021, the Manufacturing Agreement was assigned by Mylan to Nurya Brands, Inc. (“Nurya”) in connection with Nurya’s acquisitions of certain assets from Mylan, including the Cold-EEZE® brand and product line. Unless terminated sooner by the parties, the Manufacturing Agreement will remain in effect until March 29, 2023. Thereafter, the Manufacturing Agreement may be renewed by Nurya for up to four successive one-year periods by providing notice of its intent to renew not less than 90 days prior to the expiration of the then-current term.

 

Future Obligations

 

We have estimated future minimum obligations for an executive’s employment agreement over the next five years as of March 31, 2022, as follows (in thousands):

 

   Employment Contracts 
Remaining periods in 2022  $506 
2023   675 
2024   675 
2025   675 
2026   675 
Total  $3,206 

 

Litigation

 

In the normal course of our business, we may be named as a defendant in legal proceedings. It is our policy to vigorously defend litigation or to enter into a reasonable settlement where management deems it appropriate.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Leases
3 Months Ended
Mar. 31, 2022
Leases  
Leases

Note 12 - Leases

 

On October 23, 2020, we completed the acquisition of CPM, which included the acquisition of a 4,000 square foot CLIA accredited laboratory located in Old Bridge, New Jersey, which was owned by CPM (which is now known as ProPhase Diagnostics NJ, Inc.). The lease is for a term of 24 months with a monthly base lease payment of $5,950.

 

On December 8, 2020, the Company entered into a Lease Agreement (the “NY Lease”) with BRG Office L.L.C. and Unit 2 Associates L.L.C. (the “Landlord”), pursuant to which the Company has agreed to lease certain premises located on the second floor (the “Leased Premises”) of 711 Stewart Avenue, Garden City, New York (the “Building”). The Leased Premises serve as the Company’s second location and corporate headquarters, offering a wide range of laboratory testing services for diagnosis, screening and evaluation of diseases, including COVID-19 and Respiratory Pathogen Panel Molecular tests.

 

The NY Lease was effective as of December 8, 2020, and commenced in January 2021 (the “Commencement Date”) when the facility was made available to us by the landlord. The initial term of the NY Lease is 10 years and seven months (the “Initial Term”), unless sooner terminated as provided in the NY Lease. We may extend the term of the NY Lease for one additional option period of five years. We have the option to terminate the NY Lease on the sixth anniversary of the Commencement Date, provided that we give the landlord written notice not less than nine months and not more than 12 months in advance and that we pay the landlord a termination fee.

 

For the first year of the NY Lease, we will pay a base rent of $56,963 per month (subject to a seven-month abatement period), with a gradual rental rate increase of 2.75% for each 12-month period thereafter in lieu of paying its proportionate share of common area operating expenses, culminating in a monthly base rent of $74,716 during the final months of the Initial Term. In addition to the monthly base rent, we are responsible for its proportionate share of real estate tax escalations in accordance with the terms of the NY Lease.

 

We also have a right of first refusal to lease certain additional space located on the ground floor of the Building containing 4,500 square feet and 4,600 square feet, as more particularly described in the NY Lease. We also have a right of first offer to purchase the Building during the term of the NY Lease.

 

At March 31, 2022, we had operating lease liabilities for the New York and New Jersey leases of approximately $4.8 million and right of use assets of approximately $4.3 million, which were included in the condensed consolidated balance sheet.

 

The following summarizes quantitative information about our operating leases (amounts in thousands): 

 

   March 31, 2022   March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Operating leases          
Operating lease cost  $204   $204 
Operating lease expense   204    204 
Total rent expense  $204   $204 

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Maturities of the Company’s operating leases, excluding short-term leases, are as follows (in thousands):

 

      
Remaining Periods Ended December 31, 2022  $580 
Year Ended December 31, 2023   738 
Year Ended December 31, 2024   747 
Year Ended December 31, 2025   768 
Year Ended December 31, 2026   783 
Thereafter   3,876 
Total   7,492 
Less present value discount   (2,704)
Operating lease liabilities  $4,788 

 

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Consulting Agreement and Secured Promissory Note Receivable
3 Months Ended
Mar. 31, 2022
Consulting Agreement And Secured Promissory Note Receivable  
Consulting Agreement and Secured Promissory Note Receivable

Note 13 - Consulting Agreement and Secured Promissory Note Receivable

 

Promissory Note and Security Agreement

 

On September 25, 2020 (the “Restatement Effective Date”), we entered into the Secured Note with a company consulting for us (“the Consultant”), pursuant to which we loaned $3.0 million to the Consultant (inclusive of $1.0 million in the aggregate previously loaned to the Consultant, as described below).

 

The Secured Note amended and restated in its entirety (i) that certain Promissory Note and Security Agreement, dated July 21, 2020 (the “Original July 21 Note”), pursuant to which we loaned $750,000 to the Consultant and (ii) that certain Promissory Note and Security Agreement, dated July 29, 2020 (the “Original July 29 Note”, and, together with the Original July 21 Note, the “Original Notes”), pursuant to which we loaned $250,000 to the Consultant.

 

Commencing after September 1, 2021, in addition to payments of interest, the Consultant is also required to make payments on the principal amount of the loan equal to 1/36 of the then outstanding principal amount.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The entire remaining unpaid principal amount of the Secured Note, together with all accrued and unpaid interest thereon and all other amounts payable under the Secured Note, will be due and payable, if not sooner paid, on September 30, 2022.

 

The Secured Note contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the Secured Note may be accelerated.

 

Amendment and Termination Agreement

 

On January 14, 2021, we entered into an Amendment and Termination Agreement (the “Termination Agreement”) with the Consultant pursuant to which the parties amended the Secured Note and terminated the former consulting agreement with the Consultant (the “Consulting Agreement”). Pursuant to the terms of the Termination Agreement, the Company loaned an additional $1 million to the Consultant in consideration for the termination of the Consulting Agreement and termination of the Company’s obligation to pay any additional consulting fees. As a result, the initial principal amount due under the Secured Note was increased from $2.75 million to $3.75 million plus all accrued and unpaid interest arising under the Secured Note through and including January 14, 2021.

 

Under the terms of the Termination Agreement, the Consultant will continue to sell and process its viral test by RT-PCR (together with other viral and other types of tests). Until the Secured Note is paid in full, each COVID-19 Test Kit sold or processed from and after January 14, 2021, and for which payment of at least the specified amount as defined for the test, is received by the Consultant, the Consultant will pay us a specified amount (the “Test Fee”). We received the first payment in the amount of $95,000 with respect to the Test Fees from January 15 through February 2021. On June 25, 2021, we were issued 1,260,619 shares of common stock of the Consultant with a fair value of $315,000 as an interest payment under the Secured Note in lieu of Test Fees from March through June 2021.

 

Effective September 1, 2021, in addition to the payment of the Test Fees described above, the Consultant is also required to make payments to us in an amount equal to the greater of (x) the Test Fee, or (y) 1/36th of the then outstanding principal amount together with interest thereon. The Company did not receive any payments from the Consultant for either contractual principal or interest.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

On October 11, 2021, the Company provided the Consultant with a Notice of Default and demanded the Secured Note be paid in full immediately. On January 25, 2022, the Company filed a complaint with the United States District Court for the District of Delaware for judgment against the Consultant for money damages consisting of principal, interest, default interest and other fees and costs. As a result, the Company considered that it is not probable that it will collect all amounts due under the Secured Note and reduced the carrying value of the Secured Note to $0 as of December 31, 2021 with a corresponding charge-off of $3.75 million during the year ended December 31, 2021.

 

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Customer Concentrations
3 Months Ended
Mar. 31, 2022
Risks and Uncertainties [Abstract]  
Significant Customer Concentrations

Note 14 - Significant Customer Concentrations

 

Revenue for the three months ended March 31, 2022 and 2021 was $47.5 million and $15.3 million, respectively. Three diagnostic services clients accounted for 36.7%, 21.4%, and 11.0% of our revenue for the three months ended March 31, 2022. Two diagnostic services clients accounted for 46.1% and 31.6% of our revenue for the three months ended March 31, 2021. No contract manufacturing customer’s accounted for a significant portion of our revenue for the three month ended March 31, 2022 or 2021. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.

 

Two diagnostic services payers comprised 33.6% and 26.5% of our total reimbursement receivable balances from government agencies and healthcare issuers at March 31, 2022. Four diagnostic services payers comprised 43.0%, 11.6%, 10.7% and 10.7% of our total reimbursement receivable balances from government agencies and healthcare issuers at December 31, 2021.

 

Currently, we rely on a sole supplier to manufacture our saliva collection kits used by customers who purchase our personal genomics services. Change in the supplier or design of certain of the materials that we rely on, in particular the saliva collection kit, could result in a requirement for additional premarket review from the FDA before making such a change.

 

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Segment Information

Note 15 - Segment Information

 

The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO as CODM assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table is a summary of segment information for three months ended March 31, 2022 and 2021 (amounts in thousands):

 

   March 31, 2022   March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Net revenues          
Diagnostic services  $44,913   $12,737 
Consumer products   2,618    2,534 
Consolidated net revenue   47,531    15,271 
Cost of revenue          
Diagnostic services   16,702    4,345 
Consumer products   2,152    1,999 
Consolidated cost of revenue   18,854    6,344 
Depreciation and amortization expense          
Diagnostic services   576    345 
Consumer products   600    3 
Total Depreciation and amortization expense   1,176    348 
Operating and other expenses   11,591    7,522 
Income (loss) from operations, before income taxes          
Diagnostic services   20,026    2,839 
Consumer products   (1,863)   (35)
Unallocated corporate   (2,253)   (1,747)
Total income from operations, before income taxes   15,910    1,057 
Income tax expense   (3,416)   - 
Total income from operations, after income taxes   12,494    1,057 
Net income  $12,494   $1,057 

 

The following table is a summary of segment information as of March 31, 2022 and December 31, 2021 (amounts in thousands):

 

  

March 31,

2022

  

December 31,

2021

 
         
ASSETS          
Diagnostic services  $51,823   $51,150 
Consumer products   23,378    24,139 
Unallocated corporate   24,464    14,006 
Total assets  $99,665   $89,295 

 

 

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Share
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Earnings Per Share

Note 16 - Earnings Per Share

 

Basic earnings per share (“EPS”) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):

   March 31, 2022   March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Net income - basic  $12,494   $1,057 
Interest on unsecured convertible promissory note   232    - 
Net income - diluted  $12,726   $1,057 
           
Weighted average shares outstanding - basic   15,486    14,563 
Diluted shares- Stock Options   2,232    2,895 
Diluted shares- Stock Warrants   222    284 
Unsecured convertible promissory note   800    458 
Weighted average shares outstanding - diluted   18,740    18,200 

 

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):

 

   For the three months ended 
Anti-dilutive securities  March 31, 2022   March 31, 2021 
Common stock purchase warrants   455    455 
Stock Options   810    - 
Anti-dilutive securities   1,265    455 

 

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Related Parties
3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
Related Parties

Note 17 - Related Parties

 

Jason Karkus, Executive Vice President and Co-Chief Operations Officer of ProPhase Diagnostics, is the son of Ted Karkus, the Company’s Chairman and Chief Executive Officer. For the three months ended March 31, 2022 and 2021, Mr. Karkus received compensation of $55,000 and $30,000, respectively.

 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Event
3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
Subsequent Event

Note 18 – Subsequent Event

 

Appointment of Chief Financial Officer

 

On May 9, 2022, the Company announced that has appointed Bill White as Chief Financial Officer of the Company, effective May 23, 2022 (the “Effective Date”), replacing Monica Brady, who is currently serving as Chief Financial Officer of the Company. Ms. Brady will remain with the Company and continue to serve as the Company’s Chief Accounting Officer, and Chief Financial Officer of the Company’s wholly-owned subsidiary, ProPhase Diagnostics, as of the Effective Date.

 

As an inducement to his employment as Chief Financial Officer of the Company, the Compensation Committee granted Mr. White a stock option (the “Option Award”) to purchase up to 400,000 shares of the Company’s common stock. This award was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded under the Company’s stockholder approved equity plan. The option award will vest over a four year period, with 12.5% vesting every six months following the Effective Date, and contingent upon the commencement of his employment and continued service through each vesting date. The options have an exercise price of $6.74 per share, the closing price of the Company’s common stock on May 9, 2022, and will be exercisable for a period of seven years. 

 

Announcement of Cash Dividend

 

On May 9, 2022, the board of directors of the Company declared a special cash dividend of $0.30 per share for stockholders of record as of May 25, 2022, which will approximate $4.6 million. On the same date, the Compensation Committee of the board of directors approved an adjustment to the stock option granted to Mr. Karkus on February 23, 2018 (the “CEO Option”), as required under the Company’s 2018 Stock Plan, as a consequence of the special cash dividend. The board of directors has adjusted the terms of the CEO Option, such that the exercise price of the CEO Option will be reduced from $0.90 per share to $0.60 per share, effective as of June 3, 2022, the date the special cash dividend is to be paid.

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and other comprehensive loss and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of operating results that may be achieved over the course of the full year.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Segments

Segments

 

In accordance with FASB ASC 280, “Segment Reporting” (“ASC 280”), the Company discloses financial and descriptive information about its reportable operating segments.

 

ASC 280 establishes standards for reporting information about operating segments in annual and interim financial statements and requires that companies report financial and descriptive information about their reportable segments based on a management approach. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and major customers.

 

Operating segments are defined as components of an enterprise that engage in business activities for which separate financial information is available and is evaluated by the Chief Operating Decision Maker (“CODM”), which for the Company is its Chief Executive Officer, in deciding how to allocate resources and assess performance. We maintain two operating segments: diagnostic services (which includes our COVID-19 and other diagnostic testing services) and consumer products (which includes our contract manufacturing, retail customers and personal genomics products and services) (see Note 15 Segment Information).

 

Business and Liquidity Risks and Uncertainties

Business and Liquidity Risks and Uncertainties

 

We launched our diagnostic service business in December 2020 and expanded in January 2021 with the opening of our Garden City, New York CLIA accredited laboratory. Our diagnostic service business is and will continue to be influenced by the level of demand for COVID-19 and other diagnostic testing, how long this demand persists, the prices we are able to receive for performing our testing services, our ability to collect payment or reimbursement for our testing services, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.

 

While our revenues increased significantly for the year ended December 31, 2021 and the first quarter of fiscal 2022 as a result of the launch of our diagnostic services business, we will continue to be dependent on both government agency and insurance company reimbursement as well as the prevalence of COVID-19 associated strains.

 

In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), was enacted, providing for reimbursement to healthcare providers for COVID-19 tests provided to uninsured individuals, subject to continued available funding. Approximately 69% and 57% of our diagnostic services revenue for the three months ended March 31, 2022 and 2021, respectively was generated from this program for the uninsured. On March 22, 2022, the Health Resources & Services Administration (HRSA) program stopped accepting claims for COVID-19 testing and treatment due to lack of sufficient funds. Despite requests from the Acting Director of the Office of Management and Budget and the White House Coordinator for COVID-19 Response for additional emergency funding for the uninsured program, emergency funding has not been allocated to the HRSA uninsured program as of the financial statement issuance date. We continue to perform testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize any revenue related to COVID-19 testing that we performed for uninsured individuals from March 23, 2022 through March 31, 2022. If funding for the HRSA program is reinstituted in the future, we will submit eligible claims for reimbursement to HRSA and record the associated revenues. If the HRSA program remains unfunded and we are unable to submit claims for reimbursement, there could be a material adverse effect on our business and financial condition.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

In addition, our diagnostic service business is subject to extensive federal, state, and local laws and regulations, all of which are subject to change, as well as laws and regulations governing the submission of claims for payment for our services, such as those relating to: coverage of our services under Medicare, Medicaid and other federal health care programs; the amounts that we may bill for our services; and the party to which we must submit claims. Also, reimbursement policies and requirements for some payers and procedures are ambiguous, which could lead to billing errors and related disputes. There can be no assurance that our efforts to offer and perform COVID-19 or other diagnostic testing will be successful in the future or that the revenue and operating profits from such business will increase or maintain their current level.

 

We acquired and commenced our personal genomics business in August 2021. This business is and will continue to be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.

 

Our consumer sales are and will continue to be influenced by (i) the timing of acceptance of our TK Supplements® consumer products in the marketplace, and (ii) fluctuations in the timing of purchase and the ultimate level of demand for the OTC healthcare and cold remedy products that we manufacture, which is largely a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period from September to March when the incidence of the common cold rises as a result of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net revenues from our contract manufacturing business. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.

 

For the three months ended March 31, 2022, $20.3 million was provided by operating activities. The Company had cash, cash equivalents and marketable securities of $29.4 million as of March 31, 2022. Based on management’s current business plans, the Company estimates it will have enough cash and liquidity to finance its operating requirements for at least 12 months from the date of filing these unaudited condensed consolidated financial statements. However, due to the nature of the diagnostic business and the Company’s focus thus far on COVID-19 testing, there are inherent uncertainties associated with managements’ business plan and cash flow projections, particularly if the Company is unable to grow its diagnostic testing business beyond COVID-19 testing services.

 

The Company’s future capital needs and the adequacy of its available funds will depend on the Company’s ability to achieve sustained profitability from its diagnostic services, the Company’s ability to successfully diversify its diagnostic services revenue streams and the Company’s ability to market and grow its personal genomics business. The Company may be required to raise additional funds through equity or debt securities offerings or strategic collaboration and/or licensing agreements in order to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Company’s failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition.

 

Use of Estimates

Use of Estimates

 

The preparation of condensed consolidated financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration of diagnostic test reimbursement rates, the provision for uncollectible receivables and billing errors, allowances, slow moving and/or dated inventory and associated provisions, the potential impairment of long-lived assets, stock based compensation valuations, income tax asset valuations and assumptions related to accrued advertising.

 

Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the condensed consolidated financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these securities.

 

Restricted Cash

Restricted Cash

 

Restricted cash as of December 31, 2021 includes approximately $250,000 held in escrow related to a potential purchase of an additional lab facility. The potential purchase was not consummated, and we are pursuing the return of the escrow, which is in dispute. As of March 31, 2022, we recognized an expense for this balance as the recovery of the funds was no longer considered probable.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Marketable Debt Securities

Marketable Debt Securities

 

We have classified our investments in marketable debt securities as available-for-sale and as a current asset. Our investments in marketable debt securities are carried at fair value, with unrealized gains and as a separate component of stockholders’ equity. Realized gains and losses from our marketable debt securities are recorded as interest income (expense). These investments in marketable debt securities carry maturity dates between one and three years from date of purchase.

 

The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (in thousands) (see fair value of financial instruments):

 

   As of March 31, 2022 
   Amortized   Unrealized   Unrealized   Fair 
   Cost   Gains   Losses   Value 
U.S. government obligations  $667   $123   $(44)  $746 
Corporate obligations   2,839    -    (42)   2,797 
   $3,506   $123   $(86)  $3,543 

 

   As of December 31, 2021 
   Amortized   Unrealized   Unrealized   Fair 
   Cost   Gains   Losses   Value 
U.S. government obligations  $650   $17   $-   $667 
Corporate obligations   8,304    -    (192)   8,112 
   $8,954   $17   $(192)  $8,779 

 

Marketable Equity Securities

Marketable Equity Securities

 

Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within other non-operating income, net in the consolidated statements of income.

 

On June 25, 2021, we were issued 1,260,619 common shares (the “Investment Shares”) as an interest payment under our note receivable (see Note 13, Consulting Agreement and Secured Promissory Note Receivable) with a fair value of $315,000 at the time of issuance and a fair value of $76,000 at December 31, 2021. The investment was classified as a Level 1 financial instrument. We recorded a $76,000 decrease in fair value of investment securities within the statement of operations for the three months ended March 31, 2022.

 

Accounts Receivable, net

Accounts Receivable, net

 

Accounts receivable consists primarily of amounts due from government agencies and healthcare insurers. Unbilled accounts receivable relates to the delivery of our diagnostic testing services for which the related billings will occur in a future period, after a patient’s insurance information has been validated, and represent amounts for which we have a right to receive payment. Unbilled accounts receivable is classified as accounts receivable on the consolidated balance sheet. We carry our accounts receivable at the amount of consideration for which we expect to be entitled less allowances. When estimating the allowances for our diagnostics business, the Company pools its receivables based on the following payer types: healthcare insurers and government payers. The Company principally estimates the allowances by pool based on historical collection experience, current economic conditions, government and healthcare insurer payment trends, and the period of time that the receivables have been outstanding. Should a payer’s reimbursement policy change or their credit quality deteriorate, the Company removes the payer from their respective pools and establishes allowances based on the individual risk characteristics of such payer.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands):

 

   March 31, 2022   December 31, 2021 
Trade accounts receivable  $24,727   $18,520 
Unbilled accounts receivable   14,944    23,089 
 Accounts receivable, gross   39,671    41,609 
Less allowances   (2,977)   (3,901)
Total accounts receivable  $36,694   $37,708 

 

Inventory, net

Inventory, net

 

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (“FIFO”), or net realizable value. Inventory items are analyzed to determine cost and the net realizable value and appropriate valuation adjustments are established.

 

At March 31, 2022 and December 31, 2021, the components of inventory are as follows (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Diagnostic services testing material  $3,103   $2,989 
Raw materials   1,238    1,514 
Work in process   476    260 
Finished goods   322    272 
Inventory  $5,139   $5,035 
Inventory valuation reserve   (459)   (435)
Inventory, net  $4,680   $4,600 

 

Property, Plant and Equipment

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years.

 

Concentration of Financial Risks

Concentration of Financial Risks

 

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.

 

We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2022, our cash and cash equivalents and restricted cash balance was $25.8 million. Of the total bank balance, $0.9 million was covered by federal depository insurance and $24.9 million was uninsured at March 31, 2022.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection rates. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depends on information provided to the payors and meeting their requirements for reimbursement.

 

Leases

Leases

 

At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. We have elected not to recognize on the balance sheet leases with terms of 12 months or less. We typically only include an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in our assessment unless there is reasonable certainty that we will renew.

 

Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in our leases is typically not readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 12, Leases).

 

The components of a lease should be allocated between lease components (e.g., land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.

 

Goodwill and Intangible Assets

Goodwill and Intangible Assets

 

Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying identifiable assets and liabilities acquired in a business combination. Goodwill and intangible assets deemed to have an indefinite life are not amortized, but instead are assessed for impairment annually. Additionally, if an event or change in circumstances occurs that would more likely than not reduce the fair value of the reporting unit below its carrying value, we would evaluate goodwill at that time.

 

In testing for goodwill impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, we conclude that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If we conclude otherwise, we are required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than the carrying value, an impairment charge will be recorded to reduce the reporting unit to fair value.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Intangible assets deemed to have finite lives are amortized on a straight-line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to our future cash flows.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
     
  Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
     
  Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, and unsecured note payable, approximate their fair values because of the short-term nature of these instruments.

 

We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity securities change in fair value reported on the condensed consolidated statement of operations. The components of marketable securities are as follows (in thousands):

 

   As of March 31, 2022 
   Level 1   Level 2   Level 3   Total 
U.S. government obligations  $-   $746   $-   $746 
Corporate obligations   -    2,797    -    2,797 
   $-   $3,543   $-   $3,543 

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

   As of December 31, 2021 
   Level 1   Level 2   Level 3   Total 
U.S. government obligations  $-   $667   $-   $667 
Corporate obligations   -    8,112    -    8,112 
Marketable equity securities   76    -    -    76 
   $76   $8,779   $-   $8,855 

 

There were no transfers of marketable debt securities between Levels 1, 2 or 3 for the three months ended March 31, 2022 and 2021.

 

Revenue Recognition

Revenue Recognition

 

We recognize revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. We recognize revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

Contract with Customers and Performance Obligations

 

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Sales from product shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. Revenue from diagnostic services is recognized when the results are made available to the customer. Revenue from our personal genomics business is recognized when the genetic testing results are provided to the customer. For subscription services associated with our genomic testing, we recognize revenue ratably over the term of the subscription.

 

Transaction Price

 

For contract manufacturing and retail customers, the transaction price is fixed based upon either (i) the terms of a combined master agreement and each related purchase order, or (ii) if there is no master agreement, the price per individual purchase order received from each customer. The customers are invoiced at an agreed upon contractual price for each unit ordered and delivered by the Company.

 

Revenue from retail customers is reduced for trade promotions, estimated sales returns and other allowances in the same period as the related sales are recorded. No such allowance is applicable to our contract manufacturing customers. We estimate potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

We do not accept returns from our contract manufacturing customers. Our return policy for retail customers accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time during which product may be returned. All requests for product returns must be submitted to us for pre-approval. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will accept return requests only for products in their intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed.

 

For our diagnostic services business, a revenue transaction is initiated when we receive a requisition order to perform a diagnostic test. The information provided on the requisition form is used to determine the party that will be billed for the testing performed and the expected reimbursement. We provide diagnostic services to a range of customers. In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or Medicaid program and other government reimbursement programs. We bill the providers at standard price and take into consideration negotiated discounts and anticipated reimbursement remittance adjustments based on the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that vary from the listed contract price.

 

For our personal genomics business, a revenue transaction is initiated by a DNA test kit sale direct to the consumer sales via our website or through online retailers. The kit sales and subscriptions are billed at a standard price and take into consideration any discounts when revenue is recorded.

 

Recognize Revenue When the Company Satisfies a Performance Obligation

 

Recognition for contract manufacturing and retail customers is satisfied at a point in time when the goods are shipped to the customer as (i) we have transferred control of the assets to the customers upon shipping, and (ii) the customer obtains title and assumes the risks and rewards of ownership after the goods are shipped.

 

For diagnostic services, recognition occurs at the point in time that the results are made available to the customer, which is when the customer benefits from the information contained in the results and obtains control.

 

For genomic services, we satisfy our product performance obligation at a point in time when the genetic testing results are provided to the customer. For subscriptions services associated with its genomic testing, we satisfy our performance obligation ratably over the subscription period. If the customer does not return the test kit, services cannot be completed by us, potentially resulting in unexercised rights (“breakage”) revenue, including lifetime subscription services. We estimate breakage for the portion of test kits not expected to be returned using an analysis of historical data and consider other factors that could influence customer test kit return behavior. When breakage revenue is recognized on a kit, we recognize breakage on any associated subscription services ratably over the term of the subscription. The Company recognized breakage revenue from aggregate unreturned test kits and subscriptions of $0.4 million for the three months ended March 31, 2022.

 

Contract Balances

 

Deferred revenues primarily consist of amounts that have been billed to or received from customers in advance of revenue recognition and prepayments received from customers in advance of services performed for the R&D work. As of March 31, 2022 and December 31, 2021, we have deferred revenue of $3.1 million and $2.9 million, respectively. Our new personal genomics business comprised $2.9 million of the deferred revenue as of March 31, 2022. The deferred revenue balance within the personal genomics business is comprised of kits to be sequenced and subscription services, which have an average life between 12 and 36 months. The remainder of deferred revenue relates to research and development (“R&D”) stability and release testing programs recognized as contract manufacturing revenue.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table disaggregates our deferred revenue by recognition period (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Recognition Period          
0-12 Months  $2,246   $2,034 
13-24 Months   598    530 
Over 24 Months   260    375 
Total  $3,104   $2,939 

 

Disaggregation of Revenue

 

We disaggregate revenue from contracts with customers into four categories: diagnostic services, contract manufacturing, retail and others, and genomic products and services. We determined that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

The following table disaggregates the Company’s revenue by revenue source for the three months ended March 31, 2022 and 2021 (in thousands):

 

   For the three months ended 
Revenue by Customer Type  March 31, 2022   March 31, 2021 
Diagnostic services  $44,913   $12,738 
Contract manufacturing   1,154    1,908 
Retail and others   546    625 
Genomic products and services   918    - 
Total revenue, net  $47,531   $15,271 

 

Customer Consideration

 

The Company makes payments to certain diagnostic services customers for distinct services that approximate the fair value for those services. Such services include specimen collection, the collection and delivery of insurance and patient information necessary for billing and collection, and logistics services. Consideration associated with specimen collection services is classified in cost of revenues and the remaining costs are classified as diagnostic expenses within operating expenses in the accompanying statement of operations.

 

Sales Tax Exclusion from the Transaction Price

 

We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from the customer.

 

Shipping and Handling Activities

 

We account for shipping and handling activities that we perform as activities to fulfill the promise to transfer the good.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Advertising and Incentive Promotions

Advertising and Incentive Promotions

 

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of general and administrative expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net revenue, and (iii) free product, which is accounted for as part of cost of revenues. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2022 and 2021 were $60,000 and $168,000, respectively.

 

Stock-Based Compensation

Stock-Based Compensation

 

The Company accounts for stock-based compensation in accordance with FASB ASC 718, “Compensation - Stock Compensation.” Under the fair value recognition provision of the ASC, stock-based compensation cost is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options and warrants granted using the Black-Scholes-Merton option pricing model and stock grants at their closing reported market value. We recognize all stock-based payments to employees and directors, including grants of stock options, as compensation expense in the condensed consolidated financial statements based on their grant date fair values. The grant date fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. We account for forfeitures as they occur.

 

Stock and stock options to purchase our common stock have been granted to employees pursuant to the terms of certain agreements and stock option plans (see Note 7, Stockholders’ Equity). Stock options are exercisable during a period determined by us, but in no event later than seven years from the date granted.

 

Research and Development (“R&D”)

Research and Development (“R&D”)

 

R&D costs are charged to operations in the period incurred. R&D costs incurred for the three months ended March 31, 2022 and 2021 were $35,000 and $115,000, respectively. R&D costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products, dietary supplements and validation costs in association with the diagnostic services business.

 

Income Taxes

Income Taxes

 

The Company recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse.

 

The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. We evaluate, on a quarterly basis whether, based on all available evidence, it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740- 10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused.

 

The Company accounts for uncertainties in income taxes under the provisions of FASB ASC 740-10-05 (the “Subtopic”). The Subtopic clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The Subtopic prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Subtopic provides guidance on the de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Recently Issued Accounting Standards, Adopted

Recently Issued Accounting Standards, Adopted

 

The Financial Accounting Standards Board (“FASB”) recently issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The adoption of ASU 2020-06 did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.

 

Recently Issued Accounting Standards, Not Yet Adopted

Recently Issued Accounting Standards, Not Yet Adopted

 

In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Summary of Components of Marketable Securities

The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (in thousands) (see fair value of financial instruments):

 

   As of March 31, 2022 
   Amortized   Unrealized   Unrealized   Fair 
   Cost   Gains   Losses   Value 
U.S. government obligations  $667   $123   $(44)  $746 
Corporate obligations   2,839    -    (42)   2,797 
   $3,506   $123   $(86)  $3,543 

 

   As of December 31, 2021 
   Amortized   Unrealized   Unrealized   Fair 
   Cost   Gains   Losses   Value 
U.S. government obligations  $650   $17   $-   $667 
Corporate obligations   8,304    -    (192)   8,112 
   $8,954   $17   $(192)  $8,779 
Schedule of Accounts Receivable Net

Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands):

 

   March 31, 2022   December 31, 2021 
Trade accounts receivable  $24,727   $18,520 
Unbilled accounts receivable   14,944    23,089 
 Accounts receivable, gross   39,671    41,609 
Less allowances   (2,977)   (3,901)
Total accounts receivable  $36,694   $37,708 

Schedule of Components of Inventory

At March 31, 2022 and December 31, 2021, the components of inventory are as follows (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Diagnostic services testing material  $3,103   $2,989 
Raw materials   1,238    1,514 
Work in process   476    260 
Finished goods   322    272 
Inventory  $5,139   $5,035 
Inventory valuation reserve   (459)   (435)
Inventory, net  $4,680   $4,600 
Schedule of Fair Value of Financial Instruments

 

   As of March 31, 2022 
   Level 1   Level 2   Level 3   Total 
U.S. government obligations  $-   $746   $-   $746 
Corporate obligations   -    2,797    -    2,797 
   $-   $3,543   $-   $3,543 

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

   As of December 31, 2021 
   Level 1   Level 2   Level 3   Total 
U.S. government obligations  $-   $667   $-   $667 
Corporate obligations   -    8,112    -    8,112 
Marketable equity securities   76    -    -    76 
   $76   $8,779   $-   $8,855 

Schedule of Deferred Revenue

The following table disaggregates our deferred revenue by recognition period (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Recognition Period          
0-12 Months  $2,246   $2,034 
13-24 Months   598    530 
Over 24 Months   260    375 
Total  $3,104   $2,939 

Schedule of Disaggregation by Revenue

The following table disaggregates the Company’s revenue by revenue source for the three months ended March 31, 2022 and 2021 (in thousands):

 

   For the three months ended 
Revenue by Customer Type  March 31, 2022   March 31, 2021 
Diagnostic services  $44,913   $12,738 
Contract manufacturing   1,154    1,908 
Retail and others   546    625 
Genomic products and services   918    - 
Total revenue, net  $47,531   $15,271 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Business Acquisition (Tables)
3 Months Ended
Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Assets Acquired and Liabilities Assumed

 

Account  Amount 
Short term investments  $1,800 
Accounts receivable   171 
Inventory   133 
Prepaid and other current assets   379 
Definite-lived intangible assets   10,990 
Total assets acquired   13,473 
Accounts payable   (805)
Accrued expenses and other current liabilities   (43)
Deferred revenue   (2,391)
Note payable   (81)
Deferred tax liability   (1,925)
Total liabilities assumed   (5,245)
Net identifiable assets acquired   8,228 
Goodwill   4,446 
Total consideration, net of cash acquired (1)  $12,674 

 

(1) Net of $1.6 million cash acquired.
Schedule of Intangible Assets Acquisition

The intangible assets identified in conjunction with the Nebula Acquisition are as follows (in thousands):

 

   Gross Carrying Value   Estimated Useful Life (in years) 
Trade names  $5,550    15 
Proprietary intellectual property   4,260    5 
Customer relationships   1,180    1 
Total  $10,990      
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Acquired Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets

Intangible assets as of March 31, 2022 and December 31, 2021 consisted of the following (in thousands):

 

  

March 31,

2022

  

December 31,

2021

  

Estimated Useful

Life (in years)

Trade names  $5,550   $5,550   15
Proprietary intellectual property   4,260    4,260   5
Customer relationships   1,180    1,180   1
CLIA license   1,307    1,307   3
 Total intangible assets, gross   12,297    12,297    
Less: accumulated amortization   (2,154)   (1,445)   
Total intangible assets, net  $10,143   $10,852    
Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets

 

      
Remaining periods ended December 31, 2022  $1,669 
Year ended December 31, 2023   1,585 
Year ended December 31, 2024   1,222 
Year ended December 31, 2025   1,222 
Year ended December 31, 2026   890 
Thereafter   3,555 
 Total intangible assets, net  $10,143 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant and Equipment (Tables)
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment

The components of property, plant and equipment are as follows (in thousands):

 

  

March 31,

2022

  

December 31,

2021

   Estimated Useful Life
Land  $352   $352    
Building improvements   1,729    1,729   10-39 years
Machinery   4,740    4,740   3-7 years
Lab equipment   4,936    4,330   3-7 years
Computer equipment   1,589    1,211   3-5 years
Furniture and fixtures   468    468   5 years
 Property, Plant and Equipment, Gross   13,814    12,830    
Less: accumulated depreciation   (7,374)   (6,883)   
Total property, plant and equipment, net  $6,440   $5,947    

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity (Tables)
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Schedule of Stock Options Activity

The following table summarizes stock options activity during the three months ended March 31, 2022 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Awards (in thousands, except per share data).

 

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
   Total Intrinsic Value 
Outstanding as of January 1, 2022   5,110   $3.27    3.4   $20,820 
Forfeited   (20)   8.99    -    - 
Outstanding as of March 31, 2022   5,090   $3.11    3.2   $20,767 
Options vested and exercisable   4,069   $2.41    2.4   $19,398 

Summary of Warrant Activity

The following table summarizes warrant activity during the three months ended March 31, 2022 (in thousands, except per share data):

 

   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life
(in years)
 
Outstanding as of January 1, 2022   855   $8.23    1.9 
Warrants granted   -    -    - 
Outstanding as of March 31, 2022   855   $8.23    1.6 
Warrants vested and exercisable   855   $8.23    1.6 

XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Other Current Liabilities (Tables)
3 Months Ended
Mar. 31, 2022
Other Liabilities Disclosure [Abstract]  
Schedule of Other Current Liabilities

The following table sets forth the components of other current liabilities at March 31, 2022 and December 31, 2021, respectively (in thousands):

 

   March 31,   December 31, 
   2022   2021 
Accrued commissions  $1,294   $1,283 
Accrued payroll   50    514 
Accrued expenses   356    300 
Accrued returns   246    338 
Accrued benefits and vacation   50    60 
Accrued insurance reimbursement   

1,278

    

-

 
Total other current liabilities  $3,274   $2,495 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Estimated Future Minimum Obligations

We have estimated future minimum obligations for an executive’s employment agreement over the next five years as of March 31, 2022, as follows (in thousands):

 

   Employment Contracts 
Remaining periods in 2022  $506 
2023   675 
2024   675 
2025   675 
2026   675 
Total  $3,206 

XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Tables)
3 Months Ended
Mar. 31, 2022
Leases  
Summary of Quantitative Information About Operating Leases

The following summarizes quantitative information about our operating leases (amounts in thousands): 

 

   March 31, 2022   March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Operating leases          
Operating lease cost  $204   $204 
Operating lease expense   204    204 
Total rent expense  $204   $204 

Schedule of Maturity of Operating Leases

Maturities of the Company’s operating leases, excluding short-term leases, are as follows (in thousands):

 

      
Remaining Periods Ended December 31, 2022  $580 
Year Ended December 31, 2023   738 
Year Ended December 31, 2024   747 
Year Ended December 31, 2025   768 
Year Ended December 31, 2026   783 
Thereafter   3,876 
Total   7,492 
Less present value discount   (2,704)
Operating lease liabilities  $4,788 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Schedule of Segment Information

The following table is a summary of segment information for three months ended March 31, 2022 and 2021 (amounts in thousands):

 

   March 31, 2022   March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Net revenues          
Diagnostic services  $44,913   $12,737 
Consumer products   2,618    2,534 
Consolidated net revenue   47,531    15,271 
Cost of revenue          
Diagnostic services   16,702    4,345 
Consumer products   2,152    1,999 
Consolidated cost of revenue   18,854    6,344 
Depreciation and amortization expense          
Diagnostic services   576    345 
Consumer products   600    3 
Total Depreciation and amortization expense   1,176    348 
Operating and other expenses   11,591    7,522 
Income (loss) from operations, before income taxes          
Diagnostic services   20,026    2,839 
Consumer products   (1,863)   (35)
Unallocated corporate   (2,253)   (1,747)
Total income from operations, before income taxes   15,910    1,057 
Income tax expense   (3,416)   - 
Total income from operations, after income taxes   12,494    1,057 
Net income  $12,494   $1,057 

 

The following table is a summary of segment information as of March 31, 2022 and December 31, 2021 (amounts in thousands):

 

  

March 31,

2022

  

December 31,

2021

 
         
ASSETS          
Diagnostic services  $51,823   $51,150 
Consumer products   23,378    24,139 
Unallocated corporate   24,464    14,006 
Total assets  $99,665   $89,295 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Share (Tables)
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Loss Per Share

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):

   March 31, 2022   March 31, 2021 
   For the three months ended 
   March 31, 2022   March 31, 2021 
Net income - basic  $12,494   $1,057 
Interest on unsecured convertible promissory note   232    - 
Net income - diluted  $12,726   $1,057 
           
Weighted average shares outstanding - basic   15,486    14,563 
Diluted shares- Stock Options   2,232    2,895 
Diluted shares- Stock Warrants   222    284 
Unsecured convertible promissory note   800    458 
Weighted average shares outstanding - diluted   18,740    18,200 
Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):

 

   For the three months ended 
Anti-dilutive securities  March 31, 2022   March 31, 2021 
Common stock purchase warrants   455    455 
Stock Options   810    - 
Anti-dilutive securities   1,265    455 
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Components of Marketable Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost $ 3,506 $ 8,954
Unrealized Gains 123 17
Unrealized Losses (86) (192)
Fair Value 3,543 8,779
U.S. Government Obligations [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost 667 650
Unrealized Gains 123 17
Unrealized Losses (44)
Fair Value 746 667
Corporate Obligations [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost 2,839 8,304
Unrealized Gains
Unrealized Losses (42) (192)
Fair Value $ 2,797 $ 8,112
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Accounts Receivable Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Trade accounts receivable $ 24,727 $ 18,520
Unbilled accounts receivable 14,944 23,089
 Accounts receivable, gross 39,671 41,609
Less allowances (2,977) (3,901)
Total accounts receivable $ 36,694 $ 37,708
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Components of Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Diagnostic services testing material $ 3,103 $ 2,989
Raw materials 1,238 1,514
Work in process 476 260
Finished goods 322 272
Inventory 5,139 5,035
Inventory valuation reserve (459) (435)
Inventory, net $ 4,680 $ 4,600
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Fair Value of Financial Instruments (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities $ 3,543 $ 8,855
Marketable equity securities 76
U.S. Government Obligations [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities 746 667
Corporate Obligations [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities 2,797 8,112
Marketable equity securities   76
Fair Value, Inputs, Level 1 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities 76
Marketable equity securities   76
Fair Value, Inputs, Level 1 [Member] | U.S. Government Obligations [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities
Fair Value, Inputs, Level 1 [Member] | Corporate Obligations [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities
Fair Value, Inputs, Level 2 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities 3,543 8,779
Marketable equity securities  
Fair Value, Inputs, Level 2 [Member] | U.S. Government Obligations [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities 746 667
Fair Value, Inputs, Level 2 [Member] | Corporate Obligations [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities 2,797 8,112
Fair Value, Inputs, Level 3 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities
Marketable equity securities  
Fair Value, Inputs, Level 3 [Member] | U.S. Government Obligations [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities
Fair Value, Inputs, Level 3 [Member] | Corporate Obligations [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of marketable debt securities
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Deferred Revenue (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Contract with Customer, Liability $ 3,104 $ 2,939
0-12 Months [Member]    
Contract with Customer, Liability 2,246 2,034
13-24 Months [Member]    
Contract with Customer, Liability 598 530
Over 24 Months [Member]    
Contract with Customer, Liability $ 260 $ 375
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Disaggregation by Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Product Information [Line Items]    
Total revenue, net $ 47,531 $ 15,271
Diagnostic Services [Member]    
Product Information [Line Items]    
Total revenue, net 44,913 12,738
Contract Manufacturing [Member]    
Product Information [Line Items]    
Total revenue, net 1,154 1,908
Retail And Others [Member]    
Product Information [Line Items]    
Total revenue, net 546 625
Genomic Products and Services [Member]    
Product Information [Line Items]    
Total revenue, net $ 918
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Jun. 25, 2021
Product Information [Line Items]        
Risks and Uncertainties in Entity's Business We continue to perform testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize any revenue related to COVID-19 testing that we performed for uninsured individuals from March 23, 2022 through March 31, 2022.      
Net cash provided by (used in) operating activities $ 20,287,000 $ (7,892,000)    
Cash Equivalents, at Carrying Value 29,400,000      
Restricted Cash   $ 250,000  
Fair value of investment securities $ 76,000    
Description of property plant and equipment useful lives ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years      
Cash and cash equivalents and restricted cash balance $ 25,800,000      
Federal depository insurance 900,000      
Uninsured 24,900,000      
Breakage revenue 400,000      
Contract with Customer, Liability 3,104,000   2,939,000  
Deferred Revenue 2,900,000      
R&D costs incurred 35,000 115,000    
Cooperative Incentive Promotion Costs [Member]        
Product Information [Line Items]        
Advertising and incentive promotion expenses $ 60,000 $ 168,000    
Minimum [Member]        
Product Information [Line Items]        
[custom:ContractWithCustomerEstimatedLife] 12 months      
Maximum [Member]        
Product Information [Line Items]        
[custom:ContractWithCustomerEstimatedLife] 36 months      
Investment Shares [Member]        
Product Information [Line Items]        
Investment owned, balance shares       1,260,619
Investment owned, at fair value     $ 76,000 $ 315,000
Diagnostic Services [Member]        
Product Information [Line Items]        
Percentage of revenue from diagnostic services 69.00% 57.00%    
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Aug. 10, 2021
Business Combination and Asset Acquisition [Abstract]      
Short term investments     $ 1,800
Accounts receivable     171
Inventory     133
Prepaid and other current assets     379
Definite-lived intangible assets     10,990
Total assets acquired     13,473
Accounts payable     (805)
Accrued expenses and other current liabilities     (43)
Deferred revenue     (2,391)
Note payable     (81)
Deferred tax liability     (1,925)
Total liabilities assumed     (5,245)
Net identifiable assets acquired     8,228
Goodwill $ 5,709 $ 5,709 4,446
Total consideration, net of cash acquired [1]     $ 12,674
[1] Net of $1.6 million cash acquired.
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical)
$ in Millions
Aug. 10, 2021
USD ($)
Nebula Acquisition [Member]  
Business Acquisition [Line Items]  
Cash acquired from acquisition $ 1.6
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Intangible Assets Acquisition (Details) - USD ($)
$ in Thousands
Aug. 10, 2021
Mar. 31, 2022
Dec. 31, 2021
Business Acquisition [Line Items]      
Gross carying value   $ 12,297 $ 12,297
Trade Names [Member]      
Business Acquisition [Line Items]      
Gross carying value   5,550 5,550
Intellectual Property [Member]      
Business Acquisition [Line Items]      
Gross carying value   4,260 4,260
Customer Relationships [Member]      
Business Acquisition [Line Items]      
Gross carying value   $ 1,180 $ 1,180
Nebula Acquisition [Member]      
Business Acquisition [Line Items]      
Gross carying value $ 10,990    
Nebula Acquisition [Member] | Trade Names [Member]      
Business Acquisition [Line Items]      
Gross carying value $ 5,550    
Estimated useful life (in years) 15 years    
Nebula Acquisition [Member] | Intellectual Property [Member]      
Business Acquisition [Line Items]      
Gross carying value $ 4,260    
Estimated useful life (in years) 5 years    
Nebula Acquisition [Member] | Customer Relationships [Member]      
Business Acquisition [Line Items]      
Gross carying value $ 1,180    
Estimated useful life (in years) 1 year    
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Business Acquisition (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Aug. 10, 2021
Mar. 31, 2022
Mar. 31, 2021
Business Acquisition [Line Items]      
Payments for repurchase of common stock   $ 1,150
Nebula Acquisition [Member]      
Business Acquisition [Line Items]      
Business acquisition, purchase price $ 3,600    
Business combination consideration 12,700    
Cash acquired from acquisition $ 1,600    
Nebula Acquisition [Member] | Mr. Kamal Obbad [Member]      
Business Acquisition [Line Items]      
Stock options to purchase shares 250,000    
Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 7.67    
Nebula Acquisition [Member] | Nebula Stock Purchase Agreement [Member]      
Business Acquisition [Line Items]      
Payments for repurchase of common stock $ 14,300    
Shares issued, price per share $ 7.46    
Nebula Acquisition [Member] | Nebula Stock Purchase Agreement [Member] | CitiBankm, N.A. [Member]      
Business Acquisition [Line Items]      
Purchase price $ 1,080    
Escrow termination date Feb. 23, 2023    
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
 Total intangible assets, gross $ 12,297 $ 12,297
Less: accumulated amortization (2,154) (1,445)
Total intangible assets, net 10,143 10,852
Trade Names [Member]    
Finite-Lived Intangible Assets [Line Items]    
 Total intangible assets, gross $ 5,550 5,550
Finite-Lived Intangible Asset, Useful Life 15 years  
Intellectual Property [Member]    
Finite-Lived Intangible Assets [Line Items]    
 Total intangible assets, gross $ 4,260 4,260
Finite-Lived Intangible Asset, Useful Life 5 years  
Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
 Total intangible assets, gross $ 1,180 1,180
Finite-Lived Intangible Asset, Useful Life 1 year  
License [Member]    
Finite-Lived Intangible Assets [Line Items]    
 Total intangible assets, gross $ 1,307 $ 1,307
Finite-Lived Intangible Asset, Useful Life 3 years  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Remaining periods ended December 31, 2022 $ 1,669  
Year ended December 31, 2023 1,585  
Year ended December 31, 2024 1,222  
Year ended December 31, 2025 1,222  
Year ended December 31, 2026 890  
Thereafter 3,555  
Total intangible assets, net $ 10,143 $ 10,852
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Acquired Intangible Assets (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of Intangible Assets $ 709,000 $ 109,000
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
 Property, Plant and Equipment, Gross $ 13,814 $ 12,830
Less: accumulated depreciation (7,374) (6,883)
Total property, plant and equipment, net 6,440 5,947
Land [Member]    
Property, Plant and Equipment [Line Items]    
 Property, Plant and Equipment, Gross 352 352
Building Improvements [Member]    
Property, Plant and Equipment [Line Items]    
 Property, Plant and Equipment, Gross $ 1,729 1,729
Building Improvements [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 10 years  
Building Improvements [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 39 years  
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
 Property, Plant and Equipment, Gross $ 4,740 4,740
Machinery and Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 3 years  
Machinery and Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 7 years  
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
 Property, Plant and Equipment, Gross $ 4,936 4,330
Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 3 years  
Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 7 years  
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
 Property, Plant and Equipment, Gross $ 1,589 1,211
Computer Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 3 years  
Computer Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 5 years  
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
 Property, Plant and Equipment, Gross $ 468 $ 468
Property, Plant and Equipment, Useful Life 5 years  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant and Equipment (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Property, Plant and Equipment [Abstract]    
Depreciation $ 491 $ 428
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Unsecured Convertible Promissory Notes Payable (Details Narrative) - USD ($)
3 Months Ended
Feb. 28, 2022
Sep. 15, 2020
Mar. 31, 2022
Mar. 31, 2021
Short-Term Debt [Line Items]        
Debt conversion price $ 5.75      
Cash $ 1,440,548      
Remaining principal amount 1,400,000      
Accrued interest 40,548      
Conversion amount 1,150,000      
Debt instrument periodic payment 2,590,548      
Unsecured Debt [Member]        
Short-Term Debt [Line Items]        
Principal amount $ 600,000      
Shares issued 200,000      
Debt conversion price $ 3.00      
Unsecured Debt [Member] | Letter Agreement [Member]        
Short-Term Debt [Line Items]        
Principal amount $ 2,000,000      
September 2020 Notes [Member] | Unsecured Debt [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, Maturity Date   Sep. 15, 2020    
Principal amount   $ 10,000,000    
Debt conversion price   $ 3.00    
Debt Instrument, Interest Rate, Stated Percentage   10.00%    
Debt Conversion, Description   We have the right to prepay the outstanding September 2020 Note at any time after the 13-month anniversary of the initial issuance date after providing written notice to the Lender and may prepay the September 2020 Note prior to such time with the consent of the Lender. The Lender has the right, at any time, and from time to time, on and after the 13-month anniversary of the initial issuance date to convert up to an aggregate    
Convertible Debt   $ 3,000,000.0    
Interest Expense, Other     $ 233,000 $ 251,000
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Stock Options Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Equity [Abstract]    
Number of Shares Options Outstanding - Beginning 5,110  
Weighted Average Exercise Price Options Outstanding - Beginning $ 3.27  
Weighted Average Remaining Contractual Life 3 years 2 months 12 days 3 years 4 months 24 days
Total Intrinsic Value - Beginning $ 20,820  
Number of Shares, Forfeited (20)  
Weighted Average Exercise Price, Forfeited $ 8.99  
Total Intrinsic Value - Forfeited  
Number of Shares Options Outstanding - Ending 5,090 5,110
Weighted Average Exercise Price Options Outstanding - Ending $ 3.11 $ 3.27
Total Intrinsic Value - Ending $ 20,767 $ 20,820
Number of Shares Options Vested and Exercisable 4,069  
Weighted average exercise price, vested and exercisable $ 2.41  
Weighted Average Remaining Contractual Term, vested and exercisable 2 years 4 months 24 days  
Total Intrinsic Value, Options Vested and Exercisable $ 19,398  
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Warrant Activity (Details) - Warrant [Member]
shares in Thousands
3 Months Ended
Mar. 31, 2022
$ / shares
shares
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Shares Warrants Outstanding - Beginning | shares 855
Weighted Average Exercise Price Warrants Outstanding - Beginning | $ / shares $ 8.23
Weighted Average Remaining Contractual Life Warrants Outstanding - Beginning 1 year 10 months 24 days
Warrants granted | shares
Weighted Average Exercise Price, Warrants Granted | $ / shares
Weighted Average Remaining Contractual Life Warrants granted
Number of Shares Warrants Outstanding - Ending | shares 855
Weighted Average Exercise Price Warrants Outstanding - Ending | $ / shares $ 8.23
Weighted Average Remaining Contractual Life Warrants Outstanding - Ending 1 year 7 months 6 days
Number of Shares Warrants Vested and Exercisable | shares 855
Weighted Average Exercise Price, Warrants Vested and Exercisable | $ / shares $ 8.23
Weighted Average Remaining Contractual Life Warrants Vested and Exercisable 1 year 7 months 6 days
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 10, 2022
Feb. 14, 2022
Jun. 03, 2021
Feb. 14, 2021
Dec. 12, 2019
Jan. 24, 2019
Sep. 05, 2018
Apr. 12, 2018
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Sep. 08, 2021
May 20, 2021
Equity, Class of Treasury Stock [Line Items]                          
Common stock, shares authorized                 50,000,000   50,000,000    
Common stock, par value                 $ 0.0005   $ 0.0005    
Preferred stock, shares authorized                 1,000,000   1,000,000    
Preferred stock, par value                 $ 0.0005   $ 0.0005    
Preferred stock, shares issued                 0   0    
Common stock, dividends, per share, cash paid       $ 0.30                  
Payments of ordinary dividends, common stock   $ 4,600,000                      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number                 5,090,000   5,110,000    
Common Stock, Capital Shares Reserved for Future Issuance                 295,785        
Share-Based Payment Arrangement, Expense                 $ 2,746,000        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term                 3 years 2 months 12 days   3 years 4 months 24 days    
Inducement Option Award [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Business acquisition, share price                 $ 7.67        
Share-based pyment arrangement, plan modification, incremental cost                 $ 1,128,000        
Inducement Option Award [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, options, grants in period, gross                     100,000    
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage                 25.00%        
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price                     $ 0.0576    
Inducement Option Award [Member] | Next Three Years [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage                 25.00%        
Share-Based Payment Arrangement, Option [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term                 2 years 9 months 18 days        
Mr. Kamal Obbad [Member] | Inducement Option Award [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, accelerated vesting, number                 250,000        
Warrant [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-Based Payment Arrangement, Expense                 $ 0 $ 105,000      
2020 Directors Equity Compensation Plan [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-based compensation number of authorized shares                         775,000
2010 Directors Plan [Member] | Common Stock [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-based compensation number of authorized shares                 425,126        
Amended 2010 Plan [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-based compensation number of authorized shares                         4,900,000
Two Thousand Ten Equity Compensation Plan [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number                 2,014,874   2,014,874    
Common Stock, Capital Shares Reserved for Future Issuance                 295,785   295,785    
Share-Based Payment Arrangement, Expense                 $ 1,684,000        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term                 2 years 9 months 18 days        
2018 Stock Incentive Plan [Member] | CEO Options [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-based payment arrangement, option, exercise price range, upper range limit             $ 3.00            
2018 Stock Incentive Plan [Member] | Chief Executive Officer [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Stock Issued During Period, Shares, Employee Stock Ownership Plan               2,300,000          
Share-based compensation arrangement by share-based payment award, options, grants in period, gross               2,300,000          
2018 Stock Incentive Plan [Member] | CEO Options [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Share-based payment arrangement, option, exercise price range, upper range limit $ 1.20   $ 1.50   $ 1.75 $ 2.00              
Share-based payment arrangement, option, exercise price range, lower range limit 0.90   1.20   1.50 1.75 2.00            
2018 Stock Incentive Plan [Member] | Stockholders [Member] | CEO Options [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Common stock, dividends, per share, cash paid $ 0.30   $ 0.30   $ 0.2 $ 0.25 $ 1.00            
Share Repurchase Program [Member]                          
Equity, Class of Treasury Stock [Line Items]                          
Stock Repurchase Program, Remaining Authorized Repurchase Amount                       $ 6,000,000.0  
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.1
Defined Contribution Plans (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Retirement Benefits [Abstract]    
Defined contributions $ 52 $ 13
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Tax Disclosure [Abstract]    
Effective income tax rate 21.47%  
Effective income tax rate, federal 21.00%  
Effective income tax rate, state 7.10%  
Income tax expense $ 3,416
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Other Liabilities Disclosure [Abstract]    
Accrued commissions $ 1,294 $ 1,283
Accrued payroll 50 514
Accrued expenses 356 300
Accrued returns 246 338
Accrued benefits and vacation 50 60
Accrued insurance reimbursement 1,278
Total other current liabilities $ 3,274 $ 2,495
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Estimated Future Minimum Obligations (Details)
$ in Thousands
Mar. 31, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Remaining periods in 2022 $ 506
2023 675
2024 675
2025 675
2026 675
Total $ 3,206
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Quantitative Information About Operating Leases (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating leases    
Operating lease cost $ 204 $ 204
Operating lease expense 204 204
Total rent expense $ 204 $ 204
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Maturity of Operating Leases (Details)
$ in Thousands
Mar. 31, 2022
USD ($)
Leases  
Remaining Periods Ended December 31, 2022 $ 580
Year Ended December 31, 2023 738
Year Ended December 31, 2024 747
Year Ended December 31, 2025 768
Year Ended December 31, 2026 783
Thereafter 3,876
Total 7,492
Less present value discount (2,704)
Operating lease liabilities $ 4,788
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Details Narrative)
12 Months Ended
Dec. 08, 2020
USD ($)
Oct. 23, 2020
USD ($)
ft²
Dec. 31, 2021
USD ($)
Mar. 31, 2022
USD ($)
Operating lease, liability       $ 4,788,000
Operating lease, right-of-use asset     $ 4,402,000 4,319,000
Operating Lease Liabilities [Member]        
Operating lease, liability       4,800,000
Operating Lease Right Of Use Asset [Member]        
Operating lease, right-of-use asset       $ 4,300,000
Old Bridge New Jersey [Member]        
Lease term of contract 10 years      
Operating lease description We have the option to terminate the NY Lease on the sixth anniversary of the Commencement Date, provided that we give the landlord written notice not less than nine months and not more than 12 months in advance and that we pay the landlord a termination fee.      
Plaza Medical Laboratory Corp [Member]        
Area of land | ft²   4,000    
Confucius Labs [Member] | Old Bridge New Jersey [Member]        
Operating lease payments $ 56,963 $ 5,950    
Operating lease description For the first year of the NY Lease, we will pay a base rent of $56,963   We also have a right of first refusal to lease certain additional space located on the ground floor of the Building containing 4,500 square feet and 4,600 square feet, as more particularly described in the NY Lease. We also have a right of first offer to purchase the Building during the term of the NY Lease.  
Gradual rental rate increase percentage 2.75%      
Confucius Labs [Member] | Old Bridge New Jersey [Member] | Final Months [Member]        
Operating lease payments $ 74,716      
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.1
Consulting Agreement and Secured Promissory Note Receivable (Details Narrative) - USD ($)
2 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Jun. 25, 2021
Jan. 14, 2021
Sep. 25, 2020
Jul. 29, 2020
Jul. 21, 2020
Secured Debt       $ 0          
Accounts Receivable, Credit Loss Expense (Reversal)   $ (924,000)            
General and Administrative Expense [Member]                  
Accounts Receivable, Credit Loss Expense (Reversal)       3,750,000          
Investment Shares [Member]                  
Investment Owned, Balance, Shares         1,260,619        
Investment owned, at fair value       $ 76,000 $ 315,000        
Termination Agreement [Member]                  
Test fees received $ 95,000,000,000                
Unrelated Third party [Member] | Minimum [Member]                  
Debt Instrument, Face Amount           $ 2,750,000      
Unrelated Third party [Member] | Maximum [Member]                  
Debt Instrument, Face Amount           $ 3,750,000      
Unrelated Third party [Member] | Secured Debt [Member]                  
Debt Instrument, Face Amount             $ 1,000,000.0    
Unrelated Third party [Member] | Revision of Prior Period, Adjustment [Member] | Secured Debt [Member]                  
Debt Instrument, Face Amount             $ 3,000,000.0 $ 250,000 $ 750,000
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Customer Concentrations (Details Narrative) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Concentration Risk [Line Items]      
Revenues $ 47.5 $ 15.3  
Revenue Benchmark [Member] | Diagnostic Services Clients One [Member] | Customer Concentration Risk [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage 36.70% 46.10%  
Revenue Benchmark [Member] | Diagnostic Services Clients Two [Member] | Customer Concentration Risk [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage 21.40% 31.60%  
Revenue Benchmark [Member] | Diagnostic Services Clients Three [Member] | Customer Concentration Risk [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage 11.00%    
Trade Receivable [Member] | Diagnostic Services Clients One [Member] | Customer Concentration Risk [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage 33.60%   43.00%
Trade Receivable [Member] | Diagnostic Services Clients Two [Member] | Customer Concentration Risk [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage 26.50%   11.60%
Trade Receivable [Member] | Diagnostic Services Clients Three [Member] | Customer Concentration Risk [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage     10.70%
Trade Receivable [Member] | Diagnostic Services Clients Four [Member] | Customer Concentration Risk [Member]      
Concentration Risk [Line Items]      
Concentration risk, percentage     10.70%
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Segment Reporting Information [Line Items]      
Consolidated net revenue $ 47,531 $ 15,271  
Consolidated cost of revenue 18,854 6,344  
Total Depreciation and amortization expense 1,176 348  
Operating and other expenses 11,591 7,522  
Total income from operations, after income taxes 12,494 1,057  
Total income from operations, before income taxes 15,910 1,057  
Income tax expense (3,416)  
Net income 12,494 1,057  
Total assets 99,665   $ 89,295
Diagnostic Services [Member]      
Segment Reporting Information [Line Items]      
Consolidated net revenue 44,913 12,737  
Consolidated cost of revenue 16,702 4,345  
Total Depreciation and amortization expense 576 345  
Total income from operations, after income taxes 20,026 2,839  
Total assets 51,823   51,150
Consumer Products [Member]      
Segment Reporting Information [Line Items]      
Consolidated net revenue 2,618 2,534  
Consolidated cost of revenue 2,152 1,999  
Total Depreciation and amortization expense 600 3  
Total income from operations, after income taxes (1,863) (35)  
Total assets 23,378   24,139
Unallocated Corporate [Member]      
Segment Reporting Information [Line Items]      
Total income from operations, after income taxes (2,253) $ (1,747)  
Total assets $ 24,464   $ 14,006
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Earnings Per Share [Abstract]    
Net income - basic $ 12,494 $ 1,057
Interest on unsecured convertible promissory note 232
Net income - diluted $ 12,726 $ 1,057
Weighted average shares outstanding - basic 15,486 14,563
Diluted shares- Stock Options 2,232 2,895
Diluted shares- Stock Warrants 222 284
Unsecured convertible promissory note 800 458
Weighted average shares outstanding - diluted 18,740 18,200
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation (Details) - shares
shares in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 1,265 455
Common Stock Purchase Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 455 455
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 810
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.22.1
Related Parties (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Jason Karkus [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Annual base salary $ 55,000 $ 30,000
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Event (Details Narrative) - Subsequent Event [Member] - USD ($)
$ / shares in Units, $ in Millions
May 09, 2022
May 25, 2022
Subsequent Event [Line Items]    
Award vesting percentage 12.50%  
Exercise price per share $ 6.74  
Special cash dividend 0.30  
Dividend payable   $ 4.6
CEO Options [Member]    
Subsequent Event [Line Items]    
Exercise price of option 0.90  
Exercise price of option $ 0.60  
Mr White [Member]    
Subsequent Event [Line Items]    
Share-based compensation arrangement 400,000  
XML 81 form10-q_htm.xml IDEA: XBRL DOCUMENT 0000868278 2022-01-01 2022-03-31 0000868278 2022-05-13 0000868278 2022-03-31 0000868278 2021-12-31 0000868278 2021-01-01 2021-03-31 0000868278 us-gaap:CommonStockMember 2021-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000868278 us-gaap:RetainedEarningsMember 2021-12-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000868278 us-gaap:TreasuryStockMember 2021-12-31 0000868278 us-gaap:CommonStockMember 2020-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000868278 us-gaap:RetainedEarningsMember 2020-12-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000868278 us-gaap:TreasuryStockMember 2020-12-31 0000868278 2020-12-31 0000868278 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000868278 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000868278 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0000868278 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000868278 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000868278 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000868278 us-gaap:CommonStockMember 2022-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000868278 us-gaap:RetainedEarningsMember 2022-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000868278 us-gaap:TreasuryStockMember 2022-03-31 0000868278 us-gaap:CommonStockMember 2021-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000868278 us-gaap:RetainedEarningsMember 2021-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000868278 us-gaap:TreasuryStockMember 2021-03-31 0000868278 2021-03-31 0000868278 us-gaap:IPOMember 2021-01-01 2021-03-31 0000868278 PRPH:DiagnosticServicesMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesMember 2021-01-01 2021-03-31 0000868278 PRPH:InvestmentSharesMember 2021-06-25 0000868278 PRPH:InvestmentSharesMember 2021-12-31 0000868278 srt:MinimumMember 2022-01-01 2022-03-31 0000868278 srt:MaximumMember 2022-01-01 2022-03-31 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2022-01-01 2022-03-31 0000868278 PRPH:CooperativeIncentivePromotionCostsMember 2021-01-01 2021-03-31 0000868278 PRPH:USGovernmentObligationsMember 2022-03-31 0000868278 PRPH:CorporateObligationsMember 2022-03-31 0000868278 PRPH:USGovernmentObligationsMember 2021-12-31 0000868278 PRPH:CorporateObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:USGovernmentObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:USGovernmentObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:USGovernmentObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:CorporateObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:CorporateObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:CorporateObligationsMember 2022-03-31 0000868278 us-gaap:FairValueInputsLevel1Member 2022-03-31 0000868278 us-gaap:FairValueInputsLevel2Member 2022-03-31 0000868278 us-gaap:FairValueInputsLevel3Member 2022-03-31 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:USGovernmentObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:USGovernmentObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:USGovernmentObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel1Member PRPH:CorporateObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel2Member PRPH:CorporateObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel3Member PRPH:CorporateObligationsMember 2021-12-31 0000868278 us-gaap:FairValueInputsLevel1Member 2021-12-31 0000868278 us-gaap:FairValueInputsLevel2Member 2021-12-31 0000868278 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000868278 PRPH:ZeroToTwelveMonthsMember 2022-03-31 0000868278 PRPH:ZeroToTwelveMonthsMember 2021-12-31 0000868278 PRPH:ThirteenToTwentyFourMember 2022-03-31 0000868278 PRPH:ThirteenToTwentyFourMember 2021-12-31 0000868278 PRPH:OverTwentyFourMember 2022-03-31 0000868278 PRPH:OverTwentyFourMember 2021-12-31 0000868278 PRPH:DiagnosticServicesMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesMember 2021-01-01 2021-03-31 0000868278 PRPH:ContractManufacturingMember 2022-01-01 2022-03-31 0000868278 PRPH:ContractManufacturingMember 2021-01-01 2021-03-31 0000868278 PRPH:RetailAndOthersMember 2022-01-01 2022-03-31 0000868278 PRPH:RetailAndOthersMember 2021-01-01 2021-03-31 0000868278 PRPH:GenomicProductsAndServicesMember 2022-01-01 2022-03-31 0000868278 PRPH:GenomicProductsAndServicesMember 2021-01-01 2021-03-31 0000868278 PRPH:NebulaAcquisitionMember PRPH:NebulaStockPurchaseAgreementMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember PRPH:NebulaStockPurchaseAgreementMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember PRPH:CitiBankNAMember PRPH:NebulaStockPurchaseAgreementMember 2021-08-09 2021-08-10 0000868278 PRPH:MrKamalObbadMember PRPH:NebulaAcquisitionMember 2021-08-09 2021-08-10 0000868278 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:TradeNamesMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:TradeNamesMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:IntellectualPropertyMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:IntellectualPropertyMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-08-09 2021-08-10 0000868278 PRPH:NebulaAcquisitionMember 2021-08-10 0000868278 us-gaap:TradeNamesMember 2022-03-31 0000868278 us-gaap:TradeNamesMember 2021-12-31 0000868278 us-gaap:TradeNamesMember 2022-01-01 2022-03-31 0000868278 us-gaap:IntellectualPropertyMember 2022-03-31 0000868278 us-gaap:IntellectualPropertyMember 2021-12-31 0000868278 us-gaap:IntellectualPropertyMember 2022-01-01 2022-03-31 0000868278 us-gaap:CustomerRelationshipsMember 2022-03-31 0000868278 us-gaap:CustomerRelationshipsMember 2021-12-31 0000868278 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-03-31 0000868278 us-gaap:LicenseMember 2022-03-31 0000868278 us-gaap:LicenseMember 2021-12-31 0000868278 us-gaap:LicenseMember 2022-01-01 2022-03-31 0000868278 us-gaap:LandMember 2022-03-31 0000868278 us-gaap:LandMember 2021-12-31 0000868278 us-gaap:BuildingImprovementsMember 2022-03-31 0000868278 us-gaap:BuildingImprovementsMember 2021-12-31 0000868278 srt:MinimumMember us-gaap:BuildingImprovementsMember 2022-01-01 2022-03-31 0000868278 srt:MaximumMember us-gaap:BuildingImprovementsMember 2022-01-01 2022-03-31 0000868278 us-gaap:MachineryAndEquipmentMember 2022-03-31 0000868278 us-gaap:MachineryAndEquipmentMember 2021-12-31 0000868278 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-03-31 0000868278 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-03-31 0000868278 us-gaap:EquipmentMember 2022-03-31 0000868278 us-gaap:EquipmentMember 2021-12-31 0000868278 srt:MinimumMember us-gaap:EquipmentMember 2022-01-01 2022-03-31 0000868278 srt:MaximumMember us-gaap:EquipmentMember 2022-01-01 2022-03-31 0000868278 us-gaap:ComputerEquipmentMember 2022-03-31 0000868278 us-gaap:ComputerEquipmentMember 2021-12-31 0000868278 srt:MinimumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-03-31 0000868278 srt:MaximumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-03-31 0000868278 us-gaap:FurnitureAndFixturesMember 2022-03-31 0000868278 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000868278 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-03-31 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-09-13 2020-09-15 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2020-09-15 0000868278 us-gaap:UnsecuredDebtMember PRPH:LetterAgreementMember 2022-02-28 0000868278 us-gaap:UnsecuredDebtMember 2022-02-28 0000868278 us-gaap:UnsecuredDebtMember 2022-02-28 2022-02-28 0000868278 2022-02-28 0000868278 2022-02-28 2022-02-28 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2022-01-01 2022-03-31 0000868278 PRPH:SeptemberTwoThousandAndTwentyNoteMember us-gaap:UnsecuredDebtMember 2021-01-01 2021-03-31 0000868278 2021-02-14 2021-02-14 0000868278 2022-02-14 2022-02-14 0000868278 PRPH:ShareRepurchaseProgramMember 2021-09-08 0000868278 PRPH:TwoThousandAndTwentyDirectorsEquityCompensationPlanMember 2021-05-20 0000868278 PRPH:TwoThousandTenDirectorsPlanMember us-gaap:CommonStockMember 2022-03-31 0000868278 PRPH:AmendedTwoThousandTenPlanMember 2021-05-20 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2021-12-31 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2022-03-31 0000868278 PRPH:TwoThousandTenEquityCompensationPlanMember 2022-01-01 2022-03-31 0000868278 srt:ChiefExecutiveOfficerMember PRPH:TwoThousandEighteenStockIncentivePlanMember 2018-04-11 2018-04-12 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockIncentivePlanMember 2018-09-04 2018-09-05 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2018-09-04 2018-09-05 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2018-09-04 2018-09-05 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-01-23 2019-01-24 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-01-23 2019-01-24 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-12-11 2019-12-12 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2019-12-11 2019-12-12 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-06-02 2021-06-03 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2021-06-02 2021-06-03 0000868278 PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2022-03-10 2022-03-10 0000868278 PRPH:StockHoldersMember PRPH:CEOOptionsMember PRPH:TwoThousandEighteenStockMember 2022-03-10 2022-03-10 0000868278 PRPH:MrKamalObbadMember PRPH:InducementOptionAwardMember 2022-01-01 2022-03-31 0000868278 PRPH:InducementOptionAwardMember 2022-03-31 0000868278 PRPH:InducementOptionAwardMember 2022-01-01 2022-03-31 0000868278 PRPH:NextThreeYearsMember PRPH:InducementOptionAwardMember 2022-01-01 2022-03-31 0000868278 PRPH:InducementOptionAwardMember 2022-01-01 2022-03-31 0000868278 PRPH:InducementOptionAwardMember 2021-01-01 2021-12-31 0000868278 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000868278 us-gaap:WarrantMember 2022-01-01 2022-03-31 0000868278 us-gaap:WarrantMember 2021-01-01 2021-03-31 0000868278 2021-01-01 2021-12-31 0000868278 us-gaap:WarrantMember 2021-12-31 0000868278 us-gaap:WarrantMember 2022-03-31 0000868278 PRPH:PlazaMedicalLaboratoryCorpMember 2020-10-23 0000868278 PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2020-10-21 2020-10-23 0000868278 PRPH:OldBridgeNewJerseyMember 2020-12-08 0000868278 PRPH:OldBridgeNewJerseyMember 2020-12-07 2020-12-08 0000868278 PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2020-12-07 2020-12-08 0000868278 PRPH:FinalMonthsMember PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2020-12-07 2020-12-08 0000868278 PRPH:ConfuciusLabsMember PRPH:OldBridgeNewJerseyMember 2021-01-01 2021-12-31 0000868278 PRPH:OperatingLeaseLiabilitiesMember 2022-03-31 0000868278 PRPH:OperatingLeaseRightOfUseAssetMember 2022-03-31 0000868278 srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember PRPH:UnrelatedThirdPartyMember 2020-09-25 0000868278 us-gaap:SecuredDebtMember PRPH:UnrelatedThirdPartyMember 2020-09-25 0000868278 srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember PRPH:UnrelatedThirdPartyMember 2020-07-21 0000868278 srt:RestatementAdjustmentMember us-gaap:SecuredDebtMember PRPH:UnrelatedThirdPartyMember 2020-07-29 0000868278 srt:MinimumMember PRPH:UnrelatedThirdPartyMember 2021-01-14 0000868278 srt:MaximumMember PRPH:UnrelatedThirdPartyMember 2021-01-14 0000868278 PRPH:TerminationAgreementMember 2021-01-15 2021-02-28 0000868278 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0000868278 PRPH:DiagnosticServicesClientsOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesClientsTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesClientsThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesClientsOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0000868278 PRPH:DiagnosticServicesClientsTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0000868278 PRPH:DiagnosticServicesClientsOneMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesClientsTwoMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesClientsOneMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000868278 PRPH:DiagnosticServicesClientsTwoMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000868278 PRPH:DiagnosticServicesClientsThreeMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000868278 PRPH:DiagnosticServicesClientsFourMember PRPH:TradeReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000868278 PRPH:DiagnosticServicesMember 2022-01-01 2022-03-31 0000868278 PRPH:DiagnosticServicesMember 2021-01-01 2021-03-31 0000868278 PRPH:ConsumerProductsMember 2022-01-01 2022-03-31 0000868278 PRPH:ConsumerProductsMember 2021-01-01 2021-03-31 0000868278 PRPH:UnallocatedCorporateMember 2022-01-01 2022-03-31 0000868278 PRPH:UnallocatedCorporateMember 2021-01-01 2021-03-31 0000868278 PRPH:DiagnosticServicesMember 2022-03-31 0000868278 PRPH:DiagnosticServicesMember 2021-12-31 0000868278 PRPH:ConsumerProductsMember 2022-03-31 0000868278 PRPH:ConsumerProductsMember 2021-12-31 0000868278 PRPH:UnallocatedCorporateMember 2022-03-31 0000868278 PRPH:UnallocatedCorporateMember 2021-12-31 0000868278 PRPH:CommonStockPurchaseWarrantsMember 2022-01-01 2022-03-31 0000868278 PRPH:CommonStockPurchaseWarrantsMember 2021-01-01 2021-03-31 0000868278 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000868278 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000868278 PRPH:JasonKarkusMember 2022-01-01 2022-03-31 0000868278 PRPH:JasonKarkusMember 2021-01-01 2021-03-31 0000868278 PRPH:MrWhiteMember us-gaap:SubsequentEventMember 2022-05-08 2022-05-09 0000868278 us-gaap:SubsequentEventMember 2022-05-08 2022-05-09 0000868278 us-gaap:SubsequentEventMember 2022-05-09 0000868278 us-gaap:SubsequentEventMember 2022-05-25 0000868278 PRPH:CEOOptionsMember us-gaap:SubsequentEventMember 2022-05-08 2022-05-09 iso4217:USD shares iso4217:USD shares utr:sqft PRPH:Segment pure 0000868278 false --12-31 Q1 10-Q true 2022-03-31 2022 false 000-21617 ProPhase Labs, Inc. DE 23-2577138 711 Stewart Ave Suite 200 Garden City NY 11530 (215) 345-0919 Common Stock, par value $0.0005 PRPH NASDAQ Yes Yes Non-accelerated Filer true false false 15485900 25807000 8408000 250000 3543000 8779000 76000 36694000 37708000 4680000 4600000 1831000 1496000 72555000 61317000 6440000 5947000 251000 460000 4319000 4402000 10143000 10852000 5709000 5709000 248000 608000 99665000 89295000 8204000 7026000 1012000 1890000 95000 104000 654000 663000 2246000 2034000 4285000 1312000 3274000 2495000 19770000 15524000 858000 905000 443000 18000 44000 7997000 9996000 4134000 4198000 13450000 15143000 33220000 30667000 1000000 1000000 0.0005 0.0005 0 0 0 0 50000000 50000000 0.0005 0.0005 15485900 15485900 16000 16000 105634000 104552000 10490000 2642000 17018846 16818846 49557000 48407000 -138000 -175000 66445000 58628000 99665000 89295000 47531000 15271000 18854000 6344000 28677000 8927000 4672000 3809000 7824000 3782000 35000 115000 12531000 7706000 16146000 1221000 73000 87000 233000 251000 -76000 15910000 1057000 3416000 12494000 1057000 12494000 1057000 37000 -11000 12531000 1046000 0.81 0.07 0.68 0.06 15486 14563 18740 18200 15485900 16000 104552000 2642000 -175000 -48407000 58628000 200000 600000 600000 4646000 4646000 200000 1150000 1150000 37000 37000 482000 482000 12494000 12494000 15485900 16000 105634000 10490000 -138000 -49557000 66445000 11604253 14000 61674000 -3631000 -11000 -47490000 10556000 2365000 3000000 2000 35133000 35135000 550000 5500000 5500000 -11000 -11000 428000 428000 1057000 1057000 15154253 16000 102735000 -2574000 -22000 -47490000 52665000 12494000 1057000 -179000 -2000 1249000 536000 1000 2000 83000 85000 23000 482000 428000 -76000 -924000 25000 -1938000 11178000 105000 12987000 126000 -2243000 -360000 8000 1178000 4009000 -878000 165000 -443000 -73000 101000 2973000 770000 7818000 20287000 -7892000 1000000 206000 2005000 5300000 100000 85000 1095000 3927000 4084000 -6832000 35135000 5500000 1426000 1150000 4646000 -7222000 40635000 17149000 25911000 8658000 6816000 25807000 32727000 241000 250000 600000 37000 -11000 <p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zyvXgiFFHmY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span id="xdx_829_zovb2mCr3pU6">Organization and Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase Labs, Inc. (“ProPhase”, “we”, “us”, “our” or the “Company”) is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. We provide traditional CLIA molecular laboratory services, including SARS-CoV-2 (“COVID-19”) testing and seek to leverage our Clinical Laboratory Improvement Amendments (“CLIA”) accredited laboratory services to provide whole genome sequencing and research direct to consumers, while building a genomics database to be used for further research. In addition, we have deep experience with over-the-counter (“OTC”) consumer healthcare products and dietary supplements. We currently conduct our operations through two operating segments: diagnostic services and consumer products. Until late Fiscal 2020, we were engaged primarily in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. However, commencing in December 2020, we also began offering COVID-19 and other Respiratory Pathogen Panel (RPP) molecular tests through our diagnostic services business, and in August 2021 we began offering personal genomics products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our wholly owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (“PCR”) testing for COVID-19. Critical to COVID-19 testing, we provide fast turnaround times for results. We also offer rapid antigen and antibody/immunity testing for COVID-19. On October 23, 2020, we acquired Confucius Plaza Medical Laboratory Corp. (“CPM”), which included a non-operating but certified 4,000 square foot CLIA accredited laboratory located in Old Bridge, New Jersey. In December 2020, we expanded our diagnostic service business with the build-out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in January 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 10, 2021, we acquired Nebula Genomics, Inc. (“Nebula”), a privately owned personal genomics company, through our new wholly owned subsidiary, ProPhase Precision Medicine, Inc. (“ProPhase Precision”) (see Note 3, Business Acquisitions). ProPhase Precision focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our wholly owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also develop and market dietary supplements under the TK Supplements® brand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zDsP3dhlKd19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - <span id="xdx_82C_z61AJXWMoCK">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z451uKONil2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and other comprehensive loss and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of operating results that may be achieved over the course of the full year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zyazgigt6vR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with FASB ASC 280, “Segment Reporting” (“ASC 280”), the Company discloses financial and descriptive information about its reportable operating segments. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> ASC 280 establishes standards for reporting information about operating segments in annual and interim financial statements and requires that companies report financial and descriptive information about their reportable segments based on a management approach. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and major customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating segments are defined as components of an enterprise that engage in business activities for which separate financial information is available and is evaluated by the Chief Operating Decision Maker (“CODM”), which for the Company is its Chief Executive Officer, in deciding how to allocate resources and assess performance. We maintain two operating segments: diagnostic services (which includes our COVID-19 and other diagnostic testing services) and consumer products (which includes our contract manufacturing, retail customers and personal genomics products and services) (see Note 15 Segment Information).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_845_eus-gaap--UnusualRisksAndUncertaintiesTextBlock_z3RlQ7YTngN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business and Liquidity Risks and Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We launched our diagnostic service business in December 2020 and expanded in January 2021 with the opening of our Garden City, New York CLIA accredited laboratory. Our diagnostic service business is and will continue to be influenced by the level of demand for COVID-19 and other diagnostic testing, how long this demand persists, the prices we are able to receive for performing our testing services, our ability to collect payment or reimbursement for our testing services, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While our revenues increased significantly for the year ended December 31, 2021 and the first quarter of fiscal 2022 as a result of the launch of our diagnostic services business, we will continue to be dependent on both government agency and insurance company reimbursement as well as the prevalence of COVID-19 associated strains.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), was enacted, providing for reimbursement to healthcare providers for COVID-19 tests provided to uninsured individuals, subject to continued available funding. Approximately <span id="xdx_90F_ecustom--RevenuePercentage_pid_dp_c20220101__20220331__srt--ProductOrServiceAxis__custom--DiagnosticServicesMember_zg3timjCUjMl" title="Percentage of revenue from diagnostic services">69</span>% and <span id="xdx_905_ecustom--RevenuePercentage_pid_dp_c20210101__20210331__srt--ProductOrServiceAxis__custom--DiagnosticServicesMember_zQKkMzTNdnie" title="Percentage of revenue from diagnostic services">57</span>% of our diagnostic services revenue for the three months ended March 31, 2022 and 2021, respectively was generated from this program for the uninsured. On March 22, 2022, the Health Resources &amp; Services Administration (HRSA) program stopped accepting claims for COVID-19 testing and treatment due to lack of sufficient funds. Despite requests from the Acting Director of the Office of Management and Budget and the White House Coordinator for COVID-19 Response for additional emergency funding for the uninsured program, emergency funding has not been allocated to the HRSA uninsured program as of the financial statement issuance date. <span id="xdx_90F_eus-gaap--RisksAndUncertaintiesInEntitysBusiness_c20220101__20220331_zvuJXwuMJfi">We continue to perform testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize any revenue related to COVID-19 testing that we performed for uninsured individuals from March 23, 2022 through March 31, 2022.</span> If funding for the HRSA program is reinstituted in the future, we will submit eligible claims for reimbursement to HRSA and record the associated revenues. If the HRSA program remains unfunded and we are unable to submit claims for reimbursement, there could be a material adverse effect on our business and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> our diagnostic service business is subject to extensive federal, state, and local laws and regulations, all of which are subject to change, as well as laws and regulations governing the submission of claims for payment for our services, such as those relating to: coverage of our services under Medicare, Medicaid and other federal health care programs; the amounts that we may bill for our services; and the party to which we must submit claims. Also, reimbursement policies and requirements for some payers and procedures are ambiguous, which could lead to billing errors and related disputes. There can be no assurance that our efforts to offer and perform COVID-19 or other diagnostic testing will be successful in the future or that the revenue and operating profits from such business will increase or maintain their current level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We acquired and commenced our personal genomics business in August 2021. This business is and will continue to be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our consumer sales are and will continue to be influenced by (i) the timing of acceptance of our TK Supplements<sup>®</sup> consumer products in the marketplace, and (ii) fluctuations in the timing of purchase and the ultimate level of demand for the OTC healthcare and cold remedy products that we manufacture, which is largely a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period from September to March when the incidence of the common cold rises as a result of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net revenues from our contract manufacturing business. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2022, $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_c20220101__20220331_zM00pODAhbya" title="Net cash provided by (used in) operating activities">20.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million was provided by operating activities. The Company had cash, cash equivalents and marketable securities of $<span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20220331_zdFGCUuuVQy6">29.4 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of March 31, 2022. Based on management’s current business plans, the Company estimates it will have enough cash and liquidity to finance its operating requirements for at least 12 months from the date of filing these unaudited condensed consolidated financial statements. <span style="background-color: white">However, due to the nature of the diagnostic business and the Company’s focus thus far on COVID-19 testing, there are inherent uncertainties associated with managements’ business plan and cash flow projections, particularly if the Company is unable to grow its diagnostic testing business beyond COVID-19 testing services.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company’s future capital needs and the adequacy of its available funds will depend on the Company’s ability to achieve sustained profitability from its diagnostic services, the Company’s ability to successfully diversify its diagnostic services revenue streams and the Company’s ability to market and grow its personal genomics business. The Company may be required to raise additional funds through equity or debt securities offerings or strategic collaboration and/or licensing agreements in order to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Company’s failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--UseOfEstimates_zLdd8INKAh9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration of diagnostic test reimbursement rates, the provision for uncollectible receivables and billing errors, allowances, slow moving and/or dated inventory and associated provisions, the potential impairment of long-lived assets, stock based compensation valuations, income tax asset valuations and assumptions related to accrued advertising.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the condensed consolidated financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBhrdAks0FKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zIgNbWoHgVs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted Cash</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash as of December 31, 2021 includes approximately $<span id="xdx_909_eus-gaap--RestrictedCash_iI_pn3d_c20211231_zOVg0m3Ucebk">250,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">held in escrow related to a potential purchase of an additional lab facility. The potential purchase was not consummated, and we are pursuing the return of the escrow, which is in dispute. As of March 31, 2022, we recognized an expense for this balance as the recovery of the funds was no longer considered probable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_849_ecustom--MarketableDebtSecuritiesPolicyTextBlock_zOfddevehpZ7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable Debt Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have classified our investments in marketable debt securities as available-for-sale and as a current asset. Our investments in marketable debt securities are carried at fair value, with unrealized gains and as a separate component of stockholders’ equity. Realized gains and losses from our marketable debt securities are recorded as interest income (expense). These investments in marketable debt securities carry maturity dates between one and three years from date of purchase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--MarketableSecuritiesTextBlock_zoKcFVkXFvoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (in thousands) (see fair value of financial instruments):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z70ZWyxW8xRl" style="display: none">Summary of Components of Marketable Securities</span></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortized</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gains</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Losses</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_z2DBlEF6EZ2a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zXbC55pv9WTa" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zIcqzHN8LiOj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(44</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zDj7ou7fwSoc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">746</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zYblleBh8J7a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,839</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdn3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zHXLBgKHEjQg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zXhl1wH2IXxi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(42</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zjTlkeoDSWl6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331_zHRrgOzC1OC5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,506</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pn3n3_c20220331_zqSsJmmWCEpj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20220331_zZH4nD88UfT2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(86</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20220331_z063xN9puKq5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">650</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdn3_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zTNc2J0wElti" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0609">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,304</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pdn3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0615">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zpKri6ycDHUi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(192</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,954</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20211231_zBcnwgVMvwq5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(192</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--MarketableSecuritiesCurrent_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AE_zveK5N83t42d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--MarketableSecuritiesPolicy_zQk4hzrUf8nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable Equity Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within other non-operating income, net in the consolidated statements of income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 25, 2021, we were issued <span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_zItkxV2zuKq4" title="Investment owned, balance shares">1,260,619 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common shares (the “Investment Shares”) as an interest payment under our note receivable (see Note 13, Consulting Agreement and Secured Promissory Note Receivable) with a fair value of $<span id="xdx_906_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3d_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_zJAgZTimKTIe" title="Investment owned, at fair value">315,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the time of issuance and a fair value of $<span id="xdx_903_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3d_c20211231__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_zPU1TPv40Dj3">76,000</span> at December 31, 2021.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The investment was classified as a Level 1 financial instrument. We recorded a $<span id="xdx_904_ecustom--ChangeInFairValueOfInvestmentSecurities_iN_di_c20220101__20220331_zUjB6pFjGHP1" title="Fair value of investment securities">76,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decrease in fair value of investment securities within the statement of operations for the three months ended March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zLuviEnd2hu1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts Receivable, net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable consists primarily of amounts due from government agencies and healthcare insurers. Unbilled accounts receivable relates to the delivery of our diagnostic testing services for which the related billings will occur in a future period, after a patient’s insurance information has been validated, and represent amounts for which we have a right to receive payment. Unbilled accounts receivable is classified as accounts receivable on the consolidated balance sheet. We carry our accounts receivable at the amount of consideration for which we expect to be entitled less allowances. When estimating the allowances for our diagnostics business, the Company pools its receivables based on the following payer types: healthcare insurers and government payers. The Company principally estimates the allowances by pool based on historical collection experience, current economic conditions, government and healthcare insurer payment trends, and the period of time that the receivables have been outstanding. Should a payer’s reimbursement policy change or their credit quality deteriorate, the Company removes the payer from their respective pools and establishes allowances based on the individual risk characteristics of such payer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zHgORi0Z6NOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zbimDBRoEPml" style="display: none">Schedule of Accounts Receivable Net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20220331_zO24fdy09Rk5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20211231" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--TradeAccountsReceivable_iI_pn3n3_maARGzdW0_z0ZgIyueExQd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,727</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--UnbilledContractsReceivable_iI_pn3n3_maARGzdW0_zPS5MtI6EDV5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unbilled accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,944</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,089</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccountsReceivableGross_iTI_pn3n3_mtARGzdW0_maARNzV61_zdEhnjO44xR8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Accounts receivable, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,671</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,609</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_pn3n3_di_msARNzV61_zxio24rz9Bs3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less allowances</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,977</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,901</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_402_eus-gaap--AccountsReceivableNet_iTI_pn3n3_mtARNzV61_zR9KUWkaaj7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,694</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,708</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zYearezbOpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zSNJUzRgjfP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventory, net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is valued at the lower of cost, determined on a first-in, first-out basis (“FIFO”), or net realizable value. Inventory items are analyzed to determine cost and the net realizable value and appropriate valuation adjustments are established.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zHjYkHTGiDD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2022 and December 31, 2021, the components of inventory are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zoE5h8q6MKdi" style="display: none">Schedule of Components of Inventory</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220331_zItQ0FM6I2yf" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20211231_zGKVc5de9dI2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--InventoryLabMaterial_iI_pn3n3_maIGzHJR_zEfytrCuNcCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services testing material</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,103</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,989</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzHJR_zlkOdU01xRj4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw materials</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,238</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,514</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maIGzHJR_zQHJGRJ3dm4c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work in process</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">476</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzHJR_zuxOJUfWgRS2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished goods</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">322</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--InventoryGross_iTI_pn3n3_mtIGzHJR_maINzpPz_zHLn56nYbwn5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,139</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,035</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzpPz_z7adAEk93h45" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory valuation reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(459</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(435</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--InventoryNet_iTI_pn3n3_mtINzpPz_zYyEKPpocOke" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,680</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_z7PQ0fYuihM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKNZE2Ofapk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property, Plant and Equipment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20220331_zhVV1wZJEhn" title="Description of property plant and equipment useful lives">ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zbUjg0CEPEL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Financial Risks</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2022, our cash and cash equivalents and restricted cash balance was $<span id="xdx_90A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_pn5n6_c20220331_zr9FKVzp03Od" title="Cash and cash equivalents and restricted cash balance">25.8</span> million. Of the total bank balance, $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn5n6_c20220331_zMG20LsMwFF7" title="Federal depository insurance">0.9</span> million was covered by federal depository insurance and $<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20220331_z2QNG3utVFgj" title="Uninsured">24.9</span> million was uninsured at March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection rates. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depends on information provided to the payors and meeting their requirements for reimbursement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zdsioiraBer5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. We have elected not to recognize on the balance sheet leases with terms of 12 months or less. We typically only include an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in our assessment unless there is reasonable certainty that we will renew.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in our leases is typically not readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 12, Leases).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of a lease should be allocated between lease components (<i>e.g</i>., land, building, etc.) and non-lease components (<i>e.g</i>., common area maintenance, consumables, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zTmfeHl0UoH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Goodwill and Intangible Assets</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying identifiable assets and liabilities acquired in a business combination. Goodwill and intangible assets deemed to have an indefinite life are not amortized, but instead are assessed for impairment annually. Additionally, if an event or change in circumstances occurs that would more likely than not reduce the fair value of the reporting unit below its carrying value, we would evaluate goodwill at that time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In testing for goodwill impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, we conclude that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If we conclude otherwise, we are required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than the carrying value, an impairment charge will be recorded to reduce the reporting unit to fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets deemed to have finite lives are amortized on a straight-line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to our future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzrfZJGebOBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair Value of Financial Instruments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are the hierarchical levels of inputs to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, and unsecured note payable, approximate their fair values because of the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity securities change in fair value reported on the condensed consolidated statement of operations. The components of marketable securities are as follows (in thousands):</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zWnZGlKgSC5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_z5IPrL77TKwa" style="display: none">Schedule of Fair Value of Financial Instruments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zO9STRJgPZA7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zqcXCOJBtH8k" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">746</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zBEzmLiDt9m4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zmkfU7cNpugd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">746</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zuMEErVs33zc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zUj0RwjXn6V6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zliSjAplygTf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zlbg9LiPrHN6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAduZ6lh2G2b" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwLhACoJWN04" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUBwH43iUHEk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0722">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331_zTBcAFgmLUhd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0726">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--MarketableSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--MarketableSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable equity securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pdn3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdn3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdn3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--MarketableSecurities_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,855</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zFc11YqdUwY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no transfers of marketable debt securities between Levels 1, 2 or 3 for the three months ended March 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zQ9r0cmmfpd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue Recognition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. We recognize revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract with Customers and Performance Obligations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Sales from product shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. Revenue from diagnostic services is recognized when the results are made available to the customer. Revenue from our personal genomics business is recognized when the genetic testing results are provided to the customer. For subscription services associated with our genomic testing, we recognize revenue ratably over the term of the subscription.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transaction Price</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For contract manufacturing and retail customers, the transaction price is fixed based upon either (i) the terms of a combined master agreement and each related purchase order, or (ii) if there is no master agreement, the price per individual purchase order received from each customer. The customers are invoiced at an agreed upon contractual price for each unit ordered and delivered by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from retail customers is reduced for trade promotions, estimated sales returns and other allowances in the same period as the related sales are recorded. No such allowance is applicable to our contract manufacturing customers. We estimate potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not accept returns from our contract manufacturing customers. Our return policy for retail customers accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time during which product may be returned. All requests for product returns must be submitted to us for pre-approval. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will accept return requests only for products in their intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our diagnostic services business, a revenue transaction is initiated when we receive a requisition order to perform a diagnostic test. The information provided on the requisition form is used to determine the party that will be billed for the testing performed and the expected reimbursement. We provide diagnostic services to a range of customers. In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or Medicaid program and other government reimbursement programs. We bill the providers at standard price and take into consideration negotiated discounts and anticipated reimbursement remittance adjustments based on the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that vary from the listed contract price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our personal genomics business, a revenue transaction is initiated by a DNA test kit sale direct to the consumer sales via our website or through online retailers. The kit sales and subscriptions are billed at a standard price and take into consideration any discounts when revenue is recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognize Revenue When the Company Satisfies a Performance Obligation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition for</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> contract manufacturing and retail customers is satisfied at a point in time when the goods are shipped to the customer as (i) we have transferred control of the assets to the customers upon shipping, and (ii) the customer obtains title and assumes the risks and rewards of ownership after the goods are shipped.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For diagnostic services, recognition occurs at the point in time that the results are made available to the customer, which is when the customer benefits from the information contained in the results and obtains control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For genomic services, we satisfy our product performance obligation at a point in time when the genetic testing results are provided to the customer. For subscriptions services associated with its genomic testing, we satisfy our performance obligation ratably over the subscription period. If the customer does not return the test kit, services cannot be completed by us, potentially resulting in unexercised rights (“breakage”) revenue, including lifetime subscription services. We estimate breakage for the portion of test kits not expected to be returned using an analysis of historical data and consider other factors that could influence customer test kit return behavior. When breakage revenue is recognized on a kit, we recognize breakage on any associated subscription services ratably over the term of the subscription. The Company recognized breakage revenue from aggregate unreturned test kits and subscriptions of $<span id="xdx_901_ecustom--BreakageRevenue_pn5n6_c20220101__20220331_zijbHoQUxYT3" title="Breakage revenue">0.4</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for the three months ended March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract Balances</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenues primarily consist of amounts that have been billed to or received from customers in advance of revenue recognition and prepayments received from customers in advance of services performed for the R&amp;D work.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> As of March 31, 2022 and December 31, 2021, we have deferred revenue of $<span id="xdx_906_eus-gaap--ContractWithCustomerLiability_iI_pn5n6_c20220331_zWHFiMxGz2pd">3.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_901_eus-gaap--ContractWithCustomerLiability_iI_pn5n6_c20211231_zoRMW6UbCNud">2.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively. Our new personal genomics business comprised $<span id="xdx_904_eus-gaap--DeferredRevenue_iI_pn5n6_c20220331_zYVIZi8btJO5">2.9</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the deferred revenue as of March 31, 2022. The deferred revenue balance within the personal genomics business is comprised of kits to be sequenced and subscription services, which have an average life between <span id="xdx_900_ecustom--ContractWithCustomerEstimatedLife_dtM_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_znCc3gr8QVCi">12 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_906_ecustom--ContractWithCustomerEstimatedLife_dtM_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_zHKFYjgvFDq3">36 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">months.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The remainder of deferred revenue relates to research and development (“R&amp;D”) stability and release testing programs recognized as contract manufacturing revenue. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zCWCoYbMJFz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates our deferred revenue by recognition period (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zdSRzQpWxw76" style="display: none">Schedule of Deferred Revenue</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition Period</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0-12 Months</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_zqdy5D0zr8pj" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,246</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ContractWithCustomerLiability_c20211231__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-24 Months</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_zCAf0kxopT5i" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">598</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_c20211231__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">530</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over 24 Months</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331__srt--StatementScenarioAxis__custom--OverTwentyFourMember_zKpfXvoAkxw6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ContractWithCustomerLiability_c20211231__srt--StatementScenarioAxis__custom--OverTwentyFourMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">375</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331_zkmzP8r1rgWl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,104</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zQQGZKc3aTrl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,939</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_z8ld1qnsOd83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregation of Revenue</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We disaggregate revenue from contracts with customers into four categories: diagnostic services, contract manufacturing, retail and others, and genomic products and services. We determined that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_zO1sKLVGMi36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates the Company’s revenue by revenue source for the three months ended March 31, 2022 and 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_z0a3jBzy9775" style="display: none">Schedule of Disaggregation by Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue by Customer Type</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DiagnosticServicesMember_zzxnVFExvVYi" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DiagnosticServicesMember_z1k0L6g5AZG3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,738</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract manufacturing</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractManufacturingMember_zkUdOrHAUBO8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,154</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractManufacturingMember_z9LmlmVjz5V2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,908</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retail and others</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--RetailAndOthersMember_zz9IU4XWZoNa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">546</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--RetailAndOthersMember_zPrJ61s0PHi5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">625</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genomic products and services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--GenomicProductsAndServicesMember_zFFqRV4d4Abb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">918</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--GenomicProductsAndServicesMember_zfA9c6osQP19" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total revenue, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331_z4Nvax7dxSK9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,531</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331_ztYzFJCnL23l" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,271</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zw1pl1gOPLp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Customer Consideration</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company makes payments to certain diagnostic services customers for distinct services that approximate the fair value for those services. Such services include specimen collection, the collection and delivery of insurance and patient information necessary for billing and collection, and logistics services. Consideration associated with specimen collection services is classified in cost of revenues and the remaining costs are classified as diagnostic expenses within operating expenses in the accompanying statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales Tax Exclusion from the Transaction Price</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shipping and Handling Activities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for shipping and handling activities that we perform as activities to fulfill the promise to transfer the good.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zvan2mGnuWkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advertising and Incentive Promotions</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of general and administrative expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net revenue, and (iii) free product, which is accounted for as part of cost of revenues. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2022 and 2021 were $<span id="xdx_900_eus-gaap--AdvertisingExpense_pn3d_c20220101__20220331__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zx2TSiuC4l7i" title="Advertising and incentive promotion expenses">60,000</span> and $<span id="xdx_907_eus-gaap--AdvertisingExpense_pn3d_c20210101__20210331__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zFo23uUUtugl" title="Advertising and incentive promotion expenses">168,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zIeWGWEOmSF8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based Compensation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation in accordance with FASB ASC 718, “Compensation - Stock Compensation.” Under the fair value recognition provision of the ASC, stock-based compensation cost is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options and warrants granted using the Black-Scholes-Merton option pricing model and stock grants at their closing reported market value. We recognize all stock-based payments to employees and directors, including grants of stock options, as compensation expense in the condensed consolidated financial statements based on their grant date fair values. The grant date fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. We account for forfeitures as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock and stock options to purchase our common stock have been granted to employees pursuant to the terms of certain agreements and stock option plans (see Note 7, Stockholders’ Equity). Stock options are exercisable during a period determined by us, but in no event later than seven years from the date granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_z1k59WgHtjX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research and Development (“R&amp;D”)</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D costs are charged to operations in the period incurred. R&amp;D costs incurred for the three months ended March 31, 2022 and 2021 were $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn3d_c20220101__20220331_zhfXmoTjZ7ie">35,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pn3d_c20210101__20210331_zOefkItWiES" title="R&amp;D costs incurred">115,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively. R&amp;D costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products, dietary supplements and validation costs in association with the diagnostic services business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zcjl3udjU7Ti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income Taxes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. We evaluate, on a quarterly basis whether, based on all available evidence, it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740- 10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for uncertainties in income taxes under the provisions of FASB ASC 740-10-05 (the “Subtopic”). The Subtopic clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The Subtopic prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Subtopic provides guidance on the de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJPflmiOAgfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently Issued Accounting Standards, Adopted</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Financial Accounting Standards Board (“FASB”) recently issued Accounting Standards Update (“ASU”) 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</i>, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, <i>Earnings Per Share</i>, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The adoption of ASU 2020-06 did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84F_ecustom--RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_zpf3FNpmFWTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently Issued Accounting Standards, Not Yet Adopted</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.</span></p> <p id="xdx_85D_zgvCeFzezMui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z451uKONil2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and other comprehensive loss and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of operating results that may be achieved over the course of the full year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84E_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zyazgigt6vR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Segments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with FASB ASC 280, “Segment Reporting” (“ASC 280”), the Company discloses financial and descriptive information about its reportable operating segments. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> ASC 280 establishes standards for reporting information about operating segments in annual and interim financial statements and requires that companies report financial and descriptive information about their reportable segments based on a management approach. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and major customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating segments are defined as components of an enterprise that engage in business activities for which separate financial information is available and is evaluated by the Chief Operating Decision Maker (“CODM”), which for the Company is its Chief Executive Officer, in deciding how to allocate resources and assess performance. We maintain two operating segments: diagnostic services (which includes our COVID-19 and other diagnostic testing services) and consumer products (which includes our contract manufacturing, retail customers and personal genomics products and services) (see Note 15 Segment Information).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_845_eus-gaap--UnusualRisksAndUncertaintiesTextBlock_z3RlQ7YTngN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business and Liquidity Risks and Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We launched our diagnostic service business in December 2020 and expanded in January 2021 with the opening of our Garden City, New York CLIA accredited laboratory. Our diagnostic service business is and will continue to be influenced by the level of demand for COVID-19 and other diagnostic testing, how long this demand persists, the prices we are able to receive for performing our testing services, our ability to collect payment or reimbursement for our testing services, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While our revenues increased significantly for the year ended December 31, 2021 and the first quarter of fiscal 2022 as a result of the launch of our diagnostic services business, we will continue to be dependent on both government agency and insurance company reimbursement as well as the prevalence of COVID-19 associated strains.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), was enacted, providing for reimbursement to healthcare providers for COVID-19 tests provided to uninsured individuals, subject to continued available funding. Approximately <span id="xdx_90F_ecustom--RevenuePercentage_pid_dp_c20220101__20220331__srt--ProductOrServiceAxis__custom--DiagnosticServicesMember_zg3timjCUjMl" title="Percentage of revenue from diagnostic services">69</span>% and <span id="xdx_905_ecustom--RevenuePercentage_pid_dp_c20210101__20210331__srt--ProductOrServiceAxis__custom--DiagnosticServicesMember_zQKkMzTNdnie" title="Percentage of revenue from diagnostic services">57</span>% of our diagnostic services revenue for the three months ended March 31, 2022 and 2021, respectively was generated from this program for the uninsured. On March 22, 2022, the Health Resources &amp; Services Administration (HRSA) program stopped accepting claims for COVID-19 testing and treatment due to lack of sufficient funds. Despite requests from the Acting Director of the Office of Management and Budget and the White House Coordinator for COVID-19 Response for additional emergency funding for the uninsured program, emergency funding has not been allocated to the HRSA uninsured program as of the financial statement issuance date. <span id="xdx_90F_eus-gaap--RisksAndUncertaintiesInEntitysBusiness_c20220101__20220331_zvuJXwuMJfi">We continue to perform testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize any revenue related to COVID-19 testing that we performed for uninsured individuals from March 23, 2022 through March 31, 2022.</span> If funding for the HRSA program is reinstituted in the future, we will submit eligible claims for reimbursement to HRSA and record the associated revenues. If the HRSA program remains unfunded and we are unable to submit claims for reimbursement, there could be a material adverse effect on our business and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> our diagnostic service business is subject to extensive federal, state, and local laws and regulations, all of which are subject to change, as well as laws and regulations governing the submission of claims for payment for our services, such as those relating to: coverage of our services under Medicare, Medicaid and other federal health care programs; the amounts that we may bill for our services; and the party to which we must submit claims. Also, reimbursement policies and requirements for some payers and procedures are ambiguous, which could lead to billing errors and related disputes. There can be no assurance that our efforts to offer and perform COVID-19 or other diagnostic testing will be successful in the future or that the revenue and operating profits from such business will increase or maintain their current level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We acquired and commenced our personal genomics business in August 2021. This business is and will continue to be influenced by demand for our genetic testing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our consumer sales are and will continue to be influenced by (i) the timing of acceptance of our TK Supplements<sup>®</sup> consumer products in the marketplace, and (ii) fluctuations in the timing of purchase and the ultimate level of demand for the OTC healthcare and cold remedy products that we manufacture, which is largely a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period from September to March when the incidence of the common cold rises as a result of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net revenues from our contract manufacturing business. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2022, $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_c20220101__20220331_zM00pODAhbya" title="Net cash provided by (used in) operating activities">20.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million was provided by operating activities. The Company had cash, cash equivalents and marketable securities of $<span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20220331_zdFGCUuuVQy6">29.4 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of March 31, 2022. Based on management’s current business plans, the Company estimates it will have enough cash and liquidity to finance its operating requirements for at least 12 months from the date of filing these unaudited condensed consolidated financial statements. <span style="background-color: white">However, due to the nature of the diagnostic business and the Company’s focus thus far on COVID-19 testing, there are inherent uncertainties associated with managements’ business plan and cash flow projections, particularly if the Company is unable to grow its diagnostic testing business beyond COVID-19 testing services.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company’s future capital needs and the adequacy of its available funds will depend on the Company’s ability to achieve sustained profitability from its diagnostic services, the Company’s ability to successfully diversify its diagnostic services revenue streams and the Company’s ability to market and grow its personal genomics business. The Company may be required to raise additional funds through equity or debt securities offerings or strategic collaboration and/or licensing agreements in order to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Company’s failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.69 0.57 We continue to perform testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize any revenue related to COVID-19 testing that we performed for uninsured individuals from March 23, 2022 through March 31, 2022. 20300000 29400000 <p id="xdx_84A_eus-gaap--UseOfEstimates_zLdd8INKAh9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration of diagnostic test reimbursement rates, the provision for uncollectible receivables and billing errors, allowances, slow moving and/or dated inventory and associated provisions, the potential impairment of long-lived assets, stock based compensation valuations, income tax asset valuations and assumptions related to accrued advertising.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the condensed consolidated financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBhrdAks0FKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zIgNbWoHgVs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted Cash</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash as of December 31, 2021 includes approximately $<span id="xdx_909_eus-gaap--RestrictedCash_iI_pn3d_c20211231_zOVg0m3Ucebk">250,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">held in escrow related to a potential purchase of an additional lab facility. The potential purchase was not consummated, and we are pursuing the return of the escrow, which is in dispute. As of March 31, 2022, we recognized an expense for this balance as the recovery of the funds was no longer considered probable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 250000 <p id="xdx_849_ecustom--MarketableDebtSecuritiesPolicyTextBlock_zOfddevehpZ7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable Debt Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have classified our investments in marketable debt securities as available-for-sale and as a current asset. Our investments in marketable debt securities are carried at fair value, with unrealized gains and as a separate component of stockholders’ equity. Realized gains and losses from our marketable debt securities are recorded as interest income (expense). These investments in marketable debt securities carry maturity dates between one and three years from date of purchase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--MarketableSecuritiesTextBlock_zoKcFVkXFvoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (in thousands) (see fair value of financial instruments):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z70ZWyxW8xRl" style="display: none">Summary of Components of Marketable Securities</span></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortized</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gains</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Losses</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_z2DBlEF6EZ2a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zXbC55pv9WTa" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zIcqzHN8LiOj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(44</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zDj7ou7fwSoc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">746</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zYblleBh8J7a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,839</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdn3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zHXLBgKHEjQg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zXhl1wH2IXxi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(42</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zjTlkeoDSWl6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331_zHRrgOzC1OC5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,506</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pn3n3_c20220331_zqSsJmmWCEpj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20220331_zZH4nD88UfT2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(86</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20220331_z063xN9puKq5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">650</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdn3_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zTNc2J0wElti" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0609">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,304</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pdn3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0615">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zpKri6ycDHUi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(192</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,954</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20211231_zBcnwgVMvwq5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(192</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--MarketableSecuritiesCurrent_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AE_zveK5N83t42d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--MarketableSecuritiesTextBlock_zoKcFVkXFvoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (in thousands) (see fair value of financial instruments):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z70ZWyxW8xRl" style="display: none">Summary of Components of Marketable Securities</span></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortized</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gains</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Losses</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_z2DBlEF6EZ2a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zXbC55pv9WTa" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zIcqzHN8LiOj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(44</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zDj7ou7fwSoc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">746</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zYblleBh8J7a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,839</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pdn3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zHXLBgKHEjQg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zXhl1wH2IXxi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(42</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zjTlkeoDSWl6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20220331_zHRrgOzC1OC5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,506</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pn3n3_c20220331_zqSsJmmWCEpj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20220331_zZH4nD88UfT2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(86</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20220331_z063xN9puKq5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">650</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pdn3_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zTNc2J0wElti" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0609">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,304</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pdn3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0615">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zpKri6ycDHUi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(192</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortized Cost"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,954</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Gains"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20211231_zBcnwgVMvwq5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized Losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(192</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--MarketableSecuritiesCurrent_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 667000 123000 44000 746000 2839000 42000 2797000 3506000 123000 86000 3543000 650000 17000 667000 8304000 192000 8112000 8954000 17000 192000 8779000 <p id="xdx_84C_eus-gaap--MarketableSecuritiesPolicy_zQk4hzrUf8nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable Equity Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within other non-operating income, net in the consolidated statements of income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 25, 2021, we were issued <span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_zItkxV2zuKq4" title="Investment owned, balance shares">1,260,619 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common shares (the “Investment Shares”) as an interest payment under our note receivable (see Note 13, Consulting Agreement and Secured Promissory Note Receivable) with a fair value of $<span id="xdx_906_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3d_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_zJAgZTimKTIe" title="Investment owned, at fair value">315,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the time of issuance and a fair value of $<span id="xdx_903_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3d_c20211231__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_zPU1TPv40Dj3">76,000</span> at December 31, 2021.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The investment was classified as a Level 1 financial instrument. We recorded a $<span id="xdx_904_ecustom--ChangeInFairValueOfInvestmentSecurities_iN_di_c20220101__20220331_zUjB6pFjGHP1" title="Fair value of investment securities">76,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decrease in fair value of investment securities within the statement of operations for the three months ended March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1260619 315000 76000 -76000 <p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zLuviEnd2hu1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts Receivable, net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable consists primarily of amounts due from government agencies and healthcare insurers. Unbilled accounts receivable relates to the delivery of our diagnostic testing services for which the related billings will occur in a future period, after a patient’s insurance information has been validated, and represent amounts for which we have a right to receive payment. Unbilled accounts receivable is classified as accounts receivable on the consolidated balance sheet. We carry our accounts receivable at the amount of consideration for which we expect to be entitled less allowances. When estimating the allowances for our diagnostics business, the Company pools its receivables based on the following payer types: healthcare insurers and government payers. The Company principally estimates the allowances by pool based on historical collection experience, current economic conditions, government and healthcare insurer payment trends, and the period of time that the receivables have been outstanding. Should a payer’s reimbursement policy change or their credit quality deteriorate, the Company removes the payer from their respective pools and establishes allowances based on the individual risk characteristics of such payer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zHgORi0Z6NOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zbimDBRoEPml" style="display: none">Schedule of Accounts Receivable Net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20220331_zO24fdy09Rk5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20211231" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--TradeAccountsReceivable_iI_pn3n3_maARGzdW0_z0ZgIyueExQd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,727</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--UnbilledContractsReceivable_iI_pn3n3_maARGzdW0_zPS5MtI6EDV5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unbilled accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,944</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,089</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccountsReceivableGross_iTI_pn3n3_mtARGzdW0_maARNzV61_zdEhnjO44xR8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Accounts receivable, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,671</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,609</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_pn3n3_di_msARNzV61_zxio24rz9Bs3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less allowances</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,977</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,901</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_402_eus-gaap--AccountsReceivableNet_iTI_pn3n3_mtARNzV61_zR9KUWkaaj7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,694</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,708</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zYearezbOpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zHgORi0Z6NOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zbimDBRoEPml" style="display: none">Schedule of Accounts Receivable Net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20220331_zO24fdy09Rk5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20211231" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--TradeAccountsReceivable_iI_pn3n3_maARGzdW0_z0ZgIyueExQd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,727</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--UnbilledContractsReceivable_iI_pn3n3_maARGzdW0_zPS5MtI6EDV5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unbilled accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,944</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,089</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccountsReceivableGross_iTI_pn3n3_mtARGzdW0_maARNzV61_zdEhnjO44xR8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Accounts receivable, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,671</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,609</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_pn3n3_di_msARNzV61_zxio24rz9Bs3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less allowances</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,977</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,901</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_402_eus-gaap--AccountsReceivableNet_iTI_pn3n3_mtARNzV61_zR9KUWkaaj7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,694</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,708</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 24727000 18520000 14944000 23089000 39671000 41609000 2977000 3901000 36694000 37708000 <p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zSNJUzRgjfP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventory, net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is valued at the lower of cost, determined on a first-in, first-out basis (“FIFO”), or net realizable value. Inventory items are analyzed to determine cost and the net realizable value and appropriate valuation adjustments are established.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zHjYkHTGiDD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2022 and December 31, 2021, the components of inventory are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zoE5h8q6MKdi" style="display: none">Schedule of Components of Inventory</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220331_zItQ0FM6I2yf" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20211231_zGKVc5de9dI2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--InventoryLabMaterial_iI_pn3n3_maIGzHJR_zEfytrCuNcCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services testing material</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,103</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,989</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzHJR_zlkOdU01xRj4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw materials</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,238</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,514</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maIGzHJR_zQHJGRJ3dm4c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work in process</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">476</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzHJR_zuxOJUfWgRS2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished goods</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">322</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--InventoryGross_iTI_pn3n3_mtIGzHJR_maINzpPz_zHLn56nYbwn5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,139</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,035</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzpPz_z7adAEk93h45" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory valuation reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(459</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(435</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--InventoryNet_iTI_pn3n3_mtINzpPz_zYyEKPpocOke" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,680</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_z7PQ0fYuihM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zHjYkHTGiDD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2022 and December 31, 2021, the components of inventory are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zoE5h8q6MKdi" style="display: none">Schedule of Components of Inventory</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220331_zItQ0FM6I2yf" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20211231_zGKVc5de9dI2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--InventoryLabMaterial_iI_pn3n3_maIGzHJR_zEfytrCuNcCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services testing material</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,103</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,989</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzHJR_zlkOdU01xRj4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw materials</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,238</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,514</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maIGzHJR_zQHJGRJ3dm4c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work in process</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">476</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzHJR_zuxOJUfWgRS2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished goods</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">322</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--InventoryGross_iTI_pn3n3_mtIGzHJR_maINzpPz_zHLn56nYbwn5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,139</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,035</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzpPz_z7adAEk93h45" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory valuation reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(459</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(435</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--InventoryNet_iTI_pn3n3_mtINzpPz_zYyEKPpocOke" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,680</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 3103000 2989000 1238000 1514000 476000 260000 322000 272000 5139000 5035000 459000 435000 4680000 4600000 <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKNZE2Ofapk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property, Plant and Equipment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes. Depreciation expense is computed in accordance with the following <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20220331_zhVV1wZJEhn" title="Description of property plant and equipment useful lives">ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years <p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zbUjg0CEPEL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Financial Risks</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain cash and cash equivalents with certain major financial institutions. As of March 31, 2022, our cash and cash equivalents and restricted cash balance was $<span id="xdx_90A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_pn5n6_c20220331_zr9FKVzp03Od" title="Cash and cash equivalents and restricted cash balance">25.8</span> million. Of the total bank balance, $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn5n6_c20220331_zMG20LsMwFF7" title="Federal depository insurance">0.9</span> million was covered by federal depository insurance and $<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20220331_z2QNG3utVFgj" title="Uninsured">24.9</span> million was uninsured at March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection rates. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depends on information provided to the payors and meeting their requirements for reimbursement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 25800000 900000 24900000 <p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zdsioiraBer5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. We have elected not to recognize on the balance sheet leases with terms of 12 months or less. We typically only include an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in our assessment unless there is reasonable certainty that we will renew.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in our leases is typically not readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 12, Leases).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of a lease should be allocated between lease components (<i>e.g</i>., land, building, etc.) and non-lease components (<i>e.g</i>., common area maintenance, consumables, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zTmfeHl0UoH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Goodwill and Intangible Assets</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying identifiable assets and liabilities acquired in a business combination. Goodwill and intangible assets deemed to have an indefinite life are not amortized, but instead are assessed for impairment annually. Additionally, if an event or change in circumstances occurs that would more likely than not reduce the fair value of the reporting unit below its carrying value, we would evaluate goodwill at that time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In testing for goodwill impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, we conclude that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If we conclude otherwise, we are required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than the carrying value, an impairment charge will be recorded to reduce the reporting unit to fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets deemed to have finite lives are amortized on a straight-line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to our future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzrfZJGebOBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair Value of Financial Instruments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are the hierarchical levels of inputs to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, and unsecured note payable, approximate their fair values because of the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity securities change in fair value reported on the condensed consolidated statement of operations. The components of marketable securities are as follows (in thousands):</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zWnZGlKgSC5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_z5IPrL77TKwa" style="display: none">Schedule of Fair Value of Financial Instruments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zO9STRJgPZA7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zqcXCOJBtH8k" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">746</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zBEzmLiDt9m4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zmkfU7cNpugd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">746</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zuMEErVs33zc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zUj0RwjXn6V6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zliSjAplygTf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zlbg9LiPrHN6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAduZ6lh2G2b" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwLhACoJWN04" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUBwH43iUHEk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0722">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331_zTBcAFgmLUhd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0726">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--MarketableSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--MarketableSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable equity securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pdn3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdn3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdn3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--MarketableSecurities_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,855</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zFc11YqdUwY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no transfers of marketable debt securities between Levels 1, 2 or 3 for the three months ended March 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zWnZGlKgSC5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_z5IPrL77TKwa" style="display: none">Schedule of Fair Value of Financial Instruments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zO9STRJgPZA7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zqcXCOJBtH8k" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">746</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zBEzmLiDt9m4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_zmkfU7cNpugd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">746</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zuMEErVs33zc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zUj0RwjXn6V6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zliSjAplygTf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_zlbg9LiPrHN6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAduZ6lh2G2b" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwLhACoJWN04" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_pdn3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUBwH43iUHEk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0722">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_pn3n3_c20220331_zTBcAFgmLUhd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. government obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0726">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--MarketableSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--USGovernmentObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">667</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pdn3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--MarketableSecurities_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable equity securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pdn3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdn3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNi_c20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateObligationsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Marketable equity securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--MarketableSecurities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdn3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--MarketableSecurities_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value of marketable debt securities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,855</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 746000 746000 2797000 2797000 3543000 3543000 667000 667000 8112000 8112000 76000 76000 76000 8779000 8855000 <p id="xdx_842_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zQ9r0cmmfpd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue Recognition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. We recognize revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract with Customers and Performance Obligations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Sales from product shipments to contract manufacturing and retailer customers are recognized at the time ownership is transferred to the customer. Revenue from diagnostic services is recognized when the results are made available to the customer. Revenue from our personal genomics business is recognized when the genetic testing results are provided to the customer. For subscription services associated with our genomic testing, we recognize revenue ratably over the term of the subscription.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transaction Price</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For contract manufacturing and retail customers, the transaction price is fixed based upon either (i) the terms of a combined master agreement and each related purchase order, or (ii) if there is no master agreement, the price per individual purchase order received from each customer. The customers are invoiced at an agreed upon contractual price for each unit ordered and delivered by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from retail customers is reduced for trade promotions, estimated sales returns and other allowances in the same period as the related sales are recorded. No such allowance is applicable to our contract manufacturing customers. We estimate potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not accept returns from our contract manufacturing customers. Our return policy for retail customers accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time during which product may be returned. All requests for product returns must be submitted to us for pre-approval. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will accept return requests only for products in their intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our diagnostic services business, a revenue transaction is initiated when we receive a requisition order to perform a diagnostic test. The information provided on the requisition form is used to determine the party that will be billed for the testing performed and the expected reimbursement. We provide diagnostic services to a range of customers. In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or Medicaid program and other government reimbursement programs. We bill the providers at standard price and take into consideration negotiated discounts and anticipated reimbursement remittance adjustments based on the payer portfolio, when revenue is recorded. We use the most expected value method to estimate the transaction price for reimbursements that vary from the listed contract price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our personal genomics business, a revenue transaction is initiated by a DNA test kit sale direct to the consumer sales via our website or through online retailers. The kit sales and subscriptions are billed at a standard price and take into consideration any discounts when revenue is recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognize Revenue When the Company Satisfies a Performance Obligation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition for</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> contract manufacturing and retail customers is satisfied at a point in time when the goods are shipped to the customer as (i) we have transferred control of the assets to the customers upon shipping, and (ii) the customer obtains title and assumes the risks and rewards of ownership after the goods are shipped.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For diagnostic services, recognition occurs at the point in time that the results are made available to the customer, which is when the customer benefits from the information contained in the results and obtains control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For genomic services, we satisfy our product performance obligation at a point in time when the genetic testing results are provided to the customer. For subscriptions services associated with its genomic testing, we satisfy our performance obligation ratably over the subscription period. If the customer does not return the test kit, services cannot be completed by us, potentially resulting in unexercised rights (“breakage”) revenue, including lifetime subscription services. We estimate breakage for the portion of test kits not expected to be returned using an analysis of historical data and consider other factors that could influence customer test kit return behavior. When breakage revenue is recognized on a kit, we recognize breakage on any associated subscription services ratably over the term of the subscription. The Company recognized breakage revenue from aggregate unreturned test kits and subscriptions of $<span id="xdx_901_ecustom--BreakageRevenue_pn5n6_c20220101__20220331_zijbHoQUxYT3" title="Breakage revenue">0.4</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for the three months ended March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract Balances</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenues primarily consist of amounts that have been billed to or received from customers in advance of revenue recognition and prepayments received from customers in advance of services performed for the R&amp;D work.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> As of March 31, 2022 and December 31, 2021, we have deferred revenue of $<span id="xdx_906_eus-gaap--ContractWithCustomerLiability_iI_pn5n6_c20220331_zWHFiMxGz2pd">3.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_901_eus-gaap--ContractWithCustomerLiability_iI_pn5n6_c20211231_zoRMW6UbCNud">2.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively. Our new personal genomics business comprised $<span id="xdx_904_eus-gaap--DeferredRevenue_iI_pn5n6_c20220331_zYVIZi8btJO5">2.9</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the deferred revenue as of March 31, 2022. The deferred revenue balance within the personal genomics business is comprised of kits to be sequenced and subscription services, which have an average life between <span id="xdx_900_ecustom--ContractWithCustomerEstimatedLife_dtM_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_znCc3gr8QVCi">12 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_906_ecustom--ContractWithCustomerEstimatedLife_dtM_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_zHKFYjgvFDq3">36 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">months.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The remainder of deferred revenue relates to research and development (“R&amp;D”) stability and release testing programs recognized as contract manufacturing revenue. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zCWCoYbMJFz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates our deferred revenue by recognition period (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zdSRzQpWxw76" style="display: none">Schedule of Deferred Revenue</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition Period</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0-12 Months</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_zqdy5D0zr8pj" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,246</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ContractWithCustomerLiability_c20211231__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-24 Months</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_zCAf0kxopT5i" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">598</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_c20211231__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">530</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over 24 Months</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331__srt--StatementScenarioAxis__custom--OverTwentyFourMember_zKpfXvoAkxw6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ContractWithCustomerLiability_c20211231__srt--StatementScenarioAxis__custom--OverTwentyFourMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">375</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331_zkmzP8r1rgWl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,104</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zQQGZKc3aTrl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,939</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_z8ld1qnsOd83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregation of Revenue</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We disaggregate revenue from contracts with customers into four categories: diagnostic services, contract manufacturing, retail and others, and genomic products and services. We determined that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_zO1sKLVGMi36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates the Company’s revenue by revenue source for the three months ended March 31, 2022 and 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_z0a3jBzy9775" style="display: none">Schedule of Disaggregation by Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue by Customer Type</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DiagnosticServicesMember_zzxnVFExvVYi" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DiagnosticServicesMember_z1k0L6g5AZG3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,738</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract manufacturing</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractManufacturingMember_zkUdOrHAUBO8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,154</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractManufacturingMember_z9LmlmVjz5V2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,908</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retail and others</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--RetailAndOthersMember_zz9IU4XWZoNa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">546</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--RetailAndOthersMember_zPrJ61s0PHi5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">625</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genomic products and services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--GenomicProductsAndServicesMember_zFFqRV4d4Abb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">918</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--GenomicProductsAndServicesMember_zfA9c6osQP19" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total revenue, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331_z4Nvax7dxSK9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,531</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331_ztYzFJCnL23l" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,271</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zw1pl1gOPLp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Customer Consideration</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company makes payments to certain diagnostic services customers for distinct services that approximate the fair value for those services. Such services include specimen collection, the collection and delivery of insurance and patient information necessary for billing and collection, and logistics services. Consideration associated with specimen collection services is classified in cost of revenues and the remaining costs are classified as diagnostic expenses within operating expenses in the accompanying statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales Tax Exclusion from the Transaction Price</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shipping and Handling Activities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for shipping and handling activities that we perform as activities to fulfill the promise to transfer the good.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 400000 3100000 2900000 2900000 P12M P36M <p id="xdx_899_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zCWCoYbMJFz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates our deferred revenue by recognition period (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zdSRzQpWxw76" style="display: none">Schedule of Deferred Revenue</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition Period</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0-12 Months</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_zqdy5D0zr8pj" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,246</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ContractWithCustomerLiability_c20211231__srt--StatementScenarioAxis__custom--ZeroToTwelveMonthsMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-24 Months</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_zCAf0kxopT5i" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">598</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_c20211231__srt--StatementScenarioAxis__custom--ThirteenToTwentyFourMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">530</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over 24 Months</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331__srt--StatementScenarioAxis__custom--OverTwentyFourMember_zKpfXvoAkxw6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ContractWithCustomerLiability_c20211231__srt--StatementScenarioAxis__custom--OverTwentyFourMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">375</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220331_zkmzP8r1rgWl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,104</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zQQGZKc3aTrl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,939</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2246000 2034000 598000 530000 260000 375000 3104000 2939000 <p id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_zO1sKLVGMi36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates the Company’s revenue by revenue source for the three months ended March 31, 2022 and 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_z0a3jBzy9775" style="display: none">Schedule of Disaggregation by Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue by Customer Type</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DiagnosticServicesMember_zzxnVFExvVYi" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DiagnosticServicesMember_z1k0L6g5AZG3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,738</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract manufacturing</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractManufacturingMember_zkUdOrHAUBO8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,154</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractManufacturingMember_z9LmlmVjz5V2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,908</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retail and others</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--RetailAndOthersMember_zz9IU4XWZoNa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">546</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--RetailAndOthersMember_zPrJ61s0PHi5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">625</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genomic products and services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--GenomicProductsAndServicesMember_zFFqRV4d4Abb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">918</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--GenomicProductsAndServicesMember_zfA9c6osQP19" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total revenue, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220331_z4Nvax7dxSK9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,531</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331_ztYzFJCnL23l" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue, net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,271</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 44913000 12738000 1154000 1908000 546000 625000 918000 47531000 15271000 <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zvan2mGnuWkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advertising and Incentive Promotions</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of general and administrative expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net revenue, and (iii) free product, which is accounted for as part of cost of revenues. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2022 and 2021 were $<span id="xdx_900_eus-gaap--AdvertisingExpense_pn3d_c20220101__20220331__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zx2TSiuC4l7i" title="Advertising and incentive promotion expenses">60,000</span> and $<span id="xdx_907_eus-gaap--AdvertisingExpense_pn3d_c20210101__20210331__us-gaap--ValuationAllowancesAndReservesTypeAxis__custom--CooperativeIncentivePromotionCostsMember_zFo23uUUtugl" title="Advertising and incentive promotion expenses">168,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 60000 168000 <p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zIeWGWEOmSF8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based Compensation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation in accordance with FASB ASC 718, “Compensation - Stock Compensation.” Under the fair value recognition provision of the ASC, stock-based compensation cost is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options and warrants granted using the Black-Scholes-Merton option pricing model and stock grants at their closing reported market value. We recognize all stock-based payments to employees and directors, including grants of stock options, as compensation expense in the condensed consolidated financial statements based on their grant date fair values. The grant date fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. We account for forfeitures as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock and stock options to purchase our common stock have been granted to employees pursuant to the terms of certain agreements and stock option plans (see Note 7, Stockholders’ Equity). Stock options are exercisable during a period determined by us, but in no event later than seven years from the date granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_z1k59WgHtjX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research and Development (“R&amp;D”)</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D costs are charged to operations in the period incurred. R&amp;D costs incurred for the three months ended March 31, 2022 and 2021 were $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn3d_c20220101__20220331_zhfXmoTjZ7ie">35,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pn3d_c20210101__20210331_zOefkItWiES" title="R&amp;D costs incurred">115,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively. R&amp;D costs are principally related to personnel expenses and new product development initiatives and costs associated with our OTC health care products, dietary supplements and validation costs in association with the diagnostic services business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 35000 115000 <p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zcjl3udjU7Ti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income Taxes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. We evaluate, on a quarterly basis whether, based on all available evidence, it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740- 10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for uncertainties in income taxes under the provisions of FASB ASC 740-10-05 (the “Subtopic”). The Subtopic clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The Subtopic prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Subtopic provides guidance on the de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJPflmiOAgfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently Issued Accounting Standards, Adopted</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Financial Accounting Standards Board (“FASB”) recently issued Accounting Standards Update (“ASU”) 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</i>, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, <i>Earnings Per Share</i>, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities, excluding smaller reporting companies, for fiscal years beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The adoption of ASU 2020-06 did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84F_ecustom--RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_zpf3FNpmFWTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently Issued Accounting Standards, Not Yet Adopted</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. We are currently assessing the impact of the adoption of this ASU on our financial statements.</span></p> <p id="xdx_807_eus-gaap--BusinessCombinationDisclosureTextBlock_zFJDEUNcQnUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 - <span id="xdx_824_zqa6KgqGEpoj">Business Acquisition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nebula Acquisition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 10, 2021 (the “Effective Date”), the Company and its wholly owned subsidiary, ProPhase Precision, entered into and closed a Stock Purchase Agreement (the “Nebula Stock Purchase Agreement”) with Nebula, each of the stockholders of Nebula (the “Seller Parties”), and Kamal Obbad, as Seller Party Representative. Pursuant to the terms of the Nebula Stock Purchase Agreement, ProPhase Precision acquired all of the issued and outstanding shares of common stock of Nebula from the Seller Parties, for an aggregate purchase price of approximately $<span id="xdx_90E_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--TypeOfArrangementAxis__custom--NebulaStockPurchaseAgreementMember_zwJHd0y2Sue" title="Payments for repurchase of common stock">14.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, subject to post-closing adjustments (the “Nebula Acquisition”). A portion of the purchase price equal to $<span id="xdx_90B_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_pn5n6_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zfNnxbDRMO72" title="Business acquisition, purchase price">3.6 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million was paid in shares of the Company’s common stock to certain Seller Parties and noteholders of Nebula, based on their election to receive shares of the Company’s common stock in lieu of cash, which shares were valued at a price per share of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--TypeOfArrangementAxis__custom--NebulaStockPurchaseAgreementMember_zqpE2TIj81Gf" title="Shares issued, price per share">7.46</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, which is equal to the average closing price of the Company’s common stock on Nasdaq for the five trading days preceding the signing of the Nebula Stock Purchase Agreement. A portion of the purchase price equal to $<span id="xdx_907_ecustom--PurchasePriceOfEscrowAmount_pn3d_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--CreditFacilityAxis__custom--CitiBankNAMember__us-gaap--TypeOfArrangementAxis__custom--NebulaStockPurchaseAgreementMember_zWeUVc0pAdg" title="Purchase price">1,080,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the “Escrow Amount”) is being held in escrow by Citibank, N.A. (the “Escrow Agent”) until <span id="xdx_906_ecustom--EscrowMaturityDate_dd_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--CreditFacilityAxis__custom--CitiBankNAMember__us-gaap--TypeOfArrangementAxis__custom--NebulaStockPurchaseAgreementMember_zkq7OdT0NWq3" title="Escrow termination date">February 23, 2023</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(“Escrow Termination Date”), pursuant to the terms and conditions of an escrow agreement entered into with the Escrow Agent, as security for the indemnification obligations of the Seller Parties. At the Escrow Termination Date, the remaining amount, if any, of the Escrow Amount, less any amount reasonably necessary to pay any claim with respect to which a notice of claim has been timely and properly given, will be delivered to the Seller Parties, as applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Nebula Acquisition, ProPhase Precision entered into an employment agreement with Kamal Obbad, the Chief Executive Officer of Nebula, on the Effective Date, pursuant to which Mr. Obbad serves as Senior Vice President, Director of Sales and Marketing of ProPhase Precision. As a condition to the employment agreement, Mr. Obbad was awarded a stock option to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210809__20210810__srt--TitleOfIndividualAxis__custom--MrKamalObbadMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zo2Ptdiw5E27" title="Stock options to purchase shares">250,000</span> shares of Company common stock at an exercise price equal to $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210809__20210810__srt--TitleOfIndividualAxis__custom--MrKamalObbadMember__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_ztPy5VVP0Ima" title="Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price">7.67</span> per share, the closing price of the Company common stock on the Effective Date (see Note 7, Stockholders’ Equity).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the valuation, the total consideration of $<span id="xdx_90A_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zm06EY8bq3Za" title="Business combination consideration">12.7 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, which is net of $<span id="xdx_900_eus-gaap--CashAcquiredFromAcquisition_pn5n6_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zSgzLIdNIFPd" title="Cash acquired from acquisition">1.6 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in cash acquired, has been allocated to assets acquired and liabilities assumed based on their respective fair values as follows (in thousands):</span></p> <p id="xdx_891_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_z6ca3puBk4u2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z4cKyCXMVrB1" style="display: none">Schedule of Assets Acquired and Liabilities Assumed</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20210810_zdvgJh85dwO1" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationAssetsAndLiabilitiesShortTermInvestments_iI_maCzedZ_zfBgTGEOwyMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short term investments</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,800</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maCzedZ_zATYl8o75mpg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_maCzedZ_zgBZRV1FB399" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maCzedZ_zbF8LoU7v0ol" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">379</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_maCzedZ_zQfBgr6IauBe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definite-lived intangible assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,990</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_mtCzedZ_maCzRHl_zIv9OTx8Hnia" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets acquired</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,473</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_maCz1l2_z5AeJ19nQVXc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(805</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_iNI_di_maCz1l2_zWQdVeQqGFTg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(43</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_iNI_di_maCz1l2_zrU3T3F2DQah" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,391</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_iNI_di_maCz1l2_zQ6ztZSzM0mj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(81</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_maCz1l2_zbaATR59Eqz7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,925</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_di_mtCz1l2_msCzRHl_zqqo3yAjCXqa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total liabilities assumed</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,245</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtCzRHl_maCzdsJ_zh26dkEqwGvh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net identifiable assets acquired</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,228</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--Goodwill_iI_maCzdsJ_zZFPKqT9oPhh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,446</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTI_pn3n3_mtCzdsJ_zPlzVHjWahek" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total consideration, net of cash acquired <span id="xdx_F4F_z4PKziDOCdbi">(1)</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,674</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F09_zNKEmg7fTVu1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zyFmlpZIox0f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFzc2V0cyBBY3F1aXJlZCBhbmQgTGlhYmlsaXRpZXMgQXNzdW1lZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--CashAcquiredFromAcquisition_pn5n6_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zQdAu4p6ger5" title="Cash acquired from acquisition">1.6</span> million cash acquired.</span></td></tr> </table> <p id="xdx_8A6_zmPZAUjpRZ3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired. The Company believes the goodwill related to the acquisition was a result of the expected synergies to be realized from combining operations and is not deductible for income tax purposes. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zghWRiZbWgz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intangible assets identified in conjunction with the Nebula Acquisition are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_ztNLhp7eUggf" style="display: none">Schedule of Intangible Assets Acquisition</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying Value</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated Useful Life (in years)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade names</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Gross carying value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_ziCSPUN0T8E1" title="Estimated useful life (in years)">15</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proprietary intellectual property</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross carying value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zSf0GtuJ3nMk" title="Estimated useful life (in years)">5</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer relationships</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross carying value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,180</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zbs6LiH9vIh4" title="Estimated useful life (in years)">1</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross carying value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,990</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zwt3efFZvTI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 14300000 3600000 7.46 1080000 2023-02-23 250000 7.67 12700000 1600000 <p id="xdx_891_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_z6ca3puBk4u2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z4cKyCXMVrB1" style="display: none">Schedule of Assets Acquired and Liabilities Assumed</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20210810_zdvgJh85dwO1" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationAssetsAndLiabilitiesShortTermInvestments_iI_maCzedZ_zfBgTGEOwyMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short term investments</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,800</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maCzedZ_zATYl8o75mpg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_maCzedZ_zgBZRV1FB399" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maCzedZ_zbF8LoU7v0ol" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">379</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_maCzedZ_zQfBgr6IauBe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definite-lived intangible assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,990</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_mtCzedZ_maCzRHl_zIv9OTx8Hnia" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets acquired</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,473</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_maCz1l2_z5AeJ19nQVXc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(805</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_iNI_di_maCz1l2_zWQdVeQqGFTg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(43</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_iNI_di_maCz1l2_zrU3T3F2DQah" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,391</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable_iNI_di_maCz1l2_zQ6ztZSzM0mj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(81</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_maCz1l2_zbaATR59Eqz7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,925</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_di_mtCz1l2_msCzRHl_zqqo3yAjCXqa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total liabilities assumed</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,245</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtCzRHl_maCzdsJ_zh26dkEqwGvh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net identifiable assets acquired</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,228</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--Goodwill_iI_maCzdsJ_zZFPKqT9oPhh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,446</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTI_pn3n3_mtCzdsJ_zPlzVHjWahek" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total consideration, net of cash acquired <span id="xdx_F4F_z4PKziDOCdbi">(1)</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,674</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F09_zNKEmg7fTVu1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zyFmlpZIox0f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFzc2V0cyBBY3F1aXJlZCBhbmQgTGlhYmlsaXRpZXMgQXNzdW1lZCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--CashAcquiredFromAcquisition_pn5n6_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_zQdAu4p6ger5" title="Cash acquired from acquisition">1.6</span> million cash acquired.</span></td></tr> </table> 1800000 171000 133000 379000 10990000 13473000 805000 43000 2391000 81000 1925000 5245000 8228000 4446000 12674000 1600000 <p id="xdx_894_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zghWRiZbWgz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intangible assets identified in conjunction with the Nebula Acquisition are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_ztNLhp7eUggf" style="display: none">Schedule of Intangible Assets Acquisition</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying Value</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated Useful Life (in years)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade names</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Gross carying value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_ziCSPUN0T8E1" title="Estimated useful life (in years)">15</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proprietary intellectual property</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_pn3n3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross carying value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zSf0GtuJ3nMk" title="Estimated useful life (in years)">5</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer relationships</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross carying value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,180</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20210809__20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zbs6LiH9vIh4" title="Estimated useful life (in years)">1</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210810__us-gaap--BusinessAcquisitionAxis__custom--NebulaAcquisitionMember_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross carying value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,990</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 5550000 P15Y 4260000 P5Y 1180000 P1Y 10990000 <p id="xdx_805_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_z4XA0AO81cb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_82E_z8nFbLsk3yN">Goodwill and Acquired Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Goodwill</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no changes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> in goodwill for the three months ended March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible Assets, Net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_z3XnSMPi5E22" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets as of March 31, 2022 and December 31, 2021 consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_ztTxJCwIBaMi" style="display: none">Schedule of Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20220331_zqlvGJrvbtgi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20211231_zy68l1f4ljC3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated Useful</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in years)</b></span></p></td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z0k5HeTbFkib" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade names</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zgF9w2brZMz3" title="Finite-Lived Intangible Asset, Useful Life">15</span></span></td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zIYelyjkaYK3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proprietary intellectual property</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zTml2BK6ETEk" title="Finite-Lived Intangible Asset, Useful Life">5</span></span></td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zsgtt0ghoVM" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer relationships</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,180</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,180</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zPW0Zo49HFod" title="Finite-Lived Intangible Asset, Useful Life">1</span></span></td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6ZCxLNRbPxk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLIA license</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,307</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,307</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zkApEipWvGbk" title="Finite-Lived Intangible Asset, Useful Life">3</span></span></td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANzkgF_z8ex8Lafu5F8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total intangible assets, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANzkgF_zeGNOiZBHg3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: accumulated amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,154</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,445</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzkgF_zjt4GK0HJXVj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total intangible assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,143</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,852</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A3_zNICjXSPMGTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense for acquired intangible assets was $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pn3d_c20220101__20220331_zFtll57axMMl">709,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210331_zLoxfVHaMPAi">109,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">during the three months ended March 31, 2022 and 2021, respectively. The estimated future amortization expense of acquired intangible assets as of March 31, 2022 is as follows (in thousands):</span></p> <p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zK1aJWKG1Jwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zctNEugocHV1" style="display: none">Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49B_20220331_zuMI0I1pZKV5" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANza2l_zv6OlDXYlUl1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining periods ended December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,669</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANza2l_zlAddTZjDTEk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,585</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANza2l_zTMvBEiTl8u" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,222</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANza2l_zsVoiQrX6MCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,222</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANza2l_zocnkB3OL7G6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Year ended December 31, 2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">890</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANza2l_zm6vvPDCOMTb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,555</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANza2l_zM3L8JSWtrb6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total intangible assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,143</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_z1RfamUJZG0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p id="xdx_89A_eus-gaap--ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_z3XnSMPi5E22" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets as of March 31, 2022 and December 31, 2021 consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_ztTxJCwIBaMi" style="display: none">Schedule of Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20220331_zqlvGJrvbtgi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20211231_zy68l1f4ljC3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated Useful</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in years)</b></span></p></td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z0k5HeTbFkib" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade names</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zgF9w2brZMz3" title="Finite-Lived Intangible Asset, Useful Life">15</span></span></td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zIYelyjkaYK3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proprietary intellectual property</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zTml2BK6ETEk" title="Finite-Lived Intangible Asset, Useful Life">5</span></span></td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zsgtt0ghoVM" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer relationships</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,180</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,180</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zPW0Zo49HFod" title="Finite-Lived Intangible Asset, Useful Life">1</span></span></td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6ZCxLNRbPxk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLIA license</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,307</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,307</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zkApEipWvGbk" title="Finite-Lived Intangible Asset, Useful Life">3</span></span></td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANzkgF_z8ex8Lafu5F8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total intangible assets, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,297</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANzkgF_zeGNOiZBHg3g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: accumulated amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,154</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,445</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzkgF_zjt4GK0HJXVj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total intangible assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,143</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,852</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 5550000 5550000 P15Y 4260000 4260000 P5Y 1180000 1180000 P1Y 1307000 1307000 P3Y 12297000 12297000 2154000 1445000 10143000 10852000 709000 109000 <p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zK1aJWKG1Jwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zctNEugocHV1" style="display: none">Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49B_20220331_zuMI0I1pZKV5" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANza2l_zv6OlDXYlUl1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining periods ended December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,669</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANza2l_zlAddTZjDTEk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,585</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANza2l_zTMvBEiTl8u" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,222</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANza2l_zsVoiQrX6MCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,222</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANza2l_zocnkB3OL7G6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Year ended December 31, 2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">890</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANza2l_zm6vvPDCOMTb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,555</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANza2l_zM3L8JSWtrb6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total intangible assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,143</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1669000 1585000 1222000 1222000 890000 3555000 10143000 <p id="xdx_809_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z9XqzRxCmz3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 - <span id="xdx_82C_zLHdeYZrbkCg">Property, Plant and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zzPEAgipDVm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of property, plant and equipment are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zzHY6hE9CL5c" style="display: none">Schedule of Property, Plant and Equipment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220331_zBfb1FLD6ynf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_499_20211231_zBGeVn5b2Ff1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated Useful Life</b></span></td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zSKhizYgP35d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">352</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">352</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_z5RCvkdr35L3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,729</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,729</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zlFbMHJ9W1q7" title="Property, Plant and Equipment, Useful Life">10</span>-<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zGVNula36dPg" title="Property, Plant and Equipment, Useful Life">39</span> years</span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zcU3IudJavAl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,740</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,740</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zW776VZhcsZa" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zOfOv5XOko42" title="Property, Plant and Equipment, Useful Life">7</span> years</span></td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z8tCQ35A8y99" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,936</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,330</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zH9eqwLcAjyl" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLfJnBd9eiLl" title="Property, Plant and Equipment, Useful Life">7</span> years</span></td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zhrDF4RAiIb8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,589</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,211</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zaXuj8NLHpe9" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z1Fo9BULI2K3" title="Property, Plant and Equipment, Useful Life">5</span> years</span></td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z27q4jc0cimh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">468</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">468</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmBj4vLS7xM2" title="Property, Plant and Equipment, Useful Life">5</span> years</span></td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzxNd_zMHD23BO2Og7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Property, Plant and Equipment, Gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,814</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,830</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzxNd_zqewHV7S8F3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,374</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,883</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzxNd_zhwQ6rQxNEPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property, plant and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,440</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,947</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_zgKWMRsK5J8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense incurred for the three months ended March 31, 2022 and 2021 was $<span id="xdx_90E_eus-gaap--Depreciation_pn3d_c20220101__20220331_zVDvD6mzJjq8" title="Depreciation">491,000</span> and $<span id="xdx_903_eus-gaap--Depreciation_pn3d_c20210101__20210331_zw4AOjQKJEbf" title="Depreciation">428,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zzPEAgipDVm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of property, plant and equipment are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zzHY6hE9CL5c" style="display: none">Schedule of Property, Plant and Equipment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220331_zBfb1FLD6ynf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_499_20211231_zBGeVn5b2Ff1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated Useful Life</b></span></td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zSKhizYgP35d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">352</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">352</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_z5RCvkdr35L3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,729</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,729</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zlFbMHJ9W1q7" title="Property, Plant and Equipment, Useful Life">10</span>-<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zGVNula36dPg" title="Property, Plant and Equipment, Useful Life">39</span> years</span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zcU3IudJavAl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,740</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,740</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zW776VZhcsZa" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zOfOv5XOko42" title="Property, Plant and Equipment, Useful Life">7</span> years</span></td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z8tCQ35A8y99" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,936</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,330</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zH9eqwLcAjyl" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLfJnBd9eiLl" title="Property, Plant and Equipment, Useful Life">7</span> years</span></td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zhrDF4RAiIb8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,589</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,211</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zaXuj8NLHpe9" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z1Fo9BULI2K3" title="Property, Plant and Equipment, Useful Life">5</span> years</span></td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z27q4jc0cimh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">468</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">468</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmBj4vLS7xM2" title="Property, Plant and Equipment, Useful Life">5</span> years</span></td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzxNd_zMHD23BO2Og7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Property, Plant and Equipment, Gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,814</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,830</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzxNd_zqewHV7S8F3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,374</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,883</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzxNd_zhwQ6rQxNEPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property, plant and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,440</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,947</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 352000 352000 1729000 1729000 P10Y P39Y 4740000 4740000 P3Y P7Y 4936000 4330000 P3Y P7Y 1589000 1211000 P3Y P5Y 468000 468000 P5Y 13814000 12830000 7374000 6883000 6440000 5947000 491000 428000 <p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zf6QF8TEwLV2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 -<span id="xdx_82A_zZYkM7eohbJ1">Unsecured Convertible Promissory Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20200913__20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zwFJ70B7DdYa">September 15, 2020</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, we issued two unsecured, partially convertible, promissory notes (the “September 2020 Notes”) for an aggregate principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zHQCkwoejz5c">10 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to two investors (collectively, the “Lenders”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 28, 2022, we entered into a letter agreement (the “Letter Agreement”) with one of the Lenders providing for the payoff of its September 2020 Note in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3d_c20220228__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zGGRzy3F8dvk" title="Principal amount">2,000,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Letter Agreement, (i) the </span>Lender converted $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn3d_c20220228__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zk6RAs4jtSh5">600,000</span> of the principal amount due to him under his September 2020 Note into <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220228__20220228__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zR35aMFltJNd" title="Shares issued">200,000</span> shares of Company common stock (the “Conversion Shares”) at a price of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220228__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z5PqTyUbToc2" title="Debt conversion price">3.00</span> per share as provided for under the terms of the September 2020 Note (the “Conversion”), (ii) the Company paid to the Lender $<span id="xdx_905_eus-gaap--Cash_iI_c20220228_zaLFBSnwOIA7" title="Cash">1,440,548</span> in cash, representing $<span id="xdx_90D_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_pn3d_c20220228_zdxryzDLm5nj" title="Remaining principal amount">1,400,000</span> of the remaining principal under the September 2020 Note following the Conversion plus $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220228_zN3ZAQ0OUMMj" title="Accrued interest">40,548</span> in accrued and outstanding interest under the September 2020 Note, and (iii) the Company repurchased the Conversion Shares at a price of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220228_zPVDMDqsk8qh">5.75</span> per share for an aggregate amount of $<span id="xdx_90E_eus-gaap--ConversionOfStockAmountIssued1_pn3d_c20220228__20220228_zfMj0EWV2IXf" title="Conversion amount">1,150,000</span> (for a total aggregate payment to the Lender of $<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_c20220228__20220228_zDgfROac0sS3" title="Debt instrument periodic payment">2,590,548</span>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The September 2020 Note that remains outstanding as of March 31, 2022 is due and payable on September 15, 2023 and accrues interest at a rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zwgjXX8x7wab">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% per year from the closing date, payable on a quarterly basis, until the September 2020 Note is repaid in full. <span id="xdx_906_eus-gaap--DebtConversionDescription_c20200913__20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z9wgHT220e9i">We have the right to prepay the outstanding September 2020 Note at any time after the 13-month anniversary of the initial issuance date after providing written notice to the Lender and may prepay the September 2020 Note prior to such time with the consent of the Lender. The Lender has the right, at any time, and from time to time, on and after the 13-month anniversary of the initial issuance date to convert up to an aggregate</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of $<span id="xdx_901_eus-gaap--ConvertibleDebt_iI_pn5n6_c20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z1yCHqEubUXj">3.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the September 2020 Note into common stock of the Company at a conversion price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20200915__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zOgiIdtyRaZ2">3.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. Repayment of the September 2020 Note has been guaranteed by our wholly owned subsidiary, PMI.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The September 2020 Note contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the September 2020 Note may be accelerated. The September 2020 Note also contain certain restrictive covenants which, among other things, restrict our ability to create, incur, assume or permit to exist, directly or indirectly, any lien (other than certain permitted liens described in the September 2020 Note) securing any indebtedness of the Company, and prohibits us from distributing or reinvesting the proceeds from any divestment of assets (other than in the ordinary course) without the prior approval of the Lender.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2022 and 2021, we incurred $<span id="xdx_907_eus-gaap--InterestExpenseOther_pn3d_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zmAwN2IuB034">233,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--InterestExpenseOther_pn3d_c20210101__20210331__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandAndTwentyNoteMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zcH2r89LYDz2">251,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, in interest expense related to the September 2020 Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2020-09-15 10000000 2000000 600000 200000 3.00 1440548 1400000 40548 5.75 1150000 2590548 0.10 We have the right to prepay the outstanding September 2020 Note at any time after the 13-month anniversary of the initial issuance date after providing written notice to the Lender and may prepay the September 2020 Note prior to such time with the consent of the Lender. The Lender has the right, at any time, and from time to time, on and after the 13-month anniversary of the initial issuance date to convert up to an aggregate 3000000.0 3.00 233000 251000 <p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z6dDBHxAOw15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 - <span id="xdx_824_zMPbeQSfwbtk">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our authorized capital stock consists of <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20220331_zzioNMsEFpw7" title="Common stock, shares authorized">50</span> million shares of common stock, $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220331_zEbkXXSs3LH8" title="Common stock, par value">0.0005</span> par value, and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_dc_c20220331_zw7q57DCqNoe" title="Preferred stock, shares authorized">one million</span> shares of preferred stock, $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220331_zLI9QVvHrQaf" title="Preferred stock, par value">0.0005</span> par value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preferred stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of March 31, 2022 and December 31, 2021, <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20220331_zPRKXSlz24Ik" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231_z7XNBx5EDaY2" title="Preferred stock, shares issued">no</span></span> shares of preferred stock have been issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock Dividends</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 14, 2022, the board of directors of the Company declared a special cash dividend of $<span id="xdx_903_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_c20210214__20210214_zFZxodO3LwCg">0.30</span> per share on the Company’s common stock, paid on March 10, 2022, in the amount of $<span id="xdx_908_eus-gaap--PaymentsOfDividendsCommonStock_pn5n6_c20220214__20220214_zeOooHQlgc65" title="Payments of ordinary dividends, common stock">4.6</span> million to holders of record of the Company’s common stock on March 1, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock Repurchase Program</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 8, 2021, the board of directors (the “Board”) approved a stock repurchase program under which the Company was authorized to repurchase up to $<span id="xdx_904_eus-gaap--StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_iI_pn5n6_c20210908__us-gaap--ShareRepurchaseProgramAxis__custom--ShareRepurchaseProgramMember_zbIPttOZp2e6">6.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of its outstanding shares of common stock from time to time, over a six-month period. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2022, the Company did not make any common shares repurchase under the stock repurchase program. The stock repurchase program expired on March 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The 2010 Directors’ Equity Compensation Plan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Directors’ Equity Compensation Plan (the “Amended 2010 Directors’ Plan”) at the 2021 Annual Meeting of Stockholders of the Company (the “2021 Annual Meeting”). The Amended 2010 Directors’ Plan authorizes the issuance of up to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20210520__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyDirectorsEquityCompensationPlanMember_zqr67L1Vxrsl" title="Share-based compensation number of authorized shares">775,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2022, there were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandTenDirectorsPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1qH0WPe3Oi7" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross">425,126</span> stock options outstanding and there were no shares of common stock available to be issued under the Amended 2010 Directors’ Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The 2010 Equity Compensation Plan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Equity Compensation Plan (the “Amended 2010 Plan”) at the 2021 Annual Meeting. The Amended 2010 Plan authorizes the issuance of up to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210520__us-gaap--PlanNameAxis__custom--AmendedTwoThousandTenPlanMember_zKPhktXrLP66" title="Share-based compensation number of authorized shares">4,900,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and March 31, 2022, there were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zNqsZAtJkmeb"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_ztP1yRZXeTFh">2,014,874</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock options outstanding and <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_z4L0AbAdsDS4"><span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zwTv95iETi2a">295,785</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock options available to be issued under the 2010 Plan. We will recognize an aggregate of approximately $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220331__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zL8gTdKt3wAl">1,684,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of remaining share-based compensation expense related to outstanding stock options over a weighted average period of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--PlanNameAxis__custom--TwoThousandTenEquityCompensationPlanMember_zjJ9yQ0KKERi">2.8 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The 2018 Stock Incentive Plan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 12, 2018, our stockholders approved the 2018 Stock Incentive Plan (the “2018 Stock Plan”). The 2018 Stock Plan provides for the grant of incentive stock options to eligible employees of the Company, and for the grant of non-statutory stock options to eligible employees, directors and consultants. The 2018 Stock Plan provides that the total number of shares that may be issued pursuant to the 2018 Stock Plan is <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_c20180411__20180412__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockIncentivePlanMember_zfPOprGaPIhl">2,300,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares. At April 12, 2018, all <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180411__20180412__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockIncentivePlanMember_zis168MHU9D4">2,300,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares have been granted in the form of stock options to Ted Karkus (the “CEO Option”), our Chief Executive Officer. To date, no stock options have been exercised under the 2018 Stock Plan. No share based compensation expense will be recognized in forward periods related to the 2018 Stock Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2018 Stock Plan requires certain proportionate adjustments to be made to the stock options granted under the 2018 Stock Plan upon the occurrence of certain events, including a special distribution (whether in the form of cash, shares, other securities, or other property) in order to maintain parity. Accordingly, the Compensation Committee of the board of directors, as required by the terms of the 2018 Stock Plan, adjusted the terms of the CEO Option, such that the exercise price of the CEO Option was reduced from $<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20180904__20180905__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockIncentivePlanMember__us-gaap--AwardTypeAxis__custom--CEOOptionsMember_z5yFkvqB3t03" title="Share-based payment arrangement, option, exercise price range, upper range limit">3.00</span> per share to $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20180904__20180905__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_z38emC8EPgt4" title="Share-based payment arrangement, option, exercise price range, lower range limit">2.00</span> per share, effective as of September 5, 2018, the date the special $<span id="xdx_906_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_c20180904__20180905__srt--TitleOfIndividualAxis__custom--StockHoldersMember__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zJSi9uAMcdt" title="Common stock, dividends, per share, cash paid">1.00</span> special cash dividend was paid to stockholders. The exercise price of the CEO Option was further reduced from $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20190123__20190124__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zUXGImgKRDE9" title="Share-based payment arrangement, option, exercise price range, upper range limit">2.00</span> to $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20190123__20190124__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zX86pc6g1Ngg" title="Share-based payment arrangement, option, exercise price range, lower range limit">1.75</span> per share, effective as of January 24, 2019, the date the $<span id="xdx_900_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_c20190123__20190124__srt--TitleOfIndividualAxis__custom--StockHoldersMember__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_ziaTVhuDJr81" title="Common stock, dividends, per share, cash paid">0.25</span> special cash dividend was paid to stockholders. The exercise price of the CEO Option was further reduced from $<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20191211__20191212__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zrm9pYjVYSt5" title="Share-based payment arrangement, option, exercise price range, upper range limit">1.75</span> to $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20191211__20191212__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zVa0a5Rs6cmf" title="Share-based payment arrangement, option, exercise price range, lower range limit">1.50</span> per share, effective as of December 12, 2019, the date another $<span id="xdx_904_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_c20191211__20191212__srt--TitleOfIndividualAxis__custom--StockHoldersMember__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zwxaKnrIY2r7" title="Common stock, dividends, per share, cash paid">0.2</span>5 special cash dividend was paid to stockholders. The exercise price of the CEO Option was further reduced from $<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210602__20210603__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zuX9B2cFl4Ie" title="Share-based payment arrangement, option, exercise price range, upper range limit">1.50</span> to $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210602__20210603__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zHwNBtZ01pd6" title="Share-based payment arrangement, option, exercise price range, lower range limit">1.20</span> per share, effective as of June 3, 2021, the date another $<span id="xdx_903_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_c20210602__20210603__srt--TitleOfIndividualAxis__custom--StockHoldersMember__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_z9LA2GhYlWvf" title="Common stock, dividends, per share, cash paid">0.30</span> special cash dividend was paid to Company’s stockholders. The exercise price of the CEO Option was further reduced from $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220310__20220310__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zywa4OxXZIqf" title="Share-based payment arrangement, option, exercise price range, upper range limit">1.20</span> to $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220310__20220310__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zxGZGhnfHNvj" title="Share-based payment arrangement, option, exercise price range, lower range limit">0.90</span> per share, effective as of March 10, 2022, the date another $<span id="xdx_901_eus-gaap--CommonStockDividendsPerShareCashPaid_pid_c20220310__20220310__srt--TitleOfIndividualAxis__custom--StockHoldersMember__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockMember_zmU8SEtf3r42" title="Common stock, dividends, per share, cash paid">0.30</span> special cash dividend was paid to Company’s stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Inducement Option Award</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of Nebula Acquisition, the Company issued a non-qualified stock option to Kamal Obbad, the Chief Executive Officer of Nebula, as an inducement to his employment with the Company (the “Inducement Award”). The Inducement Award entitles Mr. Obbad to purchase up to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_pid_c20220101__20220331__srt--TitleOfIndividualAxis__custom--MrKamalObbadMember__us-gaap--AwardTypeAxis__custom--InducementOptionAwardMember_z6fScJhCq3H8" title="Share-based compensation arrangement by share-based payment award, accelerated vesting, number">250,000 </span>shares of the Company’s common stock at an exercise price of $<span id="xdx_908_eus-gaap--BusinessAcquisitionSharePrice_iI_pid_c20220331__us-gaap--BusinessAcquisitionAxis__custom--InducementOptionAwardMember_zkJnVNFcJzp2" title="Business acquisition, share price">7.67</span> per share, the closing price of the Company’s common stock on the closing date of the Nebula Acquisition. The Inducement Award was granted to Mr. Obbad on the closing date of the Nebula Acquisition. The Inducement Award vested <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20220101__20220331__us-gaap--AwardTypeAxis__custom--InducementOptionAwardMember_z3IvOds3Kxa5" title="Share-based compensation arrangement by share-based payment award, award vesting rights, percentage">25</span>% on the grant date and will vest <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20220101__20220331__us-gaap--AwardTypeAxis__custom--InducementOptionAwardMember__srt--StatementScenarioAxis__custom--NextThreeYearsMember_zjtCLZ3VnWZ3" title="Share-based compensation arrangement by share-based payment award, award vesting rights, percentage">25</span>% per year for the next three years subject to Mr. Obbad’s continued employment with the Company. The Inducement Award expires on the seventh anniversary of the grant date. Any portion of the Inducement Award that does not vest and become exercisable will be forfeited for no consideration. The grant date fair value of the Inducement Award was approximately $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0d_c20220101__20220331__us-gaap--BusinessAcquisitionAxis__custom--InducementOptionAwardMember_zgdoCA0F8ga1" title="Share-based pyment arrangement, plan modification, incremental cost">1,128,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, we issued an inducement award to a non-employee to purchase up to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__us-gaap--AwardTypeAxis__custom--InducementOptionAwardMember_zvswcnTz7u8k" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross">100,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__custom--InducementOptionAwardMember_zM3HiETXrxGl" title="Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price">5.76</span>, the closing price of the common stock on the date of grant. The award vests in four equal installments from the date of grant. The award expires on the seventh anniversary of the grant date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All inducement awards have been granted outside of the Company’s equity compensation plans.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zT2hokOZZeH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock options activity during the three months ended March 31, 2022 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Awards (in thousands, except per share data).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zqe7mDxvaXh3" style="display: none">Schedule of Stock Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Remaining Contractual Life <br/> (in years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Intrinsic Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of January 1, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20220101__20220331_zk8v4lKtvRBg" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Shares Options Outstanding - Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,110</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_zDBvL0IxFZie" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Options Outstanding - Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zghPk5EwUjbb" title="Weighted Average Remaining contractual Life">3.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20220101__20220331_zNxcpYJqUGcf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total Intrinsic Value - Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,820</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20220101__20220331_zwwXVYJiEvnd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_z5f9SjQ9SUql" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_pn3n3_c20220101__20220331_zn5R0xo1Sklf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Intrinsic Value - Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of March 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20220101__20220331_zGBenu2xtKT5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares Options Outstanding - Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,090</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zY84vk2Ko8i" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Options Outstanding - Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zpg2uxpdPqsc" title="Weighted Average Remaining Contractual Life">3.2</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20220101__20220331_zP3iPj8gcnMc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Intrinsic Value - Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,767</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options vested and exercisable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pn3n3_c20220101__20220331_zBVrAMM8iHoa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares Options Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,069</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zudhINdva73d" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, vested and exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_z7ISG7BkmP2k" title="Weighted Average Remaining Contractual Term, vested and exercisable">2.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20220101__20220331_zdcMzO8zIvF1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Intrinsic Value, Options Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,398</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A2_zIRiZTpkcqL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, there were <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pn3d_c20220331_zWOgQeDOpN9d">5,090,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock options outstanding and <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220331_zrZmY4vg3Ai8">295,785 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock options available to be issued. We will recognize an aggregate of approximately $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0d_c20220101__20220331_ztq5jmvkfD17">2,746,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of remaining share-based compensation expense related to outstanding stock options over a weighted average period of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK5qYcl0iN5f">2.8 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVMiFc4XFs8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes warrant activity during the three months ended March 31, 2022 (in thousands, except per share data):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B9_zivAH8dr5jaa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of Warrant Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life <br/> (in years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding as of January 1, 2022</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBpTWzKBplHd" style="width: 14%; font-weight: bold; text-align: right" title="Number of Shares Warrants Outstanding - Beginning">855</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHCzCjqHkes1" style="width: 14%; font-weight: bold; text-align: right" title="Weighted Average Exercise Price Warrants Outstanding - Beginning">8.23</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 14%; font-weight: bold; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualBeginingTerm1_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYjqrPiy2GI5" title="Weighted Average Remaining Contractual Life Warrants Outstanding - Beginning">1.9</span></td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAYbJDian1rh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice1_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zycdU71wqse3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1143">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0tRCyF3uRxg" title="Weighted Average Remaining Contractual Life Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIyfU7vArCzc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding - Ending">855</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zluryzF6sOZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Warrants Outstanding - Ending">8.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDkdaLfT8sC" title="Weighted Average Remaining Contractual Life Warrants Outstanding - Ending">1.6</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants vested and exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber_iI_pn3n3_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcRLFeZyYCj2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Vested and Exercisable">855</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znUuDKQj2TL3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Vested and Exercisable">8.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLyRi1Slp7H5" title="Weighted Average Remaining Contractual Life Warrants Vested and Exercisable">1.6</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"/> <p id="xdx_8A6_zL13HbhTf90d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognized $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n6_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHloTuutMQMf">0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCudPfpC7etg">105,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of share-based compensation expense during the three months ended March 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 50000000 0.0005 1000000 0.0005 0 0 0.30 4600000 6000000.0 775000 425126 4900000 2014874 2014874 295785 295785 1684000 P2Y9M18D 2300000 2300000 3.00 2.00 1.00 2.00 1.75 0.25 1.75 1.50 0.2 1.50 1.20 0.30 1.20 0.90 0.30 250000 7.67 0.25 0.25 1128000 100000 0.0576 <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zT2hokOZZeH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock options activity during the three months ended March 31, 2022 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan, the 2018 Stock Plan and the Inducement Awards (in thousands, except per share data).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zqe7mDxvaXh3" style="display: none">Schedule of Stock Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Remaining Contractual Life <br/> (in years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Intrinsic Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of January 1, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20220101__20220331_zk8v4lKtvRBg" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Shares Options Outstanding - Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,110</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331_zDBvL0IxFZie" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Options Outstanding - Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zghPk5EwUjbb" title="Weighted Average Remaining contractual Life">3.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20220101__20220331_zNxcpYJqUGcf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total Intrinsic Value - Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,820</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20220101__20220331_zwwXVYJiEvnd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331_z5f9SjQ9SUql" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_pn3n3_c20220101__20220331_zn5R0xo1Sklf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Intrinsic Value - Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of March 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20220101__20220331_zGBenu2xtKT5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares Options Outstanding - Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,090</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zY84vk2Ko8i" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Options Outstanding - Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zpg2uxpdPqsc" title="Weighted Average Remaining Contractual Life">3.2</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20220101__20220331_zP3iPj8gcnMc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Intrinsic Value - Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,767</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options vested and exercisable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pn3n3_c20220101__20220331_zBVrAMM8iHoa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares Options Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,069</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zudhINdva73d" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, vested and exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_z7ISG7BkmP2k" title="Weighted Average Remaining Contractual Term, vested and exercisable">2.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20220101__20220331_zdcMzO8zIvF1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Intrinsic Value, Options Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,398</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 5110000 3.27 P3Y4M24D 20820000 20000 8.99 5090000 3.11 P3Y2M12D 20767000 4069000 2.41 P2Y4M24D 19398000 5090000 295785 2746000 P2Y9M18D <p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVMiFc4XFs8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes warrant activity during the three months ended March 31, 2022 (in thousands, except per share data):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B9_zivAH8dr5jaa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of Warrant Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life <br/> (in years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding as of January 1, 2022</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBpTWzKBplHd" style="width: 14%; font-weight: bold; text-align: right" title="Number of Shares Warrants Outstanding - Beginning">855</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHCzCjqHkes1" style="width: 14%; font-weight: bold; text-align: right" title="Weighted Average Exercise Price Warrants Outstanding - Beginning">8.23</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 14%; font-weight: bold; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualBeginingTerm1_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYjqrPiy2GI5" title="Weighted Average Remaining Contractual Life Warrants Outstanding - Beginning">1.9</span></td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAYbJDian1rh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice1_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zycdU71wqse3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1143">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0tRCyF3uRxg" title="Weighted Average Remaining Contractual Life Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIyfU7vArCzc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding - Ending">855</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zluryzF6sOZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Warrants Outstanding - Ending">8.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDkdaLfT8sC" title="Weighted Average Remaining Contractual Life Warrants Outstanding - Ending">1.6</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants vested and exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber_iI_pn3n3_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcRLFeZyYCj2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Vested and Exercisable">855</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znUuDKQj2TL3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Vested and Exercisable">8.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLyRi1Slp7H5" title="Weighted Average Remaining Contractual Life Warrants Vested and Exercisable">1.6</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"/> 855000 8.23 P1Y10M24D 855000 8.23 P1Y7M6D 855000 8.23 P1Y7M6D 0 105000 <p id="xdx_800_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z0zlYuhKCKqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 - <span id="xdx_824_zP0mzKd1SrQ2">Defined Contribution Plans</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain the ProPhase Labs, Inc. 401(k) Savings and Retirement Plan, a defined contribution plan for our employees. Our contributions to the plan are based on the amount of the employee plan contributions and compensation. Our contributions to the plan in the three months ended March 31, 2022 and 2021 were $<span id="xdx_90D_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3d_c20220101__20220331_znEzu5o7tqIg" title="Defined contributions">52,000</span> and $<span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3d_c20210101__20210331_z7y1GzAxRWpa" title="Defined contributions">13,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 52000 13000 <p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_ziCtHcWkGR3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_821_zgA2BQVZZO6j">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize tax assets and liabilities for the future tax consequences related to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for net operating loss carryforwards. Management evaluated the deferred tax assets for recoverability using a consistent approach that considers the relative impact of negative and positive evidence, including historical profitability and projections of future reversals of temporary differences and future taxable income. We are required to establish a valuation allowance for deferred tax assets if management determines, based on available evidence at the time the determination is made, that it is not more likely than not that some portion or all of the deferred tax assets will be realized. As of March 31, 2022 the Company has net deferred tax liabilities for federal and combined states jurisdictions compared to net deferred tax assets with a full valuation allowance as of December 31, 2021. The decrease in deferred tax assets with a corresponding decrease in valuation allowance against those assets as of March 31, 2022 is primarily due to utilization of net operating losses. The Company has net deferred tax assets in other states jurisdictions where we maintain a full valuation allowance. Judgment is required to estimate forecasted future taxable income, which may be impacted by future business developments, actual results, tax initiatives, legislative, and other economic factors. The Company will continue to monitor income levels and potential changes to its operating and tax model, and other legislative or global developments in its determination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s effective tax rate for the three months ended March 31, 2022 is <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20220331_zeP2XqxMROD2" title="Effective income tax rate">21.47</span>% and it is primarily driven by federal tax at <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20220331_zMD1yBcfU1Oj" title="Effective income tax rate, federal">21</span>%, state taxes at <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20220331_zhcacOYKloVj" title="Effective income tax rate, state">7.1</span></span>%, and a decrease in the valuation allowance for federal and combined states jurisdictions. The total tax expense for the three months ended March 31, 2022 is $<span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefit_pn5n6_c20220101__20220331_zuVoTyuRxmKj" title="Income tax expense">3.4 </span>million and <span>it</span> mostly relates to current federal and combined state taxes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.2147 0.21 0.071 3400000 <p id="xdx_809_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zzIOIwTCSt2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 - <span id="xdx_826_ziAS5plA0Bge">Other Current Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zTHTc6cww1Lj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the components of other current liabilities at March 31, 2022 and December 31, 2021, respectively (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zSwsrFOBMDli" style="display: none">Schedule of Other Current Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_492_20220331_z75RKvZxcCl" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49E_20211231_zNC71i0xHN1l" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_403_eus-gaap--AccruedLiabilitiesForCommissionsExpenseAndTaxes_iI_pn3n3_maOLCz95d_zpxBU9svttZf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued commissions</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,294</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,283</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--AccruedPayrollTaxesCurrent_iI_pn3n3_maOLCz95d_zMeW76z25XU6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued payroll</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">514</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maOLCz95d_zAQKozNgLOnf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">356</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--AccruedReturn_iI_pn3n3_maOLCz95d_zxIvigI2WBnk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued returns</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">246</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">338</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maOLCz95d_zLxy2fN5YKsa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued benefits and vacation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_ecustom--AccruedInsuanceReimbursement_iI_pn3n3_maOLCz95d_zf7uJm5twMzl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Accrued insurance reimbursement</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">1,278</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1197"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">-</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCz95d_zmL1ZzNskLLd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,274</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,495</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zo09zbjnpQf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p id="xdx_895_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zTHTc6cww1Lj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the components of other current liabilities at March 31, 2022 and December 31, 2021, respectively (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zSwsrFOBMDli" style="display: none">Schedule of Other Current Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_492_20220331_z75RKvZxcCl" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49E_20211231_zNC71i0xHN1l" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_403_eus-gaap--AccruedLiabilitiesForCommissionsExpenseAndTaxes_iI_pn3n3_maOLCz95d_zpxBU9svttZf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued commissions</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,294</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,283</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--AccruedPayrollTaxesCurrent_iI_pn3n3_maOLCz95d_zMeW76z25XU6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued payroll</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">514</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maOLCz95d_zAQKozNgLOnf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">356</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--AccruedReturn_iI_pn3n3_maOLCz95d_zxIvigI2WBnk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued returns</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">246</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">338</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maOLCz95d_zLxy2fN5YKsa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued benefits and vacation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_ecustom--AccruedInsuanceReimbursement_iI_pn3n3_maOLCz95d_zf7uJm5twMzl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Accrued insurance reimbursement</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">1,278</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1197"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">-</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCz95d_zmL1ZzNskLLd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,274</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,495</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1294000 1283000 50000 514000 356000 300000 246000 338000 50000 60000 1278000 3274000 2495000 <p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zz5bjOSlOcE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 - <span id="xdx_826_zC2wuOiU1Ucg">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its wholly owned subsidiary, PMI, entered into a manufacturing agreement (the “Manufacturing Agreement”) with Mylan in connection with the asset purchase agreement we entered into with Mylan in 2017. Pursuant to the terms of the Manufacturing Agreement, Mylan (or an affiliate or designee) purchased the inventory of the Company’s Cold-EEZE® brand and product line, and PMI agreed to manufacture certain products for Mylan, as described in the Manufacturing Agreement, at prices that reflect current market conditions for such products and include an agreed upon mark-up on our costs. On May 1, 2021, the Manufacturing Agreement was assigned by Mylan to Nurya Brands, Inc. (“Nurya”) in connection with Nurya’s acquisitions of certain assets from Mylan, including the Cold-EEZE® brand and product line. Unless terminated sooner by the parties, the Manufacturing Agreement will remain in effect until March 29, 2023. Thereafter, the Manufacturing Agreement may be renewed by Nurya for up to four successive one-year periods by providing notice of its intent to renew not less than 90 days prior to the expiration of the then-current term. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future Obligations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zpOmjGP7Rvbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have estimated future minimum obligations for an executive’s employment agreement over the next five years as of March 31, 2022, as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zVqqhIzYtRCg" style="display: none">Schedule of Estimated Future Minimum Obligations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220331_zvcQekXwtSxl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Contracts</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_iI_pn3n3_maCOzNsv_zxjiTqzmklZ1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining periods in</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">506</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_pn3n3_maCOzNsv_zbGMtfqYPpG9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--ContractualObligationDueInSecondYear_iI_pn3n3_maCOzNsv_zbcsp4RleOSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--ContractualObligationDueInThirdYear_iI_pn3n3_maCOzNsv_zb6fF1gtnNZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--ContractualObligationDueInFourthYear_iI_pn3n3_maCOzNsv_zcWbtMrisDC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--ContractualObligation_iTI_pn3n3_mtCOzNsv_z0YLuYeDbjac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,206</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A0_zUKcfgp7zLj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of our business, we may be named as a defendant in legal proceedings. It is our policy to vigorously defend litigation or to enter into a reasonable settlement where management deems it appropriate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zpOmjGP7Rvbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have estimated future minimum obligations for an executive’s employment agreement over the next five years as of March 31, 2022, as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zVqqhIzYtRCg" style="display: none">Schedule of Estimated Future Minimum Obligations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220331_zvcQekXwtSxl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Contracts</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_iI_pn3n3_maCOzNsv_zxjiTqzmklZ1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining periods in</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">506</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_pn3n3_maCOzNsv_zbGMtfqYPpG9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--ContractualObligationDueInSecondYear_iI_pn3n3_maCOzNsv_zbcsp4RleOSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--ContractualObligationDueInThirdYear_iI_pn3n3_maCOzNsv_zb6fF1gtnNZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--ContractualObligationDueInFourthYear_iI_pn3n3_maCOzNsv_zcWbtMrisDC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--ContractualObligation_iTI_pn3n3_mtCOzNsv_z0YLuYeDbjac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,206</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 506000 675000 675000 675000 675000 3206000 <p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_ziEL2lNwTd6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 - <span id="xdx_824_zlrGCNKFNZgf">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 23, 2020, we completed the acquisition of CPM, which included the acquisition of a <span id="xdx_908_eus-gaap--AreaOfLand_iI_uSqft_c20201023__us-gaap--BusinessAcquisitionAxis__custom--PlazaMedicalLaboratoryCorpMember_z2E38xea2wrj" title="Area of land">4,000</span> square foot CLIA accredited laboratory located in Old Bridge, New Jersey, which was owned by CPM (which is now known as ProPhase Diagnostics NJ, Inc.). The lease is for a term of 24 months with a monthly base lease payment of $<span id="xdx_908_eus-gaap--OperatingLeasePayments_c20201021__20201023__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_zOjWcraAkC14" title="Operating lease payments">5,950</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 8, 2020, the Company entered into a Lease Agreement (the “NY Lease”) with BRG Office L.L.C. and Unit 2 Associates L.L.C. (the “Landlord”), pursuant to which the Company has agreed to lease certain premises located on the second floor (the “Leased Premises”) of 711 Stewart Avenue, Garden City, New York (the “Building”). The Leased Premises serve as the Company’s second location and corporate headquarters, offering a wide range of laboratory testing services for diagnosis, screening and evaluation of diseases, including COVID-19 and Respiratory Pathogen Panel Molecular tests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NY Lease was effective as of December 8, 2020, and commenced in January 2021 (the “Commencement Date”) when the facility was made available to us by the landlord. The initial term of the NY Lease is <span id="xdx_901_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtY_c20201208__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_zxTrMbhsCBv8" title="Lease term of contract">10</span> years and seven months (the “Initial Term”), unless sooner terminated as provided in the NY Lease. We may extend the term of the NY Lease for one additional option period of five years. <span id="xdx_907_eus-gaap--LesseeOperatingLeaseDescription_c20201207__20201208__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_zfpQK57Xpko9" title="Operating lease description">We have the option to terminate the NY Lease on the sixth anniversary of the Commencement Date, provided that we give the landlord written notice not less than nine months and not more than 12 months in advance and that we pay the landlord a termination fee.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--LesseeOperatingLeaseDescription_c20201207__20201208__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_z4Gow8P1Yki7" title="Operating lease description">For the first year of the NY Lease, we will pay a base rent of $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20201207__20201208__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_zjUvRPZ11Jjg" title="Operating lease payments">56,963</span></span> per month (subject to a seven-month abatement period), with a gradual rental rate increase of <span id="xdx_907_ecustom--GradualRentalIncreaseRate_pid_dp_uPure_c20201207__20201208__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_zzlP5U6sHltb" title="Gradual rental rate increase percentage">2.75</span>% for each 12-month period thereafter in lieu of paying its proportionate share of common area operating expenses, culminating in a monthly base rent of $<span id="xdx_90E_eus-gaap--OperatingLeasePayments_c20201207__20201208__srt--StatementScenarioAxis__custom--FinalMonthsMember__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_pp0p0" title="Operating lease payments">74,716</span> during the final months of the Initial Term. In addition to the monthly base rent, we are responsible for its proportionate share of real estate tax escalations in accordance with the terms of the NY Lease.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--LesseeOperatingLeaseDescription_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--ConfuciusLabsMember__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_zDTq34km5lV6" title="Operating lease description">We also have a right of first refusal to lease certain additional space located on the ground floor of the Building containing 4,500 square feet and 4,600 square feet, as more particularly described in the NY Lease. We also have a right of first offer to purchase the Building during the term of the NY Lease.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2022, we had operating lease liabilities for the New York and New Jersey leases of approximately $<span id="xdx_906_eus-gaap--OperatingLeaseLiability_iI_pn5n6_c20220331__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseLiabilitiesMember_zsdfS6ZGlo4e" title="Operating lease, liability">4.8</span> million and right of use assets of approximately $<span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20220331__us-gaap--BalanceSheetLocationAxis__custom--OperatingLeaseRightOfUseAssetMember_zmrzRiK7dSIe" title="Operating lease, right-of-use asset">4.3</span> million, which were included in the condensed consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_z1PqmsTLg5Pc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summarizes quantitative information about our operating leases (amounts in thousands):</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span id="xdx_8B8_z7CYWjzZRgac" style="display: none">Summary of Quantitative Information About Operating Leases</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220101__20220331_zu3kGffGA9lb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20210101__20210331_zuXKKMJxoyz2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityAbstract_iB_z9npfvC6Fqp8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseCost_i01_maOLEzIHf_zbXQbpFiDcYd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseExpense_i01T_pn3n3_mtOLEzIHf_maLCzRoB_zJM785B8Nyvj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--LeaseCost_i01T_pn3n3_mtLCzRoB_zK4lNhdNBS0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total rent expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_z1Q4cX5saC21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5zIWDXPRMS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities of the Company’s operating leases, excluding short-term leases, are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zsb5TCXphq99" style="display: none">Schedule of Maturity of Operating Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49A_20220331_zaC8x1jQT7m3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzVjd_z29Qwdj2bjv4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining Periods Ended December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">580</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzVjd_z6IyAVdZSwmk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">738</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzVjd_zhUVq2Z3Ibq7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzVjd_zXKu9Rr2Mjgg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">768</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzVjd_zPsd3ROwRDn8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Year Ended December 31, 2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">783</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzVjd_z8LEEPoUPSJc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,876</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzVjd_zhfV9NVTZFT2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zM30dT4S3J26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less present value discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,704</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,788</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A5_zfUZ7t19CiR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4000 5950 P10Y We have the option to terminate the NY Lease on the sixth anniversary of the Commencement Date, provided that we give the landlord written notice not less than nine months and not more than 12 months in advance and that we pay the landlord a termination fee. For the first year of the NY Lease, we will pay a base rent of $56,963 56963 0.0275 74716 We also have a right of first refusal to lease certain additional space located on the ground floor of the Building containing 4,500 square feet and 4,600 square feet, as more particularly described in the NY Lease. We also have a right of first offer to purchase the Building during the term of the NY Lease. 4800000 4300000 <p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_z1PqmsTLg5Pc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summarizes quantitative information about our operating leases (amounts in thousands):</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span id="xdx_8B8_z7CYWjzZRgac" style="display: none">Summary of Quantitative Information About Operating Leases</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220101__20220331_zu3kGffGA9lb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20210101__20210331_zuXKKMJxoyz2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityAbstract_iB_z9npfvC6Fqp8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseCost_i01_maOLEzIHf_zbXQbpFiDcYd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseExpense_i01T_pn3n3_mtOLEzIHf_maLCzRoB_zJM785B8Nyvj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--LeaseCost_i01T_pn3n3_mtLCzRoB_zK4lNhdNBS0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total rent expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 204000 204000 204000 204000 204000 204000 <p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5zIWDXPRMS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities of the Company’s operating leases, excluding short-term leases, are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zsb5TCXphq99" style="display: none">Schedule of Maturity of Operating Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49A_20220331_zaC8x1jQT7m3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzVjd_z29Qwdj2bjv4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining Periods Ended December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">580</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzVjd_z6IyAVdZSwmk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">738</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzVjd_zhUVq2Z3Ibq7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzVjd_zXKu9Rr2Mjgg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">768</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzVjd_zPsd3ROwRDn8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Year Ended December 31, 2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">783</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzVjd_z8LEEPoUPSJc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,876</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzVjd_zhfV9NVTZFT2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zM30dT4S3J26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less present value discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,704</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,788</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 580000 738000 747000 768000 783000 3876000 7492000 2704000 4788000 <p id="xdx_809_ecustom--SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock_z2BdW4cFFn4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 - <span id="xdx_82F_zDXrg82cnywl">Consulting Agreement and Secured Promissory Note Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Promissory Note and Security Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 25, 2020 (the “Restatement Effective Date”), we entered into the Secured Note with a company consulting for us (“the Consultant”), pursuant to which we loaned $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20200925__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RestatementAxis__srt--RestatementAdjustmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_pn5n6">3.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to the Consultant (inclusive of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200925__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_zz4gXF0NzcMc">1.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in the aggregate previously loaned to the Consultant, as described below).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Secured Note amended and restated in its entirety (i) that certain Promissory Note and Security Agreement, dated July 21, 2020 (the “Original July 21 Note”), pursuant to which we loaned $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3d_c20200721__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RestatementAxis__srt--RestatementAdjustmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_zKZjZfznkQMd" title="Debt Instrument, Face Amount">750,000</span> to the Consultant and (ii) that certain Promissory Note and Security Agreement, dated July 29, 2020 (the “Original July 29 Note”, and, together with the Original July 21 Note, the “Original Notes”), pursuant to which we loaned $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3d_c20200729__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RestatementAxis__srt--RestatementAdjustmentMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SecuredDebtMember_zHOFjxsZBfna" title="Debt Instrument, Face Amount">250,000</span> to the Consultant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing after September 1, 2021, in addition to payments of interest,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the Consultant is also required to make payments on the principal amount of the loan equal to 1/36 of the then outstanding principal amount. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entire remaining unpaid principal amount of the Secured Note, together with all accrued and unpaid interest thereon and all other amounts payable under the Secured Note, will be due and payable, if not sooner paid, on September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Secured Note contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the Secured Note may be accelerated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment and Termination Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 14, 2021, we entered into an Amendment and Termination Agreement (the “Termination Agreement”) with the Consultant pursuant to which the parties amended the Secured Note and terminated the former consulting agreement with the Consultant (the “Consulting Agreement”). Pursuant to the terms of the Termination Agreement, the Company loaned an additional $1 million to the Consultant in consideration for the termination of the Consulting Agreement and termination of the Company’s obligation to pay any additional consulting fees. As a result, the initial principal amount due under the Secured Note was increased from $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_c20210114__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RangeAxis__srt--MinimumMember_pn4n6">2.75 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_c20210114__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedThirdPartyMember__srt--RangeAxis__srt--MaximumMember_pn4n6">3.75 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million plus all accrued and unpaid interest arising under the Secured Note through and including January 14, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the Termination Agreement, the Consultant will continue to sell and process its viral test by RT-PCR (together with other viral and other types of tests). Until the Secured Note is paid in full, each COVID-19 Test Kit sold or processed from and after January 14, 2021, and for which payment of at least the specified amount as defined for the test, is received by the Consultant, the Consultant will pay us a specified amount (the “Test Fee”). We received the first payment in the amount of $<span id="xdx_905_ecustom--TestFeesReceived_c20210115__20210228__us-gaap--TypeOfArrangementAxis__custom--TerminationAgreementMember_pp0n6" title="Test fees received">95,000</span> with respect to the Test Fees from January 15 through February 2021. On June 25, 2021, we were issued <span id="xdx_900_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_zBSknx3Q9CO8" title="Investment Owned, Balance, Shares">1,260,619</span> shares of common stock of the Consultant with a fair value of $<span id="xdx_907_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3d_c20210625__us-gaap--InvestmentTypeAxis__custom--InvestmentSharesMember_zh5Fp3dIPOnd" title="Investment owned, at fair value">315,000</span> as an interest payment under the Secured Note in lieu of Test Fees from March through June 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective September 1, 2021, in addition to the payment of the Test Fees described above, the Consultant is also required to make payments to us in an amount equal to the greater of (x) the Test Fee, or (y) 1/36th of the then outstanding principal amount together with interest thereon. The Company did not receive any payments from the Consultant for either contractual principal or interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 11, 2021, the Company provided the Consultant with a Notice of Default and demanded the Secured Note be paid in full immediately. On January 25, 2022, the Company filed a complaint with the United States District Court for the District of Delaware for judgment against the Consultant for money damages consisting of principal, interest, default interest and other fees and costs. As a result, the Company considered that it is not probable that it will collect all amounts due under the Secured Note and reduced the carrying value of the Secured Note to $<span id="xdx_90B_eus-gaap--SecuredDebt_iI_c20211231_zdR2pcWCSuU7" title="Secured Debt">0</span> as of December 31, 2021 with a corresponding charge-off of $<span id="xdx_909_eus-gaap--ProvisionForDoubtfulAccounts_pn4n6_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zLWH4TETKMz1" title="Accounts Receivable, Credit Loss Expense (Reversal)">3.75</span> million during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3000000.0 1000000.0 750000 250000 2750000 3750000 95000000000 1260619 315000 0 3750000 <p id="xdx_800_eus-gaap--ConcentrationRiskDisclosureTextBlock_zZu77zRloQO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14 - <span id="xdx_82E_zVbw8HkKqmQg">Significant Customer Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue for the three months ended March 31, 2022 and 2021 was $<span id="xdx_907_eus-gaap--Revenues_pn5n6_c20220101__20220331_zCH9grmYQ6i">47.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90A_eus-gaap--Revenues_pn5n6_c20210101__20210331_zjyMNacEghSl">15.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively. Three diagnostic services clients accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1F3RDWmiMSb">36.7</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFrF1YfBjbdd">21.4</span>%, and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znuUN1djGujf">11.0</span>% of our revenue for the three months ended March 31, 2022. Two diagnostic services clients accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zRJ0kzBEBTR8">46.1</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgBifqlRWfi9">31.6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of our revenue for the three months ended March 31, 2021. No contract manufacturing customer’s accounted for a significant portion of our revenue for the three month ended March 31, 2022 or 2021. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two diagnostic services payers comprised <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoI5ksqVLti">33.6</span>%</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlVqtTmrEsLd">26.5</span>% of our total reimbursement receivable balances from government agencies and healthcare issuers at March 31, 2022. Four diagnostic services payers comprised <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqeCDg3tbzJk">43.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zTEtIxyqv2X5">11.6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zasH575K5E14">10.7</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TradeReceivableMember__srt--MajorCustomersAxis__custom--DiagnosticServicesClientsFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuxQogHF4oEg" title="Concentration risk, percentage">10.7</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of our total reimbursement receivable balances from government agencies and healthcare issuers at December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, we rely on a sole supplier to manufacture our saliva collection kits used by customers who purchase our personal genomics services. Change in the supplier or design of certain of the materials that we rely on, in particular the saliva collection kit, could result in a requirement for additional premarket review from the FDA before making such a change.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 47500000 15300000 0.367 0.214 0.110 0.461 0.316 0.336 0.265 0.430 0.116 0.107 0.107 <p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zmpUr7Wo5rl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 15 - <span id="xdx_822_z7MTLfT7I9Ti">Segment Information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO as CODM assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zlKtZNh4F8gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table is a summary of segment information for three months ended March 31, 2022 and 2021 (amounts in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zUVYOHjxdP2e" style="display: none">Schedule of Segment Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20220101__20220331_zm6Z8GlflSp6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20210101__20210331_zjEzlLeBEKeg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_z6q0tRnQC7ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_ziZm6drTYDh9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer products</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,618</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,534</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zpXZhUs0CwP2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated net revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,531</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,271</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zrdsGDPqBgJb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,702</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,345</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--CostOfGoodsAndServicesSold_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zATK7M5B5mMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer products</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,152</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,999</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--CostOfGoodsAndServicesSold_i_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated cost of revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,854</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,344</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zUBSsYAbAPLj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">576</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">345</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zW2UTltSjKi4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer products</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_i_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Depreciation and amortization expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,176</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">348</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--OperatingAndOtherExpenses_i_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,591</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,522</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income (loss) from operations, before income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_ziHE0KlG1Rqf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,026</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,839</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zzLUX5EhUi31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer products</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,863</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(35</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_zvCXLAOuj6E4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unallocated corporate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,253</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_maILFCOz3vW_zb02Nrf7ySfc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total income from operations, before income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,910</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_msILFCOz3vW_zGWy6gBraDaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1359"> </span></span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_mtILFCOz3vW_z4uP2GMSDnpd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total income from operations, after income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_i_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table is a summary of segment information as of March 31, 2022 and December 31, 2021 (amounts in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20220331_zZn8Z9BmFDe1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p> <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20211231_z5GZSRlmEBv1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p> <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">ASSETS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zFVO9NwC8Oqe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 56%; text-align: left">Diagnostic services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">51,823</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">51,150</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_z2CF3VvfFdu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Consumer products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,139</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_z23xsAWLQeVj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unallocated corporate</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,464</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,006</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Assets_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">99,665</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">89,295</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AE_zAtYQ4Hv4zef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zlKtZNh4F8gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table is a summary of segment information for three months ended March 31, 2022 and 2021 (amounts in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zUVYOHjxdP2e" style="display: none">Schedule of Segment Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20220101__20220331_zm6Z8GlflSp6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20210101__20210331_zjEzlLeBEKeg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_z6q0tRnQC7ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_ziZm6drTYDh9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer products</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,618</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,534</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zpXZhUs0CwP2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated net revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,531</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,271</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zrdsGDPqBgJb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,702</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,345</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--CostOfGoodsAndServicesSold_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zATK7M5B5mMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer products</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,152</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,999</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--CostOfGoodsAndServicesSold_i_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated cost of revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,854</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,344</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zUBSsYAbAPLj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">576</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">345</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zW2UTltSjKi4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer products</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_i_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Depreciation and amortization expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,176</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">348</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--OperatingAndOtherExpenses_i_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,591</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,522</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income (loss) from operations, before income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_ziHE0KlG1Rqf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostic services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,026</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,839</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_zzLUX5EhUi31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer products</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,863</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(35</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_zvCXLAOuj6E4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unallocated corporate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,253</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_maILFCOz3vW_zb02Nrf7ySfc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total income from operations, before income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,910</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_msILFCOz3vW_zGWy6gBraDaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1359"> </span></span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_mtILFCOz3vW_z4uP2GMSDnpd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total income from operations, after income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_i_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table is a summary of segment information as of March 31, 2022 and December 31, 2021 (amounts in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20220331_zZn8Z9BmFDe1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p> <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20211231_z5GZSRlmEBv1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p> <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">ASSETS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesMember_zFVO9NwC8Oqe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 56%; text-align: left">Diagnostic services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">51,823</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">51,150</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsMember_z2CF3VvfFdu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Consumer products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,139</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_z23xsAWLQeVj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unallocated corporate</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,464</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,006</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Assets_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">99,665</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">89,295</td><td style="text-align: left"> </td></tr> </table> 44913000 12737000 2618000 2534000 47531000 15271000 16702000 4345000 2152000 1999000 18854000 6344000 576000 345000 600000 3000 1176000 348000 11591000 7522000 20026000 2839000 -1863000 -35000 -2253000 -1747000 15910000 1057000 3416000 12494000 1057000 12494000 1057000 51823000 51150000 23378000 24139000 24464000 14006000 99665000 89295000 <p id="xdx_801_eus-gaap--EarningsPerShareTextBlock_z9t3BeRo2Ko9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 16 - <span id="xdx_82B_ztOWZ3p1ksxi">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings per share (“EPS”) excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted EPS also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc. and Subsidiaries</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zQWdkVDO9ti3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zUWVoFJivJGa" style="display: none">Schedule of Basic and Diluted Net Loss Per Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20220101__20220331_zXbt0G1qRPSl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20210101__20210331_zahO0s9njJol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zqTYB4diFVof" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Net income - basic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">12,494</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,057</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--InterestOnUnsecuredConvertiblePromissoryNote_pn3n3_z2bkMvkqBGng" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest on unsecured convertible promissory note</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">232</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1387"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_zoTHG0AFhI97" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net income - diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,726</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,057</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zKObQcYz2s46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares outstanding - basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,486</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,563</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--IncrementalCommonSharesAttributableToCallOptions_pid_zwVdRqWRMVWk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diluted shares- Stock Options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,895</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--IncrementalCommonSharesAttributableToWarrants_pid_zg58Z3bVbCEj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Diluted shares- Stock Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">284</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_pid_zqOS3qbc6a2j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unsecured convertible promissory note</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">458</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zK4Fb6okSU6d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares outstanding - diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">18,740</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">18,200</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AB_ztCHtGGBpKX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSmhMhlVsqRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z6XqrKyEaUG7" style="display: none">Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Anti-dilutive securities</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Common stock purchase warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPurchaseWarrantsMember_zabvmbDpCSw6" style="width: 18%; text-align: right" title="Anti-dilutive securities">455</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPurchaseWarrantsMember_z21oF150ZMT4" style="width: 18%; text-align: right" title="Anti-dilutive securities">455</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock Options</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zn4aatZpCD7c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Anti-dilutive securities">810</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zSqvT1QB7fqj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Anti-dilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl1415">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Anti-dilutive securities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220331_zTABLwEbfizc" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">1,265</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20210331_zFl6pryYjnd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">455</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zBXat9okd4jg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zQWdkVDO9ti3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zUWVoFJivJGa" style="display: none">Schedule of Basic and Diluted Net Loss Per Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20220101__20220331_zXbt0G1qRPSl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20210101__20210331_zahO0s9njJol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zqTYB4diFVof" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Net income - basic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">12,494</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,057</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--InterestOnUnsecuredConvertiblePromissoryNote_pn3n3_z2bkMvkqBGng" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest on unsecured convertible promissory note</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">232</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1387"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_zoTHG0AFhI97" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net income - diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,726</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,057</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zKObQcYz2s46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares outstanding - basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,486</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,563</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--IncrementalCommonSharesAttributableToCallOptions_pid_zwVdRqWRMVWk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diluted shares- Stock Options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,895</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--IncrementalCommonSharesAttributableToWarrants_pid_zg58Z3bVbCEj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Diluted shares- Stock Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">284</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_pid_zqOS3qbc6a2j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unsecured convertible promissory note</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">458</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zK4Fb6okSU6d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares outstanding - diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">18,740</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">18,200</td><td style="text-align: left"> </td></tr> </table> 12494000 1057000 232000 12726000 1057000 15486 14563 2232 2895 222 284 800 458 18740 18200 <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSmhMhlVsqRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z6XqrKyEaUG7" style="display: none">Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Anti-dilutive securities</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Common stock purchase warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPurchaseWarrantsMember_zabvmbDpCSw6" style="width: 18%; text-align: right" title="Anti-dilutive securities">455</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPurchaseWarrantsMember_z21oF150ZMT4" style="width: 18%; text-align: right" title="Anti-dilutive securities">455</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock Options</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zn4aatZpCD7c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Anti-dilutive securities">810</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zSqvT1QB7fqj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Anti-dilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl1415">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Anti-dilutive securities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20220331_zTABLwEbfizc" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">1,265</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20210331_zFl6pryYjnd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">455</td><td style="text-align: left"> </td></tr> </table> 455000 455000 810000 1265000 455000 <p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_ziAgoORSJDhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 17 - <span id="xdx_82B_zpgWDmpiaH2c">Related Parties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jason Karkus, Executive Vice President and Co-Chief Operations Officer of ProPhase Diagnostics, is the son of Ted Karkus, the Company’s Chairman and Chief Executive Officer. For the three months ended March 31, 2022 and 2021, Mr. Karkus received compensation of $<span id="xdx_905_eus-gaap--SalariesAndWages_c20220101__20220331__srt--TitleOfIndividualAxis__custom--JasonKarkusMember_z9Py7u8SLk71">55,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90D_eus-gaap--SalariesAndWages_c20210101__20210331__srt--TitleOfIndividualAxis__custom--JasonKarkusMember_z6JWvvFWEoC4" title="Annual base salary">30,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> 55000 30000 <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zdcHZVhxeXt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 18 – <span id="xdx_826_zb0FldVAMLJi">Subsequent Event</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Appointment of Chief Financial Officer</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 9, 2022, the Company announced that has appointed Bill White as Chief Financial Officer of the Company, effective May 23, 2022 (the “Effective Date”), replacing Monica Brady, who is currently serving as Chief Financial Officer of the Company. Ms. Brady will remain with the Company and continue to serve as the Company’s Chief Accounting Officer, and Chief Financial Officer of the Company’s wholly-owned subsidiary, ProPhase Diagnostics, as of the Effective Date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As an inducement to his employment as Chief Financial Officer of the Company, the Compensation Committee granted Mr. White a stock option (the “Option Award”) to purchase up to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220508__20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrWhiteMember_zdy0yBTYL22j" title="Share-based compensation arrangement">400,000</span> shares of the Company’s common stock. This award was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded under the Company’s stockholder approved equity plan. The option award will vest over a four year period, with <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220508__20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxppaasb8flf" title="Award vesting percentage">12.5</span>% vesting every six months following the Effective Date, and contingent upon the commencement of his employment and continued service through each vesting date. The options have an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220508__20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znWGxiM7ncF1" title="Exercise price per share">6.74</span> per share, the closing price of the Company’s common stock on May 9, 2022, and will be exercisable for a period of seven years.<b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Announcement of Cash Dividend</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 9, 2022, the board of directors of the Company declared a special cash dividend of $<span id="xdx_908_eus-gaap--DividendsPayableAmountPerShare_iI_pid_uUSDPShares_c20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqhDs5ueLeb4" title="Special cash dividend">0.30</span> per share for stockholders of record as of May 25, 2022, which will approximate $<span id="xdx_903_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_pn5n6_c20220525__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3pr0ikEHXtl" title="Dividend payable">4.6</span> million. On the same date, the Compensation Committee of the board of directors approved an adjustment to the stock option granted to Mr. Karkus on February 23, 2018 (the “CEO Option”), as required under the Company’s 2018 Stock Plan, as a consequence of the special cash dividend. The board of directors has adjusted the terms of the CEO Option, such that the exercise price of the CEO Option will be reduced from $<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220508__20220509__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHuUdqlyhUce" title="Exercise price of option">0.90</span> per share to $<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220508__20220509__us-gaap--AwardTypeAxis__custom--CEOOptionsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQUaXjP4z9Gf" title="Exercise price of option">0.60</span> per share, effective as of June 3, 2022, the date the special cash dividend is to be paid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> 400000 0.125 6.74 0.30 4600000 0.90 0.60 Net of $1.6 million cash acquired. EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( J$K50'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " *A*U4;$GDR^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)TW50^CFHGA2$%Q0O(5D=C?8I"$9:??M3>MN%]$'\)B9/]]\ M ].9*,V0\#D-$1,YS%>3[T.6)F[8@2A*@&P.Z'6N2R*4YFY(7E-YICU$;3[T M'D%P?@L>25M-&F9@%5S18Z ,3=T 4_/$ M>)SZ#BZ &4:8?/XNH%V)2_5/[-(!=DI.V:VI<1SKL5UR98<&WIX>7Y9U*QMD/SZ?7;]X7<1]H-U._>/ MC<^"JH-?=Z&^ %!+ P04 " *A*U4F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M J$K52W#U571 4 /\5 8 >&PO=V]R:W-H965T&UL ME9A=<^(V%(:O-[]"P_1B=R;$E@R!["3,$)+L9IK-DI"VDW9Z(6R!/;$M*LL0 M_GV/A+$)-<=T+S;^.B^/S['>(^ER)=5;%@JAR7L2I]E5*]1Z\=5Q,C\4"<_. MY$*D<&ZYD_ H;0TN[;6Q&ES*7,=1*L:*9'F2 M<+6^%K%<7;5H:WOA.9J'VEQP!I<+/A<3H7];C!6<.:5*$"4BS2*9$B5F5ZTA M_3KR/!-@G_@]$JMLYYB85YE*^69.[H.KEFN(1"Q\;20X_%F*D8ACHP0<_Q2B MK?(W3>#N\5;]SKX\O,R49V(DXS^B0(=7K7Z+!&+&\U@_R]5W4;Q0U^CY,L[L M_V2U>;;3:1$_S[1,BF @2*)T\Y>_%XG8"?#.#P2P(H#M!5#O0(!7!-C,.1LR M^UHW7//!I9(KHLS3H&8.;&YL-+Q-E)HR3K2"NQ'$Z<%(+H4B;9*%7(GLTM&@ M:>XX?A%_O8EG!^(]\D.F.LS(;1J(X&.\ RPE$-L"73-4\ =79\2CIX2YC-7P MC)K"UX1Z==$?:+PR/9Z5\]#T_#6<9EK!%_,JYTD+% M:_(L%E+I.B1<2JL<(^J51+TCZZ,XN)4UF\-(N%93EOHE4_\XIK%0D0S,8",P MW&L_'UQI.[Q./GUJ&"(7)=O%<6QW4>;S>(MX!Y=K_017>Z(($G4K5W/_%]2K MX.HP4H-80Z+HCM=25&B4*[4/A96R0:[=IJSMH0EC%1I#M6Y3'>DUD,6"/.;) M5*A:(%S$==TVH^>TAR%5UDN]8Y">Q3PR[@MY>^1)?9YPH;&2XQ!:_9_U^AA99>X4=^>" M[(6_D_L \*)9Y'/K9$AM<4GFM5FWUZ,>2EC9/L7-NB"$6D@%WFKA3LE$PT@@ M4I&1S"&ID%L9U%>\H:O<8I!5)Z"X?1>0PR" N1%\.<4!>8#GR,^TG@R7[%%Z M0N#?1(L5-#PR7&+]@58-@N*^CJ*^K&0M*BXYR2,H!JP',,"J2U#T.#A$&A0I[7I895G5.ACN^K:20UA#'D;!!3XSVOV"H50M M@^%._R#M#"24*=;%&D2\3K?M7M +C*CJ$0PW]I=(0T>5,T+9Y^D7,A%^KO[S MO198N-)()HE,"_.0_MLI6<#T8 ^A5749G/$S"OY%K66#%=L(*NL MGQUE_69N"9T=/'4N5?T(P'4>9=KFOB] !D2"C2"VR*^.\KO;Q.AYN;K^@8*.@2#318\KY2Z5L[/%9HIB=QXSXIMYZF:WK;Q:[FX.[9Z>4SV^V1J%)3C4-".Q MF$&H>]:#GU>;W<;-B98+NV$WE5K+Q!Z&@@="F0?@_DQ*O3TQ/U#N^0[^!5!+ M P04 " *A*U4V2$^3*H' "2( & 'AL+W=OUO<2T9B8F%E MT15I9]-/?T/9L6SQP0GN7G1CV4/J/\/1_(943U]$\UW..5?HQZ*JY=E@KM3R MRV@D\SE?,/E9+'D-OSR)9L$47#;/([EL."O:08MJA(,@'BU860_.3]OO[IOS M4[%255GS^P;)U6+!FM>OO!(O9X-P\/;%0_D\5_J+T?GIDCWS*5??EO<-7(UV MLQ3E@M>R%#5J^-/9X"+\,J94#V@M_BCYB]S[C+0KCT)\UQ>3XFP0:$6\XKG2 M4S#XL^9C7E5Z)M#QUW;2P>Z>>N#^Y[?9?VF=!V<>F>1C4?U9%FI^-D@'J.!/ M;%6I!_'R&]\Z%.GYP-"ZAB MMP/P>P>0[0#2.KI1UKIUR10[/VW$"VJT-#-V6MEW&J&OBUA''J M?"SJ A:%%P@^25&5!5-P\955K,XYFNJ))3I!WZ:7Z)^?_H4^H;)&L[E82587 M\G2D0(.>:91O[_=U:BW4)LX[@:XN M7^22Y?QL .5#\F;-!^?(MJ";>:(#)P.[^FBG/O*JAR3ZSA5[K#@\L8\*29ZO MFE*57 X16[.R:G^"&HQBSP7*\ASJ.TYAZ0'#X>HYLKF M16)&/XXSV@N_Q2I)7(F?[F2F7IF3>@U/HVA>G>)2X[8T3H.>-IM1X,CJ;"ZAT%'D,"K M>R84J]XA<3O-0=+A*(IZ(BUF<4C"Q"%S#W3AD?!"[],H6/@EL$VUT=6/X!*: M$N7,ANVD!VHH[:>#Q2K*J$MR!Z<0?R@C6I5(/.V"O12-;H:LPK&E[O83PF($ M>>R0W2$P]#.P[05/Q-/)2O)-/KC#2TP!),SZ,BU6-, .G1T#0S\$)[5B]7.I M:_$F:]TR38B%06@ PVJ61BZA'>Y"/^]^%:)X*:O**LVD5)0$1@2/6!T*ZV 6 M^FEVUU8GSR-O<@;3M*_--(I=93[L32[FUU1U& K3=S6>5RZK%OZ?[##N&A'Z([#"\9*^:P5;730ZD..CC MUV*5!-A!"]S1 OMI 0*;%;2=1:R%5F2/=J)1Y/P ;K=BD 3QYN*?59I5F MCD*&.V1@/S+>M+)B#>0H95D_[T&95; 'UKLDNW 3"5D_N2PVX=XZ'*K>V]+X MJ7'-85OK3JRM/+/RQU$_!6Q&,7'HZ_" _7BXY$\X.VL)C M:VW9[>#$6&S3"E-7H<,=(K ?$8?=X3&E)@K"#)K^OE2+611AU\)WS,")MRC? MBOK$HO2+[Z"AJ_C8O_/HI_U'FCEL[C?2J,]1BU$6N-:O PKV V4G6S\.;T%Y MM8HT@4&-%LE_MW?M8 _/93KP$#]X;H7BON>9V!C2/XHQ;:@CZTA'&>*GS+>Z M/0+01S&B;D&C.])E(Q:EE+!3134H=_>FQ(1(DF7&(9(%1YEK[T3 MVU^O;L>3*VL3[I_O ^=9_X>)#GWN^$9B+S.F2N3?YZ(J>"-_^D>*P^3G[ M;_H.2<2_C;EOWNJOU#=";*7FHBG_AB_"81 $[7_H4_ 9_D90WK9GA_ 8"B3G M#)Q%4$7:)E8WKBLE8<];0"-K70ZOEH\LQ_\^T6&\.LH2/V7'8K$0M1FL*/!& M*XR&-(V&61"T<=J[W 9Q+W)#(+A<\O;]4V4E(3%)'/9[5[_-H?<=K,F1W5]1 ME+K:0J70!T+5=6^\-N> M,XL%/)!S_99V#5@7TKXB)I%/0M+OE:Q6B:,?I1VWZ7NX+=]9=;>"32;',:7] MO9K%+$IC['K5MO>N[0BZVZ.HZ\G%U\GU9 8H;.$XG=V-?__M[OKRZF'ZYL+5 MO[]-9O^QND"-MX"VXRJ+F>VX:K3WPEB_K;]AS7-92U3Q)Q@7?$X@!LWF!?CF M0HEE^P[Y42@E%NW'.6<0?6T OS\)Z%&W%_JU].Y_0SC_+U!+ P04 " * MA*U4N#V3G=4" !,"0 & 'AL+W=OOWN]M\I#, M BLR%>P7S70^=A('962)2Z8?Q/8+J1,*C;]4,&6_T;:RC6('I:72HJC%0%!0 M7OWBI[H0.P)_<$ 0U(+@7$&_%O1MHA693>L.:SP92;%%TEB#-[.PM;%JR(9R M\QCG6L)="CH]F0J>P4,A&8*5$HQF6,/F%C/,4X+FQK%"'V=8$JYSHFF*V2?T M&7U +E(Y7%4C5P.'\>:F=\HA<8H9F@E%;:?]OEDH+:'?_AP)UF^" M]6VPP8%@,^A2(B64&!YM^GA5%Q'A4N="TA>2==6S\AE:G^;%W$Q\SWY&[F:W M<*?M6M"#!GIP&?0:2[3!K"1=L)6O> ?"ZP%"^(;UI%D+-6Q0PW?5ERI5=MLVA!1@UD]"Y(^)M5&O.,\E47:722])A%BS1N2..CI%-1%/ *7-*K M\1Y#Z'4VZQF&+>:D84XN8#[:JLEYK7K2K,4Y;#B'E]?V1 L,]U_P<)"$P[WB MGF'8@O:]_P/#.XK]'4X+JI3/;?#.*>#M0\2>GR2#Z UMEV64M"TK7'=GU)ES M!LR2%>4*,;($J=>+P8>L1G>UT6)MI]]":)BE=IG#<8=(8P#WET+HUXT9J,T! M:O(/4$L#!!0 ( J$K52"QQIZ/P4 &\4 8 >&PO=V]R:W-H965T M&ULG5A;;]LV%/XKA+&'%FABD;HZ< PTSBX%UK5HEO5AV -M MT3912?1(VLGVZWZ:M3]:*/U M]FX\5LL-JZFZ%5O6P)>5D#75,)3KL=I*1LM6J:[&)(JR<4UY,YI-VW>?Y6PJ M=KKB#?LLD=K5-97_/+!*O-R/\.CXX@M?;[1Y,9Y-MW3-GIA^WGZ6,!KW5DI> MLT9QT2#)5O>C]_AN3@JCT$K\P=F+.GE&QI6%$-_,X$-Y/XH,(E:QI38F*/SL MV9Q5E;$$./[NC([Z.8WBZ?/1^D^M\^#,@BHV%]577NK-_:@8H9*MZ*[27\3+ M+ZQS*#7VEJ)2[7_TTLE&([3<*2WJ3AD0U+PY_-+7+A G"F#'K4 Z!7*ID'@4 MXDXA;AT](&O=>J2:SJ92O"!II,&:>6ACTVJ#-[PQ:7S2$KYRT-.SN6A*2 HK M$3PI4?&2:A@\:?B!;&F%Q I]VC))3=05HDV)/ND-DR!?0^%L3$;W#/TJE$)O MGANZ*SD8>(MNT//3(WKSP]OI6 -.,]MXV6%Z.& B'DPQ^B@:O5'H1\!6GNN/ MP;_>27)T\H$$#7ZD\A;%^!TB$2$.///O5\BM%"ON#&)F34N*+,]M?+9@,2&Y%U_>X\N#-=0MR6:-V.O6+&!U M%ZB=HK=:!+U^Y'3=0';XLC?K)HZ+#1E06I&)7+38NWA)JOQ-8L M>V=CC&P4J8W5(89QZL=ZP@8XB/5WH2&PPBHN)U9L@R#.1N*0A*62^?&2 2\) MXNU:Z9L*5NM;M)*B/H('LG*")C;H#">9 [1#DA!_]\-#^\?Q%=":208]D+?H MO8VZ,W,6MM@!U!8K_ T&#SR"PT32P^R*P DQL>:^(;$+I$LP#41S(!-\A4TV MM%DSB"5:42[1GE8[9MB%-WL W_*K8LN=Y)I[ZMBFD)O<51!!'&:_?:>V=,GN M1[ O4DSNV6B& DT9#UR$PV345?E%>:,%@VT\ZZH(:?KJ\<^F()Q.3.@M#QV2 M41JHI8&MICU?+,_.%Z;!AW8X M9* X$J:XYP:.NQ7_%TXY:SCF'KD#CI1PCOW&-%U4#&AZ<:UM$)O48L?^SR%V M@_U]CPS41\+4=Z#J\RCY\]H9RZZ3M4LR2OQD30;>(^%SSX]4-K"I@&TUI%=M MJ&3!C Y$1<)$]4 57SJ=/N@5)ZY$MT7;^?H_?.F^2R?*(X_2.>2!M$B8M!YY MM=.79]L.=.H D!67,%U24>;!-3 -R8(I^MI>>\#2H'MH;4"K4$\U+(TV6PJ) MG58:MK&0Q6#J!EX@85[PI\ZF IPF1789!H=8DF:Q)PY#ER?7#D+^_#@Z9 415;@^5;0@3XEB89 MO^]MA=A]& QXN"4IYN_ICF3RFPUE*1;RE+T,^(X1')5.:3) CA,,4AQGO>FD MO/; IA.:BR3.R ,#/$]3S+Y_(@D]W/=@[\>%Q_AE*XH+@^EDAU_($Q'/NP1_AAA;S"H;3X(R8'?G8,BJFL*7TM3CY']SVGB(@D M)!0%!)8?>S(C25(@R3C^J4![]9B%X_GQ#_1E.7DYF37F9$:3/^-(;.][HQZ( MR ;GB7BDAU])-2&_P MIPLO_X%#9.CT0YES0M'*6$:1Q=OS$WZJ%.'- J,,! M50ZHY> &'0YNY>"V1QAV.'B5@]<>HAT-0.00M!^AV. PKAV%) MUG%U2VKF6.#IA-$#8(6U1"L.2GY+;\E(G!6I^"28_#:6?F(ZHUDD$XM$0!YQ MFL01%O+D2<@/F7&" [J19S1\W=(D(HS_ A;_Y+'X#MX^9SB/8FG]#O3!\],< MO'WS#KP!<0:^;FG.<1;QR4#(&(N1!F$5SZ=C/*@SGC25&5J."/[Z0M(U87]K M8&9FF(^1C$RF.D[ XZCO@QJAG>QD.<&T+D9])$(>6_+U5E@EL79"S=A+2X$ M^/OL,_@H!(O7N<#KA !!9:A,+KD)=6E&_2JK$<_9]\OKM[H 1.52-=T&,K/J M]$)U>J$2Q^O ^41>XJQ8*UDO$IR%Y [L<9(3@ 68D_ ]<.$=0 YR=)ERA Y* MZ**D[J?0FPSVYUF@F@0P&+:LYJI5WPUDCLA: $["G,G;D6CK@1&^V(D_\!T.R7U/;K6LD#J7'AC"Y0]R!3'(O_=^@.S?PZ^L2CPM=,@R5 M#0NU=MJA,E/7AZ[;NCN-,[OA[K2$L[2$L]+/WM<3/:J)'OU\HH\M@([3D1JS M4_[IHQ[748_M1\WBO104==BZ<(VCWE"/QLJT?=]I-6AS2X,M+.$L+>&L+DR^ M03AT3AK1^>F4FS*U&KX==F?@9^(6&@-?9)%>>WS!K&Z7H38DJ+;P0:LD5C;- MZH^&9V6A4I6J71_Y;96RT)JURO!29Z13(!H['P5!1\6")ST'S8*NO:(G!7)Y M29&Z7#[TNR4(/"DC>+,TTLI,?5SN%51KY)/C^3YJ4ZW:HR'.&;:I5.W\4=#6/\"3LH%G97:TW]:NJ:A+)]<@?=][5)V4"S=)$5XZ. M@14EJ)2<(>.VIK0UWM(6T.IBX$T"3Q(0F27@ M55(?:A]9' M)P&(S +P.JVO7].KU=_@[-V%XN47"2UE)P<)V4A7Y_U08K#C^R3'$T%WY>L, M:RH$3 M3@( .D$ 8 >&PO=V]R:W-H965T&UL?511;]HP$/XK MIZC2J%01"-!-58A4:*W9"QJ3!2WSGW/?= M=V>?T[TVS[9$=/!6266G4>G<[B:.;5YBQ6Q?[U#1GT*;BCERS3:V.X.,!U E MXV0PN(XK)E24I6%O:;)4UTX*A4L#MJXJ9MYG*/5^&@VCP\:CV);.;\19NF-; M7*%;[Y:&O+ACX:)"98568+"81K?#F]G$QX> 7P+W]L@&7\E&ZV?O+/@T&GA! M*#%WGH'1\HISE-(3D8R7EC/J4GK@L7U@_QIJIUHVS.) *0M( DZ&X2 M!95WS+$L-7H/QD<3FS="J0%-XH3RA[)RAOX*PKELKA6G%B,'LJR6@C-'SLK1 M0KUW%G1!GLZ?2RTY&OL)[E]JX=ZAMU:LYH*B+Z&W9(:"2W0B9_(2+D H^%GJ MVC+%;1H[4NKSQ7FK:M:H2DZH&L&#)CH+]Z2._XN/J<*NS.10YBPY2_C 3!]& MPRM(!LEPO;J#WL7E&=I1U[U1H!V?H%TL?\#3 U8;-'_.T(T[NG&@&YV@6]4; M*[B@X;B"%9/8]1Z>OE,H+.A,[+E$DR[1Y*SN9;V1(B?Z HU06\BU=?\]IH;F M.M#X^7[-DM'U)(U?CY/'1]>O0K,-0V:)M%:NN8G=;C?'M\WU_1O>/ )T3ENA M+$@L"#KH?R8!IAFLQG%Z%R[S1CL:C6"6]!:A\0'TO]#:'1R?H'O=L@]02P,$ M% @ "H2M5 H*"RF&" 22@ !@ !X;"]W;W)KYY37\LI)JPPR\JH>9WBK.2M=H4\U(',]G&R;JR<69^W:K+L[DSE2B MYKI/%MH&3^%/P)]U[CJPI]U)^MR^?R_-);#7B%2^,[8+!OT=^ MS:O*]@1Z_-UV.NG&M W[SR^]_^*,!V/NF>;7LOI+E&9]/LDG49K_+I M-]X:E-G^"EEI]S=Z:F7C253LM)&;MC%HL!%U\Y_]:!W1:P#]X U(VX"\;I". M-*!M _JZP7RD0=HV2)UG&E.<'VZ881=G2CY%RDI#;_;!.=.U!O-%;>?]SBCX M54 [+DS\ ^FU^A(KJ)KIM?1+Q B.OKPK6:[4H#, MQV@:?;N[B3[\]/%L9D 5V^&L:(>]:H8E(\/2Z(NLS5I'/\/P)=+^)MP^(8$. M9N"#SA'DQ1%7)-CC%Z8^130YB4A,"*+0]=N;)Y@]X>8WO!AKOF<-[::5NO[H MV+3:&5NY&5LIN8D )Q0SHGYH%IHP@NO ,&DW3.J&24>&^0. 2=2%W' L!)JV M<]?6XL\C3%NZ3.,X/IL]]EV+",;9HB^WIUW6:9<%G7!9_A<64!/%1@)*%;(N M1,6C&M2NI'9?[7-AO;55\E% +$7WS]&'G5T1HOZ(.NXTX+EYI]L\Z+FOG%7B M'QC$Z0$ "*C[G1MV#^J5_-Y$FA<[A5#=RYYV%LN< MS9(P[J_"MD%E97S2!NP;OC:K8=]368$D31\( V#3K56U;P\PF$ MH>;JD4\NHL""3'I,F 1MN3.R^#ZU2409 :1!9J6;N> _[#,*<6V7?:O2G"!6 M(7(D'Y\ XI4F0:6OUZQ^X !5T8H)%3VR:N M5 ?9,_'TF83Y$XD*U'$(42YICKAN*#A-DF016*.>,),P8W:3C6HXI+TI9#^( MAI@@6>;C>5+B.3()D^2MXELF2C=5TJRY"@'YD/M #PPR$)(D*1U7UQ-E$F;* M_QQ2<&73I*)0.Z"6EDU0Q3+\4J.>$(E^5'[+TTZ_N;]%^*ID(2I\+/6.YL( MVYS?)?K@+?#?1FAML\M:&GX@10H/\*:X;-V)L*E=AZ/NI)Y0:9A0;W>J6%O, M "M[&R7ARH9B%6>,)"JX8#Q>'U//IC3,IK=*%IR7;12\5,G'[?70(<5F-$:6 M)B*8A-SO&92&&73?BE+HK=3"UBQN=QC"#9:F>7Y3]DB'1)LC/!M6Z'BPI+V- MTS#/7K.M,*QJTK12&%A1N"%(D9G$2\P61)(NR7C>3CV1TL/[KP'(/(PZK2U# M"DWC'"F8$<'I/*?CB$D]V](#%>0KQ%R)&G#MS8A)/1O2,!ON![/HX2?0_<;N M9=E]H.;7[>Z^@@18KB#W E5.[&XQZL#@D$=@*!VR*\T2&H B3Z\T3*]OM-LN MXB>F%+/U2^,$!>1A>.<%U '!L8]Q +(+G(5 S%,R#=>X7Z'$?78;8F"RX\5 M5D>Q(C?%JMSPJ.] *D_]-$S]8%!+B[H_BVLVAE@8/R<91B3_?TJP?YSDB3X] M0/1^BDIA$:TN45M2A++3>8K,3WC =]CBN3\-T$( MLLF,2*;Q/ >J<\ TG & +6083$CJZOTB'AY_,,V1-!!.=Y,@SBFU9P'A#<]T3O #><0;S#$]RF>0=]@.U8 MYS%2A2&2E"S(4/(F'9X3O_;KOA=\\I&&DX^[W79;N?L.D/G9P\%*:IOXA?:J M4Y]QI.&,PZ4V;G]U)55[7FZW%4;6^[^52_P+'>T;[%.-]-"&M^$V>J*.<>LF M7/8+4]Q\I'Q/D1-83"X;SQ-2GR>DX=)])!::K*&>NJ722ZQA,6!('HP<3_'I MVZO[/7YWD>1JQT*"+DJ/G+VG0\Z?8Z5C6(_C8R7SC)^%&=^RY*Y6+]+C2>\0TYTL'5G!WU73D-OJ;6T;= MU^X^W*6[!?;J^U5R>MW<:O/=-)?LOC %'*.CBJ^@R_C3 J9--??6FAO/@?4$L#!!0 ( J$K50- >#Q ME@< (,1 8 >&PO=V]R:W-H965T&ULK5C;;ALY$GW7 M5Q :8) K:L].S.);<"6=S*>C6/!S@6+Q3Y0W:5NPFRR0[*MR%^_I]@7R;=L ML-@7NYM-%D]5G3HLZFACW:TOB(+X5FKCCX=%"-6;R<2G!972CVU%!E_6UI4R MX-7E$U\YDEE<5.K)?#K]VZ24R@Q/CN+8TIT?.^M_1-_A MRTIZ6EC]166A.![^-A09K66MP[7=_$FM/[^PO=1J'_^*33MW.A1I[8,MV\5 M4"K3_)??VCC\R()YNV ><3<;193G,LB3(V/%WDU'V ME\/HKV#'_ U$0MKO-4JV[F^ M=.3)A&; KL4?RDB3*JG%#08)5 Q>_.MTY8,#F?[]'42'/:+#B.CP_Q'][YKB MXGWC*YG2\;!B/]P=#4\^V$"#F1B)%S>"TW99@-:#]W+E$W%ATK%X]?-/O\WG MT[?=M_@Z>YN(=GSS9*3VCT=L[=HA89T(!74?%K:LI-FV'U\+Y844&4K3>;56 ME W29@+6R( TK/$!,YPT.7%6V#65DA?*I+K.E,FQ6N;&^J!2$0C_3)Z(G(PM M5>J[D>AU"H)R[E!!IE[CH7;X-!9?2%3.WJF,!+YGBL,D]6#Q_N)4E!8*4FOI MA)8KZV2P;MN#2/90W)Q>WXP6]O-HW@=PBWW,4:Q219(WF? M%8G: P8.#K&N'1C@>KMC\$S(K DT#)(HY!U!3:D2]*TBIP &$%4H!#QW(ZP> MI;8V@=R@\_OJXZ)WNT,G"I(Z%*ET,:-9G2)0[%&F*$B.1%U5NBGEF/:T=@XO M>LLF>'K, LX\%VL%$2N#/8XUX?Y99J#:(.QEA\,D%I MI"40I,5SDB%LT^C^A@"83 X:9%BA<$ J8%(F5DX7M@01NL,Y6O'>R1Z)*0$. MR)):U4U$L?Z6=DR3.I8.(O8_1:K#\*7(= M[7+#*=OE8=#G8=6*7!(W ;33.L>1RL!FC.L1)&37<]WO^/P@,)W9L;BJW8#+ M!QFR&X.(^'KE%1"X;=(+JCCO$;VDJ_M3.BK'\D+E;:3GTBEA'9)]E0;+(?T] M::/:Z.) BI6S,A/2.;GE%*>=?NSQDL%WPK/C:! *CD6)2\F%J+T[S5 /!-9S MQD=V'>M0NB JJ[<@$?N0%FC]!F@(FS:K]W%Q_43U6 JZO(_%PJ'\&2K$HF=# MK]^;G22O)7(&EAN)=+,OZ IC<+@PT'TUEGZ0[#$X_5I#"C/N&M9UJFH2W$)L7THUYCBJG&O M4HOEY>/4-G&%,2F,-:.=JJ!Z]W)QF$RG4[2I-9?HVMK0).MYA=W:HQKJ>-*74*/%+ )1]T?H[YEN$A-9 M.!-@<3D,/X(XV(,(:.^DRY"1!1*0",;V3[3LB/I.;D'+4* E:,PB]:G2G*Y6 M8AH/_X+PL41Q'7/.!FU=SZ8Q9;.'*?M *VB&>-<6]:-:;+[N4B19?N\0R[ZX MG\I"VZ$D#P3(T.8'1 $]9JKBC28R![%]21OZF7T9O4+'(+BE$Z!FW\"=LI\^ MGJ3^]7CPS$YKBXL$*@:/3[JB0&EAK+:YXF9&1M<<%7SKPH%<$E2X.<(E(K"] MYR4X$1#7MG-XT $Q/3!,T"4^ 1&Q$D[_W Z%A\Q@YL$859YT%D9QOI0T$QNG#6.*BBLF7!CX2B2/A ME+]M/_7&N,M(HRU7YZPC%<)'S4$!1>,F$9O=-_YP091UI=3V7ESNMZ2/27%YL6-H;)C7M=:CKDB?:6O)15=: M+K-2D!ZTW0.^Q=)MCHZ^L68M>G=YA;,E7A::<\-(&)-ZQ%T=-S7,]LS9J@D] M<*-I:3L>[BYB-)_O(O8:H2\TB"U!BRO/S!"ZCN8) M:5ICZ73\ZR]#$"M>^9N78*MXS5[9@$M[?$2+!>0\ =]9P;L7WJ#_W>7D/U!+ M P04 " *A*U4>CTFY9TK "'A0 & 'AL+W=O_T*A,8Q046 +39W2K(CJ,4S.L<>*41Y%#=NW =T MHYH-"PWT8"'%^?4GO\RL!6@T)<^-XP=;)!NH)2LK\\NU7][7S9=V;6V7?-V4 M5?OCDW77;9\_>]8NUW:3M;-Z:ROZ9%4WFZRC7YO;9^VVL5G.+VW*9\='1^?/ M-EE1/?GI)?_M0_/3R[KORJ*R'YJD[3>;K'EX94VN[4WMOMM^Z&AWY[Y4?)B8ZNVJ*NDL:L?GUS/G[\ZQ?/\P#\+>]]&/R?8 MR:*NO^"7=_F/3XZP(%O:98<1,OKGSKZV98F!:!G_TC&?^"GQ8ORS&_UGWCOM M99&U]G5=?B[R;OWCD\LG26Y765]V'^O[OUO=SQG&6]9ER_]/[N79TY,GR;)O MNWJC+],*-D4E_V9?E0[1"Y='>UXXUA>.>=TR$:_R3=9E/[ULZONDP=,T&G[@ MK?+;M+BBPJ'<= U]6M![W4\W='9/%G6 M=%I5*S^U]&:>X<^KHLJJ99&524NO6;J779NLLSN;+*RM$I((VZRAYPK4#/K%;C):%Q6V;@L;=EK8U)&/H_K=:4V8-G7SDL"H&YOD=5+5';VR+/O<)K2S)"_:95FW M/9&5'LPZNJHD#>@Q$AS8^(+6;/_5%Z 0=CFYNVD:&J;A),&F*$OO@BB_57R8 M-QB=*76]H?TM,T^*OUU??W"TF($%>(K--JL>,,D$/YC_B!\6#R2N*I+O>(+Y M@51#PH,S65OZOZ[Y)HM7X-9BI-:1Z+M@$"$$GQ6=" MA]?5*4[=9@T^I)DP\'55]33 1[NMFRZA*2'LD_G1X7_S06&(%1TN/?) +R86 MHBQY8Y=VL[ -A)$A832?)>^$[O6VJ+!PHGC8=LH\DN6_DSP70E4T0-OBUF*2 M+%EE10.:A4NIS+V'YMNZ+?!8.B0(#4#:B,^;U';#(\FMJ$&!! ?$LURXB%Z*HV.>I/E5CA(IS?#Z=T@W;JQ M-MF(2A ZDD!?KKU$3XAA^&8YZA3$V#HEUAN&I>-S6Y7;EO$5RY;KPM[1N/6= M;8R0KV]:ZXBYZDLYQAD)P/K#FK2Y^25;T$;?54'9D?:I5]1?6WW!W=R4]_5:[JV30K3RP"G85&[;95-L04135(+D&!(M=;D>MH@I')#,NG^W$XLA>A5-O%^_)H"['!(@BZZN(8'1U,18@0A9V=:/ M4J)DYHA5@DQ- ^7]4K?4VN:N(#9/28C7MTVV71=+7(!,/MYDO]-8 @!M0T?P MWA'1^ 7CNA )5Q "K5ELM05?T+\GE5TQXBLI"U:*W2SU2WM"K1?]"V]A=L/ M4"RZ$VN_IT6L:6DDNFD/$5UC.A;TVEU6E*">X>.CZWR7E3UOF^0]LR3=Q%58 M-"1FP:KXU^P+"2+'SJ_?O_DU\+),[^2%XVH:'BPJ([[]2MJ>C_;]BH".;5+B M:*+"LF")OR9\1O>5Q&T-.04I01)@J= @:UMLFA;%NZ&K.$L^DT@BVZ7+H#CO MZPEF?4Y'F=U6==O1";EC2PYDL0H"2.:1+GG]_I_OWAS.KR*)&[U*LD3'E2&> M>MG;TQ$'[AB-S%J*GF)0"L[L5_1##QV6TOYHX67@$SX/VD%;5W1J! _J3;%L MISGO:7+0DD"&D$OF9TY6D:CR1TW X)5R"@_\2T'7D$3;0_*Q:+_(:+\1%1M0 MCYGHLS5E1LI[C9O4-Q.4"[Q'!/=ZE,3_$0]GO]*9YX)C_HOV"A4)!2LR4S2L MK4!&: .:X6]T\4@)O:95I_O+L&H"$$PK"!F+6F8ZV;![I) MWUJ7;.R^(&4!NA=5SQ!QP>*D["WMV/-Y2?JFQ%IR,I8K 7>.#_!D=(0*\N8;F<-/?%2D]R1 M.J_[UKRE*T)W8OF0_$8R\5K'$IA"DF!=D$##WALZ5#ITL.@2$IEF:X-E53YX M$;4'$@K'NGVNBJ;MDG\1*Y,XQG853PKDH6TIEJ&/&+/(!7+\/25['*NF(-44 MG^9VBU55#&@7-6PP0***3S@3$HCB)?W$D$2AOQDRP^C("3N2G ?_#PZ(KY/0/0\JD5!FA6408 !T^%J0 M++7$,^=7R=D%!&1\5GI]PYVA!85919"K[FH@?H@VC;-L!O;:DEB$R/[W^IYX MMTE'?,7/MWV[56^:\0[6U?BN01ZY .2:0?#CKF,'9F#*3O MU"!ZP8$/Y:P7SO=! R_+K-@(PG-RWXGY(-[;'I/CHI,%(2?,QUD_)^:BL0$= M529Y023B]5<+$ZVA1CB3:UKG"(K-"N "SM02B0"*Z=_P M+91TO4!X:*3-HKCM29,XJ+IDWT4)QP4$+RT:)+--4S=N!KXHAHR!;4^LR78R MC41Z!'*ZJB$\503S_K%?NZ*U@""U:+9$@0%+"G_?0)Q]$)-UP@)LL(0E378O M73LC)C!!1YNP_LHZ<:;II6:TXM$O;7T%V,U7E'G#LSV/[E0CA@H FHTK""G0 MFK$1$#;9ONK[$L2[V0B&PF9WP6H,$*_[6QRLN%@^ 2?]<9@6D!DK=_C,8EKM MLPZAK5@(L)F8\!J3&FP%M M5CIN^Z[='11/Q;M2;!05BRLP4RV-M7WZ;Y*2M!#E]+_^97YQ^@*.+O-=?IDT M^8'^G9V8#1@<7KDLTI.TAL UP9Z-$:QXN>;;9E5K5#MPD88<-^TJ(3 MBK-SB_@1>H@7S!+<6S]T#F(:6[9,8Z?42*!DN 59VYGYL:,P7RA,#XTD<+!4 ME4ZWZ3_RPP>];W)A$_9\9G+51?M'4B)8_RI.E1".:+1R,BCI$_K?B@ N47:L MY5/QJ"HJP8]59_J!*1BA0KX)X7!:G6AX*"(;G/,1_/6[1.[HM"#OBR7=G@8> MP=7(/8#@A=H*MPC0X$PFA**?;6$?B+:[R,5=?A;29H^#>@3>0C"FA," 'H(G#-S'X9C.BPYG1\Y( M_,*Q)5>7YL N@:X7-N(4CE&SZ&9FMLT&:HAE" '$=/]MI0' F8Y4QK'H_=I6 MS*,?L MO-,-5()&?OX0<:96Z!T9ZEK#>'3->V=#(F"TE1..//@:[9DE;[]F&XXSNE!G ML/_8*G07B-=;T*DLO;$)EPOS,18/8]L?>B2S('A'ECHXSSN_"&&P"2,&I+JN M"L%2<(%A MG;$'JS157?0T'#L($ZV=!8@N-PVR5:5E2T&W8@Z5G=BLA M-J,3A!^<-EDTXCE;L??NL"SN;*[G"HNO7G[14 (8E2@N.Q<'N8Q)Y"1#PW39 M5WDO^G"'"2-3&_Y,=C7@UG9%RTX&@,?]+ S][.,:!)_A@H,="EX@@YD(E'JX M3@*^RN-H(?S,,&0TQ.9OS@)^FSO;*AZE%=J[#*&2SB%1^\Y]KJ(2C.NJ"0S@>>1 S.),0@G*2361D M7K#-I3 -MK ?=):\)GS"0^.'Y&T$8\6QPZS.]ORZN%W33 (:$[":B_V*70 A M+(XNOC$1!(V?:$>F%P"=7'.%K6%O_%N%O+C^+\F3L MVN.GLFB MQ-=.?[(/3G.S@A6]3/9ZPZ)6I$J2!9^6G E'KO4]L#$)L0!!VS6)E$.H,C/< M+J!NT-2SY",MA#@3MY*W$?TN^)O%V:Z/U0=)LH&OC^>V M(U75-SZ^+^MR_H2BY6B6. N(/R?,'?;.>:]SJE8:-G)5LG*C;%D^3 MQ'"D=Y"4%\TRS#:>=T7Z+2!9_RR7VZ_>^#-O@."B?!ZZ5 Q9EB7=\F)5J,\@ MODW@W6 ]CB%@%D'Q0Z+/(LLFI/! M63%-A4:8H,DE4LSQ=NA>443)@7*0) *U]AL$-M'0+!^"+,M9+BQL=X_,$-J: MP@.(-P1+=+T.Y[@;)!;7JH;6YAP"IE+(:Q-M$H>WO[5C!27LH"Q9@(7SH2W1 M_=+0'3W>D+ F@$)+@3L%?K*Z;VD$%R&-WF1S/03%24CU3*6GS^,TO->#I0;^ MCEC;7'.:S/!NF^L-(!@XYK? /-&//]-*R#"ED_L;\\$OP@/_Q-K,;[.;F8GB M//6B+&X55?R0G)]?T/_GQR?T_X/3T^0I_7MQ>DZC-5O80B3[HN>/T\N3J^20 MGCRF)X_3BZL+\T-RDIX=G8=1+L]Y%/KKZ8GN9T="_Z]NZ>P(B\&^#F6'>W9S MF9XERLII3>)W2E01&>GS(>A'#[\QKBC96"Y! ,%\9R%5U=1B<5'+I4[(, MN\D51:@,W@Q^FF1C9?ZKI_M\?"8'*[%'^( * F#TVCP]/C]*S^=7[."M*].N M,SC.XQC>.R]7DAO^-&1CY"RM;/? M.0C!IT:K(U6&@ C /K_TT8_TU &R(:V)K^=G@!!TAB;&8=BN:%>(\YVW+L[Y M)1QCD*)0MB928JP%?F'Y,Y\4*)R7$K@HC)M;<;N;'>:(9HNX4?F P9@[UY$) M_]WY>3.74]R:0#[A(_]!=$(,*22D2KB,D_D K]0Z!4ID73".3#OQ'05L)72( M+*C?*EAZ(8&XC5E"P!W,$CZPW,(T$XD\BN2-/7Y1\H$ )D&):E6J^ZY>+AD? MX-#%%RB&,D&]%2+[!"B)HK'S.837X_PI4GB2.$E')U9C^R& MN)$T[DS(X'V3 ^>.8:/]P:DW$3N(%W*6%LQS]B#G%MY)UN+#.$UC-_6=TD]. MQ\52.*/3>[+DF-GE%;(T34SQ^,1#/@+=K?8+5H=,.UJ"L!*0.;RW/..?91-Y M>0J.NR=9WH'@*_@<1YZPV$N O T0;T.\[U)E'?\(,.FKLOA"%G(0Y='A*B20 M3%*DC>:*O2-D?L#*Q.%C0KU(]>M+UD!^R* =DG_8SK 6,3[+VV%$XS'BIR;+ M[:38(D/^-+TX9NAZF9X='YE'I=S\-+TB;'M\DAY=7ID)I90B(D'BY>0J/;^8 M)Z?S]/SHROS""8Z!/PZ.TZN+"T*#!R?IU=$\>6H^U5U6[EGAR7EZ?@4<>7*1 M7AQ=)N^<6S$UH*?_%0B-M77N#HTFE(PP9.^DX>PT"YD3QPZ+*M6?D$/,GBN? M/OOSNY_?AW0HNE"84* U+XZGFX4ED.RS&V&JK,K*AW^+*R0P#1;BQ<'48()Z MX&PA#H$5YUV7@_H&S! N7T[LIFP0)?M7$TESZ82I%[EI&_9I"#>VC_+BT 0+ M9Q!X,69#PRMB7GRS&U+S<,''36#TS(]@!!&G$*=]S.Z-^[ %$CZYI/^?S4_- M9V2C%I5DDA#CG5Z<)X23#4D I@Q9-RBL.,'T%\!,_[AQ=*J+Z;KK>;*C'&R@;Y@*G@=5;GP >DFY?]$69 MNR2/8@/GOTKDPP1BE^%D030YK+ I=F.\(%Y8$K"V&CP() K51W =AK\?*K[F MA%8Z(#>.;J2)J8QDDWK5W8/8@>FL^ERTJ1@! M,1+B1^#4C;Q,Z2..-L$G$[)7'';3N2,@'5&$&81]7(/)0J;=T$TO*0B5T6HT MF"S.195S$+DN@RZ?.QP/MR_J5_OP[9:L0X,5L)TB.0 M<]C5A_B7Q0ZG7.;N/>3+2:V$I%(-4WZ1Y!452@@&[+< M^K/D%SAE6L K;KJ7L1QS^G$9F MAY9+7Y'4LARFU3K.HEGVFY9S_UKCO GJ_HE&GR6_ N>5LF9U?V%%A(XM^!/R M7]SW7.'@U+[Z%G7Z@6< N(Q=$X?UZA!H($IT"%% #5Q4M_*;["G*@Y"\=9\R MR7=<,V 3!D?,YZ MP;H"<,ZYQ?*9NF#%H6PXW$;@#ED#G2.Z\@G1.+"!B&O1_>Z:"B]>AY(*OL2D MH4MF0?8*+D4X$,,LB, .>G9>&C=V!1YN)0N;D0FO"4MLIK;%FYX/; *>[V:;1,?,]+4>"P0"$5H5UQ M;_J<+S.X7B[!G:GI,TUIFPMB'\F(<^MW)<]N>SIDCJ@%*R+Q]$("<74OL3I= MY97UY?&9"ZFE-%/'N!T5"&(=0XRX.Q*2E:38FOT^/K>A))XHI%#X3DL!0^!I MH$K$]>TJ-/AL-VB$(;XD5A9&[@V!++N'HL&Z([W%242:&NI33%SPW.H."@?46I*GY< "(:3%@$]YJO?H:/N5 M8(ZK@&.ZD7)I1N1R!2%9D" R,]8N*:-C^HEF+(4,U?.N33?O6X5:(P_J[BJE==\ M7Q\2U;K!T#G_>%ZU-C:;BQ(G%OOCND2E$C4RPEE] J'/S MWO+!EB7-8/$@)9:-J] *SHCA8>^0C%&,Q"R\AWMX97C;>\>$>+2YB,K153/# MB[5GZ4IDV;H2>>]L@P.>F)+E6B BG.VW:'$C]4H>=3!N\L)DM"Q<8#_CGU<8 MZ 2VF1;87E+?^6HQE_G JGSH&A--[A00;290DX /"K9*2;N^9QC(*LG]?04R MFSA@@V%"^%)0$[HR* ISE:I-0?K">E.*/<8(?[A?U8#VE0ZN$]_$6G*6?IDD7#NI>0>H2[]54-_VA7C\ MZD$<7!<@;A[CD-< +BARBG39PGK4Z( NIXFY+"48<$Q2KI\LQ%A4& ',HSM\ M2%W"W1(01U KMZ?(M(X $A/O96(;.TBDV9-2Y%)L,VFY(N@V'>Q.@'!H5#). M5I\82?9H>L[J8N**T1ZVY->O;:#^*)T'O5 RY_'C(M.&$"BZ\K%^EG<@_V*) M1\=?L':%X'/ES37GK(3?Y;;P55@\2/H678V^%< 5?#>=7:[9*(8E*7Q8W')[ M%)_BQ0X*K4P<)IUE>L]VG]0P!&;EL@'E\K"-Y^:O?[DZO[AZ(4D=9OX\>;^ M.T-B[_HF3DC- (=M62:2S,1$C1L"D'2,'1CS(D%Z%6*SDE2=[6?H?<\CE9P M_)SN)D\[/>-W3J*CR]H]_N297TR,Z,P(-?Z_M>@7CC2UXBMBR^&@?MXZD-/E MJTPN^H7(-$]P(TUR&K[IM(#&2BOQNIBH9;QQ7? M$B]4.\0_>9[\5M4[#* GX5#-3HU6=)OAM-9,MKTL+OP_0*J16C22R3DN!HCQ MS\+&EU6+],8"9*(BAH=1G\1#R*]5BW (Z'RR9M2C:5(YA )TJ1.=\/='?R13 M5_]"H_15JUE>G"3F/C-13K@JV4 ?I. LLS[T!HN<5(/"29:;7LEI-3.OPB>> M[(E 3*0$NZCJ3FHPF%@2'X=I?N.\UE#DTYILF#Y,J^HWO20N375[TSB(SC0N MN]W-8YQ,0O3SAU2AJ>: >U+-G!\X]AGL#]]\9Z07T"1Y')I,)]NJJ'8"T]W= M1&+]CZ>>'DKV;/AI3^;IH>3.NG^-/,\9LTG\\Y^"8??FZ/[_4D)RBQ_/P3V4 MM%OWKWDTA_;BG)X[I'\,$A]]4J[,<9E>GIU)'P7#":A5@&/?NC\.MT\X*?";J<$OW MD9DN^# Z:]^U,X3;0NP(]7 MLA"1%!(:F_F0"3L?O.M']R7/#'1=X',R?.M?>PW :+ZK=\E\D!\>CA_=LG9X\>3I(PK(# MR,^PYH4Y.'T:>M1-/N/G#W==S0'!\VBV#]%2WD>G?6VF%RE5',K;XAB-3S*RH'*DVE7T9W!?Q'R. M".X<$NTVJ,$OI_;8X66N_>@>4>U2M6@CES1Z]F2(#;KI]^Q#DG-#Q54[(+74 M:&NFZ7Y*1&Q_PRT^&("ZN'2[EMR/UIOJ.\W^=!GH]X=ZK7 TP^#M,!EAGL"%Y@-S(3JO?/.0@_!,]XB(HM5 4I3+H,:T[PJ#Z*>X%246P;DJ M+;N%79T$AUOX(KB\=U_8R%X+9O"#@D:4SAL2E:SJG8&BGH4XVSBS=CAB4$+, M"YC;A./Z%!U>JQU&[NIB*5:/:HZSK5[CY1XQJ7447)I')Q3_YVOTY1F M4:$%D/.'S@C[J7WD!F)1-FAAOK]/:-Q']G-PW$:EK*Z@0<61;L!,;B"JH75Y MZ+H/O1P\B>:7QFDA.NJXXER,.$$B3)Z!N'?9/$;;.+$L<.DZKAA NZ_X^_?- M4_BSO,8$!S4%2%I[^$5Y(?CM$WO/'2FY:%@3Z"7_9,2EW!AC4TL%II^&K^Y3 M]!\+K0I=QZM4;C7.!R6V=A@BDVR.L4 !*7&FA+"G'8.B[T<7_LA?$BYSK ]Z%)."-^ ME2YP"VU_URF3]NY9>\@> >*=F?FLJ1,[1Q,FV$J2@C3!"TP9TI$U"?L]>JB@ M=C=JUTWSZ:$XSGI.34**=.7%1R!=^!4R6:4#?^@0Y,*) MV;C23%JA3::=U0Y&A?%XC&+*N\?:53H?$MP M]R!T09.TXD!V(R4[JU@PO>..:P\<[E"0XF^)-#,$:=I!#T?C0[9(06H+Y]#= M9@\NCM]I=PAG?[[AU#T."VBRER;YQ?ER6I;@U&&9W2L:X51)E23R!Z[1,YP, M@[SN7&@:_(^9ZU6)#/C4=[<$9_O^EMK!,M(MD8-DU'%2FUTRG;FOI: DUX.6 MZ.0:R+O8%\X+K8GHRM>C])7*WM;*EBS3>Q? SRKQV.Z<+\JF2!9*R6J4;Q4G M=ADA$WQ[9"P7=2H\[VZ&HG%!(E&V_P99A)ZK7&2(<_Z[.L",:?2ZDT39BLOB MCK\5PS7)*XM6F^&)EN1WP]W>;T)\U\TF@9(E;_YQ+<'\+R1-)/#'$5%O2 Q; M,]X5&7/TO26@ "<7.%8RPFO^DAYOI*F_TPVK'28CVT#[\VA%:\=!XN_F!/>% M#Y)3O?^\/CK;Q3@#[+,SIUQAW4WD&9BV\I/(Q\72^0^8+R:V?F6;V[K0Q%0N M6_/F'3N?N $NJ:KMKBV'ZPG3QF?U1#8MKZ@N'0;4*(/6 @>8Q%8##\_&G:*= MI\-IZH6DW7)%:FBJI+6'C6]^W]A[_MX'>+F]K2U9-Y/[$<:=$+*I,S%%I4BZ ME9KR0V)%19G?:WJ'[C),Z@%!2"Q6-C1Z[4:*2A.0K?]>(3\K!)]222DOFW/F M<]C9O=7CEZ)AASSV.5L>XX]1Z]9'S'^SW_QO]]O_H,.4_3]8__2Z8X? CA/ M"-SUJ3.>^GEMG3YD$.44.(1&&M:YS"IM%\B]9:W*+C0BCHMTA![ZY49]9;_: M9LE^90:#K7%E@PN"\8"0OON""H[XNY.09L+4G_2<#.U(-U[XOB!DOF@MA>Y& MMNGS@ITS6J"].FNY"2B9C9P:LXI-1X[!.G.0>VQ-M"B3]%G?'C<"(TZZ*Y47 MEJ1'43=D!H"U_/)'\C.DNV=R'@-/D']+97'HR,F-N&=:01RO9 M62C?V>SVMK&W. >$%96@@>R[2H?[5!S-3A/75O%\30FX?)QG0YOM&\DV$$Y)LXPUE)M'LD=J7'5->-%3'=0_C3UJ*\8"RU$'O?8#LK& MP7MZRUM8M]RO>LR+L99@%>52GS-M.,_);BYH-S]FA]3)N1$6%;M**@QRB:3M M;"+T!&'KF/N9>*K:^5DETO:M@\'W#&=>;86A@#S#RKK$_ MQ^\TS&S26&C1>E$A1MGND3\,;I4Z:1Z+OKO;[UVHWRRPCI'D!Y[ '!TB("QB M!R75QQQ9/TZ/3D[-_.3P^-1]>'9UF9R='!FX7,SQJ?M^T>/SH^3DXDRJ]+4X M^U2*LT^NDC=AWWHS/!"V)B;*4*RZ@W35FI$,00*J5&!V9([AQ":_(RK]UMY;$M0'ZJ#'9$MZ<:.%%@$L2*/E1UPF2Q0[.JS1M966U-&X0ZWK\BONAFU! M"^8OTEJ[)N)I2,^6-O.2=A/*D2*Q["M2.754,CFXAZY@%E=A8E1UC[/PIGAU M*EMJP+(:!N:O^OH/0OF/<_B ?3"?8_7]#?2=J67H:1=$33X];&TRZH4Q^'6Z M^< /R>EI>C4_X;YKZ<7)I?$Z>"ABYNG\[)3^?W5T2?.#P8+_GJX.W:GSXS/S M-^$Q,\ECR=7\,CG4;A<>%&H7@8OT[&2.59REQQ=SOR\L)S)+/T7]=M!?N0UE M23!AM?!KRL\4;AA.T =E@Q^*D\^&.5UQ;I)/8C#ARG#?[1#$U+( Z%A\LW14 MJ.H:3_C"U2A@]"#IGZZ7$V,-\2(-;*7A=WJJD\H(: W32 7DK3:7"2L=4G%L MF$RL>!";C7H[<;<%P5P.D1E7HQNJ\?C[@J2%Y: M5'0POE^TZR7G.\CY3UQI M:=R3>V_N%X>]S:?L*[ZBM^REL[,S.J,@:2)!TL]P6,IY^:>BM&-GY^\ZEM!] MM\N^6E>HZ?P\P4.')$3-,H[]!Y,*20VST??9WCZ&N8 MI.57^!0-[AJ[46 &I-)_?NJS779/20+_P,\=B( MM95/\Q&$+:0GB2^8D,8R6LZ),%.8)-DWB0YMQK 7WBFR(XHL[M*=NL)9N6/P M-^-9;1,@_J5\@XXPW._@SJ]<(W3+6N^1I'&.%].JD&'7EO-,NSL:-[M0!E(S M)UJ)=/I1<1\"@"OH-544D1-IWS!F+'?^$"E;_7JS.)3Q_1J<$P%_2,ZYZW,R M/[_D?V\0ECOD[X=AI>2[L<=:RB<5\[WB-R;ZMT_TF?'?X'LQO_3?X#N8YE!6 MD,1_G+D8X6\P6LQ(B0W@MV^ K[*.YDKWKY"I7[1QFQOQ%!(_5)U4LPQ[W0UJ M]5B0PYTY=#\,V]8-:]6DV7WM?-F(SG-,!EXT_#/(PGM59K1N0E8UJ8'#7XDM ML+&M%]RXTIN:5*X@$A[Z5@;+W-?V:I ZI"''C<='F8I0 S&M8AAB-]NR?K#^ MRQK@[N?O#?#^+Z-3CW>9NF_:]63W38E&&='?T?0^/@W:771.4:*Z6+G3GTT< M0C,R$B0RT4G]F&.DP5F,#B'A0PBIVFZCQO'7T-Z-^H][QY8+9_HH7ASN=VSF M!$K?_L\](=YD7?;32_[^S]>V++G9?]7]^&3^)/HKTFE_?'(]?WY]_.09O1D> M_^GE-KNU)'QNX? N[8I>/9I=G#T1UZK[I:NW&!)0@O0Z_[BV&5US/$"?KVK2 MDOH+)H!WB9?WT_\ 4$L#!!0 ( J$K533A1@_D@@ "<4 9 >&PO M=V]R:W-H965T0VTYO$$^>F#YT^@"0D(2$)!@ CJ[^^9Q7N-@: M^]UME/+BOLA+=SG8>%^]&HUK78]<997,>%.1CZ;C M\>FHD+H<7%WPVJV]NC"USW6I;JUP=5%(N[M6N=E>#B:#=N&S7F\\+8RN+BJY M5G?*_U'=6KR-.BV9+E3IM"F%5:O+P7+RZGI.\BSP5:NMZST+\B0QYCN]O,\N M!V,R2.4J]:1!XM]/=:/RG!3!C!^-SD%W)&WL/[?:W['O\"613MV8_!\Z\YO+ MP?E 9&HEZ]Q_-MN_J<:?!>E+3>[XK]@&V<5\(-+:>5,TFV%!HAM M.!\_LF':;)BRW>$@MO*-]/+JPIJML"0-;?3 KO)N&*=+2LJ=M_A58Y^_NJX= M5IP3R_1'K9VF4%V,/#33[Z.TT7(=M$P?T3(3'TSI-TZ\+3.5'>X?P:+.K&EK MUO7T284?I!V*V206T_%T^H2^6>?FC/7-_LS-&U,DNI0!$64FELX!^3WGQ3^7 MB?,6:/G7$^?.NW/G?.[\_PSODUJH,%^Y2J;JB&-G MB(\JJ7,9]9<^E=&R7@-28C+FP$[$B=\H\=>_G$^GX]=O5RO%)2( ),6+D]?/ M8T$BB%HERQU'3'LGMAN3YSMAMJ7*4,^)TYE&2E6T-1=WX3>,VSI3I M1I@5&^]H)PS.E'6TUH2F?\8=6$%9<2NMU\KM?2=__RX+F8M/22(S+#C1D]V) MSXH34GI)D1N2?:Z6\ "NDGYX7KC6D*.>1)TGQZ('UD("*7HRSUL]VKF:5F < M:-9Y/.AR+=Q&PA822DU18"\[OO=8K*PI6,&AN[$ MT<29ZUARAK)%U4;YLKJ M5)$*6576W&O0H$+BGXG)?#B+"IWGG&) X!O 0UY7QOD7E&$R26;?@#=RSD5' MI'H@9=.F)R] M=M%!=* G5=:C>SV("H>W1(W]@IR8VP!B7Y)Z;4778J ,B5-40T^:T"0H"B;@ MZ%RKFA,GW29&=6F@M]&P1>V(GS+GC'L438A"!4M9@K8]$V?#^:F(H[!3NWV0 MZ'3Y4UDT6-%FI4OJXZ:UV &12)?)'P01%E^1(Y M>@KR^^+]G[(]B"X' %+1 M_Y6XCK+V@Y8G5%'E9L<9W>>6E1YT%Z['C58K\?8>&:66$GU:(8G(4X]^ O&( MPX8=BS[.0L@^8(ABU8)G!A?:5ZD!DJ\421B,SLT@>H,FDWK#Y]S)O.$_C&'? ME6_J^5<_ 1K([6',Z\:$,T>>*,AY!A!GDC94MG8 RIL.S?9?JV+'$R!=^[S40D 31;]=QXSV^ MT'L-"@GG4SII8G2]QHPXY5HF.M>A;Z [%UA_T"0:/%.Z5A+O3.F^E7&BA *.[#<@U(L*! M>P! :,7,I>?@T4;:1:%K$?+%Y&P2O80/.6'R76,O) M#5;-SEY&;]0*Q.#5"RHS8EQ,)6M-"ALAS)PO7XZC+Y2JZ&$,)[-X?C;;VP,^ M8&-.SL<+\9S6+?I?I.[Q+>H:;!Z:TL_ R7R&3;!(X;<,SL&;&LJF\>SE!+_P MY+P_8M(7]O*^T[43)Y/XY90L"&8?2_/)(I[.2>2C\A$7$UA7]ASOG#R/I]/S MZ#=C,B:E>3R?GS:*#Z ;M_@\@"-L> ?&+U.-6KK#0*L"6$[J4M:H;Y4] M%ZWQB&DS][I0\/=$YH^T< />Y75RZR!">XR4S)4/(-.Z/A1?>M\@"9A<$9E! M9;1NHVE5SBZT(T_ONX?9ANH/'^JMB82DE.3=KE1V3<'!SH0ZG,SUO_$##\LI M?RU2OZ.N$OIG,-91-T)7R6K4-&R.J//J$AO(K7N* 29AZJMD.X*5:^JG**D' MT6FXA1G(-0.S"E\:78N,15V1?:948J>D%7+EFYCV'6WFNXB228VYD"7&/J9A MD]"(ZT1A+ T'X3(GW*NLP_0=02P,$% @ "H2M5#"X'ZLR! V0D !D !X;"]W M;W)K&ULK5;;;N,V$'WG5PS419$ @BW)5N*DM@$G MV6P#9!=!DFU1%'V@I;%%K$1J26J=].L[I"S%FXN1ASY((JF9,V"_PA<&-VQN \62KUS4VN\ED0.4)88F8= M J?/#SS'LG1 1./[%C/H33K%W7&'?NE])U^6W."Y*O\4N2UFP22 '%>\*>VM MVOR.6W]2AY>ITO@W;%K9=!1 UABKJJTR,:B$;+_\81N''85)](9"LE5(/._6 MD&=YP2V?3[7:@';2A.8&WE6O3>2$=$FYLYK^"M*S\T]*Y1M1EL!E#HOL>R,T MYG E+9=KL2P1%L:@-=.A)6-.99AM@<]:X.0-X!%\5M(6!C[*'/.?]8=$LF>: M=$S/DKV G[D>P"@.(8F29 _>J/=\Y/%&[_'\A<-P(4Q6*M-HA+\72V,UU<\_ M>\R.>[-C;W;\_P=\+[#;O:>FYAG. MJ>!O4/#.9?E$4VAE]_F21Q_!N\T_B3 MW'V!&MF&7B 59 7)H0$A8=U)4%\ 6R ]&A$JGW.&+N= &'0R*A2Y-S2Y%)(+C/!2[BS MM$#]@?@>-)(WN:#_ASO>L-:;$+Y0<]M9YJV3W(!:/2/I^5Q@AM42=;<:0T8, MA''F2<-YNU(EM3,AUW! P;"%:@QIFL-3N*.VF3<42I)\$5CFK;'>6F>)]98^ M&BLJYRC[:G#5E' M5LB\US9))7%*L/D(9I&O7?.&44XYKB:*G! M,B$M=3MJ?PU%JZ8?J.TCC,/D*-J^4W;N6PPQT%ARUR=-(6H#<1A/HN[-SJ^O M%JP4F4L'+8ZBX^U[Q.Z5Y:6SU#G*MS%?:V4()PF3D^/MAUVC,:>,9UE3-:7/ M)J^4MN)?;QD.DC!.QW (!W$X'J=P^#:ZI(Q^@#@*X_&H'4S2!!8[: P?:L_7 M%2CO2OT%%&RXB^-Q=!)&4<1<^AU<.\L;[5+\O+SAM?+VJBZ%(9U5ID9_VI2/ M [>% +NLPJJQKJ7\Y'?'E"IF#]%7RU7X];8:C:M%]EHM,E+L"PLN6PJ[P8*/ M3Q3>;@OL%MTQ3R%A5$I"Y5TDGF^8Q,4P/#HZ87]1T;+7A48DDD[2?2)C$DDH MM'M$TAV1-]@

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

QU2M*9XH/K@7#-4_A'YRA?]2N38 @.3PB,.K'ARP?&\5!=(;D74076\B MT;L1ONM0)'X+PN.C[CLBPT/".R-9O7>EUC3!B6<$G3*4H3>%4T7X>W*A1)DY M%:4@$177]77;KK9*[=KIDX/U&ZO@G S9P=3RSURF&>,*"EP9R-[EP&R%K!55 M/=%B[43)4F@C<=PP-RH4I34PWU="Z.>)#=#JVNE_4$L#!!0 ( J$K530 M1_D:L 8 .$7 9 >&PO=V]R:W-H965T9H2^7Q%$[&Y MZ/B=[<(]6ZZT6>A.SC.RI'.J'[(["6_=2DO$4LH5$QQ)&E]T+OVSZP ; ;OC M*Z,;M?.,#)2%$(_FY2:ZZ'C&(YK04!L5!/ZMZ90FB=$$?OPLE78JFT9P]WFK M_:,%#V 61-&I2+ZQ2*\N.J,.BFA,\D3?B\TG6@+J&WVA2)3]BS;%WF'006&N MM$A+8? @9;SX3Y[*0.P(C+P] K@4P+\)^+T] D$I$!PJT"L%>H<*]$L!"[U; M8+>!FQ%-)N=2;) TNT&;>;#1M](0+\9-HLRUA%\9R.G)O$@0)&(T9TO.8A82 MKM%E&(J<:\:7Z$XD+&14H7"ZY5"USRBT4OY+J"HH. ME"OL5'A+Y"D*_&.$/8Q;_)D> M+NZWB,_+_Y/P4X7Z;^(M@!-6Y!E9?L$??G111'FITPPLR,47Y M_3-L0C>:INJ'PT2O,M&S)GI[3-PS]:@0X1%ZX"&5D!N0,) GC,.1:J:?_U;H M*E<@I51;>KBU?Z-'H3 9F%.D!42"C4*09X<]F(10*F!5]$ANZIO(8$9 "QE- +*8(S'Z5JZRD0A$? MF95/]_/+77-2+"5)C]&&HHA%B L-*D(!]?,+S/%G>%M3X[FD"=$@ 0BF_WZ] MF9WXXPJ"7A%M-)308-=+4(Q';,VBG"3J*)8B19"AX0KAH,APD) "^+)[1NUQ9I]XCZ%*F_@&"I7EF3KWM@ LC M VO$-*SU!!P<#3W/.^^N=PNSN?%D.!KCW8TO< PJ' ,GCJG!E%!Z8"1>6:=B:HC:N&S=#W]P,850!&3@ ?"9-H;<)F2H7Q-0""H4$C M1:'>]N;!J.',<-!, J?I@Z"_P#2N,(V=F&94A9)ENJAVD_&0W?H998GI@X90 M*"109F%"!<1Y@A)H?:U W98DX4N@1S!B"""UO$"4@EJS"L_0(F=)9,L*K++4 M%!\U=A6T64TYD B0$0/G3K@A\F=*I/H PT"X@E?HX2^=!0Y,CT;$Y:<:%W8=E'6Y65_7Q XPK"UPDL[+^MCY"AQ?V>>\MTU M0B-@QP2&U4PHI@6V"K^:!AWD6P?CV2^.ZI80HC@X2N!%.T7J&IG9]-E__,R((E M,).T>M-K>!/X7J]!4;.6C7@T?0^BW675&KVZ3O M[I/W?Y$T^S K9J-R>-J3-\W>&/2;7-ZRS??[^SVM.ZCO;J%340X?P"LW4%'< M/L&PFPK+X%.+X/LM31=4NH9,LS1/#XD\KJD4^V\5>5S3 M)';3Y/?B(_MLRQS?@#BVO'&][=.?64Q_M,7]%>4^1JG]R'6Y6C,K=C/K+7DZ M.,@U8^+>FP6YIC?LIK?_&62W\F!P0)!K+L1N+KRII]KYBI@QYI!PUP2&AV\6 M[IJRL'M.W\$@-IQ&Q]M9""D+J?5Z8M2D;#SP!OYX#S?4W(;=W-;T!K["XNI3 MHO6JI;"6HZ"]QT-F-DR:&5L!#-X5.#A8>E05!36_!FU!;4 MU!:XV>>.2M-%S"P&'QW;*PE[E1#5 %4)L*WR7C$P&)]ZWI]M5VVO"/:'3<$" M9'?G*A/(86GOD!6RMY'%56"U6MU37]K;V=_6K_RS:7';7*LI+K]OB5S":(P2 M&H-*[W0(.2^+^^3B18O,7I@NA :&LH\K2F"L-QO@]U@(O7TQ!JI;_&PO=V]R:W-H965TO,>9\A'%6HX.6A]O/$\E M!\B9&HLC%-BS$S)G&E_EWE-'"2RUH#SS M^?>CGCQ6BUL&T/\/VC1XJ\61[>$1]-?C@\0WKXF2\AP*Q45!).R6 MHS6]N:=S [!?_,/AK"Z>B1G*5H@?YN5CNASY1A%DD&@3@N'?">X@RTPDU/&S M#CIJ. WP\OE7]-_MX'$P6Z;@3F3_\E0?EJ/9B*2P8V6F/XOSGU /:&+B)2)3 M]I>@U%!SHOJGSW5B;@ T+ '$-2 X/^ J <0UH#PK8"H!D1O M!4QJ@!VZ5XW=)F[#-%LMI#@3:;[&:.;!9M^B,5^\,!/E44OLY8C3JT><>6F9 M 1$[LE8*M"+KY&?)):2$%2GYB[,MS[CFH$Q_F6/[NPUHQC/UGER3KX\;\N[J M/;DBO"!?#J)4B%(+3Z,VP^ EM8Z[2D?0H^-O)L! [X9AF\@:>#4 M ;\?AJ_+_9A0WP7W,*%-5H,FJX&-%_;$NRT5MBA%[D2^Y06KU@2FTZ:XRK#B MMO7;>JNTQ/7R?8 W;'A#RQOU5?,@I"8:9([E.('2N*2UJQKW59RIC6/,Y+2B M,]]?>"<'>]2P1X/LZR01)?*A@23 3VR;@8NZ"C*YI(ZIFWG2,$\&F3_B8 LM MY+.+;]+E"T,WW[3AFP[R/4@X,EZM$*$/('&I2HD2"+-KR"5CVI$1QG.WC+B1 M$0_*V,".%US#=89FFV+)-2OV'-,^("/N9L.?SWLJ/VN$S :%?!&:934I>G_E M'R[VF:,64=Q3C7G#/G_;O#NRY[Y)-^\07\_\B9N7^JUY^J\QRQ(S#T^X<2NT MR.Z$R%H#=?J2WQ46]>2#7I@Z?6UB@#06+@$71NG,2!WB!7,0SGM6(FVMCP:# MW)^$AJ%*U/"7I>AC;8V/#CM?,V+-GIJ<.^V@#O2"G\Z#OKG0FA\==K]J#5R4 MVZP'LU\Z171-\'H21'TB6A^DPT;X"7<7GN*\XSO.6B,87).T:Y"S()CU2&DM MD@Y[Y!]"I&>>9LM_RU?WM&NL411->^2WUDJ'O;4J9R+P M2)R"M#OX!U)@>O&@E#!U&$KI[2NQO]'OSD+$W4TYF,91SU",.;]L:0V3#CNF M6\#M*RB<7+_AZ*\('4]=AQ7OXAB:@]S;\[\BUIRK,TS3VMPQ;NU1O-,^N]G@ M^+H]*!%[[+7$:RFJ2PT>(?>\4"2#'=+YXQBGA*SN"=6+%D=[$-X*C<=J^WC MNQ5(\P'V[P1:5_UB")K;VNH_4$L#!!0 ( J$K50P,!=Q( ( &8$ 9 M >&PO=V]R:W-H965T#%R"51M3^Q*Z?S_;$)1*2U[ ]_J><\^Q+R2=TJ^F M D#R+D5MED&%V-Q3:O(*)#,SU4!M=TJE)4,;Z@,UC096>) 4- [#.RH9KX,T M\;F=3A/5HN U[#0QK91,_UV#4-TRB()3XID?*G0)FB8-.\ >\*79:1O1D:7@ M$FK#54TTE,M@%=VO%Z[>%_SDT)FS-7%.,J5>7?!0+(/0"0(!.3H&9E]'V( 0 MCLC*>!LX@[&E YZO3^S?O'?K)6,&-DK\X@56R^!+0 HH62OP677?8?!SZ_AR M)8Q_DFZH#0.2MP:5',!6@>1U_V;OPSF< >+H B > +'7W3?R*K<,69IHU1'M MJBV;6WBK'FW%\=I=RAZUW>46A^G>WG+1"B"J)"MC U9Y6\MUU 05A?DD;., M"XX@Q]K2+"[0_(&L%ZWT9[H?A M]Q/(#/2?*^SSD7WNV><7V->ML1EC/O(_VAQY0)#F6H_%V&-QU<&&FSS;4!T M/]5]@*KQDY0IM'/IEY7]$8!V!7:_5 I/@1O.\=>2_@-02P,$% @ "H2M M5(_G4>V2 P 9A !D !X;"]W;W)K&ULM5A; M;]HP&/TK5K2'5MJ:V! N$R"5LDNE;:K:71ZF/1CR 5:=F-I.::7]^-E.FD + MAE7P0FS'YWR?CYUCF]Y2R%LU!]#H(>69Z@=SK1?OPU!-YI!2=286D)DW4R%3 MJDU5SD*UD$ 3!TIY2**H%::49<&@Y]JNY* G@LZ@QO0/Q97TM3"BB5A*62*B0Q)F/:#<_Q^1-H6X'K\9+!4 M*V5DAS(6XM96+I-^$-F,@,-$6PIJ'O=P 9Q;)I/'74D:5#$M<+7\Q/[1#=X, M9DP57 C^BR5ZW@\Z 4I@2G.NK\7R,Y0#BBW?1'#E?M&RZ-MN!VB2*RW2$FPR M2%E6/.E#*<0* #>W $@)(/L"&B6@L2^@60*:3IEB*$Z'$=5TT)-BB:3M;=AL MP8GIT&;X++/S?J.E>9F MZ&0$FC*N3M$[].-FA$[>G*(WB&7H^USDBF:)ZH7:9&1YPTD9?5A$)UNBG^>S M,X2CMXA$!&^ 7_CA7ZD\0PWLX&0#?.2'CV!2P9]%#XV,E9:DTI(XOL86OF&N M3(M:E^WW%].&+C6DZH\G1J.*T7 QFEMB?)+"!)B83Y1E,W1/>0Z;="M(6H[$ M?OKW TQ(M]T+[U?EV=5K+<-FE6'3F^%W21- WV@*"OW^"ND8I&_@<44;'TW< M5A6C=0AQ"Y)X1;8XCJ-GVN[HM)9?N\JO[,5V\5'4QK7AH3)(;0N6=:, '>>B[VKUWJ.M:%AOZ-]@W'.Z;H.>RA=VQ%N M'D_IVIUP? "EAR7+FH91M[M-Q-JXL-^Y/"*BO^@_+1G7?H3;Q].V-B7<.8BV MG1?:;K=<7-L5]OO5!Z69.5]"@G(%TYPCSJ: 3LS!YQ&H5*<;4_%3XKC ^LX< MM5L1OUOYI_[56P:IK8PLTBV$&YQQJH M/8[XSUS^-?#Z_8S4_D>.=SPCM&ULM5=-;]LX$#UW?\5 Z*$%7$N4/QO8!IRD MW2VV28UFLSTL]D!+8UN()*HD9:? _O@.*45R&DGU+C876Y3T9MX,'Q^IV4'( M.[5#U'"?Q*F:.SNMLS/75<$.$Z[Z(L.4GFR$3+BFH=RZ*I/(0PM*8M?WO+&; M\"AU%C-[;R47,Y'K.$IQ)4'E2<+EMW.,Q6'N,.?AQN=HN]/FAKN897R+-ZAO MLY6DD5M%":,$4Q6)%"1NYLZ2G5WZG@'8-_Z,\*".KL&4LA;BS@P^A'/',XPP MQD";$)S^]GB!<6PB$8^O95"GRFF Q](O4:AWYHCM*P3+XFD/7R-;P$%]2. M2U00I7";1EKUZ"9=_[$3N>)IJ&:N)FXF@QN4/,X+'GX+CV6^[0/S>N![/FN M7W3#K[CLPX!9N-\ OSP=_D-VEQI:==6ONNK;>(-_T]6_/M(]^* Q47]WY!A4 M.08VQ[ EQXI_H_6G%=#BIQ68Y3+8T0( L8% ) DE)/$$=TV]+ */;6!C#/L% M8R-OYNZ/.]:9W=C1FLW#4Y3'O-IIO6?3'COR<]99X(U9 M]" R$UV!%K7P"L]NM&;V9,+]D>>U]9K5-LC\;C(FY1NS+X=0^A4L#UR&/?A4 M,.S!KY(;%Z/M8X4R$O3HB]VL";+-+" MO[98UNVQW6HIGQ8=7SVT>;F5B+;24]13VR(;/I]Z:GMDHV?:5,[+R(^6ZW#0 MJJ':35FWG=Z41PVE^O^(@5Z](/ Y M3^^2'ESWE_V3=%*[+)L^GTYJ%V7=-KKZZ6Y6!G@D!V_:H@:_-E'?ZTS\3@4& MHU$F#]M9R'4C@Y]$>H_K/OB#WB\O7M"I;]#4%O?H7&V^@NB8N(W(56/<4$BO M/R')R^+#HAAHD=FC]EIH.KC;RQU]C*$T+]#SC1#Z86!.[]7GW>([4$L#!!0 M ( J$K52DA4)-PP, ($/ 9 >&PO=V]R:W-H965T\U)EK(![@629 MYU2\7$/&-Q,'.Z\W'MARI:H;;CQ>TR4\@GI:WPN]=?J\5M.G&\"A%DD*@J!-5_SS"%+*LB:1S_-$&= M-F?EN'W]&OVS*5X7,Z<2ICS[DZ5J-7&&#DIA0)YXZP1Y*RH_^FWIA%;#OB8 VD.MJ6%%MXZ,2^BG3?BI^U+Q(RPP07Z#;0M%BR>9Z=24E M*(D^WH"B+).?T#EZ>KQ!'S]\0A\0*]"7%2\E+5(Y=I5&4<5RDR;C=9V1',GH MHSM>J)5$OQ8II+O^KD;?ED!>2[@FUH!W5%P@'Y\AXA'2@V=J=[^!I'7'%CA^ MVU'?Q/./Q/O,"J;@?*;9F?:T]*^9MD>W"G+YMR5;T&8+3+:@/UMURB_EFB8P MP8E__@E'WB]?N**9WJP6 34(SM!2<-F[<76JR*2JSO]SC D9#<;N M\W8[W[+:J2-LZPAM=<0SD/)2'^JDS,N,*MTZFG.AV+^T.NU]8.MXX1:,F'.FBA#NQ0!4T! M_4YST-2[@WP.PD:[81MV> *2C]ILH].1?'1 WS ,O;V]&!WLQ8[13A78Z[36 MLVZ&M6MGZ$G"HLS0C"V@5U;MP7&(7H *:>DWWGHK8&LP#4Z_6?6KMM3=O1?Z MJT&HE_<0"),N!3D!A7 GR]@_'8F:7-LL"DBTSZ+&*CQFM5M))_G8JOG_ET;V MX.]@4:?IV"[J4_/] @(]0&9T7*[8^ETZA#LIQM$I:-3I*;8*ZG>FT>#P78J' M!S0:'+X9MJUV*^DD' ]_)(WLP;&AD:WCG?ACJ_K',Y;HL0'>0QO223'Q3D ; MT@DJL0KJ]Z5-DVN'-KZW_YWVEM5N)9UN$_(#:?-&%FH>MYI[[;SY969JMS.O!Y.]<2P9(5$&2RTJWO5!\;4:F.5=: MP,SE2L_(("H#_7S!N7I=5 G:J3O^#U!+ P04 " *A*U46='<2L(" #3 M!P &0 'AL+W=OR-)P)N%-$ET5!U<\KX+*:>#WO;>&>;7)C%_SI>$LW ML 3SN+U3./-;+QDK0&@F!5&PGGBSWN5\9.V=P1<&E=X9$YO)2LHG.[G-)EY@ M@8!#:JP'BJ\7F /GUA%B/#<^O3:D%>Z.W[S?N-PQEQ75,)?\*\M,/O&&'LE@ M34MN[F7U"9I\8NLOE5R[)ZD:V\ C::F-+!HQ$A1,U&_ZVM1A1]#K'Q"$C2#\ M5T'4""*7:$WFTEI00Z=C)2NBK#5ZLP-7&Z?&;)BPN[@T"K\RU)GI$G^+K.1 MY)I<:\.P,)"1F]*4"LBLD,JP7]05_/H5_QSM#&?I<\D4VMT*0\6&K5 _TQJ, M)J<+,)1Q?48^D,?E@IR>G)$3P@1YR&6IJX#I0;$"=:Q" M5[7KQ+FV!_MEVDN2T=A_Z0#JMT#]HT#?@*H##%$70^TMWF6(AW$W0]PRQ.]E MZ' ULC:@N@(.]P)&<7Q@\T=MQ-'QB-)0CKVE/8'4G&+EU77@E#?9T-\SQ MU@5E#?#[6DKS-K&-O;W'I[\!4$L#!!0 ( J$K51*F3QG1 ( #\% 9 M >&PO=V]R:W-H965T@5A=^[[."BBI'L@*A#E92U52-*;:^+I20','*KD?!L&57U(F MO"1V>PN5Q+)&S@0L%-%U65+U/ 4NFXDW]'8;=VQ3H-WPD[BB&U@"WE<+92R_ M9\E9"4(S*8B"]<1+A]>SD?5W#C\9-'IO36PF*RD?K'&33[S !@0<,K0,U/RV M, /.+9$)X['C]'I)"]Q?[]B_NMQ-+BNJ82;Y+Y9C,?$^>22'-:TYWLGF.W3Y M?+1\F>3:?4G3^HX#CV2U1EEV8!-!R43[IT]='?8 AN= M[+25#4_(1N16"BPT^2)RR%_B?9-"GT>XRV,:GB6\I6I HN%[$@9A>"2>V=OA MPS/A1'U9(\<7O:6LA]6<,YUQJ6L%Y'>ZTJC,:_YS1G;4RXZ<[.B$;%I*A>PO M=1TBUX?*QVZJI;QRE+;IM\DX^!P$0>QO]PMXZ#9\Z=9&[.^]Q1+4QK6H)IFL M!;;7V>_V4R!UC__5_M1,A[:9_].TH\54FV[M@;*RKWX ME433/VY9F D'RCJ8\[64N#.L0#\SDW]02P,$% @ "H2M5(@'D+'P! M1QT !D !X;"]W;W)K&ULO9E;;]LV&(;_"J$5 M0PNDD7BP)6>V@29IM@ )$#3-=E'L@I%H6Z@DNB1E)\!^_"A9$7V0*0>&=1/K M\/$[\"6?D.)PR<5/.6-,@93(F2DUOW!=&5[?36F<.>-A^>Q!C(<\5TFLH0O1PYTWAY\ MBZ <$F(^<+O+@B@Z)!:?%WS)9R M[1H4I3QS_K.XN8U&CE=DQ!(6JL(%U3\+=L62I/"D\_A5.77JF$7#]>LW[S=E M\;J89RK9%4_^B2,U&SF! R(VH7FBOO'E7ZPJJ%?X"WDBR[]@N;+U?0>$N50\ MK1KK#-(X6_W2EZHCUAIH/\T-4-4 ;3<@>QK@J@$N"UUE5I9U314=#P5? E%8 M:V_%1=DW96M=39P5,CXJH=_&NIT:/^IQ$>4) WP"'H0>'4*]GH&'A&8*T"P" M7W_E\5S+IL#':Z9HG,A/X#-X>KP&'S]\ A] G('O,YY+;2N'KM(9%7[=L(I^ MN8J.]D3'X)YG:B;!URQBT69[5U=2EX/>RKE$5H?W5)P##,\ \A!JR.?*WOR: MA75S:$D'U[V+2W]XCS][C_ZXT^;@5K%4_FL)1NI@I Q&FH,5$_Y"SFG(1HZ> MT9*)!7/&O_\&^]X?UCS.P)^"RT;U5@'[9< ""(LQQ $D0W>QWJ<-5BC 7FVU M44VOKJ9GJV9\QZ2\T+,\S-,\H8I%>G+JLL*8%M._*=F5O]Y:&I]][&\GVV#5 M#P+TO./U@']3!!ET/]L%.'^,>VM+!;K-1"?0,@CVK M$)=YG$1Q-@6WJ1Y""U;D*0]1!JY1'IY>&XA,.-2U.E7$#U M68_!.,1'* 3^ _=Q%J=Y>I!HAN>0="": 2ZT$[=%F2?))GD"[N():]3'[AQZ MX)51(6V9&MI".V[;Y: O!\MA< G]#N0P-(7!*>6P.\>#=CD,BJ&5Q7K1%<[T M(_&ZW27MO8\,))%W^MY'!I@(=DVP*N(ZP8B_\Y^^LNKML]JLQQ 968GAC:(CL0WTH\CY.8<-'C#H0:NV[@'U!>=R\:''>SBEL@(KMS#N63-@0$?3B9L$(KME+OBZ3Q73+QO884-^7 'VW9LB(@[W[A7$3>V MAKU@>VN(=_?N$$'8C"ABD$OLFW>+/.]C%3%4)!ULYHE!([$O'8^;*2W.VUE% M#%2)G7LM4AP.+;+VR;6#+3HQC"2GW**W..^U2V'H2NP O,E%%JM)X22QKA!/\GD]V%U;]8/MK^MVH\UJ#(:)?<]^Y$BR.[>, M)'?MJ"IE8EJ>X$D0\CQ3JU.K^FE]2OBE/!MSC?GJB/&>BFF<29"PB6[JG?MZ M>(O5J=WJ1O%Y>?#US)7B:7DY8S1BHC#0[R>;(D!]=CK^'U!+ P04 M" *A*U4A]LP,C4" =!0 &0 'AL+W=OIA8T_B%>M=LSLF\.^9 M73MNB@BJ>K'W8]Z;>?.QXXVQ]ZY$)'BJE':3J"2J+^+8Y256PIV8&C7?K(RM M!/'6KF-76Q1% %4J3@:#L[@24D?9.)PM;#8V#2FI<6'!-54E[/,4E=E,HF&T M/;B1ZY+\09R-:['&6Z2[>F%Y%_NMF,H6UAN"$O/Q[!00A,(7<#50R-KKA3!X1Q)2.7@F[!6^(0?P0>XNYW# MX<$1'(#4\+TTC6.4&\?$\7C6..]\3UO?R1[?*5P;3:6#*UU@\3<^9AV]F&0K M9IJ\2W@M[ FDPV-(!DGR1CRS?X&PO=V]R:W-H965T^R$)"R) MRU[:AT)BGW.^<_OLPV3'Q0\9 2CRG,2IO.Q$2F4?'4>&$214]G@&*:ZLN4BH MPD>Q<60F@*Z,4!([ONL.G82RM#.=F'=S,9WPK8I9"G-!Y#9)J'CY!#'?77:\ MSO[% ]M$2K]PII.,;F !ZC&;"WQR2BTKED J&4^)@/5EY\K[>.,'6L#L^)7! M3M:^$^W*DO,?^N%V==EQ-2*((51:!<6/)YA!'&M-B../0FFGM*D%Z]_WVC\; MY]&9)94PX_%WME+196?<(2M8TVVL'OCN"Q0.&8 ACZ7Y3W;YWM&H0\*M5#PI MA!%!PM+\DSX7@:@)>(,6 ;\0\/\F,'9;!/J%0/]4"X-"8'"J0% (&->=W'<3 MN&NJZ'0B^(X(O1NUZ2\F^D8:X\5272@+)7"5H9R:/J82PJV %9GQ] F$8LL8 MR%SPA$G)Q0OYRA5(,J\0?=XGO^GZ#^,PNOH"L1[S B+L-XM=V\7LJ>J3OM5J_ M.5W<.Q1W, ME*OPR%;[1UV_S)N)"G7\#D9!K6"KRVQUN(+<*$OF[17V_5-\W MZ@&3:XOVH-#RR![M*_QZ ME;%4*K'%XT21# 3C*Q:2C+[H%TU0QD=0_."B/0P7)90+*Y2*VO)VNH=D"<+6 M2IY;L:;[%KWJU6C9LX*?GU"WA8IZ]PPM=>M51.3Y5N.+B&+!$CP!L'X;+?O' M*;-9KCC*^Y](JM!3][W?8KSB*,].4BT%0_XD=Z"PA\G51@"8LCZEF"JR\H(W M*::*B#P[$YU43,.C@.8I;G8[PE%8F6N:8+BX4M>#^BSZMV,@;OTEH M*X[Q["1CM-Z6?-T7A_DYS]N[=\:WF\%Y1L97O_M?\ MSPH5!T>Q:RL O^(RW\YEIS;US#\FM):F]FN7*CN7'27HMCB.R0,FJ$L6"C]6 M9 XBQ&6\%1% MN)8RC11'3,+79@VO78IAI>G#@Z8AG*VHVLMF@C\Q8VN'+:(@)2E76 L:E):] M@W2%VQ /CC@O=9Q-V+",N-"BJP9G7^CZ%*_\H#F?[.! 3!]25-X(BVTP_4=2YP6-E<\06 MAP54'6+^*S?MVABGBZFQ:(ZOW7UKJU='F6^_>)?-=?.< ::@2W[!8(BFV:S0 M='#@]/MU#/D0UK0O\(ZQ.K4A6/_&@>/9!B^B)(8U"KHXPG3R9.\?%,_,7+SD M"J=L\S4"BK6A-^#ZFF.5%0]ZU"Y_O)G^!5!+ P04 " *A*U4K%?G:]$# M X#@ &0 'AL+W=O_<,-6:V46 MW/%P0UH8O(!'TOZB7;[7$V:W1S,#:QDIK;5ABW#A70G]E M6DZ-YSHNPC0"Q)=HKGCP@+YMC'TEFA@#,_6$WEV"HBR2[]$'=#>_1._.WJ,S MY"*YI@(D8@FZ2YB2YP<+MVN>2IJ$>O'LM_G059JT.=H-BCKSQ1 M:XFNDA#""OE9LSPF#0"NME9A,K(WV90T(GZEHH5\?(Z(1T@5H6;Q2P@*<=Q MQR\\Z%L\OP;OZE=JO/1CLI!*Z%OQLP&S76"V+6:[!O._-%Z L#&1^70?%-]2 M)95V)$M6.AJFL&))HL=5;LU.Z-@33#+9CCL8>T-W6\&K4_#J-/+Z;F\EA&BR M!:&S#+IZ!!$P">A:L !.H9D=V#^@Z;=(KYIFMZ#9?1O-&S 9U;"9Z5@T7DII MA+ZP)511:@;WT1-0(1%!<1;7.L)#^E1UM6:O0VKOD4B[ NDW"_0*"_0:H6^Y MT@I^UKHRG?$#=$^C%%YR10;9/7 %\?JD)F3Z!9/^FT+Y'.GTOP2F*I/)M'\4 MM1_J& P*!H,_"=H7" V.XK/?&@RJ&6&OS/K>2?YII-*,:1X<%W)# Q@Y^D4A M06S!&:.&8,('10K_C7QT90>5U/%Q-O(&I6/S2E*QJS9G85*R)_\@:S4H0RIR M%L;/E:G:59?9<%EML']2Y#30]2ON=:_;>\ZW:EOM]<=E*<,GUK)[D,8IVN![ MA]!%5)F0\7$M:WO=NDM8%C/\RFI&\[B ?5QLLL2P+1G""PR/RQAIM7$-P[*. MX;]2R&Y!Q&]BVWPJ>7M=PF5APB=4IO-3@N*X7.&!/^@_L[E[\#:/0:QLRR)1 MP--$9<_T8K5HBR:V&7#+[5E/I1^>NGI*%,%2BWJMGG:ZR-J4;*+XQK[T%USI MOL$.U[JU V$VZ.]+SM5^8@XHFL7Q_U!+ P04 " *A*U4Z1:;Y78# #G M# &0 'AL+W=OX&2+9!TC8/11]H:6P1%4DO2=D)T(]?4I1E%Y 9NY<7B:0X M<\XAAS/4:"/D5U4@:GAB)5?CH-!Z=1&&*BN0$74F5LC-EX60C&C3E0 M1@<,DL8@J7D[H)KE.Z+)9"3%!J2=;;S91BVUMC;D*+>[\J"E^4J-G9X\N-T ML8!'(B7A&J9VH:A^AE?O4!-:JM?P9_OQ\RVR.W1)Y!&K^!)$J2 M/R!L:+JGQW_:+E=:^T\/^)]F6<6JDFC,X;TN4,*E8.8X%#9.UPC7/!,,X=6- M4&;9/M\8<[C6R-07#WBO!>_5X+T#X/]6=NGM5CVXQ6\V1<'[2BMMMH#RI=FK M&2XIY[;]#;J4NX5T6/T:RY[=]638[X_"=0?!?DNP[R7X6)\!LS33-4ISIN'J M"65&%<*=I!D>PW>W9UV<'?QPG_-9DG:3/F])GY]&^AYM-K-T+DUP2I,W*E+" M#5V\+*"+LQ\]AFV-%RH M%EF'BO8,6_(\FT?/WATX ?EV+B9$J=$S*Z4QB?6TF,BIEM")VL_^O$Q$^[=/1G*97W#5I")BFMW M#6U'VUO\U-U==]/=+X"YO)DZJJ#$A3&-S@:&HW2W:M?18E7?9.="FWMQW2S, MGPA*.\%\7PBAMQT+T/[;3/X'4$L#!!0 ( J$K50I7_@SPP@ '$Q 9 M >&PO=V]R:W-H965TC7BTH"GA!_F29O#+/& C>QCQ M):-D5H'29(0=)QRE),X&1X?5=[?LZ# OBR3.Z"U#O$Q3PIY/:)*OW@WD3(K/^>H]E0L*Q'A1GO#J?[22LLX M124O\E2"08,TSNI7\B0-T0"X?@< 2P"V!7@2X-D"? GP;0&!! 2V@% "0EO M6 +&MH")!$QL 5,)F.X <-#E.&?M.<=V#G?C[%UO=\^R=K=K[6]W[7"WY7&O M"[)VN5OY?%2';Q7[9Z0@1XB:,$9$2OZ(?D*_WIVA'_[Z MX^&H@-G%&*-(SG12SX0[9KHB[ "YSA!A!V,-_-0,OZ#W /<[X6=F^(Y0DHC_U.^'LS_(XN8>U!!9]HX)=F M^/&2;937P3]8^-US.QWWT1ZNL_PG"\L;X% M)"NNAO,ZAJL3CP*G_'8X>FUZS M$-S2V=_H[+] YR5AZ)$D)=7I6@\T;JC@',#\P8ZFO6);>@8;/0.CGK?0TE#& MZ.Q%Y@U:5G.UUNV7VU(ZW"@=ODQIHWU#._OVBFVI.MZH.GZ5?6/.2[UMQRV; M[5K5)+&EY&2CY.0%P3J+'^,9S68<[$I9K? 0180OP,ZQ3N?S>OC)ENT\O4[3 MC4Y3L^'(,[3R155>/6RHY(>&T',=U:@X1L7NA#U^ M.H&^?H; <+#9X:3:+AQ#=Y(]4*$UNH=2V)"3BT''*\)F0W2S% !8Q$U9\()D ML+J'(;HNTWO*M,3F:*K45)-O.D'7-:RZT9ZY-B%R5X?(*5G&!4GJ-7+TF7+* M'F&=L.=#%V51,JC^$. DB[09*>=JJHFGP7C2D6NNXB476_MF8W/EEB$Z?Q+^ MTBN%6Q&#QU7,=&BEZ,LU\]=WBYBOU0X2I(\?*8,=,3A";*OA-Y@G*QAL8$OP MTA?*4NV*S6I[Z)D2QA%&X/EBP:'W0C/RS+7-C]U0_GHH[&N&VC:O8EK73+67 MV:R,:B/69JJ-AGZ[HB*A3!V(JVC2#?;1\KB*XEPSQYV4'+Z!N4@$4_-8+$RR M!UJRN".QPE8A'A^$XXX 5ASFFDFL#LS[*C"7=5R29E8M$Y*!9V?Q/(Y(K6B< M1:SZ%>(ORGFAU7;XC)+!B'FS#/+4;HF8= M(=MUA#?=)>L(J>M(OJXC#X J2\$$6/B7)8MRV1"+T';9+T:(4#:/O^9G)88YMD0T?F!?+7>VRU+O]$ MEG_Z! N/>7>!^"05WNER@W'8X4O%<=A[\6-BBJPF2K^ MK,U9C]I8=E3337,VZ>NHL&(V;-Y[7;$#])&DH-W-_3W92N(W,*NGB,YS]G*^ MI)C(^_Y,%$4T 4<+C\N,'J*LI>HIS/#/G?*U4+JP.QP0VJJ'L] MU=%QFV[8,CD4L>9AAI4K5.7T]K(G\%6I]%^Y)WB9*S[X[2;?QX&+.QI#7Y56 MWUQ:CR%?9S!UY1+;V/=5N?/W,FN^= IEYU=;&*SDHF MLNI6'I75]1'*2;I,\F=*I0XWJXPROHB7E8ETCZ0$[2ML[!EH.E#T%=C0U[Y/ MI$(I)@LE>PDV11&!#$M^U0IQ(%9KW.>X!WB;G,ZW0 M#H-?:(7&.U*_!.U;<]SQJ(8BCM!^A_(*.R7YJM].4@5Q_=TXUY[N&$HGU3+G MA5YJUU)ZJ5V#O@_;VZHN@RHN#'LN*&SRK/D\Y1OR+U2$&>YE(Q8JI@M?\E38 MRQ]:.9'C=SVU(F/&0NA""DVWA/!NQ.A&PJV \=I-;4? *"8.+0[3H-50@!^G^=YL?X@'JC>_)7%T?\ 4$L#!!0 ( J$K539.)2 . ( !<% M 9 >&PO=V]R:W-H965T$E\9WO][MO3QIM M'FT!@.RYE,I.@P*QN@M#FQ90-ZS?_"Y4RY;;F&AY3>183$-W@4L@YS7$M>Z^0A= M/M>.+]72^B]K6MO;*&!I;5&7'9@B*(5J__RYJ\,!@'B. Z(.$+T&C$\ X@X0 M^T3;R'Q:2XX\F1C=,..LB$P64).FHPMM$(CMK6O M[4IR9=GE$I +:=EG;@QWU;YB;]G#9LDN+Z[8!1.*?2ET;;G*["1$"L91AFGG M>-XZCDXXCMD]N2PL>Z\RR/[$AY1$GTFTSV0>G26\YV; XM$;%@VCZ$@\B_^' MC\Z$$_>%C3U??()O#2@,T+PCFX.B*J-EWV=;BX8F]\<9!^/>P=@[&/^C<^E! MYX[VH:6Y\31NJ9^2:ZK/TV%I_C89Q;U)&UUX,&,EF)U?/4O>:X5MDWIMO]TS M/]2O]'/:^G9)?].T3P:U8"=H\"3D1#DKG M. .ZS[7&O> <]&]A\@M02P,$% @ "H2M5/[\"V&( @ ^@8 !D !X M;"]W;W)K&ULG57);MLP$/T50DB!!$BMS4L1R )B M.T5S2!%D:0]%#[0TLHA0I$K22_^^0TI6W,!6BUPDDIJWS) :)ENI7G0)8,BN MXD)/O=*8^LKW=59"1?5 UB#P2R%510U.U#6?V'@7\(W!5A^,B6+G=SF4R^PAH!#9BP#Q=<&YL"Y M)4(;OUI.KY.TP,/QGOVSRQUS65(-<\F_L]R44^^31W(HZ)J;![G] FT^(\N7 M2:[=DVR;V!$&9VMM9-6"T4'%1/.FN[8.!P#D.0Z(6D#T%C \ 8A;0.P2;9RY MM!;4T#11&.)/>BDQ60)[H#C0Y7X"AC&OR ME2I%;7TOR$?R_+@@YV<7Y(PP09Y*N=94Y#KQ#434@<7A)HB"*COB9_S\\[+$3=Z6,'5_\SU*2 M!=,9EWJM@/RX7FJC\+3^[)$8=A)#)S$\(7%3%.#./6Z%$S,HACL%QW:CGRH* M!\/)AQY/H\[3Z'V>+DD!.2C*CYGKYT1S0=!G;MR9&[_7G#8GZM;/.!F$OO-^@P;>].'7VF:6P'_N143 MFG HD#(83/ LEM)@ZW/#$B\G4#8 OQ=2FOW$"G377?H'4$L# M!!0 ( J$K50(LCH^Y0( &X( 9 >&PO=V]R:W-H965T#!S!JL', M-DG[W\\VE*4)R?(2;+COW>>.G(]XR_BS* $D>JEH+>96*65S8]LB*Z'"XIHU M4*LG!>,5EFK+U[9H..#XXSL2M,:BN)S;U[GL2LE934<,^1:*L*\]<[ MH&P[MUSK[<8#69=2W["3N,%K6(%\:NZYVMF#EYQ44 O":L2AF%NW[LUBINV- MP0\"6[&S1CJ3E+%GO?F2SRU' P&%3&H/6%TVL !*M2.%\:?W:0TAM7!W_>;] MD\E=Y9)B 0M&?Y)/O=+_=#XV\8!;NE=[>F09Z$JN#=JWJBB@42N9<3U7->#?=NHUD MC1D0*9-JW)AEJ3X(@&L#];Q@3+YM],P9/C&2OU!+ P04 " *A*U4,CDU MA%\" V,?705 +)G);6;1Q5B?1''KJA <7=N:M TLS%6<:2NW<:NML#+ M$*1DG P&6:RXT%$^"V.W-I^9!J70<&N9:Y3B]N4*I-G-HV'T.G GMA7Z@3B? MU7P+*\"'^M92+^Y42J% .V$TL["91Y?#BZNI7Q\6_!2P_E M/!KXA$!"@5Z!T^L)%B"E%Z(T_NXUHP[I P_;K^K7P3MY67,'"R-_B1*K>32- M6 D;WDB\,[MOL/>3>KW"2!>>;->NG8PC5C0.C=H'4P9*Z/;-G_?[4[+K!Q@*[$5JH1K$?:RFVW.^B8Z=+0"ZD.V,G3&AV7YG&<5VZ68R4 MCA>-BSWZJD4G1] WW)ZST? +2P9)\K!:LM.3L_]58C+3.4HZ1TF0'1V171BE M!-*Y0<@BX$.+84KI#&>7>_+]<.+1V+/^]01QUU%*CC(]0[\!5 M'%:#%:9T?G.\L;Y]::6R(.6KYBE/!]DL?NKACSO^^%T^H49]J#8J/4!ED[0? ME7:H]"/4N ^5?AZ5=:CL(U3:A\H^CYITJ,E'J*P/-?D\:MJAIN^B[@URV<>: MOCD7H^3-P8@/BMW?FU1&6T&%*6%#88/S">5JV[NH[:"I0_VO#=)M$IH57=]@ M_0*:WQB#KQU_I70_A/P?4$L#!!0 ( J$K503_7=!8 ( %\& 9 M>&PO=V]R:W-H965TRCR?[]SC:A:96@[@OX['O/[Y[-D6Z5?C(% +)= M54HS"0K$^BH,S:J BIM+58.DE;72%4<*]28TM0:>.U!5AG$4C<.*"QEDJ9N[ MTUFJ&BR%A#O-3%-57/^=0:FVDV 0["?NQ:9 .Q%F:E!1Z.]^Q?7>U4RY(;F*ORM\BQF 2? Y;#FC[)MFQL%;-485%4+)@65D/[-=ZT/!P#B.0Z(6T#\%C \ 4A:0.(*]99JM67:9A.;'3AO')JJ$=*>X@(UK0K"8;;PI\?4FOULN$2!W/K*;J2_ M(=;JZ9*.G_VH05,L-^P[D&^&G5\#S&Q=";V4 X[RJ&C'+Z/DJV4P6/&>Y:Q8['? M]G,61\,T?#XTHS_GE;Q1)V_T7_)@1PW(P#&%GFC4J[ _YY7"<:=PW*OP02$O MJ2-)[!,W?H=]_3E>7'CPK5:@-ZZ%&3JU1J*_UMULUR6GKCF\F9]1]_3-[H7& MMUZZM!LA#1F^)LKH\A/9I7T[\P&JVG6$I4+J+VY8T!\ M$V@];52N _L!MT_ M)?L'4$L#!!0 ( J$K52E0*;'J@( -<' 9 >&PO=V]R:W-H965T M'?SW9*Z*C3"VX2?YWW?4X^SIGNN'B2-8!"SPUEIQLQ!ZYO:M+)70NT3'J7RI7W/94D"\0G=8M8*H%S/^N0&!%6%K= LZ:8G.YZ P MH?("G2'"T$/-6XE9*:>^TAA&S"_VEM>=931@>8?%)8K#3R@*HNAQ.4?G9Q?_ MJ_@ZB3Z3J,\DLK+Q@&S'>4(H[H5B*S0:$+H'\S6;U!<@""\E^LI**-$<"FA6 M('IV5^J==&*ES1^QS<=9,/6W#IY1SS,ZR?,'L!A B%T(G=KX "&-,S?"N$<8 M?Q1AY$(8'R.,4C="TB,D'T48NQ"28X1DX"FD/4+Z483$A9 >(V2Q&R'K$;*3 M" \UZ-I;*1 NP^S(,,[2Q.TXZ1TGIQVYPM1E-G&\XTGD-@N#MW(4G+2[!2F1 M[B\2F$);3%M )9$%;YER5IK@B.)SE :C 8R#JAB>Q'@K?]24%40)7A%*%'E? M8?88X=%O/TJS]Y^;?U"F3&ULM5?;;N,V$'W/5Q#NMM@" M7NOB:[:.@<3)]H(D&VR0!D71!UH:V<12HI:DXJ3HQW>&DF4[L;7.HGVQQRU_ 4J0GW"BY0T[I@6XET#U40Z\2Z#W7$.P1Z%<"CKI7..^>63\9:+9FFW8A& M'\[[3AK])3(*E%NK<56@G)U< GK9L+?G8+F0AEUSK3F=W8]CSR(^[?*B"NNL MQ KW8)U#U&'^J,U"/_3O;L_9VS>[4*;-*!\CVV%A=PLEL3]\%PQ'/^U .S_ MIF[@T(+]-ETTHUQQ7:.$.U$\]'OM_+!V?NA@>_NHYD#.SN9,TC&TF11\)J2P M3[M,++$&#HON_\.D-QR-?-\?>P\[C.C61G1?9X2FN_5.)>\* XP; W:7V[LO MK>GA@6U84UI=[NMO[NL&QWNM[M56]PZTVD4PNZP\)S"8_[R"= ;ZKX83ZM=J M^O_A"?5?!57E\W9QX3=X>"4#N@0RL-:V_!_B(>+X [O&JO,;: -/A] ]KA4<-RHH76I!ITPE+%*9U5B\=B6_ M9IS 9T_ M6DP*?#72=E_S1E@Y3.1%CF5UIUIN1GM'MB"/R#)!3#E0)A5CK+( MN"WGK_^H@HL6<6S$HUTPGF58"K3!%H*\0PM3E6*?$ '^6(8E!P,DU^I!Q!#C M.K=L"6PN*FV29[%4.CY::F$M9"Q35D1 ?\C,&)+ 2;27I>CYA4&-L5M-E89R M-0A7:P+[BOB!HW*W;:4MYT];RABON1'5!*#3="@;E3)H=..-Y']S=@6QB+AD MEWRF\(P4>F:J='Y(2 ;KNA T%X93[/G(X42)_<,:RM^T0MI*.GMO7; N"D%S M59BJ+"DB41@BNDZI:,PWW\A@G=N#0Y-[&?YXPA1N9F?L]UXDGO[@>-#=+D/3 M7=N.^_O^Z0_:COF.)JE9\3T<<6E4F29XF?$)L30$6_?"8,ACTBA91J"Q6Z3; M& NBBFLFYW@MI8HP(\2K)#+7JL 3J12-9.S0LB8'$:I%D'HL]?N^SZ^$0JN MX2BAYQ'%?:\]J&?I%MLV5I\R,>1<8QXI)-?RJ?+Y#-6*;,M9'8:9KX&72A+0 MQ"HO=+1P96##P*.XT&0,7ES^86\8#)[=?F_C&46O9.SZYR(SJ"!!.1_]V2I#:#6P*G*&57 WJLU<__R;]02P,$% @ "H2M5+<8V#9J! *A$ M !D !X;"]W;W)K&ULO5C;;MLX$/T50MB'%D@C M4;9\"6P#CITT"9HVB)ONPV(?:&EL:RN)7I*R$V _?D>4(JFQ3"M88%^L&\_, MF>',(>G1GHN?<@.@R',<)7)L;93:7MBV]#<0,WG.MY#@EQ47,5/X*-:VW I@ M@0;%D>TZ3L^.69A8DY%^]R F(YZJ*$S@01"9QC$3+Y<0\?W8HM;KB\=PO5'9 M"WLRVK(U+$ ];1\$/MFEE2",(9$A3XB U=B:THL[.LP >L2/$/:R=D^R4):< M_\P>;H.QY62,( )?92887G8P@RC*+"&/OPNC5NDS ];O7ZU?Z^ QF"63,./1 M[V&@-F-K8)$ 5BR-U"/?WT 1D)?9\WDD]2_9%V,=B_BI5#PNP,@@#I/\RIZ+ M1-0 M'<$X!8 ]RW .P+H%(#.6T#W"*!; +IM*7D%P&OKH5< >FT!_0+0;PL8 M%(!!6\"P S; JCS.G..KJ!\RG6]S)EBDY'@>R*R\6@ON]%%I_%8)F&2]<=" M"?P:(DY-9CR16$IALB;3M0# TE>$)0%9@)\*",B#X'$H)17MXD_P5$T3F:-[&ITMB+L) M>MTU..R6#KM&AU/?YVFB9*W;S\@,*82*?.$2.^09%VB)$O (.Q"214W]/NL> M\/HT=+N.4['+Z]A()MLA7,@M\V%LX19 @MB!-2&&M'IEE)XQRL^0@&"1EKMI M@/(:2I7K6!G?'_<0+T'\:?#6*[WU_H><7N5.O%I..WW/J>?T%W;]DEW?R.XV MV8%46OT7&X9I;A/ZH#0^:&O\VSZ!X(QE'&_=U#$UX>C.M0[.B_4J19HQTCX.P@L M3:9WD]42W6)V:&T/0$^XD)@#P$D7NC8;5\_+PD@]PJ&N/.=X^5&WXN :.3PE M B*F4.6^;T(1D"T3ZJ4,D_Q#[K$_XS1N%7DEK-2LK)FBDML$^S[-TGI&KE%G MR#3..K5IT:*'4NN:VH]6BDO-DGLZ?O;<.OY* :E9 M\=OW=8Y<;X*W6D9GD\ M&7]]$6R5A$KZJ%G[WIF$F\)1( !D !X;"]W;W)K&UL MQ5A=C]HX%/TK5M256JF;Q$Y@/@1(!5IMI<[N"-K=AU4?3+@0:Q*;M0VT4G_\ MVDDF@9E@JE%07R!Q[CGWXY![L0=[(1]4"J#1MSSC:NBE6F]N@T E*>14^6(# MW#Q9"9E3;6[E.E ;"719@/(L(&'8#W+*N#<:%&OW4_E] M#)G8#SWL/2[,V#K5=B$8#39T#7/07S;WTMP%-J&-"#)(M*6@YFL'$\@RRV3B^*\B]6J?%GAX M_)+.@"B8B^XBC9 M*BWR"FPBR!DOO^FWJA ' ,/3#B 5@#P%Q"< 406(G@+Z)P!Q!8B+RI2I%'68 M4DU' RGV2%IKPV8OBF(6:),^XU;WN9;F*3,X/9JS-6H-_1E_D4O7[U!KU"C*,[EF76=A!H$Y2E#I(J M@'$9 #D10(3N!->I0N_Y$I8M^*D;CXF#(##5J$M"'DLR)D[&.RI]%.&WB(2$ MM 0T^7DX;LO'#9]"<@I^E$U4"QP5?-$)OB,MT8RI!_3O)V.#/FK(U5>'A[CV M$!<>XA,>9K #OH56[4OD38&T+6@WBJ_\WB#8'=;SN1'N^5%M=!14KPZJ]S-! MH3'P)#4=S61]!_D"Y%?T TT977.A-$O0'.2.):#0)&.F3 K]94IS8-K^3E1U MK,P<->S7X?8OI-)5[>'*69!C#])X>(LV(.V:Z>]MVKGYHKY_%?[6]GJX<7'? MQT]Q1PE=UPE=7T;ASWO1H<(W=;@W%U(8ATTO#SO6^ PAP7[<+O(98(3]OE-E M?#"@\(5T3B5T^2YCTH1,+J5UT]9QU+76;D*,_= M63,0L'LB?)9T"6@&"; = M763P:WHO;F8%[EU*KZ;!XW[7>KD)H^CY*U;]87(#X^BYF_E*ANVW! MN!D9^/I20C=]'M]T+;2;D/3]W@FAW4!\K@F39K(0=S]_L= =]V#2C V"+R0U M:?H\(=U*/3U#B,/G?ZJ.8VOF W&W\Y"-4.#Q)<2K>Q+TK>(%@ M;L+3@@4'>W)3OG5QMJ%0(K9K4^/WE7G!H\61_CVTEY"M+0E(Y M9F9_GL'*4)I(3*RR/.0W&ZY^*'7 ,H])2EN;RTUDIM M+B83&:TA8_*<;R#7;Y9<9$SI6[&:R(T %I=.63HAMNU-,I;DUFQ:/KL5LRG? MJC3)X58@NZN#4#DXY,E4IY3@LF&*SJ>![) IK':VX* >S]-;E)WDQ[_=*Z+>)]E.S M>]U(\38%Q)?H'E9Z1A6ZSJM^*N;EXP(42U+Y"9VAA_L%^OCA$_J DAQ]6_.M M9'DLIQ.E<131)E&=\ZK*209R4G3#<[66Z*<\AOC8?Z+Q-T60YR*NR&C &R;. M$<6?$;$),>"9G^Z.#>Z+PX4(E^>IH0KY_ MU>;H6D$F_QQ)YC3)G#*9,Y!LSG/)TR1F"F*4:YX1L(-\"Z99K2)Y9:2"3W8S MQW>I+GEW.-9]*^P2O[4Z@NDV,-W3849(9I7.&^ :<;=GNA;^6[Q0HU(0T:I,$) YSD M$<\ +07/$*^PZQ;YC-A2:>3U6\6>S.B#/GKBA-WV,%C9KF]&'S;HPS>@?P2] MT.%%^&$?F!Y[NP/?8#4(']NM7MBC!5PWV,;:N YRF/R,.KC;R..YBCW/A=RP M""XMO9PDB!U8,S3">OA ]O!H&;]JJJN&V0@?G]0@)K/A(28M-G)"CS I09G5 ME?32AJ'GN?]!1"WTH)?H2TO2"#N2X;CA)AV&\.@/\2G0YW1:@L>%Y?7RB V MR(GGVZ0+MV_F4&>H45I)P>.:\D8IQ'WU<'M2:# :1MY*#'Y_C<%]^= ?8Z17 M@,$LH.% !:W,X%-T9H1#^NK@XH#0+H>8S+!KF^&15D7(N(H4C;S-]"C>"AYO M(W42@Y"6W0E^?P8A+6&3<<)^#8.0/GD3#P>=KC!9N71@:TI:ZB;CU/U:_JC# M'<'0N_DNV+X5#L.!%B:M#)#Q3Y,WTD<=_6AW;W?W2 8C.H"[U1,RKB?_!7F0 MOH"HC;2R0L9EY2%G M:$O4WA&?:= M@9T);0F=CA/Z2SU3NWM'S>!XG1WUPF"&'=OV.O F!P=>6D56Y<&AU(RVS55U M;-0\;0XGOY1'KXI$C1'N;-_ 5!+ P04 " *A*U4/4<\ M$%$# H"@ &0 'AL+W=O[%%ZNZKSQV/Y"U/0CZI$D"3KW7%U>(+ M.Y3:3/CK94,/L 7]T-Q+'/F#2L%JX(H)3B3L5]Y->'T;6@=K\1>#DQH]$Q/* M3H@G,_A8K+S $$$%N382%/^.< M59920X]]>U!N^:1S'S\_JO]K@,9@=57 K MJD=6Z'+E91XI8$_;2G\1I]^@#R@U>KFHE/TEI]XV\$C>*BWJWAD):L:[?_JU M3\3( 77<#E'O$)T[)!<BG%B4ACC6KFP>;&>F,TC)ME MW&J);QGZZ?46ZZ)H*R!B3S94L9Q07I [5K4:"O([UM$GH12Y!TFV)95 WMZ! MIJQ2[\A[\K"](V_?O"-O"./DSU*T"IW5TM<(9N3]O(?8=!#1!8B8?!9O$%O0]4 M[;EBO(6XG%E0M^!*G9#JNO MD:)F2@GYC7"AP87??2(=@45Q= 8_B6%.Q&O5T!Q6'AYY"N01O#69R/]LB&_V MX_DONKWC"F'F6(%Y-#L+PF%U<07F ^%\DO#1'F>8=(HIQ^.9*%.%BN#!KC1N M6JS.J=*9O\I]F";9.;C#*DEGL9L\&\BS2?+GHZ@#?D^V6N1/Y(_&7 +.HR9[ M72>O"\5AE"U2-^EB(%W\!.DCE9)R[41=.%#/21TV6>(/OAWXPB?KPLYNP MUQWC9$%PANPP2M+L O/HH@K_AQ*>V'V]_HOZS.;)*WJ7630*LN/W1W=N#?)@ M6Q&%^6RY[BZJ879H=V[L)7\VOS%MD+W+O\MT/11>0P?&%:E@CY+!U1R99->6 M= ,M&GNS[X3&/L$^EMC*@30&^'XO&ULS59= M3]LP%/TK5WG:)" ?_02UE=K"-*2A570;#V@/;G+;6,1V9CLM_/O93IH&5C(> M>."E_CS'Y]Z3^GJT$_)!I8@:'EG&U=A+M+"#ZV3L!5819AAK2T%,L\4Y9IEE,CK^5*1>?:8%-OM[]B\N>!/,BBBT,/$ER3(M.W8O<5JX!ZEB\6F7*_L*OV!A[$A=*"56"C@%%>MN2Q2D0# M8'B. Z(*$+T$=%\!="I QP5:*G-A71)-)B,I=B#M;L-F.RXW#FVBH=S:N-32 MK%*#TY.E^2Z2(D,0:YAR34\3FA4VL[#$N)!44U1P]1AG18()K*5@H%.$:QX+ MAK! "K@1\QSOF[CKX*-]\+.HE?"&R#/HA"<0!5%T1,_\[?"P M14ZG]J+C^#JO\-G\_S_]S4P;TZZ(Y)1O5,.+^V^&&*XU,O6[15:WEM5ULKHM ML@Z?A:IU'3.P9.HY)GN#;"=AU.^-_&TSJ_]NZO8.>YYI[-4:>ZT:35*8R<=2 MB_@!%H6,4_/7ACLB)>%:P?T-LA7*MFSTZY/Z'\FD02UK\&XF#5KS7WK4ON>9 MQ&$M<=@JT<5].C/&)+ @3Z86:)A:@S9H^R?P/7?Y>H-9Y_61YQ_)K# XW+K! MN]E5436]&(;!"[_:S[./@0N5DQC'GJGV"N46O0D<"\5OU!*&+^9GMKR[&G6@*=\&YM[<4*X@P[6A#,X&)C19EMMRH$7N*M9* M:%/_7#&PO=V]R:W-H965TX-..@MG9]$X8FKT%08I6M:P1+L MXWJAT0I[EH()D(8I2324XV RN)F-7+P/^,Y@:P[6Q&6R4NK9&7?%.(B<(."0 M6\= \;>!&7#NB%#&KXXSZ(]TP,/UGOVCSQUS65$#,\5_L,+6X^!#0 HH:4<_;>GC(_0)N5?2UH;< MR@**O_$A2NWUQGN]T_@DX3W55R097) XBN,W],S^'SXX(2?IKR_Q?,,C?)^I MP5K\0O5S8\C3/8@5Z)\G>(<][]#S)D=XYU""UO@N,R6P80WU-3_!)Y$58!-9 M+!-;DSM9L TK&LHOR.TNYTW!9$66-=5P.<7B=N_ZXL(-H1(-9:P&RW1+,04) M)<.]IZ]X/+FS(,PI\:->_.CDI4RD1$6^NXBA'(?#6X73F\_>B:^XU[YISB2V@GRAZ:= M9U@Y%9.&<"B1,KIZC\IT.R-:PZJU;[.5LMBT?EGC6 7M G"_5,KN#7= /ZBS MWU!+ P04 " *A*U4UEJ'>_," ""0 &0 'AL+W=ONS$QF0GKJO# M&!.F6S+#E-ZLI$J8H:E:NSI3R*+<*!%NX'D]-V$\=2:C?.U*349R8P1/\4J! MWB0)4\]G*.1N[/C.R\(U7\?&+KB34<;6N$!SDUTIFKD52L033#67*2A&X-U92GE@YU<1&/'LXI08&@L!*._+4Y1"(M$.AY+4*?B MM(;[XQ?T+[GSY,R2:9Q*< M ^%&&YF4QJ0@X6GQSY[*0.P9D*/U!D%I$+S7H%T:Y)%S"V6Y6S-FV&2DY Z4 MW4UH=I#')KS- P+C1\9THQ&^-# M.(8_MMW-,5FBNJ=W-XL9''PZA$_@@HZ90@T\A9N4&WU$BS2>D#=GS^ -CR#P@J#&>OIWZZ!;9^U2F*I8!56L@ARN_=Y8W7VC M'7!A,-'W#?CM"K^=XW?>P#_=,17!%K7AZ1HR5"&1T+=4%[9F)#]H=;W/#9(Z ME:1.(]#Y$ZG@&B%3/$2KJ4AQG:0":9 CV>JQG?1:_<[(W=;P=RO^;B/_(L.0 M,P$ATS%$?,LC3*,Z\@+&]_;8O5:[GKQ7D?<:R6II^Q5MOY%V>GX)EYDMH<5_O!?CHI<@/OV=]O@73W&I2]'6QEI(P:U60EV-V?,1,M2R'I(YL94'^.XGLY92>MS53%I MD4+IDAH[U;.XKC2C>0U.I8A[G4X:EY1+,AK(17E3FCJ:JH4T0W+1FB)_^Y(/ M23>]()&G&ZN<#=^R% M,CL4HT\/H]]'CE%?'42]A]D1QTWN1X-"R4T)$N(--C(M6?1(Q9",J> 3S<&K MH"47*V_N@6&JA-*1L;6W4KI@J9\\W/4S:(N&I^12:1?;1_!_)\WR'6 ] X%< MB%9@CWC#:%!18YB6-W;B%COC"RAJQO>KRBJ<:;KJ]B[)QL'=;)")TCG3;9@N M69M& \$*D*/Y; YWHZH80&-4:0W0"FJ&GL9/@'^;S7-OT[Z.-ZKXHS*?%W8[TLVA5]BM9@5?NOFR: 5@ M[%V2W7^57<%!C&RF!Q4,,;REJ;P M#;-AVL #BP.1_BS7>+7Q#MG?!UA-]W4(ME.\$[&=XKD&))PW\,BR<+6Q.."! M50'K'8@?C@,]%?9)$J@JI@U[@G$DRS $>C'%3[@^V%.2)%D61@ + M*T@2#(&G$4* MNQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %( MMB6/:(7->=I3W;+T]! M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B M':5_' MI+V?)9<\PR%?WEIW,[?V1GQK&^-/1^L0-B_&8U^O52O]GW:C#!Q96M?* )MN M-?8;I^3"KY4*;3/.3DZJ<2NU&;UZN;O7E1OC#1M4';0UL#/N^*S5K;\_'C?% M5GL]UXT.=Z>C]+]1(]%JHUO]72U.1RD^TM@W"HXN=_J@GVKFZ#< M5 ;USMENH\TJW@;>8HQ>(Y7#[K8$9'X4R%G$@4L19$% %D>$')1D24"6QX3, M$61%0%;'A"P0Y%,"\BDOY*5;2:._IP-"&F@RG==&>8_PGA%XSWCQ9EW;2GU,T CR.0'YG!=R5V2 ];6#A\<3<-]]0G7>)[QL[ZQ= MW.JF276;^!Q\@Q>@4[,"%(Q).H99,A P;$#G=[^+JR96<*0]!]A-O Y#4HZ9 M,$OF'VC,=>?Z!KV-T0<\7P!ZJ[VW UU3EIDP:V86;'VSMLU".?\EE6*XPVR4 M7";,=IFJ)3255(#!Z7F7NIU8Y;B_F5!FF3"KY<+4ME7BD_RF!DR42";,)KD, M:^7$6><:YG"9CT$I"0R8;;(F6U;'>))/C7=6+T0.BM3/X"D5#)A=LE[ M)?V0AG+&A%D:,2;HFEA*XO7*J1@ ]MW>+/4Q.*RF_)$Q^P-;]ZSS =J&B]5; MPV5.XJXYH_R1,?MCIE:I "],?_G0P!DY,F&VQKET!FK9BRLHN=E:#NN6$D7& M+(KKN!,ZXROI'G0F&>6(C-D1LV[NU=?)%#XWS DI8R,61ED]#RLAPM[&2G=Y,RZ>1PW[$6D5),?3C7P/6ZL29\C;'V0[D9A<>>4:G)F MUCBG9),SRP9C MOI7:B<^RZ?HM;>0@BTW)IN"6#<*N,2:EFX)9-W10B7/9!:6;@COUA5NZ]RKX^Z@-+(DQR2D6;OU0 MF(.PLJ ,5' />!#FSXRQ^DF,,2D+%/%1XQ)6:@XH(4>ER:. MV K*0L4!+73N@VY3BN!M%SH(0%ZW&).R4,%L(7IDAD>Y)66A\H 6VC-*PYB4 MA;=!)\J$%O,29EH9(]S_;3Z?]* MYWJ? U\:E4]Q6%R24_W<%MJ;-=C7O9>4A4IF"_UZ9BO!8DS*0B6SA?#T%BK% M6/]Q*13&I"Q4'M!">S(R&).R4'G L= C67[ F!5EH8K;0O\.VKD.J;)W MZ0^,25FH.N!8Z(.$,HPM/7X X"8Y6.Q141:JF"VTRVD]:CPX+U-1 JKX%YK] M>FYQX,F*$E#%+2!J;G&(20FH.N PB)YGK,C59MS).(3Y1GI=IQJ?ZJ:+?1+V M9$4)J#ID,@ZZHC\6D3#V1FGB&V-2 JJ8!?1@;O1A:\>8E( J;@$]F"M]P(G7 M&%(">IH$-$XG^UX6%_+9OZRHGXTZ_!*LJX=&+9-&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'/-VDMNHT 4A>&M6"P@N.Z+I!5GU)-,HVP M.>6'8AM$T4JR^[:<@7U0#WH2<4:H0%S^T0<"'E_RH1WWW:GL]GU9?!X/I[*J M=N/8_ZKKLM[E8UONNCZ?SDRR[GL5J\ML,VCZNJ_CQ<=Y?ZLDEW MY\G5XOEM50W/;ZFJYPX2")+Y@Q2"=/X@@R";/\@AR.@GH+@=Z">@N!WH)Z M"X'>@GH+@=Z">@N!WH)Z"X'>@GH+@=Z*>BN!WHIZ*X'>BGHK@=XZ>5E"H+>B MWDJ@MZ+>2J"WHMY*H+>BWDJ@MZ+>2J"WHMY*H+>AWD:@MZ'>1J"WH=Y&H+>A MWD:@MTU>=A/H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z.VHMQ/H[:BW$^CM MJ+<3Z.VHMQ/H[:BW$^CMDX^5!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>@?J'01Z M!^H=!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>L?D9Q,"O0/U#@*] _4. KT#]0X" MO1O4N_E)O?ZMJ(\_0502P,$ M% @ "H2M5*3(PW?Z 0 M"@ !, !;0V]N=&5N=%]4>7!E&UL MS=K+3L,P$ 707ZFR18WK)P_1;H ML. '3#*E49/8LETH?X^3 A((*E"1N)M& MK>VY$X]T5CV_>_84)]NN[>.\6*7DSQB+U8HZ&TOGJ<\K2QTM)LV3:ZV^>?8N'Y>!&IC,;G8;1RRYH7UOFTJ MF_(Z>^SK3RG3UX0RGQSWQ%7CXU'>4+ O$X:5[P->S]T\4@A-39-;&]*U[?(N MMFU93,\MQ7)_B2]Z=,ME4U'MJDV7CY31![)U7!&EKBUW18_V)Z=\P[3[Y ?G MCV7V!>:=M\'YF"<6Z/=Q;R,93D]]+D0A-?M?\3TQES[X_6B8=DWU#[/S]3ZY ML![G$=GX./R./\[XO?XO^Q @?4B0/A1('QJD#P/2QS%('R<@?9R"],%G*(V@ MB,I12.4HIG(45#F*JAR%58[B*D>!E:/(*E!D%2BR"A19!8JL D56@2*K0)%5 MH,@J4&05*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4626*K I%5H4BJT*1 M5:'(JE!D52BR*A19%8JL"D56A2*K1I%5H\BJ4635*+)J%%DUBJP:15:-(JM& MD56CR&I09#4HLAH460V*K 9%5H,BJT&1U:#(:E!D-2BR'O^GK/?.K?\X?GR6 MG6WZMWPV_EEQ\0)02P$"% ,4 " *A*U4!T%-8H$ "Q $ M @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( J$K51L M2>3+[@ "L" 1 " :\ !D;V-0&UL4$L! A0#% @ "H2M5+&PO=V]R:W-H965T&UL4$L! A0#% @ "H2M5(+'&GH_!0 ;Q0 !@ M ("!<= !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ "H2M5 H*"RF&" 22@ !@ ("!U28 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ "H2M5-.%&#^2" M)Q0 !D ("!,&, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H2M5&8;)Q]"!@ 6@X !D M ("!TW, 'AL+W=O@ >&PO=V]R:W-H M965TN# !X;"]W;W)K&UL4$L! M A0#% @ "H2M5-N ;!Q!!0 T0L !D ("!NH8 'AL M+W=O&PO=V]R:W-H965T/ !X;"]W;W)K&UL4$L! A0#% @ "H2M M5#"23O6'!@ B@X !D ("!!I4 'AL+W=O&PO=V]R:W-H965TC !X;"]W;W)K M&UL4$L! A0#% @ "H2M5.Q(W6'U!0 UPT M !D ("!T*< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H2M5,,[=/YX P T < !D M ("!!K8 'AL+W=O&PO=V]R:W-H965T MUS 8 )H2 9 M " @7'N !X;"]W;W)K&UL4$L! A0# M% @ "H2M5'>H-_#D P M0@ !D ("!=/4 'AL+W=O M7)\WL# "8 M" &0 @(&/^0 >&PO=V]R:W-H965T&UL4$L! A0#% @ "H2M5 J MLN*G P #PD !D ("!?P ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H2M5$8TPB)! P ,@@ !D M ("!7PH! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ "H2M5&^(#QR0 P K@T !D ("! M^14! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ "H2M5/(42"E(! 7AL !D ("!K1\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H2M5(_G4>V2 P 9A !D M ("!R30]? # #J#0 &0 @(&2.P$ >&PO=V]R M:W-H965T&UL M4$L! A0#% @ "H2M5%G1W$K" @ TP< !D ("!LT,! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M"H2M5(?;,#(U @ '04 !D ("!3DX! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H2M5/[\"V&( @ ^@8 !D M ("![V@! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ "H2M5!/]=T%@ @ 7P8 !D ("!8'$! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H2M M5+<8V#9J! *A$ !D ("!\7L! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H2M5#U'/!!1 P * H M !D ("!KXD! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H2M5-9:AWOS @ @D !D M ("!$I,! 'AL+W=O&PO&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " *A*U4I,C#=_H! "T* $P M @ &RH@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 3@!. %D5 ( #=I $ ! end XML 83 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 221 371 1 true 81 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://prophaselabs.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://prophaselabs.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://prophaselabs.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) Sheet http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://prophaselabs.com/role/StatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://prophaselabs.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Business Sheet http://prophaselabs.com/role/OrganizationAndBusiness Organization and Business Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://prophaselabs.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Business Acquisition Sheet http://prophaselabs.com/role/BusinessAcquisition Business Acquisition Notes 10 false false R11.htm 00000011 - Disclosure - Goodwill and Acquired Intangible Assets Sheet http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssets Goodwill and Acquired Intangible Assets Notes 11 false false R12.htm 00000012 - Disclosure - Property, Plant and Equipment Sheet http://prophaselabs.com/role/PropertyPlantAndEquipment Property, Plant and Equipment Notes 12 false false R13.htm 00000013 - Disclosure - Unsecured Convertible Promissory Notes Payable Notes http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayable Unsecured Convertible Promissory Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders??? Equity Sheet http://prophaselabs.com/role/StockholdersEquity Stockholders??? Equity Notes 14 false false R15.htm 00000015 - Disclosure - Defined Contribution Plans Sheet http://prophaselabs.com/role/DefinedContributionPlans Defined Contribution Plans Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://prophaselabs.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Other Current Liabilities Sheet http://prophaselabs.com/role/OtherCurrentLiabilities Other Current Liabilities Notes 17 false false R18.htm 00000018 - Disclosure - Commitments and Contingencies Sheet http://prophaselabs.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 00000019 - Disclosure - Leases Sheet http://prophaselabs.com/role/Leases Leases Notes 19 false false R20.htm 00000020 - Disclosure - Consulting Agreement and Secured Promissory Note Receivable Sheet http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivable Consulting Agreement and Secured Promissory Note Receivable Notes 20 false false R21.htm 00000021 - Disclosure - Significant Customer Concentrations Sheet http://prophaselabs.com/role/SignificantCustomerConcentrations Significant Customer Concentrations Notes 21 false false R22.htm 00000022 - Disclosure - Segment Information Sheet http://prophaselabs.com/role/SegmentInformation Segment Information Notes 22 false false R23.htm 00000023 - Disclosure - Earnings Per Share Sheet http://prophaselabs.com/role/EarningsPerShare Earnings Per Share Notes 23 false false R24.htm 00000024 - Disclosure - Related Parties Sheet http://prophaselabs.com/role/RelatedParties Related Parties Notes 24 false false R25.htm 00000025 - Disclosure - Subsequent Event Sheet http://prophaselabs.com/role/SubsequentEvent Subsequent Event Notes 25 false false R26.htm 00000026 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://prophaselabs.com/role/SummaryOfSignificantAccountingPolicies 26 false false R27.htm 00000027 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://prophaselabs.com/role/SummaryOfSignificantAccountingPolicies 27 false false R28.htm 00000028 - Disclosure - Business Acquisition (Tables) Sheet http://prophaselabs.com/role/BusinessAcquisitionTables Business Acquisition (Tables) Tables http://prophaselabs.com/role/BusinessAcquisition 28 false false R29.htm 00000029 - Disclosure - Goodwill and Acquired Intangible Assets (Tables) Sheet http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables Goodwill and Acquired Intangible Assets (Tables) Tables http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssets 29 false false R30.htm 00000030 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://prophaselabs.com/role/PropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://prophaselabs.com/role/PropertyPlantAndEquipment 30 false false R31.htm 00000031 - Disclosure - Stockholders??? Equity (Tables) Sheet http://prophaselabs.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://prophaselabs.com/role/StockholdersEquity 31 false false R32.htm 00000032 - Disclosure - Other Current Liabilities (Tables) Sheet http://prophaselabs.com/role/OtherCurrentLiabilitiesTables Other Current Liabilities (Tables) Tables http://prophaselabs.com/role/OtherCurrentLiabilities 32 false false R33.htm 00000033 - Disclosure - Commitments and Contingencies (Tables) Sheet http://prophaselabs.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://prophaselabs.com/role/CommitmentsAndContingencies 33 false false R34.htm 00000034 - Disclosure - Leases (Tables) Sheet http://prophaselabs.com/role/LeasesTables Leases (Tables) Tables http://prophaselabs.com/role/Leases 34 false false R35.htm 00000035 - Disclosure - Segment Information (Tables) Sheet http://prophaselabs.com/role/SegmentInformationTables Segment Information (Tables) Tables http://prophaselabs.com/role/SegmentInformation 35 false false R36.htm 00000036 - Disclosure - Earnings Per Share (Tables) Sheet http://prophaselabs.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://prophaselabs.com/role/EarningsPerShare 36 false false R37.htm 00000037 - Disclosure - Summary of Components of Marketable Securities (Details) Sheet http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails Summary of Components of Marketable Securities (Details) Details 37 false false R38.htm 00000038 - Disclosure - Schedule of Accounts Receivable Net (Details) Sheet http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails Schedule of Accounts Receivable Net (Details) Details 38 false false R39.htm 00000039 - Disclosure - Schedule of Components of Inventory (Details) Sheet http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails Schedule of Components of Inventory (Details) Details 39 false false R40.htm 00000040 - Disclosure - Schedule of Fair Value of Financial Instruments (Details) Sheet http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails Schedule of Fair Value of Financial Instruments (Details) Details 40 false false R41.htm 00000041 - Disclosure - Schedule of Deferred Revenue (Details) Sheet http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails Schedule of Deferred Revenue (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule of Disaggregation by Revenue (Details) Sheet http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails Schedule of Disaggregation by Revenue (Details) Details 42 false false R43.htm 00000043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables 43 false false R44.htm 00000044 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details) Sheet http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails Schedule of Assets Acquired and Liabilities Assumed (Details) Details 44 false false R45.htm 00000045 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) Sheet http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) Details 45 false false R46.htm 00000046 - Disclosure - Schedule of Intangible Assets Acquisition (Details) Sheet http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails Schedule of Intangible Assets Acquisition (Details) Details 46 false false R47.htm 00000047 - Disclosure - Business Acquisition (Details Narrative) Sheet http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative Business Acquisition (Details Narrative) Details http://prophaselabs.com/role/BusinessAcquisitionTables 47 false false R48.htm 00000048 - Disclosure - Schedule of Intangible Assets (Details) Sheet http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails Schedule of Intangible Assets (Details) Details 48 false false R49.htm 00000049 - Disclosure - Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets (Details) Sheet http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets (Details) Details 49 false false R50.htm 00000050 - Disclosure - Goodwill and Acquired Intangible Assets (Details Narrative) Sheet http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsDetailsNarrative Goodwill and Acquired Intangible Assets (Details Narrative) Details http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables 50 false false R51.htm 00000051 - Disclosure - Schedule of Property, Plant and Equipment (Details) Sheet http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails Schedule of Property, Plant and Equipment (Details) Details 51 false false R52.htm 00000052 - Disclosure - Property, Plant and Equipment (Details Narrative) Sheet http://prophaselabs.com/role/PropertyPlantAndEquipmentDetailsNarrative Property, Plant and Equipment (Details Narrative) Details http://prophaselabs.com/role/PropertyPlantAndEquipmentTables 52 false false R53.htm 00000053 - Disclosure - Unsecured Convertible Promissory Notes Payable (Details Narrative) Notes http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative Unsecured Convertible Promissory Notes Payable (Details Narrative) Details http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayable 53 false false R54.htm 00000054 - Disclosure - Schedule of Stock Options Activity (Details) Sheet http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails Schedule of Stock Options Activity (Details) Details 54 false false R55.htm 00000055 - Disclosure - Summary of Warrant Activity (Details) Sheet http://prophaselabs.com/role/SummaryOfWarrantActivityDetails Summary of Warrant Activity (Details) Details 55 false false R56.htm 00000056 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://prophaselabs.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://prophaselabs.com/role/StockholdersEquityTables 56 false false R57.htm 00000057 - Disclosure - Defined Contribution Plans (Details Narrative) Sheet http://prophaselabs.com/role/DefinedContributionPlansDetailsNarrative Defined Contribution Plans (Details Narrative) Details http://prophaselabs.com/role/DefinedContributionPlans 57 false false R58.htm 00000058 - Disclosure - Income Taxes (Details Narrative) Sheet http://prophaselabs.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://prophaselabs.com/role/IncomeTaxes 58 false false R59.htm 00000059 - Disclosure - Schedule of Other Current Liabilities (Details) Sheet http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails Schedule of Other Current Liabilities (Details) Details 59 false false R60.htm 00000060 - Disclosure - Schedule of Estimated Future Minimum Obligations (Details) Sheet http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails Schedule of Estimated Future Minimum Obligations (Details) Details 60 false false R61.htm 00000061 - Disclosure - Summary of Quantitative Information About Operating Leases (Details) Sheet http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails Summary of Quantitative Information About Operating Leases (Details) Details 61 false false R62.htm 00000062 - Disclosure - Schedule of Maturity of Operating Leases (Details) Sheet http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails Schedule of Maturity of Operating Leases (Details) Details 62 false false R63.htm 00000063 - Disclosure - Leases (Details Narrative) Sheet http://prophaselabs.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://prophaselabs.com/role/LeasesTables 63 false false R64.htm 00000064 - Disclosure - Consulting Agreement and Secured Promissory Note Receivable (Details Narrative) Sheet http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative Consulting Agreement and Secured Promissory Note Receivable (Details Narrative) Details http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivable 64 false false R65.htm 00000065 - Disclosure - Significant Customer Concentrations (Details Narrative) Sheet http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative Significant Customer Concentrations (Details Narrative) Details http://prophaselabs.com/role/SignificantCustomerConcentrations 65 false false R66.htm 00000066 - Disclosure - Schedule of Segment Information (Details) Sheet http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails Schedule of Segment Information (Details) Details 66 false false R67.htm 00000067 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details) Sheet http://prophaselabs.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails Schedule of Basic and Diluted Net Loss Per Share (Details) Details 67 false false R68.htm 00000068 - Disclosure - Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation (Details) Sheet http://prophaselabs.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromIncomePerShareComputationDetails Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation (Details) Details 68 false false R69.htm 00000069 - Disclosure - Related Parties (Details Narrative) Sheet http://prophaselabs.com/role/RelatedPartiesDetailsNarrative Related Parties (Details Narrative) Details http://prophaselabs.com/role/RelatedParties 69 false false R70.htm 00000070 - Disclosure - Subsequent Event (Details Narrative) Sheet http://prophaselabs.com/role/SubsequentEventDetailsNarrative Subsequent Event (Details Narrative) Details http://prophaselabs.com/role/SubsequentEvent 70 false false All Reports Book All Reports form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm prph-20220331.xsd prph-20220331_cal.xml prph-20220331_def.xml prph-20220331_lab.xml prph-20220331_pre.xml http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 87 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 31, "contextCount": 221, "dts": { "calculationLink": { "local": [ "prph-20220331_cal.xml" ] }, "definitionLink": { "local": [ "prph-20220331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "prph-20220331_lab.xml" ] }, "presentationLink": { "local": [ "prph-20220331_pre.xml" ] }, "schema": { "local": [ "prph-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 611, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 76, "http://prophaselabs.com/20220331": 19, "http://xbrl.sec.gov/dei/2022": 4, "total": 99 }, "keyCustom": 44, "keyStandard": 327, "memberCustom": 46, "memberStandard": 31, "nsprefix": "PRPH", "nsuri": "http://prophaselabs.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://prophaselabs.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Business Acquisition", "role": "http://prophaselabs.com/role/BusinessAcquisition", "shortName": "Business Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Goodwill and Acquired Intangible Assets", "role": "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssets", "shortName": "Goodwill and Acquired Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Property, Plant and Equipment", "role": "http://prophaselabs.com/role/PropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Unsecured Convertible Promissory Notes Payable", "role": "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayable", "shortName": "Unsecured Convertible Promissory Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Stockholders\u2019 Equity", "role": "http://prophaselabs.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Defined Contribution Plans", "role": "http://prophaselabs.com/role/DefinedContributionPlans", "shortName": "Defined Contribution Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Income Taxes", "role": "http://prophaselabs.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Other Current Liabilities", "role": "http://prophaselabs.com/role/OtherCurrentLiabilities", "shortName": "Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Commitments and Contingencies", "role": "http://prophaselabs.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Leases", "role": "http://prophaselabs.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://prophaselabs.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "PRPH:SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Consulting Agreement and Secured Promissory Note Receivable", "role": "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivable", "shortName": "Consulting Agreement and Secured Promissory Note Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "PRPH:SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Significant Customer Concentrations", "role": "http://prophaselabs.com/role/SignificantCustomerConcentrations", "shortName": "Significant Customer Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Segment Information", "role": "http://prophaselabs.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Earnings Per Share", "role": "http://prophaselabs.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Related Parties", "role": "http://prophaselabs.com/role/RelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Subsequent Event", "role": "http://prophaselabs.com/role/SubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "PRPH:MarketableDebtSecuritiesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "PRPH:MarketableDebtSecuritiesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Business Acquisition (Tables)", "role": "http://prophaselabs.com/role/BusinessAcquisitionTables", "shortName": "Business Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Goodwill and Acquired Intangible Assets (Tables)", "role": "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables", "shortName": "Goodwill and Acquired Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://prophaselabs.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesIssued", "us-gaap:PreferredStockSharesIssued", "span", "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Property, Plant and Equipment (Tables)", "role": "http://prophaselabs.com/role/PropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Stockholders\u2019 Equity (Tables)", "role": "http://prophaselabs.com/role/StockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Other Current Liabilities (Tables)", "role": "http://prophaselabs.com/role/OtherCurrentLiabilitiesTables", "shortName": "Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://prophaselabs.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Leases (Tables)", "role": "http://prophaselabs.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Segment Information (Tables)", "role": "http://prophaselabs.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Earnings Per Share (Tables)", "role": "http://prophaselabs.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "PRPH:MarketableDebtSecuritiesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Summary of Components of Marketable Securities (Details)", "role": "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails", "shortName": "Summary of Components of Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "PRPH:MarketableDebtSecuritiesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "PRPH:TradeAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Schedule of Accounts Receivable Net (Details)", "role": "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails", "shortName": "Schedule of Accounts Receivable Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "PRPH:TradeAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "PRPH:InventoryLabMaterial", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Schedule of Components of Inventory (Details)", "role": "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails", "shortName": "Schedule of Components of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "PRPH:InventoryLabMaterial", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)", "role": "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Fair Value of Financial Instruments (Details)", "role": "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "shortName": "Schedule of Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Deferred Revenue (Details)", "role": "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails", "shortName": "Schedule of Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31_custom_ZeroToTwelveMonthsMember", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Disaggregation by Revenue (Details)", "role": "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "shortName": "Schedule of Disaggregation by Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31_custom_DiagnosticServicesMember10343312", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:UnusualRisksAndUncertaintiesTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RisksAndUncertaintiesInEntitysBusiness", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:UnusualRisksAndUncertaintiesTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RisksAndUncertaintiesInEntitysBusiness", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-08-10", "decimals": "-3", "first": true, "lang": null, "name": "PRPH:BusinessCombinationAssetsAndLiabilitiesShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details)", "role": "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "Schedule of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-08-10", "decimals": "-3", "first": true, "lang": null, "name": "PRPH:BusinessCombinationAssetsAndLiabilitiesShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-092021-08-10_custom_NebulaAcquisitionMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical)", "role": "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "shortName": "Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Schedule of Intangible Assets Acquisition (Details)", "role": "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "shortName": "Schedule of Intangible Assets Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-08-10_custom_NebulaAcquisitionMember", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Business Acquisition (Details Narrative)", "role": "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "shortName": "Business Acquisition (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-08-092021-08-10_custom_NebulaAcquisitionMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Schedule of Intangible Assets (Details)", "role": "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails", "shortName": "Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets (Details)", "role": "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails", "shortName": "Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://prophaselabs.com/role/StatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Goodwill and Acquired Intangible Assets (Details Narrative)", "role": "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsDetailsNarrative", "shortName": "Goodwill and Acquired Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - Schedule of Property, Plant and Equipment (Details)", "role": "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "shortName": "Schedule of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Property, Plant and Equipment (Details Narrative)", "role": "http://prophaselabs.com/role/PropertyPlantAndEquipmentDetailsNarrative", "shortName": "Property, Plant and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-02-28", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Unsecured Convertible Promissory Notes Payable (Details Narrative)", "role": "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative", "shortName": "Unsecured Convertible Promissory Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-02-28", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - Schedule of Stock Options Activity (Details)", "role": "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails", "shortName": "Schedule of Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - Summary of Warrant Activity (Details)", "role": "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails", "shortName": "Summary of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "role": "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-02-142021-02-14", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - Defined Contribution Plans (Details Narrative)", "role": "http://prophaselabs.com/role/DefinedContributionPlansDetailsNarrative", "shortName": "Defined Contribution Plans (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - Income Taxes (Details Narrative)", "role": "http://prophaselabs.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - Schedule of Other Current Liabilities (Details)", "role": "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails", "shortName": "Schedule of Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-03-31_us-gaap_IPOMember", "decimals": "-3", "first": true, "lang": null, "name": "PRPH:OfferingCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "role": "http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-03-31_us-gaap_IPOMember", "decimals": "-3", "first": true, "lang": null, "name": "PRPH:OfferingCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - Schedule of Estimated Future Minimum Obligations (Details)", "role": "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails", "shortName": "Schedule of Estimated Future Minimum Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - Summary of Quantitative Information About Operating Leases (Details)", "role": "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails", "shortName": "Summary of Quantitative Information About Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - Schedule of Maturity of Operating Leases (Details)", "role": "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails", "shortName": "Schedule of Maturity of Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - Leases (Details Narrative)", "role": "http://prophaselabs.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31_custom_OperatingLeaseLiabilitiesMember", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "p", "PRPH:SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SecuredDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - Consulting Agreement and Secured Promissory Note Receivable (Details Narrative)", "role": "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "shortName": "Consulting Agreement and Secured Promissory Note Receivable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "PRPH:SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SecuredDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000065 - Disclosure - Significant Customer Concentrations (Details Narrative)", "role": "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative", "shortName": "Significant Customer Concentrations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000066 - Disclosure - Schedule of Segment Information (Details)", "role": "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "shortName": "Schedule of Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000067 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)", "role": "http://prophaselabs.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails", "shortName": "Schedule of Basic and Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000068 - Disclosure - Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation (Details)", "role": "http://prophaselabs.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromIncomePerShareComputationDetails", "shortName": "Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31_custom_JasonKarkusMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesAndWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000069 - Disclosure - Related Parties (Details Narrative)", "role": "http://prophaselabs.com/role/RelatedPartiesDetailsNarrative", "shortName": "Related Parties (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31_custom_JasonKarkusMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesAndWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://prophaselabs.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-05-082022-05-09_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000070 - Disclosure - Subsequent Event (Details Narrative)", "role": "http://prophaselabs.com/role/SubsequentEventDetailsNarrative", "shortName": "Subsequent Event (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-05-082022-05-09_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Organization and Business", "role": "http://prophaselabs.com/role/OrganizationAndBusiness", "shortName": "Organization and Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "role": "http://prophaselabs.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 81, "tag": { "PRPH_AccruedInsuanceReimbursement": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued insuance reimbursement.", "label": "Accrued insurance reimbursement" } } }, "localname": "AccruedInsuanceReimbursement", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_AccruedReturn": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued return.", "label": "Accrued returns" } } }, "localname": "AccruedReturn", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_AmendedTwoThousandTenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended 2010 Plan [Member]", "label": "Amended 2010 Plan [Member]" } } }, "localname": "AmendedTwoThousandTenPlanMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_BreakageRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Breakage revenue.", "label": "Breakage revenue" } } }, "localname": "BreakageRevenue", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_BusinessCombinationAssetsAndLiabilitiesShortTermInvestments": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination assets and liabilities short term investments", "label": "Short term investments" } } }, "localname": "BusinessCombinationAssetsAndLiabilitiesShortTermInvestments", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assumed current liabilities accrued expenses and other current liabilities", "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities", "negatedLabel": "Accrued expenses and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assumed current liabilities note payable", "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable", "negatedLabel": "Note payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotePayable", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_CEOOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO Options [Member]", "label": "CEO Options [Member]" } } }, "localname": "CEOOptionsMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ChangeInFairValueOfInvestmentSecurities": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of investment securities", "label": "Change in fair value of investment securities", "negatedLabel": "Change in fair value of investment securities", "negatedTerseLabel": "Fair value of investment securities" } } }, "localname": "ChangeInFairValueOfInvestmentSecurities", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_CitiBankNAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CitiBankm, N.A. [Member]", "label": "CitiBankm, N.A. [Member]" } } }, "localname": "CitiBankNAMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_CommonStockPurchaseWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Purchase Warrants [Member]", "label": "Common Stock Purchase Warrants [Member]" } } }, "localname": "CommonStockPurchaseWarrantsMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromIncomePerShareComputationDetails" ], "xbrltype": "domainItemType" }, "PRPH_ConfuciusLabsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Confucius Labs [Member]", "label": "Confucius Labs [Member]" } } }, "localname": "ConfuciusLabsMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ConsumerProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consumer Products [Member]" } } }, "localname": "ConsumerProductsMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "PRPH_ContractManufacturingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Manufacturing [Member]", "label": "Contract Manufacturing [Member]" } } }, "localname": "ContractManufacturingMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails" ], "xbrltype": "domainItemType" }, "PRPH_ContractWithCustomerEstimatedLife": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:ContractWithCustomerEstimatedLife]" } } }, "localname": "ContractWithCustomerEstimatedLife", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "PRPH_CooperativeIncentivePromotionCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cooperative Incentive Promotion Costs [Member]", "label": "Cooperative Incentive Promotion Costs [Member]" } } }, "localname": "CooperativeIncentivePromotionCostsMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_CorporateObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate Obligations [Member]", "label": "Corporate Obligations [Member]" } } }, "localname": "CorporateObligationsMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "PRPH_DiagnosticExpenses": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Diagnostic expenses", "label": "Diagnostic expenses" } } }, "localname": "DiagnosticExpenses", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "PRPH_DiagnosticServicesClientsFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostic Services Clients Four [Member]", "label": "Diagnostic Services Clients Four [Member]" } } }, "localname": "DiagnosticServicesClientsFourMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DiagnosticServicesClientsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostic Services Clients One [Member]", "label": "Diagnostic Services Clients One [Member]" } } }, "localname": "DiagnosticServicesClientsOneMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DiagnosticServicesClientsThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostic Services Clients Three [Member]", "label": "Diagnostic Services Clients Three [Member]" } } }, "localname": "DiagnosticServicesClientsThreeMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DiagnosticServicesClientsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostic Services Clients Two [Member]", "label": "Diagnostic Services Clients Two [Member]" } } }, "localname": "DiagnosticServicesClientsTwoMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DiagnosticServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostic Services [Member]", "label": "Diagnostic Services [Member]" } } }, "localname": "DiagnosticServicesMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_DisclosureConsultingAgreementAndSecuredPromissoryNoteReceivableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreement And Secured Promissory Note Receivable" } } }, "localname": "DisclosureConsultingAgreementAndSecuredPromissoryNoteReceivableAbstract", "nsuri": "http://prophaselabs.com/20220331", "xbrltype": "stringItemType" }, "PRPH_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "terseLabel": "Schedule Of Maturity Of Operating Leases", "verboseLabel": "Summary Of Quantitative Information About Operating Leases" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://prophaselabs.com/20220331", "xbrltype": "stringItemType" }, "PRPH_EscrowMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Escrow Maturity Date.", "label": "Escrow termination date" } } }, "localname": "EscrowMaturityDate", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative" ], "xbrltype": "dateItemType" }, "PRPH_FinalMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Final Months [Member]", "label": "Final Months [Member]" } } }, "localname": "FinalMonthsMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_GenomicProductsAndServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genomic Products and Services [Member]", "label": "Genomic Products and Services [Member]" } } }, "localname": "GenomicProductsAndServicesMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails" ], "xbrltype": "domainItemType" }, "PRPH_GradualRentalIncreaseRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gradual rental rate increase percentage.", "label": "Gradual rental rate increase percentage" } } }, "localname": "GradualRentalIncreaseRate", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "PRPH_IncreaseDecreaseInAccruedDiagnosticServices": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued diagnostic services", "label": "IncreaseDecreaseInAccruedDiagnosticServices", "verboseLabel": "Accrued diagnostic services" } } }, "localname": "IncreaseDecreaseInAccruedDiagnosticServices", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in lease liabilities", "label": "IncreaseDecreaseInLeaseLiabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_IncrementalCommonSharesAttributableToCallOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to warrants.to call options", "label": "Diluted shares- Stock Options" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptions", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "PRPH_IncrementalCommonSharesAttributableToWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to warrants.", "label": "Diluted shares- Stock Warrants" } } }, "localname": "IncrementalCommonSharesAttributableToWarrants", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "PRPH_InducementOptionAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inducement Option Award [Member]", "label": "Inducement Option Award [Member]" } } }, "localname": "InducementOptionAwardMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_InterestOnUnsecuredConvertiblePromissoryNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest on unsecured convertible promissory note", "label": "Interest on unsecured convertible promissory note" } } }, "localname": "InterestOnUnsecuredConvertiblePromissoryNote", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_InventoryLabMaterial": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory lab material.", "label": "Diagnostic services testing material" } } }, "localname": "InventoryLabMaterial", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_InventoryValuationReserve": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory valuation reserve", "label": "Inventory valuation reserve" } } }, "localname": "InventoryValuationReserve", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_InvestmentSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment Shares [Member]", "label": "Investment Shares [Member]" } } }, "localname": "InvestmentSharesMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_IssuanceOfCommonSharesForDebtConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common shares for debt conversion", "label": "IssuanceOfCommonSharesForDebtConversion", "verboseLabel": "Issuance of common shares for debt conversion" } } }, "localname": "IssuanceOfCommonSharesForDebtConversion", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_IssuanceOfCommonStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common Stock and warrants", "label": "Issuance of common stock and warrants for cash from public offering, net of $2,365 offering cost" } } }, "localname": "IssuanceOfCommonStockAndWarrants", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRPH_IssuanceOfCommonStockAndWarrantsForCashFromPrivateOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and warrants for cash from private offering.", "label": "Issuance of common stock and warrants for cash from private offering" } } }, "localname": "IssuanceOfCommonStockAndWarrantsForCashFromPrivateOffering", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRPH_IssuanceOfCommonStockAndWarrantsForCashFromPrivateOfferingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and warrants for cash from private offering shares.", "label": "Issuance of common stock and warrants for cash from private offering, shares" } } }, "localname": "IssuanceOfCommonStockAndWarrantsForCashFromPrivateOfferingShares", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PRPH_IssuanceOfCommonStockAndWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common Stock and warrants shares.", "label": "Issuance of common stock and warrants for cash from public offering, shares" } } }, "localname": "IssuanceOfCommonStockAndWarrantsShares", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PRPH_IssuanceOfSecuredPromissoryNoteReceivable": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Note receivable", "label": "IssuanceOfSecuredPromissoryNoteReceivable", "negatedLabel": "Issuance of secured promissory note receivable" } } }, "localname": "IssuanceOfSecuredPromissoryNoteReceivable", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_JasonKarkusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jason Karkus [Member]", "label": "Jason Karkus [Member]" } } }, "localname": "JasonKarkusMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_LetterAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Letter Agreement [Member]", "label": "Letter Agreement [Member]" } } }, "localname": "LetterAgreementMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_MarketableDebtSecuritiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Debt Securities [Policy Text Block]", "label": "Marketable Debt Securities" } } }, "localname": "MarketableDebtSecuritiesPolicyTextBlock", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "PRPH_MrKamalObbadMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr. Kamal Obbad [Member]", "label": "Mr. Kamal Obbad [Member]" } } }, "localname": "MrKamalObbadMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_MrWhiteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mr White [Member]" } } }, "localname": "MrWhiteMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_NebulaAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nebula acquisition [Member]", "label": "Nebula Acquisition [Member]" } } }, "localname": "NebulaAcquisitionMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails" ], "xbrltype": "domainItemType" }, "PRPH_NebulaStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nebula Stock Purchase Agreement [Member]", "label": "Nebula Stock Purchase Agreement [Member]" } } }, "localname": "NebulaStockPurchaseAgreementMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_NextThreeYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Next Three Years [Member]", "label": "Next Three Years [Member]" } } }, "localname": "NextThreeYearsMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_OfferingCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering cost.", "label": "Public offering costs" } } }, "localname": "OfferingCost", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "PRPH_OldBridgeNewJerseyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Old Bridge New Jersey [Member]", "label": "Old Bridge New Jersey [Member]" } } }, "localname": "OldBridgeNewJerseyMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_OperatingAndOtherExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating and other expenses.", "label": "Operating and other expenses" } } }, "localname": "OperatingAndOtherExpenses", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_OperatingLeaseLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease Liabilities [Member]", "label": "Operating Lease Liabilities [Member]" } } }, "localname": "OperatingLeaseLiabilitiesMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_OperatingLeaseRightOfUseAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease Right Of Use Asset [Member]", "label": "Operating Lease Right Of Use Asset [Member]" } } }, "localname": "OperatingLeaseRightOfUseAssetMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_OverTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Over 24 Months [Member]", "label": "Over 24 Months [Member]" } } }, "localname": "OverTwentyFourMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "PRPH_PlazaMedicalLaboratoryCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plaza Medical Laboratory Corp [Member]", "label": "Plaza Medical Laboratory Corp [Member]" } } }, "localname": "PlazaMedicalLaboratoryCorpMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and warrants from private offering", "label": "Proceeds from issuance of common stock and warrants from private offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_ProceedsFromMaturitiesOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from maturities of marketable securities", "label": "Proceeds from sale of marketable debt securities" } } }, "localname": "ProceedsFromMaturitiesOfMarketableSecurities", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRPH_PurchasePriceOfEscrowAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Price Of Escrow Amount.", "label": "Purchase price" } } }, "localname": "PurchasePriceOfEscrowAmount", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recently Issued Accounting Standards Not Yet Adopted [Policy Text Block]", "label": "Recently Issued Accounting Standards, Not Yet Adopted" } } }, "localname": "RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "PRPH_RetailAndOthersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retail And Others [Member]" } } }, "localname": "RetailAndOthersMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails" ], "xbrltype": "domainItemType" }, "PRPH_RevenuePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of revenue from diagnostic services" } } }, "localname": "RevenuePercentage", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "PRPH_SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Promissory Note Receivable And Consulting Agreement [Text Block]", "label": "Consulting Agreement and Secured Promissory Note Receivable" } } }, "localname": "SecuredPromissoryNoteReceivableAndConsultingAgreementTextBlock", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivable" ], "xbrltype": "textBlockItemType" }, "PRPH_SeptemberTwoThousandAndTwentyNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September 2020 Notes [Member]", "label": "September 2020 Notes [Member]" } } }, "localname": "SeptemberTwoThousandAndTwentyNoteMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options outstanding granted weighted average exercise price 1.", "label": "Weighted Average Exercise Price, Warrants Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice1", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price 1.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1", "periodEndLabel": "Weighted Average Exercise Price Warrants Outstanding - Ending", "periodStartLabel": "Weighted Average Exercise Price Warrants Outstanding - Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vested and exercisable weighted average exercise price", "label": "Weighted Average Exercise Price, Warrants Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Shares Warrants Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "PRPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation Arrangement by share Based payment award options forfeited in Period intrinsic value.", "label": "Total Intrinsic Value - Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program [Member]", "label": "Share Repurchase Program [Member]" } } }, "localname": "ShareRepurchaseProgramMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options granted weighted average remaining contractual term.", "label": "Weighted Average Remaining Contractual Life Warrants granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualBeginingTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life Warrants Outstanding - Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualBeginingTerm1", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term 1.", "label": "Weighted Average Remaining Contractual Life Warrants Outstanding - Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non options vested and exercisable weighted average remaining contractual term 2.", "label": "Weighted Average Remaining Contractual Life Warrants Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm2", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "PRPH_StockHoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Holders [Member]", "label": "Stockholders [Member]" } } }, "localname": "StockHoldersMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TerminationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination Agreement [Member]", "label": "Termination Agreement [Member]" } } }, "localname": "TerminationAgreementMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TestFeesReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Test fees received.", "label": "Test fees received" } } }, "localname": "TestFeesReceived", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRPH_ThirteenToTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "13-24 Months [Member]", "label": "13-24 Months [Member]" } } }, "localname": "ThirteenToTwentyFourMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "PRPH_TradeAccountsReceivable": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Trade accounts receivable" } } }, "localname": "TradeAccountsReceivable", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "PRPH_TradeReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade Receivable [Member]", "label": "Trade Receivable [Member]" } } }, "localname": "TradeReceivableMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandAndTwentyDirectorsEquityCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Directors Equity Compensation Plan [Member]", "label": "2020 Directors Equity Compensation Plan [Member]" } } }, "localname": "TwoThousandAndTwentyDirectorsEquityCompensationPlanMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandEighteenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Eighteen Stock Incentive Plan [Member]", "label": "2018 Stock Incentive Plan [Member]" } } }, "localname": "TwoThousandEighteenStockIncentivePlanMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandEighteenStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Stock Incentive Plan [Member]", "label": "2018 Stock Incentive Plan [Member] [Default Label]", "verboseLabel": "2018 Stock Incentive Plan [Member]" } } }, "localname": "TwoThousandEighteenStockMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandTenDirectorsPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2010 Directors Plan [Member]", "label": "2010 Directors Plan [Member]" } } }, "localname": "TwoThousandTenDirectorsPlanMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_TwoThousandTenEquityCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Ten Equity Compensation Plan [Member]", "label": "Two Thousand Ten Equity Compensation Plan [Member]" } } }, "localname": "TwoThousandTenEquityCompensationPlanMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_USGovernmentObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Government Obligations [Member]", "label": "U.S. Government Obligations [Member]" } } }, "localname": "USGovernmentObligationsMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "PRPH_UnallocatedCorporateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unallocated Corporate [Member]" } } }, "localname": "UnallocatedCorporateMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "PRPH_UnrelatedThirdPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unrelated Third party [Member]", "label": "Unrelated Third party [Member]" } } }, "localname": "UnrelatedThirdPartyMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRPH_ZeroToTwelveMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0-12 Months [Member]", "label": "0-12 Months [Member]" } } }, "localname": "ZeroToTwelveMonthsMember", "nsuri": "http://prophaselabs.com/20220331", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r733" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r733" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r732" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r730", "r732", "r733" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r732" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r732" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r734" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r757" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r754" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r733" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r755" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r732" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r720" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r724" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r723" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r756" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of chief executive officer.", "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r753" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Schedule of Estimated Future Minimum Obligations" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r219", "r390", "r393", "r675" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r304", "r305", "r306", "r307", "r324", "r357", "r422", "r425", "r589", "r590", "r591", "r592", "r593", "r594", "r613", "r673", "r676", "r716", "r717" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r304", "r305", "r306", "r307", "r324", "r357", "r422", "r425", "r589", "r590", "r591", "r592", "r593", "r594", "r613", "r673", "r676", "r716", "r717" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r219", "r390", "r393", "r675" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers." } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r216", "r305", "r306", "r390", "r392", "r617", "r672", "r674" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r216", "r305", "r306", "r390", "r392", "r617", "r672", "r674" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services." } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r296", "r304", "r305", "r306", "r307", "r324", "r357", "r397", "r422", "r425", "r456", "r457", "r458", "r589", "r590", "r591", "r592", "r593", "r594", "r613", "r673", "r676", "r716", "r717" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r296", "r304", "r305", "r306", "r307", "r324", "r357", "r397", "r422", "r425", "r456", "r457", "r458", "r589", "r590", "r591", "r592", "r593", "r594", "r613", "r673", "r676", "r716", "r717" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r133", "r135", "r136", "r138", "r139", "r159", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period, Adjustment [Member]" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r135", "r136", "r137", "r138", "r139", "r140", "r159", "r241", "r242", "r486", "r525", "r526", "r527", "r528", "r552", "r566", "r567", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686" ], "lang": { "en-us": { "role": { "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r135", "r136", "r137", "r138", "r139", "r140", "r159", "r241", "r242", "r486", "r525", "r526", "r527", "r528", "r552", "r566", "r567", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686" ], "lang": { "en-us": { "role": { "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r134", "r140", "r303", "r423" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r134", "r140", "r303", "r423", "r581" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r221", "r572" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/RelatedPartiesDetailsNarrative", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/RelatedPartiesDetailsNarrative", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r46", "r578" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r30", "r222" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, before Allowance for Credit Loss", "totalLabel": "Accounts receivable, gross" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r655", "r710" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "totalLabel": "Total accounts receivable" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r222", "r223" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued benefits and vacation" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes": { "auth_ref": [ "r666" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.", "label": "Accrued commissions" } } }, "localname": "AccruedLiabilitiesForCommissionsExpenseAndTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued advertising and other allowances" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued payroll" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued diagnostic services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r16", "r290" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r33", "r64", "r65", "r66", "r660", "r682", "r686" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r73", "r74", "r539", "r540", "r541", "r542", "r543", "r544" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r63", "r66", "r73", "r74", "r75", "r125", "r126", "r127", "r516", "r567", "r677", "r678" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Estimated useful life (in years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r31", "r578" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r125", "r126", "r127", "r464", "r465", "r466", "r526" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r427", "r467", "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising and Incentive Promotions" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r471" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising and incentive promotion expenses" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r461" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r37", "r225", "r243", "r245", "r247" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedLabel": "Less allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r88", "r100", "r344", "r547" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r100", "r274", "r282" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromIncomePerShareComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromIncomePerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromIncomePerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromIncomePerShareComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r20", "r115", "r192", "r205", "r212", "r239", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r514", "r517", "r537", "r576", "r578", "r635", "r656" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r45", "r115", "r239", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r514", "r517", "r537", "r576", "r578" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r231", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r429", "r430", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingImprovementsMember": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building Improvements [Member]" } } }, "localname": "BuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r421", "r424", "r500" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r421", "r424", "r495", "r496", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business acquisition, share price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r505", "r506", "r507" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business combination consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r505", "r506" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business acquisition, purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r501", "r511" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Acquisition" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Prepaid and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "negatedLabel": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r497", "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Definite-lived intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r497", "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r497", "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net identifiable assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r498" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total consideration, net of cash acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r14", "r578", "r688", "r689" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash acquired from acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r14", "r102" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r103", "r633" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r96", "r102", "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and cash equivalents and restricted cash balance" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r96", "r102", "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, at the end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash, at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r96", "r538" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r14" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Federal depository insurance" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Uninsured" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r373", "r374", "r375", "r376" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r56", "r641", "r664" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r300", "r301", "r302", "r308", "r712" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common stock, dividends, per share, cash paid" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r125", "r126", "r526" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r29", "r370" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r29", "r578" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock authorized 50,000,000, $0.0005 par value, 15,485,900 and 15,485,900 shares outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r68", "r70", "r71", "r80", "r645", "r668" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r171", "r173", "r219", "r534", "r535", "r711" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r171", "r173", "r219", "r534", "r535", "r687", "r711" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r171", "r173", "r219", "r534", "r535", "r687", "r711" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r166", "r653" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration of Financial Risks" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Significant Customer Concentrations" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r171", "r173", "r219", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r169", "r171", "r173", "r174", "r534", "r536", "r711" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r171", "r173", "r219", "r534", "r535", "r711" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r379", "r380", "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r379", "r380", "r391" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "totalLabel": "Total" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFourthYear": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "ContractualObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "ContractualObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "ContractualObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "ContractualObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in remainder of current fiscal year.", "label": "Remaining periods in 2022" } } }, "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureMinimumObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r105", "r106", "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion amount" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r24", "r638", "r658" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r86", "r617" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of revenues", "verboseLabel": "Consolidated cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r170", "r219" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Description" } } }, "localname": "DebtConversionDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r112", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r338", "r345", "r346", "r348", "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Unsecured Convertible Promissory Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r23", "r24", "r114", "r118", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r342", "r343", "r344", "r350", "r351", "r352", "r353", "r550", "r636", "r638", "r654" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r323", "r349" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r321", "r350", "r351", "r548", "r550", "r551" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Principal amount", "verboseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r53", "r322" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r54", "r324", "r530" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r55", "r114", "r118", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r342", "r343", "r344", "r350", "r351", "r352", "r353", "r550" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r55", "r652" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt instrument periodic payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]" } } }, "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r475", "r476" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Schedule of Deferred Revenue" } } }, "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined contributions" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/DefinedContributionPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r100", "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/PropertyPlantAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r100", "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Total Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r100", "r187" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Schedule of Disaggregation by Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Special cash dividend" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r23", "r26", "r637", "r657" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividend payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r81", "r130", "r131", "r133", "r134", "r135", "r141", "r144", "r153", "r154", "r155", "r159", "r160", "r527", "r528", "r646", "r669" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r81", "r130", "r131", "r133", "r134", "r135", "r144", "r153", "r154", "r155", "r159", "r160", "r527", "r528", "r646", "r669" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r156", "r157", "r158", "r161" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r116", "r478", "r489" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective income tax rate, federal" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r478", "r489" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective income tax rate, state" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromIncomePerShareComputationDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r73", "r74", "r75", "r125", "r126", "r127", "r129", "r136", "r139", "r163", "r240", "r370", "r372", "r464", "r465", "r466", "r485", "r486", "r526", "r539", "r540", "r541", "r542", "r543", "r544", "r567", "r677", "r678", "r679" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r7", "r22", "r532" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Marketable equity securities, at fair value", "verboseLabel": "Marketable equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r336", "r350", "r351", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r417", "r529", "r586", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r336", "r398", "r400", "r405", "r417", "r529", "r586" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r336", "r350", "r351", "r398", "r400", "r405", "r417", "r529", "r587" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r336", "r350", "r351", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r417", "r529", "r588" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r336", "r350", "r351", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r417", "r586", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r531", "r533" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r234", "r235", "r236", "r237", "r238", "r244", "r248", "r249", "r250", "r251", "r254", "r255", "r256", "r257", "r347", "r368", "r523", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r735", "r736", "r737", "r738", "r743", "r744", "r745" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r18", "r281" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less: accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r283" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Remaining periods ended December 31, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r283" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r283" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r283" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r283" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r275", "r277", "r281", "r284", "r618", "r619" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r281", "r619" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Gross carying value", "verboseLabel": "Total intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r275", "r280" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r281", "r618" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfEstimatedFutureAmortizationExpenseOfAcquiredIntangibleAssetsDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfProperties": { "auth_ref": [ "r100", "r287", "r292" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of real estate or properties that were intended to be sold or held for capital appreciation or rental income. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method.", "label": "Gain (Loss) on Sale of Properties", "negatedLabel": "Gain on sale of assets" } } }, "localname": "GainLossOnSaleOfProperties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administration" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r252", "r648", "r649", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r648", "r649", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r17", "r262", "r263", "r270", "r272", "r578", "r634" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Acquired Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r271", "r278" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r85", "r115", "r192", "r204", "r208", "r211", "r214", "r239", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r537" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r78", "r192", "r204", "r208", "r211", "r214", "r632", "r643", "r649", "r670" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Total income from operations, before income taxes", "totalLabel": "Income from operations before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r115", "r128", "r192", "r204", "r208", "r211", "r214", "r239", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r513", "r528", "r537" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Total income from operations, after income taxes", "totalLabel": "Income from operations after income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r293", "r297" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r116", "r479", "r480", "r483", "r487", "r490", "r492", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r117", "r138", "r139", "r190", "r477", "r488", "r491", "r671" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 }, "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/IncomeTaxesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r72", "r473", "r474", "r480", "r481", "r482", "r484" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r99" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r99" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r99" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income tax payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r99" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred tax liability" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r99" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r99" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r99" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r99" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r99" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r149", "r150", "r155" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Unsecured convertible promissory note" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r273", "r279" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r76", "r186", "r546", "r549", "r647" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income, net" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r95", "r97", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest payment on the promissory notes" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r640", "r665" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r38" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": 4.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r44" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Inventory" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r44", "r578" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, net", "totalLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r10", "r42", "r110", "r162", "r258", "r259", "r261", "r615" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory, net" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r40" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r44", "r260" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Inventory valuation reserve" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r39" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfComponentsOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r690", "r699", "r705" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Investment owned, at fair value" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "auth_ref": [ "r691", "r695" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For investments which are quantified by principal amount, the principle balance held at close of period.", "label": "Remaining principal amount" } } }, "localname": "InvestmentOwnedBalancePrincipalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r691", "r695" ], "lang": { "en-us": { "role": { "documentation": "Balance held at close of period in number of shares.", "label": "Investment owned, balance shares", "verboseLabel": "Investment Owned, Balance, Shares" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r692", "r693", "r694", "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r704", "r706", "r707", "r708", "r709" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r692", "r693", "r694", "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r704", "r706", "r707", "r708", "r709" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value." } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r561", "r563" ], "calculation": { "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total rent expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Summary of Quantitative Information About Operating Leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Operating lease description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Maturity of Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r562" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r562" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r562" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Remaining Periods Ended December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r562" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year Ended December 31, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r562" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year Ended December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r562" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year Ended December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r562" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year Ended December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r562" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease term of contract" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r49", "r115", "r206", "r239", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r515", "r517", "r518", "r537", "r576", "r577" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r36", "r115", "r239", "r537", "r578", "r639", "r662" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r52", "r115", "r239", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r515", "r517", "r518", "r537", "r576", "r577", "r578" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r11", "r12", "r13", "r24", "r25", "r115", "r239", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r515", "r517", "r518", "r537", "r576", "r577" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r55" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Note payable" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r55", "r309" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r642" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Fair value of marketable debt securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable debt securities, available for sale", "verboseLabel": "Fair Value" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Equity Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesRealizedGainLoss": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Realized Gain (Loss)", "negatedLabel": "Realized loss on marketable debt securities" } } }, "localname": "MarketableSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Summary of Components of Marketable Securities" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r84" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Unrealized gain (loss) on marketable debt securities", "verboseLabel": "Unrealized loss on marketable debt securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss", "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r96" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r96" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r96", "r98", "r101" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash provided by (used in) operating activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r67", "r69", "r75", "r79", "r101", "r115", "r128", "r130", "r131", "r133", "r134", "r138", "r139", "r151", "r192", "r204", "r208", "r211", "r214", "r239", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r528", "r537", "r644", "r667" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/StatementsOfCashFlows", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss", "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r130", "r131", "r133", "r134", "r141", "r142", "r152", "r155", "r192", "r204", "r208", "r211", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net income - basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r143", "r145", "r146", "r147", "r148", "r152", "r155" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net income - diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Standards, Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r192", "r204", "r208", "r211", "r214" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r559", "r563" ], "calculation": { "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r555" ], "calculation": { "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "totalLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r554" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating lease liabilities", "verboseLabel": "Operating lease, liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfMaturityOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating leases" } } }, "localname": "OperatingLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfQuantitativeInformationAboutOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r554" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r554" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r556", "r560" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r553" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use asset, net", "verboseLabel": "Operating lease, right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r100" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization on right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r519" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization and Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/OrganizationAndBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r19" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r62", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Net unrealized gain (loss), investments in marketable debt securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Schedule of Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/OtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r50", "r578" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities", "totalLabel": "Total other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Current Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/OtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r93" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for repurchase of common stock", "negatedLabel": "Repurchases of common shares" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r93" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Payment of dividends" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of ordinary dividends, common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r230" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r91", "r508", "r509", "r510" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r397", "r399", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r417", "r418", "r419", "r420", "r426" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Defined Contribution Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/DefinedContributionPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r429", "r430", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r429", "r430", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r28", "r355" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r28", "r355" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r28", "r578" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseNoncurrent": { "auth_ref": [ "r19" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid expenses, net of current portion" } } }, "localname": "PrepaidExpenseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r92" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from issuance of common stock from public offering, net" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment": { "auth_ref": [ "r90" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for the sale of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Proceeds from dispositions of property and other assets" } } }, "localname": "ProceedsFromSaleOfOtherPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r295", "r713", "r714", "r715" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/PropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Description of property plant and equipment useful lives" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r15", "r289" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r291", "r578", "r651", "r663" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, net", "totalLabel": "Total property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r291", "r713", "r714" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/PropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r83", "r246" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts receivable allowances", "verboseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r224", "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Accounts Receivable, net" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r407", "r570", "r571" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r407", "r570", "r573", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r568", "r569", "r571", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/RelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r94" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayment of note payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r472", "r616", "r718" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "R&D costs incurred" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development (\u201cR&D\u201d)" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r14", "r108", "r633", "r659" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash", "verboseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r32", "r372", "r578", "r661", "r681", "r686" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r125", "r126", "r127", "r129", "r136", "r139", "r240", "r464", "r465", "r466", "r485", "r486", "r526", "r677", "r679" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r183", "r184", "r203", "r209", "r210", "r216", "r217", "r219", "r389", "r390", "r617" ], "calculation": { "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenues, net", "terseLabel": "Consolidated net revenue", "verboseLabel": "Total revenue, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r111", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r394" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r77", "r115", "r183", "r184", "r203", "r209", "r210", "r216", "r217", "r219", "r239", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r537", "r649" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RisksAndUncertaintiesInEntitysBusiness": { "auth_ref": [ "r172", "r175" ], "lang": { "en-us": { "role": { "documentation": "Description of the risk factors inherent in the entity's business, excluding risks associated with certain significant estimates or concentration risks.", "label": "Risks and Uncertainties in Entity's Business" } } }, "localname": "RisksAndUncertaintiesInEntitysBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Annual base salary" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r171", "r219" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SignificantCustomerConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts Receivable Net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromIncomePerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r495", "r496", "r500" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r413", "r414", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Fair Value of Financial Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Basic and Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r275", "r280", "r618" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r275", "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Intangible Assets Acquisition" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r41", "r42", "r43" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Components of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfDisaggregationByRevenueDetails", "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r192", "r195", "r207", "r271" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r192", "r195", "r207", "r271" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r433", "r449", "r452" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Options Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r377", "r428" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Summary of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/GoodwillAndAcquiredIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r24", "r638", "r658" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r180", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r203", "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r214", "r219", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r298", "r299", "r672" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r180", "r181", "r182", "r192", "r196", "r208", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r220" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r197", "r198", "r199", "r200", "r201", "r202", "r217" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r99" ], "calculation": { "http://prophaselabs.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Warrants granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Shares Warrants Outstanding - Ending", "periodStartLabel": "Number of Shares Warrants Outstanding - Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based compensation number of authorized shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of Shares Options Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Stock options to purchase shares", "terseLabel": "Share-based compensation arrangement", "verboseLabel": "Share-based compensation arrangement by share-based payment award, options, grants in period, gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r463" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Total Intrinsic Value - Ending", "periodStartLabel": "Total Intrinsic Value - Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares Options Outstanding - Ending", "periodStartLabel": "Number of Shares Options Outstanding - Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Options Outstanding - Ending", "periodStartLabel": "Weighted Average Exercise Price Options Outstanding - Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r462" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based pyment arrangement, plan modification, incremental cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r429", "r430", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Exercise price per share", "verboseLabel": "Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based payment arrangement, option, exercise price range, lower range limit", "verboseLabel": "Exercise price of option" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based payment arrangement, option, exercise price range, upper range limit", "verboseLabel": "Exercise price of option" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program." } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.", "label": "Share-based compensation arrangement by share-based payment award, accelerated vesting, number" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based compensation arrangement by share-based payment award, award vesting rights, percentage", "verboseLabel": "Award vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r463" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "periodEndLabel": "Total Intrinsic Value, Options Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Term, vested and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life", "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfStockOptionsActivityDetails", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r109", "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r180", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r203", "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r214", "r219", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r294", "r298", "r299", "r672" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r60", "r73", "r74", "r75", "r125", "r126", "r127", "r129", "r136", "r139", "r163", "r240", "r370", "r372", "r464", "r465", "r466", "r485", "r486", "r526", "r539", "r540", "r541", "r542", "r543", "r544", "r567", "r677", "r678", "r679" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity", "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails", "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r125", "r126", "r127", "r163", "r617" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/LeasesDetailsNarrative", "http://prophaselabs.com/role/ScheduleOfDeferredRevenueDetails", "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r59", "r339", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Issuance of common shares for debt conversion, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "auth_ref": [ "r28", "r29", "r370", "r372", "r469" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.", "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r28", "r29", "r370", "r372" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r60", "r370", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Issuance of common shares for debt conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r28", "r29", "r370", "r372" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchases of common share, shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r28", "r29", "r370", "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchases of common shares" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r29", "r34", "r35", "r115", "r226", "r239", "r537", "r578" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets", "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r113", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r372", "r378", "r524" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r545", "r580" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r545", "r580" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r545", "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r545", "r580" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r579", "r582" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Income tax payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsAcquisitionDetails", "http://prophaselabs.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r234", "r235", "r236", "r237", "r238", "r347", "r368", "r523", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r735", "r736", "r737", "r738", "r743", "r744", "r745" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfFairValueOfFinancialInstrumentsDetails", "http://prophaselabs.com/role/SummaryOfComponentsOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r58", "r373" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r58", "r373" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r58", "r373", "r376" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 17,018,846 and 16,818,846 shares, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BusinessAcquisitionDetailsNarrative", "http://prophaselabs.com/role/ConsultingAgreementAndSecuredPromissoryNoteReceivableDetailsNarrative", "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnbilledContractsReceivable": { "auth_ref": [ "r614" ], "calculation": { "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.", "label": "Unbilled accounts receivable" } } }, "localname": "UnbilledContractsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/UnsecuredConvertiblePromissoryNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UnsecuredLongTermDebt": { "auth_ref": [ "r55" ], "calculation": { "http://prophaselabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Unsecured convertible promissory notes, net" } } }, "localname": "UnsecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnusualRisksAndUncertaintiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.", "label": "Business and Liquidity Risks and Uncertainties" } } }, "localname": "UnusualRisksAndUncertaintiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r164", "r165", "r167", "r168", "r176", "r177", "r178" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r119", "r120", "r121", "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves." } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r119", "r120", "r121", "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StockholdersEquityDetailsNarrative", "http://prophaselabs.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r143", "r155" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average shares outstanding - diluted", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r141", "r155" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares outstanding - basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://prophaselabs.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://prophaselabs.com/role/StatementsOfOperationsAndOtherComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6003-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=SL51803626-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r378": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r394": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r426": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r494": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498" }, "r511": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r519": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r564": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r575": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r582": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r719": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r720": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r721": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r722": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r723": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r724": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r725": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r726": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r727": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r728": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r729": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r730": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r731": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r732": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r733": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r734": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r735": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r736": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r737": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r738": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r739": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r740": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)" }, "r741": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(i)" }, "r742": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(ii)" }, "r743": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r744": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r745": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r746": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1402", "Subsection": "Instruction 5" }, "r747": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(1)" }, "r748": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(2)" }, "r749": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(3)" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r750": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(4)" }, "r751": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(5)" }, "r752": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1406" }, "r753": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r754": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r755": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r756": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r757": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" } }, "version": "2.1" } ZIP 88 0001493152-22-013346-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-013346-xbrl.zip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a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�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

JRV@+A%S68Q&!;)?A&8L X,5 M:F"2HC-]$LH8H M5A]I%%!?8[\[JS=)=)+'T2.^QB__3M;J6)X=SB#KKNB> 6Y7>$\AZ)T>-NB$ M GQ)A+@\(@J(:^Q[MKF(TR QE6J5"#GC@A)@2P)! L;75\&2I",E3@:TJHLG M 0$9XOLGC,LK^@1#^2&EN-,T. ;0@R0X"EGOY+$$*"3 X>*(R:-&8<_3R@;3 M:B/IXQ4F2_&K.%C2W/^QKBJ:4<7=)&,'OIMK]/+>>3,!I##S-%J(J:&>WM[+ M \ W]&3IYO5EX)G=+:ED4+-$Y6T1BCH)-6!2"D=4!.MF"ZZ6:$O19OQ#\I\ MQ]*CXN@VR,NWASQ(BR!D9^$G;_U?-#/@E 9O/DO;:WLDZ&[)8792) M(2:WWPGT2YKSA]%2[1R8>LS3"#L;Z8R V_%-*>F=*%;PQ&ODM3QB"F@3[#]- MMR&\]PX7)4&DR)HCE7 5QJN UH3NCG[VS@@U)G%L>(X+ZE=G*W2;QUF.;C'Y M3[37+!03>!#]=U64RLP#1FD?_%! EG%E) J.-W)\MAPZ0ET#\NL)A(Y MI_D(;#*:"$+>&61")B9/>:830R#;,UOF_&2HL]1:V&VR(U1NC#*C5*<>_4LL&AJH0B&B%/0BD>I M3)?7Q!YHHUH=SO!W'R2X()X?3BM\K=C9-,@Z=:=T< LAFS94_+ M_VPIF&">+5L5[XR:AG/*;$FS[7AC%;VS-H=7?3T S!+-L.!6IP2=70+22?QB M]Q+WO9E.RX;?X1#'S\$RT5!*(>AN"UT'M-L]ETG!8(D.FKR8>R?L;9RY(/;/ M&&;Z:OY'&=$(\R#3Z9ERM*B(N[^;9Y%5:@HB:N5='DO40.U M?S51(N:="F9LDL4_$T:-]+YGL"]ID#!Y'-'+L/1BK,:9T4D[C%DT0>X%+:I$ M87##B$\,6VP54*L!9R9:I&49"G9,WH,L0N,\G.LTWN/]7-\A>N+_'>>]:[FP4,BOV%%"G ML>_I?+W.>'*WV[H829TD0SNS&Y4<3O*6!O3F>X.&=PY.@BFI'$STZD1\C29J M5/?M$OQ[4&3I7X/\:Z7ACT3(&5^4 %M^"!(P^*""-?[^3 YQ03B3^WVU+/#/ M%5F?G#^3_S$<*BJEG2XM]9 'BTJYJ'?BV.$3%I*M-&+BH(X01Z;H8Z?DLAY) MI(F=D@E")9 ^+'U,GSU/.9_SGYYBW<)S).!LJI$":Z>9P:_>/[02TOCK?LX1 M$]K/U%+@\/O'[/F'",=\,"!_Z,8 \A?B%CWC?+&DP9UA.3)"\KN+CZV$1;^U M\*/W3ZU")#J2SRS3C\2"X<^N/K,,5/.5^[^!^,@20,(Y M12W"IGC''Y@5:J(/OTB"1PG\T>^N/K$45O.-!S^"^,@R1-*26.PS4R%?G_D, M%V$>LURL.CL&8LX_N@2D\.U[,K H( )3,Z$GZVE@O\./]1T-NLU1GW=IAC&% MO.NA7PM[/!=(A4&0Q@:A*( IUZ2M/)^F7+_A).$'O8%J7E D0F[ M9HL:\)@OHB0HQBCA*3G#-%"M HOGQS2I"6U\%:-D+(Q=PR0 YRR(*A#" F M2($IV-#)(BKLA1&GF.:'2"[3"+_^%;\I[1+DW')" 7-(BI$0(%;(D2EH40LC M)HV(N!=BW.;Q.LC?[N/0,%6(@FZIH0(ZY,98"A Y%- 4[*BET?WEJ<^9Y"%X MO8P(4>-5S/.,&EBBE'=+%@/L(6<4PH"HHT>H8!!10D,MGT2BB6OYQ<$P*RFA2*M8 HBUX8=PB MBLB+*NK_7,4I?J^T7RKKEET:N$-.200!,4F-3L&?6O*H^0.B.C0W(Q#2?)A@ MZ@?_I/E@2YH/H$GS80YI'EXR(*3Y.,'4C_Y)\]&6-!]!D^;C+-+0O&,^:7-* M_GB3/V0OLN!LI:07RHA0I83IQ.#11XT?,ZUG"GW-A)&C$_H\P0I'R(X3+P2#($ M9AQD@!2TDRD(1'%1D\$V&X#B)*/A;6-5WI M@8;T*MGH=W=7@"6PNBO O1]!D$"&2+P"S'=/N)#KSTPYFN- ,2(,?W;VD26@ MVF_<^PW&)Q8!"5^8]6LBXZ,CTZIAR>U3EJH#!$015U]:!:[YVN/?07QQ!:CQ M5V=BB,EYVHU_+7%:R(?OWF_.9O8QG'8B;WX \77':(1INOG=\=?\*8]+\F2: M>:Q*ZU,>6=R@0L[55];";+ZX5 C$U]TN,^2.(S+.'W\3!:? M>1S(K)()N2*$&F##!E$"!!64L(1<3*T@:B0=D^ VQY2$F'P(=@D0IQ'.;U8K MZ6RO$W9%"C/@AAQJ21 D,<(;DX4H'(<]#<15$-/Q2YO+HJAP/HD\$A5/%%*" M5Q!)D(=()Q5((ZFXHD]NU;EUW]Y_6#[$92);7(HBSN8D!;AV1AK]#H(;"E!" MA17Z&\I6Z/V'WRQ_V^0X=KWO>)W12B]D2KQ_6R^S1)%]2BKEB@0:B T/)"(@ MJ*#&-6;#=89J4<1E?62G&H"5F#/ZW14!I+":3S_X$<1'ER&2E5?JOK6G(?_\ M-7PBH+#B0H)JA1JU>B?,"Y/^EB556@8YNTN>RT8FA9Q;YBA@#ADS$@+$ M%#DR!4-:8<2E_5S0YMDC6B>+#GC2%#!Z<VI;* .*,%J+K#7>?\ MZ'QCKN7IBF6):;V(^!F?!6508U/:JQ)W?:E2!WI\FU(F"XA"6H#*^Y.M#DT5 M$S2<\I8R)C\EKM9CIHD2'TFY3QPC0!1SQ[0B@.@APZ7)().C1M8+%^[709(T M5;"5-HVDW')!"G'(A8$(("[(<"FXP$11(^N%"^=KG#^2Z>U3GKV43W5^5J5M M"FFWW-!"'G)$*@J(*SI\"LXT*HCK-"EU_9#GM4LHSK,LJBV5B#JFC1+LB#." M'"3"J, );$EP2/=;KK,2/63H2X%1^801"V>-R+_W,L'S=GQ5&@E#>B&">^5I M%.0R"NF$G5<=40(6:H\(DB"(9(2GKD/2:J!&Q3%K;@B'\_XZCH&X+/%:>=O! MK.**0;;@&QZ9Y$&PR1+DF%-,;;BX9HJ(:OK,9M1/;J]V\09"CCUC"<"18]R3 M ,$1)2R56]RO%> G=UZU3.+P(LD"]2[+0,9QQCP1WBA97B< B $B*E6*/":( MF*27[W\2I%_S:E.&;[=Y%F),HZR*=K0R[;]9:KOES"23AFRR4@7$LREX%0SL MFD"]-HYZ,Y;/S3P:-$ZSN67AU_NG@+S FZHLZ Q*@*EWP;5*CH\7+ P8'3)H M- !1SP*FZL"!:2*F>H2X,NII>UJ?%5T60!R=O-WA%<[IO8,'_%J>D =]U:PP M+'1=K]ZLS1DOYHR*($@X%:UJJ5>@?@-H26/$ZB;0/V@CB+6RV_KEJZ!8,CNK MXO@Q"#:LX *P0L-JHTU+6+(&JTT3\:??^\7!0%+@L# \="+KDF!]AGU5 "#'^DL(1H ML_O[\X=[("RH/44K,@BR[CFA@"M28R0(C"%R=*K2+@'3\4Z8TZ!X6J01_<_Y MSU7\'"1T,EZ4IT&>OQ$G\&]!4HVO54S4=4FH2>;T"6:E"(9P4] *!"1*B'CX M**1_P)VZ=R[>8=)S8GJ(1#$J3!\+N627'&"?1D,),'R1PAH3HQ-BU/!.A\]! M_A67P3+!];V1&!?RC3 K#9=$L8#>9XU&' R%S!C'?.HT4(27)2I:O2,4/ =Q MPGY:93DJR #DG6YT("W?.N,NGJ]CQ;N0B[HDF YLGUDR.3"4TH#3< DSK2&; M2K0*XAP]TVG/.Y'J0^OB#H>8S*T$\S4N]0.77L6I1VX!?N"8:^3!$,T"I+"> MJU50WNH"TP&0AP((;!JM0A:U6FBX9,\&4/I$LU,#PRQZK).T2U428 MJQ9LV9:Q0)80UC:"#?<\LLS()W_,*;,R2*YL-Y=4Z1AH(] X<9MG&YR7;[<$ M:DEH3]V]#=U,5\]<>A6WXY(9_'! 4LL#&HF,(,4AB*LK+K9 'Q2@O0-*TQ&M$3MF8 8Q$O.\X(,H=9-X3Z 8V] MN<)!@>_BQZ?R9O6%S.%T@%6\"X..2XY9P>\33:L AFTV*(6]32IUG*V.JP+S M^1'&V'69E@1F3%:7?)HG _'Y:YA4-/[F4Y9%+W&B7K;8J+I=_=D;,UP5FO7 ML&\"6'$5V:C6+AH,#AIXYH=+.KZ XX3ANS<_>__2O86GT4U2R#J=OW1P!_.6 M3! ,.W3HY+=4@"S@.&;MLM3',EZ]?H>X<%>MV&\>%E<(2-3051PLXX0=II!5 M(0L(?LJ2".<%/Z(Q!!+9J[LDRU2C^G2RU04SQDP$+)02NER<7%Y=/ER>WZ/% M]1FZ?[@Y_>M?;J[.SN_N?_VK/WYX_R]_1N?_\>7RX>^0N&H7YJ93\,1'BX W MM31$SDT+?4LZ1>]T:L[Y;H,W>L9G=TP[%O9Q0"L'+#N:'4J"H8\6GO(X=L.E M(? FKW!TFV/:5:4 M<8@*G#_'(8PABF+C(3#T.B'!9T]AYK@&&=%4S!LZ>RH#RN M,WJO+\?1'7[&:67PN%3"+@FE!]PGDEP2#(&T\(2+F;4PRKFT=]X\!*_8SDV7 M2KIDC 9JGRX2,3!<46,33S7";(U1&;R"<<[9+JJX/-7MS\JDG>]UJR$+N]VB M*!CJZ/')=[R;DW]($Y4U@7QSQXXVGAECW"ZW9LPPV TH8[J3'OOM29F.)QZI MX2LH)2J &8]L4(IE#=-C"WEP_ M7%Y_.K\^O3SW'V0\.:P82B#QM-#A P@6GAP>W%=HPH%Y&A[OK+K-ZWT)AE&7 MK5 JZ?C*KPKJZ+;O6 P,<]38)'=\Z_VB@HJBH"J?LCS^A?S#^Z-W[]ZQ_X_^ MU[OOR7]_CS9!G;R)^-D9*G@J\IA65HYXE-2>LI+/G27KA.O:Y)B"F.OY4 9R M/ GV9<"P3 %,F.YX_GJ!7[]_IR78^]\?_>Z/OS_Z\=T[1JW>7VO>]LB#T$^Y*!A:ZO$) M 9^M-*+)#H[C%(5F8VB MVWRLMH8,<[2:M,!0SAJJF,N5*R)<:WHGW4..@Z+*WXP3ITS0:?">$N@@=D^0 MC=^__>/3'W_V!SY1_ M./IC_5<^4T*;';O.P8+*:#FW'#_AM"#X^&'G55;0(\Z;U4/PJAKEI[;B^#;% M'!-'%RRF- %F*)R'6W(-HVFE2:37;P][9\1N1P365JT2 MGWS'MH"[&6*Z!6[>JU:H0;JW;S@&D.K (IPE6GG*B .ZJC_<+>(%YA;M.MUJ MBTE4\K=CIS) O7DWU@ SF5K!-&SI'37[)=W6"S#&W0;Y3$7,_[W%.3/5 MZJ6HE?TQT&20FHDJ3:",-, U,K/=[@/&2-[3+MG&]H2NV2CX'ON&P$WC'I<& MRC )1-OQCI]+@&26NBJOM99OCBGJ\EJJ@&:;N3*OBG) S[\L73JMAJ=3,1MG M3B,.AF=FC+IC,X@^7,^BB0ZA+4$Y/(=S;=WLZ)I]=D! M2IVH\3Y+U"M0M8);]\P$?.B["4BWAG07A*MZU<5!N]*(^_EZJX* MMO3*[E@8S$AB0BCD#6ODVS)B6R?GV>2;)T:/=Q\_OF<4N;V[_/_T>EQ" I(N-7/SQ;T/'9]P2EB8D*EO$:WC-*:,I=&0 MM2FJ\=&DY722L3-A,/'H5;SS:AI.86[B6BSD->CI ;CL?X<+3-[E$['HC/A/ M2<:J<.K)9M!QNR*S@#]<>VD4P-#,!J6XGN(ZC&51I^6=8L(T;#M=>W9^K)P> M6&ZR"IX\[#03_!TX7.G"KTVF]B6]\$6$*F5,)P:4,P) Q2[D;VA$^V\1?1L- MA;+4/W4NTQ*3%U1RE"R@7[GW*I%T7-54!754Q'0L!F:&4F.3E"AEDBAFHC"V M^QI0>D='D/)!$HTS,Q*!=EU,#D_)CWH2VM.2^_2)/!1?IA=!G+-8@IO59?I, MGDM]I'N:)$Z6K&B:JK/%^41CVA6[I9[W468&6&%7F&F300>MB#X/!*&[Q''; M!"K:-@",1\W>AH-1GTCP\_1; MGAQT499YO*Q*FO[X(=OQ@#_O8;#&^FU>V+1A?LZ3#FV$W\)&R\$]6!$M6&/[ M-2Z-NT\C&9=]0 JO3]V! "S&R: )&=YQLU7@G0FZK!"+YR!.:#^XR/+[(,'= M@F01_7?%5QC<0;K#81(41;R*0T;Z[O%RGR\9J$$FDL0WA?9 MOBU7E&T3DJ?XKY#$J_+2U]#9_R7-<9#0ZTV?@CC53!6VRBY[W#2#^MW$3A,, MMR?!%8M'-(+HD4@V!Q]9BM9MLRC"2U [29*.;$A/I=5P?-/(!'UTT4@E#LOK M,0-5U",<#(5 ?*(F;V!S%>\D*.+0X+\8=%QRS I^GV5:!3#CG W*,?"(KZOU$N81;>8[.L)>B&& %1*CE8* M'D'&T#0DH:*(R6J9LM?7/C-U^0>G+WZ#\SB+R)O+2]U@KL$IN!CX,4[I@A M M _)#B(^ Y-VR]2L\>PY6OH'?V=^6-)9SO(0Q0+(B,=KS'*YG54XC7YCE+/[X ME)40+^(LO5F==N7$E<'C.VK3>?F%;!L63XLVIQ5T2VP2Z3UF5++3(< -.X:X0^0E%C8YW&C&X=WA#7LQ3 M4$BF'%U/U.LY'S%MS! &19T2-*K9 A;3-30JA3#(@6:@-K.LC2(4#JKSSIJU M#HF%VN2T&AK:3*N''*/H=MO%8O]\(FY-N"(-5 0>I]B+#W[(%'60&7.7E,\T MA ZG!8LLOJ.E\8JXQ'5N2,[R.QQFCREK13='[O^Q;DMANWF)PYK:^WTFF(6- M(T/%/6TRE!^S-ED$:-.HIV%XXG4CMX.J[O/)<>WOMI$B[T2SDJ7KWW8MLDBC MGX(\#PBU1N@M=9QEFK"%WZ:8,"EXY\<4E#;;$E23Y5Q[J779%D5(EY3LLN.F M6B9Q2#16F/ID+/\-U?]?'XX^_N'W[;^S MF>."AUZ2=I@N&CZ-1/4#L,;FK] M^9TP=#>KT)EDO,ARNA]#KR3?YO$S6?G .MG#N*F!@^]!^Q^X!_U \\[/K,#:#YZB(4X3\T; M M P]C>AW_9L5X=O(F"C=BVNC5G3["Z;[^'E[.@.([;-_[M+-'HX3-JU8+D9F& MZR'^%-3H'R'Z(#I/L4>AY1N2JC7R< * 6Y2]-W5E"@8V*/GI-3H#Y/U I@&0 MV1J8:JZ.&6D;3+S%VJ#QZ6CQ*IF7./S=F<\N@]7ZW_T?O7]Z%2*A_OEPLMTP?S^/\A8EL..7 MI8P,V-%SP/2O/1HW[H&]1Z$R0WGS,'9RR$)[R+_2/[.=O$W]/+J.^DU%HP;B M]+?27NL_6X$LPNEN?AH]4=5W$CV5,:;PM+$>M/C""9C%",/#"4H[PQO2VV(6 M;T/^G&"6R3*-%FN:__@7]N^*-V2GZC2P?X(Q@R!_"STPP_($L$*B@9XJ+\W8 MT_%.Q;X!-ZLSTE'.XB+,JK2\S?$ZKM:J>-ROBS2R* I=]Z/KR6=.;\5*_;Z*1TN)^ MEFV X>U,X'H:IRBG#1UGJV/BAZ* MN5_3F_ QSGY^%^K!+^;']'WHM_2++S[)J6:ZJ M9!$RQTXUX^A57 X1-N#[ X5.'LQP80%2<&SJG^GF&XZ?V69%D"39"PT1VEMD M-.%S2H3?:">I+Q(5.'\>^]BF2M([2:S@B<6L:GDV&/'I).<: MWL>?RS3,J5-_AOE_>SO0]:4UPX''E 8<%W^;:-BHH)NEMG=*SH8LGS@+.G/V MS@.8]\PVO)(X6,8)D+,!T=IF$+YKQV#K%R53]_66@4''+_,D\/64ZRG YYH(5CE9 Z36;8XW01R=X17.*,^!STO#L.\(F^D\X@G M>SOZQF!XGS8&V_FCNI8 KZ FP%$IZ@ZWCR8;U=M0LM:%DN9K)FX)#1GCHE8!%;4&P)&V<6SN,''" ME5FY+/3\CI\*,_1#Y4@)"@^G A;CIK@46;0S,<"LX[&Y#\'KA.EL3R+1]((ZC]E4C%*YG2 ,S+ MKC)JVFL[Y6:9E4&B&SLGXY;E>IUX90XJAWG\W XN<&L; L!I"T,MN*UI!!4M(&I%@/XFHW^=W#GZLXQ[)[KHK^:JGK-'IWBCF# M,%X;12A$G0-:S K$BYY0GO;N(^\NC%PQ0)+N%&(<%32[Y^>@K!]VL[+@W0Q] M9\/D'+/:D7**LO?9>BYB,7B#-\&GZ.9F$^"K\7V;^;TMMN"K+V^]W1+KRD4: MT=Q]&]HM59UVK6X$4M M"=,),22JJ,>,M?%*%GI>?0"5&=KY?ZP$?NY7 !;71BQNGH=K1#$9N@$,K?8K MOZV7CE#7]-NMY0]BGTJ->^(^U3[6\_OB\$6=Z[OT(B9]!]6FME' MH:6MA_,[O*E7#CT=NKVF_@X4R/4YM9C^?WHJ\1PDF&6=*,H\#DG?I3\0AW?X#SU)7I==#'P, MDXJ6A#M_#5D"E3LR#IP3#U:Y9^4:A,N^Y.<%]_NC6P2P^K07VR4AYTR3YA&B MX\,1'R5P]R2V],M;'.SWPQX:VK=TQ@XP@^13GE4;HL'R.Z=EG%8XJD-/LU0U M0;J%<###PLR7N[-!8>+S/10WO2^#O-S;P##/?MG^O=U0<(2"$I5/&"WQ8YRF MU(4@CC#]!VZMIV*W_Z,X#+!$KQ?[=\!B3$-7;/GKJ#+I9I.P4G1!TE2ONTQ7 M6;YFUILJ"]IJNZU5.LFD8=%2*U7O._;S\(IE3#MM5D(BR0H:U@(BHV-WIS&. MR/)2\0)D@HYO^BF CJ[TC:3 ,$@)37KFSK*&$7H1?[ZY2PI@)7^9EIB.N":J MC*3<\D0*<4B2@0@@ALAPB2L]+H7:TY:43W/#*QS^R4+3D!$J=S%5:=3N<[&Z MS:8H(WM]IQN74\T:[%O:*H,AY53$EE,?/R-,CYE3UXN6(VZ;; ]SZXG2>!FN M/EMB)T4T!SU>EJ<9P9478L&0::H>+L)9&2.Y!J?5@Y*G809FW16XP1DAFW+9 MM8ZP;]E+*(H\+N@*K M:&P'WVTD<\O-BC@BBAZ_O\!F03V;*#LD*MJFT:/M+;4 M;VAITM\>]0K*L)SY@&]CW>2/05H77B,C4I$E<134I2]O:24*,B7RFH3UA!HD M;;5ZDV^TH[:==LA=OHY![]M%PW"ZV@ZM$=*_]-H^0H/6F>?5;Y].C>T34/<( M](_F(?]UV#WLK/5%'_!K>9*HH\!V_YB#Z7>:E[2S+BAYQK?1&]6&Z3HFZXDG M%9DR<>%_$JL3*M.9F]@>FN\&Z12<%C4V A]4,U9*@Z&B$:(B%S9=2#<:D ;O M^_@QC5=Q2&\L"Z:9AF1;9:>G(9,,&AR&6&F"8>(DN.)^T)KX[&_4O>BU@R1D M]<[09A F"Y\E&=V;JO6L_#*]T+;US\5.612]Q MDI"^=TD>8-Z@7/Z4!,#R=@UHH)U^WP<;3 MKA4^M!:H:P?2T&IEN&F(G=H(.$)KA]QI+1P6I4U#\(#3=4H<";F]TUB93,HP M$EOH.4Z?8&?&*&V"7@D,)6V12NZ),[TCQ#09&5M=2*.ITD#[L71:$R#(:3F. M3M&'3UG[,53+7N^4I;$'UHZK2M@E#?6 ^X232X*AEA:>6))H60)U(8=VF,8W MI;0_#FE'+84H4!:9QJ(O:9,]F\<;E0^C0HZP2E>Q;"BD6YI9"2SC>?DS@BP%G$#>,+B M=79S3A>R6QH]6-3.; L,Q;UGF\;)B1XETW>M_C["]S&8]%&LU MO%PDM!MJ->)@>&?&J*A0252 +H0E)ID&3+V*9XII!SZ=/&22F0:PCF4 HGG8 MD-PKD6D]5->YI !S>U@<90=!M-&&34!XR; MU0Z CL:P;L;'NCIOGY?>&4@O3<;\%A7Q5D]9+I9'G(93QL6);3A>7D\W;[3 MMF\ #%/GH!:R3W1ML-.U02M QU,KNTU#Z]1&P/%9.^!.:^&P&&T:AK64WE-B M@0[=%4W+J+HU8Y!UECK !+?-%: 2],X8&W1C8G A[\/7%2X*C-L:Z1R5:;@R M*;D@THF28FH=T/N8S#"[V56"4L,\MCCME.(QDI#96A[4:C+9OV M,'CMY&5(QKJMVH4V-.["&'&*;=I$;:.(M(KJ9L=A$>AN9P7&%3W$9 _S)L;O M037H[J1%9_UA-Z:WW6"[YF"P?R;^_<.P]R6JN!UI%A*3!-\=U*<:>1W@;0@YAOA2P8/AD "G'@M3@B\H@I M0!K*QL:8!C"-O$]":0/UND^U6+NRWWHP<]K.\CEP7#*0- ,6U= M(XZX/*31;FR+<=FIEO?))_T24R4,EE'F3(A#2GFGT4E0Q,7-:I33\8W_KS$U MG*6RT]1PDPP:I(:ST@1#O4EPA=1P5)GFX^PG-/9.QO$VS10N6NKZW%BS9J*5 M(A@B3D&KV%[S[YQ]2:NB"A+I89R)>I:Z+JDWR9P^]:P4P5!O"EIE=DQZC'H5 M_US%$4W6H#A:]4_0 M^LSHLR7I-%C:JN]5C(*>6D ?<&DC (9$,EI#XI6"% MHUHQ[WRHZ_".2\M;S966NJ[KEEN;,R[6;%0$P[4I:*4U0EDL._U#3QTH%X6: MT5*K)[THVR;],W>:\69"V[4'G.>3C!"W\]JJWU1M3R&DG]O:8C0Q6%?03#^P M3E-U%A0ZT9@V^M-2SSO;9H =LZK31BQ%X#V<6G(=M+%1BDZG4W Y(IJ!]\<[ MM;1W?EE#U+"JS@$'B%==1+*ENZA3<'L*9@(^//1228/AE1&BHKQ3T8LJ/T(I M]K^-3$M%IZ19R\TZM;C;E"UZT,-T+7)9:-?6##C%;"VU. P:*;-%V]'*7AU$ MWF\+VMGJ0J/A1-R'E?);")0_S7$4E_1/JN603L/K1081NO;^0B<.9A(U8Y3< MX>HTAC5OV>ZO=X+QN\?\,K'=R*?5<'\M7 M=O!,N%8N M*0T *4UD03U[;3!#W63(TTIL>6?J11#G?PN2"O=**U^F19E7:^.&L:6N2WY. M,J=/32M%,*R<@G9,2*J+F/)P'N[I>V?E'29KI I?D&_+LO(&8?E37#XU]QQM M]U"F->)V7V6.@<.]EBDM@&'N+-CBN01KA&[)9(\IC"*;BXC5)BGB]/$T*VSG M>:.6TUKN=B8,"KKK5<#0S@ZGL/?7:=73-UW$Q,^\_$P&XY)U/^%_'7\_@8#6 MVK[*-EB8I"K9H%$%0\QI>*5518Y/R)J'IMOK6O).RCM<8/)&Z8'S&1FLDXQM M(YV_4H18ZU1::;J=JJU-&<[/1C4P)+3'*HD08)IL>.SIHM_0(CO/G,_:W]W_^K7=BMNG5;4]-5.)>$MU;G9K(9:'M[1AP@LYQ?XU?>G< \BPE M?PQQ;^EE1Z[IS;@DW5PC^V211<8064;8A\_Z>PJL:#!Q"AZ %<)V5?\=E#<(BZ&K+!IV%8NW$\#9 :ZO6 MO/-Z9R;,8SAI&)&6=\7TO<1YF49K@X[O:"_M.*Q5\$[.*2C%VYWK=9"_T:U, MN@#*4G9IF/RM%P\&*!#L/GS"497@]A)AP:K77F5!2F_3U+NQZ6,7;&2\A+=- MBTZOYFUO^N#"WOSFP!!^>QN$[E"W2'N )'(-70.(..JL;D.AZMHM#],(;U+W MPVX[H^14UNL"Y*T58!U)AX-VVQP@DI[AG'0>NNO;.R&[3(EW4[(%0>\([C8K MV&%$>SQGS^4=/<4/Y7?ZBN0]8R>/ -B!=FF7KI\=PJGO&5YA,HI$]?'>R=LB MSXD]H^K%ICXUN167?6:FB?T^,;$),)R?AUO'Z:9%5#?IG\!Q$3P^YOB1'<+< MK&I<5FZ-I:Y3LDXQ9T!1&T4XQ)R 5DO'03MH^0:&E]UT4T=,_(*CRX@>9:]B M'/%(M$7XAVN2< MURK WK&E*9,Z"Y@.DND&A8NJI!6#US29VR_,>ZQC;R;-#;MYA(].L\N7(^L^ MNV@?7$?:H5&Z+M6DWXH0;Q/U&T5UJ_RXH?;&X'5"Y=78V;>;H=UKGG>C&1ZY MK:'J* O[*G,W$;(2$BQXMQ^[RV)Z;S:\2$!8QL]Q^39QC3"_83\NT[8O0NXR MS6T53&?8F2FZSL(:074KJ&D&4B^A )^R),)YP3/[T$/RGP*Z>UP6-_E=_/AD MD8M]?GN>^L0\LQ5=85IC$'O + LTT4*U*AS&WY1/.*^/T7N;659#OZ6N2R9/ M,J?/6BM%, R=@E8W#+-V4-U0?S-S/[PL\K+'2?*WCH_D+_]LKF9607*S3&)^ MHG$1%V&0_!T'^>>@I %U;XT!6H[NH#T7O-V9V93+6S?FG=^[LF#2TO(S6="N MJS7JGN9_[<@RBM K>58#L5+:;4(8+>1A,ABIJ'?ZV>'33.__49')/2Y99$V_ MDBA:++.J)/XNIKF(TD<$)&,,3W73PF*HFEG@K>EIEA2-(O,GH!&\Y\J/BI?T>N?)6_WCA.7;FF*Q8RDUI"@SA MM\.OW;\ 6"VZLW9<8I86@0KI->LXJ!O@?">S<=5F[X"TZBAZQQ(!=)DKT$A, 76WPC_O'J(S'$:(-'I?9<=/D$6H;1<1-0[Q9/G/]@[7LO[JO M^$K*;*U])5=QBB]+O%:5AMNJ1;\=8[+I^LYAW1S@#C+5AMUV$MHZ8LW[[RF+ MYR!.:*QP3: MVS5\*'UADC5"B=-6&E%Q_[NT1 ME-YK) #VT%-D1FEZ"A77'VCLD1&R'$5UU(;L.VO$__D!6DI&&[#J;/)[2E_W MD <1;E+9=)EL1B;H19VEG#. ;9/)*>2\SWD6X,8$8-(H:'(-Y:V\][GL2[J, MDX1ZJ3R,1*PVGA=W-T =5WM7BWBEECU$<\KD&2'*)_8--:JJ9427MU)G1 M0QZX)W)1IV0JLS)(M.Z&%N283;_^U?L_O/OS0J32$7JD:OX9U=M5.LNJ9;FJ M$N.\-U79*=\F&32@GY4F./=W"FJQ<%E1H*!I 0 ;!>#7N+3NB$S6[]C6@ZL? MV8@@]'&M@RAX7[2Q?4R0"F^\3=!'#/A,.D0>!U(?4B[GS _7P6R=<)F0=W?) MA$PX58B#QS0KRCA$!^Z"E\8>E:NDD/52I%H& M5UJANB_HG4(VZ(0TWL%+2Q?_DT^+_*&/24!D4IVC#I>#0AB9&*)YP1&MO&FDS$O9"&RE@*6T&DO!H(X,G;!G6 M,NB1"L%AC6X!/Q;RPA+E M6*($+F6,( UM56U$JN02>FXTR+J(J7@Z,VH1*=:D_=\=GPK9=]\^-N4K/T(I MJ (#9W@5IS@ZP2GY0TFSP11=JF%M0.O$-GSE7;#N65,0;52M=Q#G1[7M!76&] M0<=M 7$+^,.RX1H%,/W>!N689HT.>B%*J-$Z:E,,^5]R=X[=;9Y%55CVKG+; MN>A*/3]NN<$,N2NN4 +#/5NDAL2<5'.0CP6*DRU:97*MM1J.L\*:H(_2P:K$ MP;#-C'',,RFW+-WD/7Z;N@0,OX(LCM[\TG"3_(D6\^(QFX+E'VQ@A M#WS(>8L[V792EL]FC[C%.2UT'#Q*(X\E0@[+7"L ]DI7CR2\=W,M+*%GMP)T M#JD_.;]E'XG1#]XGDKNX^$JKMWXAGRTO@SBE#OUE>D[3D;T5)U5!QB3E.9.M MLLOI99I!@U'+2M,[&V?!%2(HJ#++S3)0I^?CO('_MT!-$Y[FHFMEI'*"A1HVB^?;57][8H\S@L<40QRCW7O@1$IU2* M3QC>6S%$Y;SW<'KD6I2L0O +/64($AHWSM(,Z2(5U"JN8Q5,X,<'Y"IY,#W; M J3LW)RKH(SJ'*$EUT(%4X/&LD79UIZV>PD#!8\,DP#7\*LG#95=(D0SM\B< ML6I/@QS/%VS!=_I$ZSU?=@7,;U8=2OEQW!2]?W[T$;OT@'/Y!#,+NO[X+NZ^ M*:"S(F7-IC:_.W&Z5U5""Y5I]E*GM &BYI;./*OR6[(&P PXL MM!"E[Z9N$FW:LERX:155K#64T.:\4YJZ>"-/?>@GDA>I,;SWZ)-UZNO MKIG2<*1H ML:;7#S5O32+KFL]*N&.>"H*@^*=")S@..,)YD* (;[(B9N'0,54#0Y\O:6Q) M'D'2-7444,?$&8F!HHT(5SPC,Y$912CJ.491!'\^,T..2Q!@S M*72W&U(H^KSTI+]90ES%*^DH8*'D;%RP-J#;KS!I>&?*))ACXOPC9,)_,NK[ M#^I:1,]DP1D7G%PR).%W.G9&Q,WY7U,V9$!0B0R%44ED>UMI/O?:Y08>H?#[#&ER6XO M(SHXKF(:(UV;'_Y+ST8*W@/ %.![O)UM#?I';SZWK,.M8L*KVM??;)]T#?9"A MYS;'FR".:B>8R-^43SCGO[D>!O58#K6O3G[=3N97'9!OLJ]/M5Z\9\54V-H] MH](HY"VB@*E]4T/$95H2VV-'+O3@:8?:S26O;'^3X2T8/JM\?;DC5TTC7RC7L3=B%@CC%\ M.]Z$1?B:4P!0A@F?QBLC\'84ENG%F[C.2BQ?$;A^^#?B$4A>J*,YO_=D*-W5 MB]5"!A BL2N/']2LW Q #\&KVNUW^>!#G7_U+W)?DZ[\J5"ZKG.+E=-K&;RV MCO6W=83MMM=^$UW58?_TW"D?7.Z6F[LCWS+O+7#I]CE5_:9ZI+I*ZLZ?/^'8/IM358&FJNKC7V+=R0$6KR;W$2>*FQYF?=@ ]S_:5[: 'FA[U M3?1$2R/EDQ[YS$45W;]X0,[V(*>;BY*WW-[ND M_+;-^,G1/\U(>YS_!\];2 MMJ_&L)TTMWDP'6;W-BG7-SV?\PBUW6N3QP 2./*L]MRD6XKH%N?LWU1;#VIY MI]L_)MB#?1Z5,!@RFA"*"5"H/(J9PA&G$MK@G%<;V%/TV6W-7 ;P9G5>D*_U M(LWY:19W%N%E ;J-R=+(>F>*)4!A;M_I:*,@!L?Q.2AI'ONW,^+_R<#+I)S1 M0 VQ_?JB"(R/KL0E.M]4D*5%JB^ MLG_;A$F8KHI0QM50F76N'9":/\9744QZ%Z/-@/-7G(=Q/1G-_1B[1 "JH^[^ MU4[JP+M[_.%T[)W;+/6ZCY>T>52WC]@#CE#]B"/$'T)KA?+''*'F0:A^$FH> MA6Y!K G+(3?;[^6?@]V8^2]K*--T0?34V: 5NY=A%T;P^ 7[[SM@B T&]AV M 2[F!OR$MM@:)@]J,6F#X>MDR+I %M[$,6L#=8T@W@J8"!:-I5>&2!8[52!G MP((QEN? 5^ B7": %4KX&#AY91?S_9F'@ JI MN8[0(U4&/*083_+M5&$,*?J3>1N] QA2C"?MVB'E"'%]1!L S$N:AZ-:5PF- M&%BLL[R,?PDTP75S&H+!69.AEL.JHA5H]T1G6S F^159@?P)!9T."GI*D(FM MOLIB4@)"6,7%$KT&K/LA5ECEUSPDF.JW1-7XM'UYP\HP_9VGY M-&,Y8=4H$,).> &VHZVYQ0/P)":8(=0)PNN M)L^TM"".(L*A-.(#,)G.,3K M)<[1Q_='B)+TP#K&WW&0/[QD.WF5;5MPN\'(W/GLKQLZ4-(/T8^Y3G]5T/OC M(=*;/'GZ8L_0&G"*]TW>DN2TJ4.F>0__!*+_[@")?D%>]<[>&V\,-LW[!F_' M_>4:#B!<%KKG7!=M,1MGFUP7K[=$@O*1-*QTAIL9RS[>*8 ) MD,'E8:,6&#I:0YU(Q"M F5R4-NJNDYB40+!0&9ZCUX#//MW5"QZ/H^4?#<6& M$)6CM,\8E&.E"8*#^I <"S7X;#0&Y!C(""D@IQ>$<88W.0YCYNZ2/R>8W:E( M!\$9RG>B\KMWUKS;%#&[?2G#=#&[:1M:H,^.[3*'_T2]I_C*):,R0A$QHY-W M'"%KC)BQPBJ/F-FTP]^F'?YP-_Q!B)[I4U3Q H8B+H/FVB"@/AD$6('67?9C2,=5" M5 W,YL? &-.&ATK8[7UF'>#AU6.9)!Q"Z>")%WI'](&T94$17:9%F5=T"M5D M5[%1<#N5F8 /)S:5-!A.&2&*DQXA4Z=QA!H== 8A(KNR,$#M]Y,D.>%JR:_S"?E+. M=Y;*3N>_208-YD,K33#,FP17FW;..PF'G>@T2Y_) I2>U/(_%FS'(0ZQ*FO% M!'U_ YV%6>J13Z,,AI!3$4OGVK"5!9)6DV:>5QC,?W)="T!&%OKO8'C0 R-+ MX^_]BUX2AA4EY>C-2XJCDX! #'$[,VL]*$M=EYR89$Z?-%:*8%@U!:WF^A,T M_ZO)15Q7.ZY+(2_2Z)I\>?X7Y0NQT'1+1&M3AC0TJ@$BH2U6(1HM#'/B:M'[ MJ*P%[\3K)N6;%7,E>0_B#J7*T3(I.9T+K0P8S)):#3 DLX(IS*R=WP1D9!NZ M@WQQ$H=UMCTK%U+0\>>\*^"K'?:1 AARV:"4.N9QJU3?(8Y#M.%JP*C6#-)W M08GO2WK:3,P,R0_!H]V&J[X!?R2T,4S-2)TV4'I:0#9NV#9M(-K($>+-H*X= M$.3M1N\S7(1YO-&>;"OE75-3"WO,1*DP*.+I$$IYUBDZ@(7]V7DN,/Q'WGD$3L*J_51KP%TC$[P8YS2 MG<-OJ2?NH_S#KIY^H+UVYV4?=O/H;[R'SZC\8*CA96E'$9.%-XUN\ MD8LL7^&XK&BMV;H,UI[>O?1)A]0M-:]JEQU2\AAHESSW9Z)I=7V$:ET P:9; M5Y^3O 8?!14GPP#5:??TDG=:6G$B!EA>LWO#)RZU=S@F**I9[VB\H[GN^$O0 M>L-N'NFLSK:CE]<6[=[S\[QW3H=&VKK#5OT/L&?GZ=3$[?8(7V*=IWOU[-1& MSCPW.6=_.'Q>0=W7_[8Y:&7Z;G;VOQ6B^MQQ^K;)J##6=I(U$PS&JM?P0NK. M1&\][#600_(<4.O6N:]IESU1>,BWU_]4)EJ[(W_#!:LR2'/W=6U]2]W00Q2' M]=,/M,NZ]O8L'_U-=^]M-I:"VM/#C:>WX1M+SUWGQ] Z_Q:GV>JWICK-5MWC M\X+DD&(WMGC5NXS=F '#^T:7?]MGQF[0)OXGC!W#!8V#(4)XX(&.!(H7MZ<. M/WH:4"=@G[9:+;&/H+O\O=3*[$X'?5DY?B+O*WXFAH?9&E]E1:%+73JM"4^Y MMJV-4^33-NJ#F=EF@):D@VA38;,VT* 1Q%M!OZ'M_!9,,E1+PZ\,:5*G-P.0 MTH*1,VA]!2[IZDS@6]+["E"RUME+V^LLY3,1S;5>OG5WT/=_"6[2HP]B;V;& MR]S)QLR$YWY3@;;3[3;NQ/X4T,>6>[M*L^N@G_85V)Y$CE=.[A\//QAH_DO= M/C!H^K,A=6E/MD\]5??9R^>L/6U>C&Q_B1E$_DFVJPH"D=NQP/NK'PX/WN!X M=]SAO(,M;LSM?12!N"KX1"W&.[^V8_' U\!C%[.[HS$X5^W/3- M1RYV$'Y[;9)G]]T.Q8%Z\5->\9Z<>1L(WCNN7[LG7\IIN_NG_7?W[5P6^5M0 M'0[OR6^:"N*0W/1Y+WB7GODT!("ZN@>S=^)_6\SQA^4LPMDN_I:BY.?8/7?# MV,L-C?]1NYZ F.G-]AWM>^[FM@>434\XFYW?_"8GD,W-_\F;FGO>S-S_T+#= MD,G#YVBM^-<-#LD?'[*_L>3%^HM?[A]_2/LE4U_J+N=_VV<#ZNY.#;9W2/<3 M6>JD*UO=L]G75N@,' ?:N:>]YCWU/F[7 AL@P?0F.'])>QD:0#TKLII$A3%S>HAQT%1Y6^L^J#N8HI& MWFDQ(1/L05DAE;!WDMLB%$H-47GJMS8:B*F N3;"-XEE5ET9;HI8:;IDV@13 M^IRS4 /#/GNL8QYRS2.DY.,5H'L>9 I99RD#=A8_QQ%.H^(6YVP"H67*;X-8 M%9MEI^JVFIJ],<,2:V8],,2< %8LQD9544%UCU#4:!_14J:HH T_4K%T7TOU:.WNV*]Z.2T,Z!-1KP&&@E8PQ^1KE.B(F.51G 9D1.QQ M,.R1TSOWF"%W>$/>VE- %\[98QZL6Y=V495/61[_@J-.AI>G5N81V*)!IX&J M6QL^B"B8W1H8KF]MPK@?<">@DT9UDT>]%5/7:E]P :.B^?P]*[:S?+/B^\J= MC3L/RU ^YS!"O@VO:3[),Z(Y4[)CME= IJ'T22MMSD*#KC MYX">NW<:;.(R2'AWN\,%SI]Q=)'E%Q6MG'!9%%60*E,QSFC'TX)RFIF*U:5= M(V#ZRUSDBG7G/5]WUDTUQ\M-8VB5Y8@WAYKVO/-\D;!V<20?.NHRU8K79ZOL M-*W+)(,&R5RL-,%P=Q)4IP73_'F MEKQ%W?)_3FO.-VWFFRSLV$QO"LRPOQU^^5X-;P[Q]A!O\*@MZ= S0 7Y/1EIO1@3# ;SHR6WJ 3S@ WC6#."/ M/,0B3M&F9NPC?;;_\5GZ/L>[-5_2".>\GS*#:&JK[,5UKQ8>>;"]6O'R]M:K1\_[-GNUW,@=]^J$/@1>KYZSN%V$ M(4[(4I&L&6F,IU7*U]T^YR"2ZYM>TTYV6U0/@=53]V#9'KSKH'LB*Y'!=D=2 M&&(XY0W#V$C"&%=CWG MDYG%I"WLG9<'W=WC#_#T8 _&SYG*BOG'"B_Z.J3>9[DSO"+>=,0.JN-EU>SR MU.=V^5E$.;98]Y CM.+-'417H3;C11I=$01)*X>G MC?"V34+K'";CI_8*57L'U1T,1DSH!T5IF##V^/E;X'44]@E.B<\E=505HH[7 MB;K/9D(X_B:7W9? YB!T5_5P\PI'5W&P)$0K8UQ<9+1DZCHNBIA5N&8X">]T MP\_D5AQ7PYUCXJ@8[I0FP!!T'FY)*5S:"KOE7RM"X>UM\$9>0L+0GU9YCI6+ M?IV"!S9J@$N()Y&&QC$U1!6=-EP#"I5ZG<2*23)YO\.:F4>B,#0:*1&J6%1/ MI%N/2(H4EO5C[G!9Y>-[)C(!9^D=I<#:9(N#7[U_8R4DU4?-F1"86::Y)E+[ M=W;C@U+)PR!A,$ R4B@TO%-I$DP5O9:U-$M>^1SP([_]#B"7*;\5?8?C];+* M"W9PH^DF"GG7PXL6]GBTD0I[9XPM0A598J*34R4R*O6T/*V?;\HGG-O-^0I1 MQ^OG,BN#1'?*:H(Y_BX/M$&442T4YXS>I=J;91(_LL&%YT;X'*?Q MNEHWV=3.JOJ><$1SWES$11@D?\>!*M!Z%PV[3<"QJQ1Z2=FS+N M(MT-;W[.SX[\*5%A=@YBW65ZC5_+AQ>760QR0EW/@(F(_W=/,]FCH<"ZHP."@:8\>^3N\ >"> E3#N=X 9]_ 4Y_,( MU].$P3?!%#NZM6H'P+8Q5@G9?@^8;!?D-95/L]C65X5!-]$8.[YU>@= . &L MA'%_@,FX*;8"X)0UB6 MI'40I8MH'P6):5QFDA5DB7.%@P(7BV7!0 M[2BI! M.&'B=C"%@.YJO:;9TV]6Z#^J("WC,F!1&I?I*LO7=A4P,X<=SC$=.Y(E$$FFN84F$_1' M)=4-+U$**&$TMZ=&'#%>A_+ $WTR5X6L/[9H4K5*!6$Y&CJ()NY B7LSC2Z> M!A7M6.)G"#'2P31\\ ,;=DYC\?7A.IYN<^&7.)_C=BJ3VH=/.*H23/W.ST%9 MY<0UH'\&YV1>X:+ 6.',],Y#+,\+YC?GMMMO9_1PE)C7%AB_9$L#U(=AM_5A MV'D:T92P.,2L2LC']TJ?+79[0#EL1],V?3F#9RF$3N(9] 9?_'=%.,I#OS.WA7 MO!FH1.X;.9?'M(V#I'$/^ 06^S__FV1C_+R+\9@W Y;%/2-GLYBT<9@L[H!/ M8+'_,T5;&Q$95';4'DL]3<.:0>- 3E=&T71@@[44\XQP$5/!A.;_E6 M8#)W&[)"V_N'OCYR_*7ZDZ:YG,]A@Q)C.M"VT(4#I7O]SD%08-?K>2:ZP<-IA.HA@A0E! M"F#<5#T^TZ$AI.L]"^)!W*RN@E15^KPOX/2JIP!L<*VS_14,)P1(P@T\(D!K M>)-_C+Q_]R&#FZG=BNZ=L+_18PQ8/7@TDF!XHH5G&CKJ5*C^QPTZ-V;YT!9: M<_-FU<1M:B9HDZ)K]\G.D+&OI-<"PS=KJ*+[0QE'5I=K.FJ%M3 (YHT]O#-< MA'F\T01G&[5\N^P2$TS.>4\%%-O,.$W#7-1I["F/P:<\B*H@N6,9T5D&=O)< M2=9.D["S# 9&P&W$CU+2.TFLX(VY4KXXKTI(#J M>OI>9WA97J9%F5?4N;T(0JS+]RZ7A?>5C$C%=.W+$G4:1XCJ(*ZTIVGP 1?E M!<;%'0YQ_(S'FP *&6>3G@I>.]>-!6!,<0I4PG8Y$4,K(D?F-B[H+8LMK0Q% M.4=+QD=< E$13_WT-L^>8YJP]B++S[)J6:ZJ M9!&R PEI/]7)P^NG5F@E:>>TB]-=U/H^O8N+KX^4-B*MZ(2=GRM7 -X=*]<(@FFEVOAC:DU$$94 M&OV#R?\7/ 9=Q2F^+/%:DV=*J>"520)P+9M::;B,&D.T817504S)/[7H,)E6 MRM3XW<\N:3,&U2=)\QL82HP B1=X^,_>O[1 W:X0[7M;M@]4O XD$O#:H:0G M#X8Y%B#UPTE.=&"5]:WO:=ZL[O$C74W=X4V6TTVH7H*0D[?Z1YT?-*LEIXN> M^:8.%D?3FP'#W_G8E?=[LQ6JQ5';6#^YS!$M%MI(0''/--:;'#4[5;>+>7MC MAJM\LQXXN,\2:?B<6AK>MI %5NVWH>E]Z#1B\7TY#BL:T*FT6)-1XU? M!IGZA(,DC8;;ZLU&Z,.C.J4XF('?C%&>_Z6OQ^IN!#W-7:4%4AS:M0>Y!# K M-U#O<8Y]"I.PLV,\(^#V/$\IZ9TP5O#41^Z4(KS(@TV%I[V>]=&BC71KO)D& MQ[6:B02?!F\IHVGA6EX\G/K6#]DU>02=.[,D87X2F72Q/+_3?IX$KE[FW@R4 M#SQU^5/Z45'6/N@(L7N O>*H@ EV@HE_C'LU7\]?B2^6Y>1%!?D;\Y5WR;+9 MCSLHJFUOY32^+=GS(!".13W)ZYRR7P!]QA$@^1MGD5C^MX>O<=FQ;O$9O!ZB;]0GPG%HA!!D&R>BQC ON6?-68WG)XN\[D$=S3])TYQG/, M:GWE*>3<7L1B7Q9M 9)55-8W0RRE-*VC3-H/23%\8'M@X>A8G52G$8&[1 M#LRQ=&3FO-&T;L0[K[=%KAU1(R[JR:_Z"=/X0YS[S>!#JM >\$W0:U<-F CRTU*X\1&Z)0K>.3 MD#\%>1Z(=]'G- "+BF/#IO&PT3X@$HX@VS&P4?+NM]GU,^9XTJ#EFQ4-#&=! MXBRSAWHC9[M67?IT.WH%H^VZ;9KTSO[=VC'N$E^V7=&X=P?K7BPX1Q,<0E43 M\%U"(_)Y3J&%W^\X>F^1EC%#%3_CCL4\8 )'?$]ZO:E*MCM\LSH/3C@+IX IC_MQ2Q=$&'_,:A[#FH>Q \X>H^B2LW# M:*D%?NT/3(CAEJ_MRA"&N+OFG>8,V_%+&9PE[:AM,%UPQP8)%_-VU>&N %V. MV?*=:5.-[JCM ^IOZB0/.VGX6^EIVAREM.WCMI\5;>O>NTHWPY_A%<[94<^: M1C[Q4#NZR']D"R@:@7M)/-_GF*;Y:6-PF>DG08&C)D7>(HUNLZ+,<1GSI=<) M3O$J+HN3MX>XI$_JFB&RY%^)>?+'V_FC<('[\7'AO@^=WPP5-9CAZ6!>ENG@YF!'-NLIBYR^'H VM)=!\D04X< M3O+N?@H>E><>HIA3'T8!.7C&PP>1%J<8_LT<[0 M*EFH+#+-?B*3+">H?7Z/=G)7. 4G;\+\OW@)\JB.@/G$@A N4UYD^5.>%?)/ MN?O'0+LTO4\3!28Q5VC)7*&P[TH%W>-\$FII?@W+\6M@__,W7-!K@"Q5;]%E M=5%2:MM>[]F"LX154+/7,M_UG!CGRHF=:I1=,+Y*[$O+O!M'H=JBKEY M_,&-9GLP?4S&1@IMJ!AE(P\#\>YYG='5*4ZC@MA-?4%^\M"<0Z@6WP8EISLO M5@8,=DNT&F \,BN8PFRZH1D*$A0&Q1.*ZA; D>RTRFEI![*ZI?=3^5\LWX)< MU2?A=,;H:"?3 TL^#5@QQI>KTL)55!74?%N';%;E4Y;'O^#H2QJ1#D6CD/E8 M?TM,*09#^AV=);YLR(C-_G05KV-YANL]/@^H*[=O:PV3:+9"F;%>T*$P["I[ M<\62;Q(T\SIOA<:E%87\B(4TQ<6RN@ MGH;7K_+E_E-&%F@I*Y]F_#!::5C?Q@:J<#WW^_OO4:<&YB/18G5IF>5O9 W] MF; GCX-$G E0K ^B0:AK#P?$T6D ;2NA;W,.3?/= 2F8^X%>26*CB$3@O7R M-0@%-_^9SAJ_0Y^SM'SRR_S_Q'GVD!'.#4B*-&WNIK;)'5Z Z709PT&<&'+[MOB5S.68XB'3@QE^BD6KJP7G9,U01:F+'.:2^HNT>9-;Z([S><)K5!6^><=?3R<\9M9V& M0:C/I^P487VYB:C%E5VKWO^(30.(M>#U>U[C994$BY#,JT5,,2D^GT(.UM?2 M@Q3+"E!I%'3B +X$Z_"WY,T\!05>/.:87<#1?A2="L3O8X%7\:GX:-BHHE;7 M[XA(J',2I%^O%ZJ1;R0 ZYLHT DC62VV/D+7WR^^][SA$%4A^_ \IIE=15/N M.BAE87T',U!Q_Z'1J$L4('ZCT^>G^9S_-5@'RWX>+$:X,59Z[Q]) M[OWW4R@MWWAH(>*IDC;\X2A@ P&_FL%B$_GS49PBCH#\J8: GBD&[8IOBT.& MA^#UM"KIPN??LV6Q"$>>S&"1I!)U=KQ@ -LM/>5RL$BK!RGLQ02O**SJ'%O_ M3100/8_RNI\=AGF%HSM<5GDJ?(+!K[!>O R:L#/-95#.A+QLMW1! MQ*<)@/!4:9R[VD]TW+Y,+X(X9R,_S?G9'CA)2\1,T8/U<::!%I8;3)O. M5RNBS^ 9*:G-6VZ&C?B>L1.#]:WG ;:Y@(% M/R^EER8BTD1=V:]HO^YBH-EG,C] M+[,*] ^IP&OU_1+VAZ13WM,4W>[F/^!\':?,NK- 7KI>+>ML"C;![9:J"D%8 MG#&@%!:P[=%+V0 MM-ML-8+]]CNJ,WQX7]V4$&3Z)_<3==)>Z&].?QO#E.$F!@U8W](6KAA@TLM3 MT1Z,-ZI>-W!OD^"7X#..8C) 7 5+>H6;^/?T-K?BDYD48'TQ2[3C#\;44*V' M.D5$-7U?QEE585P5!)2Z5PDRL+Z*&J#DT@V7I!_!;T^Y2:*3/(X>\35^^7>: MK/=-=6-:(0CK&QA0"C>GDPAQ>404$-?P^CTNB#^;:&]."Q*POH *WOC5,SD( M]W,_Y0&M '3'')%F%7HG6TTI)6%] 1/,\9>HY5'.73&6[B1N5N-=:G8OSM>_ M!T66_C7(OU:J[B!(P/H8*GCCC\#D$!?<]^W+7DK..QSB^!E'TM 3F9BS/0X- MR"X22)2!]?75 (6(&^9%\Z4LZ8E'M8'L0,KN F- M%F)JJ*?G-QE4FN.$#-<1S8X1W09YJ?+>E)*P/H\)II JI%'3 %MJ(9??WI M,%8/Y6;UI<"+HL"JF"X+'5B?R1ZPJ21950"(H; M#J,EG4K8V41H!-Q?(,!%>8%QH?1+Q@*PWK\"G1"6 M2<30BLCY=4?$ ^#3)";F%3>I*GNH6076!['&:Y-*=\-WHSW>O@E@<1YD,#/7Y1A:'+I&!]'1U$8:RCLJ@3AMES-&G\ M+'1@?1U[P%,Z#U6&^>T>B%,Z>;[J*1W(UQ,13QK[J+;?A!M5$:>X*$ZS];*. M+&&K$EKLN[?JOW_*19B'!4TB__GH*QO -RL9'G4Q!/F"*RW/4A+R!7E47&?EWW&YB+)-B2/3)]ZJ-5@??A>F MB(F >9N(-XJZ5E';+*V @DC#J&YY*E&V.1_5%7(A_R86KAF<^4W0=G>:.MDD MNUH\ U58Q)V,6\CF_^&'=S_^0.G!JO'L_50^?,)1E9 ILYY'%V$9/\<$*XNF M'8\U U-M5=WQ;9HQ'=GL]( Q;1)HX>2_UJ:G8+4^:AI _V!-^)X3E"C;$L?NPSEMDQGRX\R0XF4NXM@W4,I@B &7_CS1&GY3DHUH M/K%-'57D8++9!V[T]_1%^61S@$]Y].Q:WWN(<>G) ZD]D4W#0Q03EIR]]0=I MQ7*ZX9^*8M_DS.-:PJ780X=AIB_]^$]2-X ^6Q#1WR=LDP25Q M)SZ[SZ>BG+XJ4E'F;,-/TE"(=IDDV0^X:[,?^1VD,]9&Z@7;NF>QTN&RAWZ0 MYMV(II8U?2--'^1*O-YJ,;CNO2PXVX_E,US6F-?=;EI<^A@&:EQ3-[M'S@(' M-[K)GE+VB\;7 M,1\LVS(XL:OW44COG=.X^T[*?\?E$G^N5T3363T.>I.00N M7.:%2RA&%@O9,-E(ALZ3MTY;HQ,&BIN%3)3,LY"?WT2 Z]:[Z WX9S;U5L^_ MDS&;PQYCKBG9SVO-!?5 M:9XCEO*?ZTJ(592 $\L'YPW4W##FN[0/)^3N;>2\&'!-]' "L-Z=6G* 1Y8< MX.N>%.!9@XC\4)!()#&17(."-(@:E?#V^A!DA[=WOO6;+%4:^).?X,3*>_F3 MYAM6P+*XHPKU&WD$<4R"F4$@G 5A)+ [#60[8@M&FY9,2U:_I.";U']:#_$= M;.0R?H'X>-1UZD D^+^&1Q'UX1_$@V @7 U"R< ,83WHLS;1PM"$Y&;\D, _ MT6]760XB*/@)E>5U3L5B18M-SEZ&0WO'M#/;I#QDF)9X:_]&<$V( T;@CLA. M,G#(A\8@-[5H#6X@5',BP69!XJ;!J>JVW-4I9_B@OI7\E/E+(+C=/D0_X=M[ MG?+]J/7EPIMU-H,=.9CF-MV/#Y=9C@-MW++7W"(W>M7P@T-X*5N S$2\B2EK M!N4T9J685&H:?&7/3 ZZ^_31>>WV8YRUGI#W0#K5A0:Y<-G<&,C6RD."6:Y[ MBILD-3N)AE]XCFUN]89DI+49?&&-S3&,?EO;83H!4[,C]K6T9I_H86A3J:^) MYQ%Q&7P+S7_'BB++W^!BN F+-G3HS8E+D6-A&R5AX<([KZG"9)[FAPE:E+?I MM[20@Y#%2$K&$77'8ZIM!#,RS8U';J:=EDT0OKI7NA%5A$6T0E[J9L331I!K MR'Z[7*:Q)8M.CUO]0BBBP=WZK:L)0 MAB@W*2X=#^(TDQ4UE2!P)(FJS]7:,\!9ZM!)B4LG0S#=%PN-]X)V:#C5IQWW M+>+T+SJ^?>.RFOD'[EW+V/:.26P/F2G<0/C<^G:?@,C)OF"V)/X%XM%H'-+: M?2" W,_&!W1F>4@& CG0B@9!/P6N%\ 3W=.V%'P#T!3M7\/3R*9O7K. 3/V4V-(PACVHGRZNE'UO/A M^!ADYGRE)>]]Z&K)2H7+ROH@[NI>TB*Y2[JA/TN1&_,O&CG#8FU$N.3?@]!X M88$K59D.5! '%;\*];E.Y:O1/67/ZRHOA%T8:N@CQJ4.#Z1&%(@*3&**AR]6 M+:8@JU,KS<"E6$FIS$:3>! OE[1;=1E910>9 F<\<%N2!$)GN]/-UZR;PAQBM^"KU<##7UX M)0R('J? ?<0<2+0/4!JRRM_$E^;/**FH3<(F%2)!]X S:T-(4OEA71!!'4CR M L)WF3!&9K6R2=ZD>OPW&LGW@+/FQU&D_]!9O)8[M>'O(AR+#&0-]-+.$ ^B M6>(-M6>-$A<>DCR0DK[D65'J5>D.&4>X6=&[)2V+R#LC?!Q*_]A]55F 3 M_0X)(K&[D#F=9!5A(%G#:T!.OW,$[%4%#]W04H03V>3>0XY(!SXHS1J8+9[N M-.!G+5I"A!3G7^#:'HD'E/;SO76WNDN$X!)N&)OUK8B?>UNT@82^8J\LIFE< MM(JS0.)!F^Q=M(AFRR!$L\"88E@0R:(/;L 5\MS69*&.5Q44K;FC./'*DYRG8CF=L".5IWD#Z0[6WFR>QHE MD##M2\12U[[9AP^1_D;![:G+U' OB.8GT$#8W;8>PFWZWP@J;/#3[@O$:=EG MGIL:D<8\0!HG_48/$+8&?+#C:SB#G84V<#M*5U3^>9VJ4DZ%/6AT#!\BC8V" M:QZE)!-YI]G?$ZY-W4(KQ R-$J& 9UIFN6.6]3*@5IL-IZ>^6JQH]'27TY>( MQ2NZI7E>YZ+5\5GR%=I/@3XMH=;LJ %XJERUJ>] Q$VV:([(]M#8@0#5O+B. M4;R5%;6F^Q%[JE:JL6DEC$952+OEXP)>5F:1[;9*Q_(BN%79&[)+J1YMH)FC M>F6ZI_P[8C_P#S*AGIA )M>,J?OH.,B$67U.K#ZJ:YC#GOMO: E/F!P./'#& MG]Z^%?"E@(NI0N3ED46C'5/0GQN1(O< ;4:2E>+EE^A&(&+S';3#/Y/O2=T4 M:=H*I-][JH)'B]LM+/=]^QT7+2+=#4(T*Q]J!GC;$"R!=BZ[Z\CMMG8JZ%L: M6V2(]-"'SKG\<074U+B6NRN6\BW2OLN=A1N1JO8 /7*YJYL*O]P!2O@/?,-? MHX2*U[1.I=0T[OZ@12D]#,SSTR:I8N',N_D.$?KW44DOMUNZL7I^SXL D9T% M&KCAU,@;EFY9I-4^N!_4)7 E"3R\[/RPRR$Q$$%J9$1#(X"-2'"G:/SU MB%:L>,F**/F29]4+Y^#_AIP1+*UHK)RFL]2Z/,[9/X+S>=!A3V?VC6EK2$1@ M$IQM5*2!%?822#EQ"K^PJRQ?T74I\S<7MD(MGGP(#&PON.[KGU[^4+%NE!]^ M:5-Y!I;7PIIRVH\#T??0$ZB9(P;8%J2)3Y&<(3-"-U?+TEWE[2Y+V.:M5T\N M6D0:&H1H7HLK!KXY$"SD;_5G>-THM[TWR,Q10L8JOJ:_P+G+0U>^O(AT-QJR M<2I5#2Q$+I.RCB@5C2#4KUP7Y%K@H=(>[*TE5!: M*$5I/'#DR:IUN:T2OW@"/TY,:AP'V$NKZ-1IC.>&VI.]V0@Q*:L7GY=NHJW( M)HI,0_4AR;D@=BD0Z<0!K.<8* A#"QJ"6<4]W#TM:/[J"R! F'-RN >FN2*LON#?7O9%V=\I91[OQR,S;[<14JL]% M6*^>8XI/I;UL_T)]C'I<268%<*9VZS_NF4Q: 2*=G)SUSB2@/_#D4@?W:9V@ M2X?_F83&4Q,27%B>LK")PS5M N,[RV^&1Z3:K !^FV^&;P3=G-^,P&%Y,RQ& MX&AJV1[-V_/OL>[;!CSORMY"< 9KMYZ<#]'/@73GT_=ZIJOTP&!G6IKK59C# M(.>U_YC1<,_?6@.:Z'E9I>.EXLA=G*D5]KV.3&1]O,O3LKHO61;_8$DR@_4- M=77Z5N@]PJ-:XX+H?A<8#?.*I:RD7]DKA!"5?-2L);?::V/YG.4E^]4I$M>V MN?&M(#*G \#O6HILZD*T19K&B"[UU7:$:3>(3_F.Q:6?XS24VC?5AQ08;J*V M3&=%7W*Z8<)R^-\3*LK@IAT3=;K3.EPKCM(V(OT??4@6!XYZ*K=[@&.8ZD.L M]^U>%F3'27G1]5(.F8#_TW!=Y4^[=9554>56-ON=6LJJRC*]R]G&>D4\4]<( M+LY"C=A:@N!"M$[:",BR6ZZZ3:=@$($#(ED$DDX9@P71:(B"0S0>(@"=OFWS MST'.TH)MW+GXI^KL/.W7,<;9++;N/VSU@ ,%>I7E6\K*BBOZ.I4ASE/8IJ4; M1)_[*479^GL7J->#831KP/70^+>STL[NZVZ8/3G"?I#9L%3SO(V8SVQ+>B M-UDJQR5+^%ZG19E7,I]8L^&>8%,PHM]S.$+M,]P)3)C#N) X=+GM%I*=,U:0 M#85P4CI.Z^$11M#S9DJVW/@R%8J5O^H8@V914EM^N$/3E?Y*R$ MB#[>_?C,PK8U-6G(0U?6%@DK>@H\6PD1Z: ?G[N^MB!?!"[Z+$!\S@KK@U;] M2T32-C&9B5"$7($&4?8N[;#PIM.^KBJZA$#EOVB47[%7J^GOU1 J91V"WS,% M6.,.][: 5.)K?D2-6*SCP*%9 NTB-X9#]'^"*C^2EC$J]1O?]Q0B^@_"FC:< M=/D,_QJM85=#IZ+N0?S[Z+[=*)&M$MFLQ1;:/_K*_\9_K'_$_P=7&OPG_P=0 M2P,$% @ "H2M5*3QR" 56 OKT% !4 !PWQ>.SCNZ'7MM9JE592N]?[ M98(B455PL\@R2$JJ^?47 ,DJ%HF7!(NL1&ET8M>CEI @,I\$D$@D,O_K?[XL MX\D381E-D[]^]_[W/WPW(4F81C29__6[+_?O3N[/KJZ^FV1YD$1!G";DK]\E MZ7?_\__[;__/A/_??_V_[]Y-+BF)HS]/SM/PW54R2_\RN0F6Y,^33R0A+,A3 M]I?)/X*X$+])+VE,V.0L7:YBDA/^A_+#?Y[\^/OW'Q\G[]X!^OT'2:*4?;F[ MVO2[R/-5]N?OOW]^?OY]DCX%SRG[EOT^3)>P#N_S("^R36\_O/Q0_5])_E\Q M3;[]6?S/8Y"1"9=7DOWY):-__4Y\M_KL\\??IVS^_8$<3(;>0?%=3B5Y4=.]__OGG[^5?ZZ:=EB^/+*Z_\?'[>CB;GOE?J:%]8R09 M_7,FAW>=AD$N8;=^9J)M(?[UKF[V3OSJW?L/[SZ^__U+%GU7"U]*D*4QN2.S MB?@O1V_SU15+5PM.' >/$K3O18/OSU*NE'RTDG3!R.ROWZW8:L&_\.'##Q_+ M_O]CIU&^7G'ES*C0K>\FW^_Q[=,@%K*Z7Q"29[8Q*!N/-);;@)$D7Y"95:8]NQN' MG_L\#;\MTCCB:]7%OPN:KUV&KZ<^U&B=E*9'5^/P<19DB\LX?7;2E0[1<&.; MLGF0T%^E)G)%/"TRFA"[)EO(!I1=L5P&;,U1H_.$SCA 27X2AFF1Y'PKOTUC M&E)B%Z93+P.N="'OSS2YIE*5O?I#GAN]8Z>!3?,0_:O:&-G27-Y?[&IZ, AB_$_(0&&". =+AQ7A/^*^N0=EL-*:4D*V+!W\F<$6D. M<);ORU5A=RFX(R&A3Y!E9:].!UQAMEOQ69'E?"IP"Y@;]GR*EG:Q=<&!=C#@ MF,EHKA1G41L(2CF=T2=K_@IJQM3+KVPXWHCO\[Y\H4,,BB MHVX]I WYF)%_%QR&BR> K:!I?FB;=EC;=CP;%_;]![&(#,3+;E^C6NNP85L) M#VJYP\;LW-$!K'C8R('D8]K"0&VVT(UN[<&&"2(^B.4'&R^X@Z&M0-CP5&W' MM$" NFBA&\\:@8W/3#7";B6\K6E2^M<^!^P;R<47I14LU?^<_X+&\!W+L;\! M.0H7)"IB,IU5.V6VM=IO2 [EPZF7,4;?%.!5(BPO?@AQ'CVDES%&?QE0)B_: M^(\T"?AJ%,1729:S0BY4SGRX]3<&1^=D1OB>$-T1+L6".'-@IA]EQ#0+YOQ( M.Y?KV^FZ]\A!_1S:@JX^?Q,P<;Q]LI[R]NMUE/5)6I6UMVY+/*"D9-ERO+J'O'B94623%H@ZO.H,W\#?NR@)WA7/=RCRS$PUA[0G0&$ M]G0 WX0K)LX=8=Q NC*U?\]CZ)OTLTQ793!-R+]&<_># Z"3$2R^KT(^PBYS M&S6,?$P/F+,U"NYA_-MBU[&[]C/*;;+KH &D8\Q%C3/1>3K"^CF A?*9)G19 M+*>/,2W/@WN;(=8>1UAG_G?!EPF:2_@;/L"3Q[3(JTC$9%YZ+EW7H/Y=CX'> MYR 7#K?U)L#2E2WGGH;V,KM.=#,5QGSIW ^[6 MDZV+,<9]&F0TY.IQ3N."KZXW)!=1T_4-@C,/3MV-XD7BZ^B[2'R= [Z].;AX M">,BXKL'5_]R5Z_'))S=1=X/L0$_-E;$?B^$(WZ04I(2XO_X17[HY#'C"V.X MB<7AHR:Q[/\7WJ;5Y/L#C*J6Q /O43VHW1;M,36!.V'A)&7\8,1E7?<5L' ' MKNX#I:K%]ROI[WT7+FB\07K&)Z]..I4D4LU FX+BGSB,-$_X]R,QALLXF*O% MV6H"E.=[#($JN<&2Z#G)0D97S#BSF>N[3]P(*DO%B$"+S;&BCQ/Z(:'AH>D41^OR!Q+ X[ M00+2B/C6 I=]@P0H_C_Y(OX.MT@(\*,^32.^I3. M[#N-@5+_&5/J&@Y1Y7V11%!I;YJ"SS_XPFZQAR3J2YJ%05R.Z)+_+C.+6]$< M*G*4,Z>5352Q_Y,$#"ST1F.HR%&.H186#RSPZJIT.QCCJJ)O#14YR@'4QN2! M97XA[CW7(O?33;%\W#I.=V7=;065,?$87R41>?D[69L$W6D*E33*&=/('HJH;QD5<1/W-+0O&MVV4&&C MG"S-#*)(^R%XN8HX5_*N70C)+G0M"53V*,=*$+LH$(A;9+9*&^[B,_$&A:W/ MTLBXI%L(H7"@G#<=6$ 8V/1'[!S>Q M?X"+'>4<:F73$[%_=!/[1[C84+!U<3HH1V,)>["::$+)6HU@W!52@* =0%3,'EN=U*NX^%FEB],=V6T'EBG*2U#%UZ(57!!-GVJG?^#,X M@@UE66VS<6 Q?F4TYR,0*:R*I/+1:&[%-$VAXD4Y_AG9.["H[V6&$_&4Z#.W M$!G=9L/8E;.J'53(*(<]/6,'EO"M?!2R)-SLEG%8BR(53"* <\ VL'%O+..-3B;36!"A;E9*=D M!VE-N'@)%T$R)_KH!75+J(!13GHFYM#6WCEH[9T[KKTH)SX=4TBR+6/#^8S: M)JPPBUE) 'YG@REQ ZN'?K\GG_PTGM-?\A_48M\.]2PAQ-[608U;_:>LFRK2>(Z M"JC@$2\1SMMI$K:& "ITQ,A6(ZLXPG_9OB,OW[\9):]H#*G?4AY5Z1@\L>9D8M6D_R<%<\7.;*>C!3@5% >6X"F4:9V]MO.0W M;JT[[:#R1CR8JAC#>3-5/,8TO(S3P&B7[S2#RA?Q%*I@"T6\IT'RC16K/%S? MLC0D1%R?9)O9!C@0 3N 0H)X/G42!8Z[(%TNQ6.B-/PFTW)FTR+/Q(+(QV=T M&ACIH-!@/N($,(YD!67;AUXD$O6B9H2),(4'\I*?\@]],QM% '(H/J@9A'R;(PV/]T[6TP^3=Y.-5URF/>7?2#(2B9^R M-*:1X'52]32INMI;]69!]BB!*K)W\R!8E?I'XCRK?[-5Q.H7OVR&V:@8=YN6 M9P5#_M2*'$:]_Z3JPUE5$\K*0[L=5M)5)Y'NSB8-)R.L;OV!J'9!*!Z=YFBY M6\W"52&@814=B+,@6XC:M_P_HIC*4Q"+Y?JW0XM.VP/1-0\HHM>59M7?\2IJ(Q$:"ED>X " MX!X=H;(\U'9\ET\W5 ^-NC5:IMD>F)CX10=#60W:.E_,5&A):7N ^$?':1- MH6L^-CTHNZW04M3V $'%'[K0;QE9!32J"HERVT,ZJ7?8TF,!(D9+8]L#(@=I MH",'Q*@?&L-?RO99M2QRYV,OB[-?EUQK1RB'EZ=Y$,N6>'--4TS5N."9J?!2 MZ+J<0R&T?DBG\Z^9&4U:#TN M%C*\A+PNX(!X1T>H7:&;3^BR^)H(JZD*>IN,.0@U7C9?%[Q<)($.FQT:=_&/ M[!JPB-\[$3=,1\A>HFF.EP'8::TR\8J.1#DPFXF,F0/8W:?_"LSA1D%L41VW M4UK=?C4#[P$OX_#^UVBNKN-I!>!NLA7<0 M[!IMM\=+9PR7M=HUJN;R[E*X]7DKFO@"9.4<'YB%X(6#;0=D8+U5S7T@,/*/C(<_C78XLW@<5 M 5Y*Y]YKF9EW=&Q<8-D'D=&\%,Z(@, X8N_%UN7E=,Y5D>%EFQ[\J*N7"OH4 M/$L3.:"O-%^<%5F>+KP_X@.) A^TZ3>8/A"UOTGQC2!D63F5KO#3=>P!D8AP=E2]))F(X M^3Y=2H;XV5JATNY$UFKXQD= MCT8*"ML+VTY+O)3N?9'0<8L.PTD4R>B?(+X-*#^LGP4KFBO+^]1WJCH"O#SP M?4&Q\(Z.S1W) YJ0Z")@B,S-^7Z3T'!_Q M8=IVB@%Y2#24>)GX!W>;&&4S*/SHFM M[8@F[J"XC9WQ=D^?*'S+,Q)AYU/; S2 ,'P"S'VK Q%C)U\;!D#O-SG'3. Z M%>VS8(YVIS?DW/-QM=SQ-Y;#!+I8Z\;8>=OV0,C O"<9P;<%,*>S*D2*GZ?K M;&8[GD'A$U0?SO\ .YQOOS5)9Y/MUR9<92?R>Y.=#T[$%R>_^Y($9>U.I/-[ MZ1'=#-Y^9-<28%U0R7=@EURO5=':F\0S(ED$_W^1T3W>JS/D\[P%P,[M56]Q MH2^VXNGL=";2VTCW(6%/-"39?1H;+5,]#?;YW0TY._?H 'UB?$D3S])-M\([ MC; /XFX0*/@[XIN*3W?[MU_.:3!/^$2F8?UAA;!%2U5#[(.T76BIF0%?EBF2<$9BOHJ>1$N:4,&$ MJ*!;#=2P=-D(L4_*8(2@#'F"V!T7(_^\J AQS@V8.)4I4ZUX6N:(&D M@(Y5ARN'[03_..R*B9;;UV 8;*-E !@V&V-G.N]I#'3Y/6(496EXDN4E4](! M83K4*QIC9TAW0]' +_J:6(_-NF-U&J)G->\'@GY3.GCPI<82/UL$R9Q<)9IG6[Q%8YZ#J='3GP/QU.XLF!5_&M[[74S)+ M&=D\_R?9Q0OGGLN<)@%;BWK3\B6F<(2E<2QW@%)_;>[/D3Z*GH_==;:/#L!1 M;\ 5U]5B>,H/6T;/F)8 />U['[70,G[4D?AVE>I9P\!306 M2GN9LON@6=?Q)/I74=IBY:YZ1\(XR#(ZHV$)W.;OF\"7ES T3N M!1:Z?:TJ+OHE822(10#D@ /8GLU5[W T?5#(3'["T0C$7I] M U\T 2#:(][_ZJ?3=0CF:9#1T+Y764H'2'RH,;" -!X M"\DYC8O<%)VO)4"OIK ?+"W&T8'Y2D1I0A*=//%#Z9S<%,M'PJ:S3O2R?:5S M[PF]TH(;E'U%=3086]9)QV[0RS2,@ZYN776S9_A''M.,H%HT&HZK%1QV>6H&9. C 6?N$3>,@+P:+3U M#),=C=()OS'\YG$*&8!2@80[(TW$ G7R0B%8J,F.$18U)XVG)4B'R-UAG:?+ M@":&(Z2ZN6> F)2M?994,]0(^45_!/R9"-O(Z$EM-\5^T=0'"2W'Z&<]36Y. M&RX6,NPG3WTP DD"':]V9DX;4+KVV$^9^B!DYAT=&D!21NNT@G>!_5"JUQ1S ME1 ZICO/_VWH*1MC/Y?J@Y.!:W1$#I1"='SSH7-L&S]SZ(HPFD9\!"Q']20Z M^ KW\ ;B(SBXI\\; (5NEAG9S@LF A+EP&1 _5F:/'&5Y6!,9^7/.=V)]K#, MU_[=>F/3@*;VON+S8R7N+=BV M;&\06NS7[H/ KQ;Q/&+M*"#NO2.2CR^$HQ&D^Y!J')Y2U1_%!!"^ M I)D$K$[PH^@&S%LB^,_V7LE_Q@?3L4".B&X;COMD:L ME@4$TO9D:\BG_.*8(.IBB,/ QN \2:*O 6,!UR2%> 6=G0S]\;Y=W#!&4,6O M-90@8W>TE,9[&3\,%-8LN8< Y#)EXC@F7M+>,OK$^9K.^&:M]C5"N#)UB/YV M?1C@[#+S#LR]YIV]6_07Y&,#.^Q<1;[<^>6#!Z^^][C?$>,?Y(+@(D%V*>QQ MO^,"H@U=:;C7%^U=/&8TH@%;3UDYHL\D7Z11 MF3"+$/% N!KWZ;K;N&YFBQ4?]"N>16OVB30?5!X>Q*EOAM@8>6==->F%FLX3 MI$>8(UJ%4 O"@TAXU0@M4?!ZDM\VL)[$SC=&=!,L^8\/_"21\56+@V +I(?0 M^@:R1G';B $XVY9"0=CNU!2HVFJ"'PX'UK)TMKO1O=L.IT@%!0H=W[ MB+'PC\ '> P][SB_OA)*0QV1GK0SK8'!WG:]AAWH.IR)A@H&N:*GCF;J]8 MHBXU=ESWJ #:8Y%TXCSJ*+1SPL<<4HDA_SDF$LPD.EF*U,:_RM_K]09&C1T( M?D"]<1$G^IK1'-1T=DX>\W.:A6F1Y+>,+&FQ-&PU=E+L$/(#H@X6)#KD&]ZN M"3_DW8G\2-,99UN48,V;;%BKQ[CWA!UO?D"%Z"MF=/VH][9I4GHMN"A6XL6+ M*?C<1(,=='Y S.VB.VI#H4Y.NAL):PDH4+3'#D<_H$:813:2G]2O6E.C17D? M L;]ZE0=WQ27HA(O'2]3=IX6C_FLB$]":<<8EG\S%7H4^0'G.T1^8T5N..UT-'JC4)&V)/*@).1BOKVZ('HAYK:5IFA6V.<89$!A)R3\K\-%JOW*7:G MH$L?Z('O!YRL[K+U4!WJU86+BM GT/O5+;B)8(1)*CG105@Q)#.*?!/$FSG(;5JW;MKEA>Y9AL?8ZB%VZ0.]D-R0<>>. MDNN]%.#74M8P6UZ(#_.@Q-@75&W&3RJR]Y,2@,Q&3_(CPQ=(Q(>VI%F6LO5- MFA/C5=)NDALK/12OT1Q_>PA?F=8'*+&C]O]QRZ7.B1C^NZ",J&+A#>$@,'*H M:HSFW=M?-=P8QM<,S7K )1 2$F4B*]7G(*\&/)T!81=]N'4!A7XTE^ PJT(? MN:$;>LU!EV&JTC2M8E77MW&0Y"=))'(GK(16&\.^''N"XCZ:]V^X*=]3BOCP MM]O4]] )GA[Q&-S:T^^5R)M.9!?%L\QC0T)/!5[(^6 M+J#@CN;MVP,IO5$ DMM(YWO5.+0):<%IF??N%0KTH5U^#D /(@=/9OD=654V MSG0FG!CV2QX]!13:T=QR@\UAFU2.VMRKC=K+E&VKZ^SHKMWZ-]%"U>#0WKX> M2SE84J]"(::S314UNP;L-(9"?F@O7G_(%;(X:HSA AK":(=KQ*&=>^X:X2ZY M(S[C"4[%_Q)814]["C .9=>BV+WQ.GH2X#_]I3;H3+)'\:OEN:G>K^>$C;% M:A5+00=Q+>BK9):R98FU/3$OM .H2OGD9G:4#KK7:2= ED;EG)GME6(2;8Z> M,H4\X+(-W@441*\B*UTE=*BJB;(6F<@!1![SLY0/CV7J5&G*FH$Z:BA$X[E7 MG>5M*HUH%M)1OY7C[:MWHHM$N*A@5.J9L'B154E$NHM."CYLT M5*@3Q MMIZ(?5\N1<&/LD:^!=64$F1)].S;[5'/M!V?Z*4;IM/M"Z9&G7S]06U/2 M35:>3,E/:1H]TSB629SD(X'HBG>?S*G([+3[2F!GBKYO3]&Z)VEYUWU-MIU- MJMYP*@)LV6RSMV7"/FD=NT&J?@ 9)&#NNO:#/(=[0=RN?M!+=)Y,9?O#K9T) M_*$]@6OZ_S&1/D&>FF 8NX\1G$7E MR63\DF3E*_O2*YR+A63WP7TG*GMG=GYLS\Y-AY-&CY-MEQ/9YZ3N%*D,VV/N MLIWJVF,5D7MTFX-: N3I9H:A4^O-R+4GTTF&JR_2F,LM$ZM OE9/FS]TO#0- MPO_\CS]]>/_37R95!RA*5G[;/C7:[9"\+QVQBU7&:9(X=($\;=30M/TNKA+Q M9 *=DQD_G(K=*&?TL1#=BEU5<[C[L3V-*O))DWY2=H 3+]@H124#SG)^VMRU M#.QSS*D3)&-17/;)T96Y&5(^G,TP3TG"87$\U?7O$7EZ]H"\;4[N*4Q/IK(J M*^O.[/UC>_:6%).2!#=DSF5^&HF00_^ :#1!0#Z/U=L*2MWYLU/ MG8 "03VIR"=->KR(G,8H7.82A!8QSD@Y,LCM/H08^\(>#)LJZ I -RMP\L6U/'E*.UZ=(-TCL;#J7NV#5?=O=/VE\8939V(M9\.3=L_[)Q-N+PSHHLY^=BQDETY$M&]1SJA*+49!-.-RD)<>[26\,'W*IK*7"F4'L\ M@(EC(,&^/[? T9HN5MX]F21W_-\Y-U<#IKTY^- ).ZF()C454G;4S3+;[HO'C/R[X%U>/.E" MES]TPE.V5).2#"G+S\[8 ?-,3X&5IVAW/!!#3D^";;Y9X.AD(;+P[LT,@3QB M-3YF_=")$($_9IW\KO[IO[^]:]WC85V0T6PZ:PUL7?XOY&$=D/[8WK6ZR04] MOU'[S.>((I <6G'>&Q2=Q((.XI>DR(H@5KK. " "R<&%XGT!T4DL^""*W/87 M64Z7W/(UY/ALMP.7^_(&%B6CZ/*O4G^V$S5#5T(@.3@AL"]H.8G%4Q [^5V5 MW+AB"^T5"/EH.?T&@MQ-B",E^=M6]13/OK89PNS35)"#J8&0C9;C#PZ9$UN> M3%)5:5;;%#31 -$:+3>>\P2S"P =HVTX WP+--$ ,1JM'HDS1G8!H&,DDC$F MO%OX<4U/ <1GM (Z L>8)9,^-%%='CAAVX RB&_OB '&6#CN4=%RC_O'#\GO,5)$[EB>OB M13!!;)LDB!B*H4\^(K!,T/';Y+QP0M,G-_U,>2&_+<$ A+$_YC M2!I6&AAR]Y[ 00'>J$)?:8UTHR7\S$D>KT5E)A)M1W;/3T]1P*+L)LW_2?*3 M*%V)@%C0/=>>?4(Q]2UDQQ8%"9("NDUT'RY(5,1D$ZZ9R1S$UVF09,T"9]N[0$A(Y#Z='E^@ MY/XB]$@--I>*5B\.@%6KM+3]0EC03)O)6L%)5AW[.CHPD-[ MB@H?8IH%\SDC\ZH<8#5^Z((/)#^ZT$\GL7AR9E(493,=D#H9&U6EV9"/0K^M M&FW;;81;B2D_HOY*HJN(JP@_JY)RM%E=CXL/OY%0E/^-;S61NYDVT(=>0]6W MD:2/OL)O^>*F!\W)-3=..D$)[IKCT!GV86Y@]7 6HR?[ Z!"H&F_Z&0/!=8) M1-Y"?DL% YM.B!(.@ZZ>KC\'_TK961QDH/0 _3]"@H+#B=B;S:&U+2B71:Y M$,I2//\MRXE7U[JN.\8P7\'>2H94H2'E[LD6HXU(-VPL'SO9^4PQ0U@]RD MF*>K,OM7F-.G&B#('#<5\3/.PDRK96,X*>2X>?5VKC.4-/OF_MCSR?_Q2/\\I@GCZ&-/R3NZ2 M#RF(_TD"]CG(1635NMXVK+.5][EGE\=2JM]]U/5?A@/7H#.W4,%#],J"T M/%G1NB513*M;-X5VMS *LGWR"BJD;$^DK9$UI'RZKO[H=H1WZQ [%;=C)97] MY.;)A.P4N#!,QTY"[FZ-%6QOZM$76]EJ57MD(NET*%ZATKC(^\1#.7:([4MU M*]2RI]S0#:'&W3L_\41BK/2I\;#FXB6,"SZURY0.RU615]&;/:KSC/$M=.=K M7W496MR>K.N;1X9B]&DBCM/3F>K%UCG_!8TU*[[IH>&V8_&O;=>3;=^3WU6] MO[TVW.NE0C/AZ]]('#VDM;%_$L?I)!KG*R-&27WZM3/W1@SSEA51 '@32S'R!E M-^NF[CIYH08%T!*\1G"US#9,$AS<9-&S&6&9+%7-GJAX1*O.Q/; AY&I_W3. M594F>K"'_8H?&F+1^)8&#"N![;EGR!0A7^X_I4^$)?(AY>;>(OM,EH^$*< 5 M1!8:;)-\#/5NY@0!B6RDC"YG*5NE+,@)%"L3 ?9[\;&!L@L+_?A]\L2/*6(3 MX=O*?= NLE"%*I?9VV3Q+\/YP;DG9$?+ "9F.W5A3V'ZK@5A6"P+F<7O$^-B M^)(P$L2"DT]<\4_)+!7NTY?>J@'M'GM=/[C"N,G]:+5(2&I$+6IUC[WI^*-% M2KF[)PO\N72\)>)=?=76I_Q456R;7J^,1-AI2X;7%H",!DX8B>(&[J1NVB9I MNB&YT?G;2:)0=R;\O75WDVU_$][AF\=7?V;@9G9$NC!H#@S:UD>3)L[(A2=[ M]9?DD<8QB>JH03,N%961"-LZZU%!U2H"=)BZ&B3W<.N<[A)@FSWN>>#-K/?> MH_(T#V)4*Z6Y;Y^GQ6,^*V+0\EA+!DB/;;NX0^XDF*.V5)56BU!IS2NT=D,/MBDEC0:G9U,+$VCE;EIXA;=B-D,[BYXK@=G,&$TS8_.OC2R[0\H7U/V[2JY96E(3(:EKOW1 MV95FQOW!1>21R?@6(++30'!IM3\ZX\_,N#^X6 Y@[79'9Z*I&3WBX]:&(9&0 MN2I)E1'V1" H*FB.+N^M70!'?93:L&<\0>VV F+H3U4\%9.OZ+QDJ<=I.CG] MH9-JK'ER$AU/9,_R7W7?DT;G;Z>HH2L3S&A"HE.2\!]RD6BK\8#=%J+MV(T? M47E[U18 <.E#.'9[F(T7O)# :Q"Y'VCVTN1NY0 (PQZ$4-<+[^EZ\^/?*&%< M8HOUM:C[:(FH!M*_'FBA'*-'66]&]YD$@BNYV76'; NC=NS&#Z#=U%J',(SC M/>.BA\/Y*ED5>2:Y>Z^-R6WSJ"+"=K7UTEP=B'JIH/L45&/\T >Y#[Y$5(^% MW(KG1\FH_LU M1HL-_'N*S8@Z*X8!A&OO;B"4:J03_O7H]PF65-Z;D=R') D8334':MY6T_08 MQ*X?_3B>?IO0JR%\2;(5"64Y4^TQ5PQ=WQQ9^'JY=N6O9V*<(^?_)2Q]2!^> M2?Q$/J=)OC"?8/3-T8PKL]2Z!Q$;QR,=%A\6E.6$)/+32;Z^3 MF%+6) ,V5 MZBIL.]*LR/)TN:WALM8;+A8R M[&S26A.L9<" N/R04\$ M&^1N61H582<%/R0634OJA^&Z1_R9EC/\LUQW:(!#G9'(#[3 &MDM7:IG#3^2 MC"_G?&/.61E@3K-OI^M3DH2+9<"^F6]8[93'#9R=/_18L>X0ZP':[D[ME'Z M!U5/*W9M]L8Y>9[38)ZD64[#\KJ)F$^>^N;8;GVH9C6-=AOSH]U8E@;IYR I M9J*2&N,[JN7*TD"!'='31_( $8PD_#MIZYXDD2Q(:=9V35OL2^(^ C>R/9*H M/Y$D7=*PVL2V5]J6-<9.!@3@)Y\ @ H#W5E0G0K+PAS=DW-9N$-4;\HR42TM M,N92[-49LF,!O*(=T*@R2QR*3 M!>!%"+'99:IJ>Z1KCX$C].^T%H?4#,KWB&3%2LS3. M)L-0&N%7\:PZQ10-\0II(7 ME&7@<_!BE>IN$Z!4?T:0JHH7=)-PD[!MDQE;V+IU]C:[F0BE/])EVI'+1JI% M'^&TW;3#J/V TDUQG? <]UQ\EJ8K4GJIK^1E$O^!:^,R%>,1A=ML;UBAY.!S M\UC6J(LR[EX1NTEHM/MB>;=S2Y@80S#7E9-1M#N>>RP- Y[L3N*&5>C,%ZX& M+.?J(IY>7B47_+_Y.CLM,LZ6*54NE!X[A*7'Q:.39-"!O"'Y69 M.)]/-"+1 MZ?I+1J*K9%K.\V1^$O));GGP[=('=I8B=T#=)80.JABO>!?]%,1<(MD)9X"Q M-1^KS-"C!])&AQW6Y X>3!+H@/&M-V1Q2"(A455>NP@/F(5%78\FSNP$"F@S[/6($_R3=HR,% [--ANY;UA M4DA@K C;A7#"7"6-=-\-][8IK8P\>4"IL>,0'2U\1ZFXKY.[R?H?"$->++E\ MN.&4KT62EYR;R6)S7@EF+[*<+L48N7DU*^)K:BS2X-@-FDNW]SSM)2?T]57L MZ2V3:W?#+]T,C5\T6IKMTCVZ17,][V6V[BU'+[3A\OSJ["H1D:/1R5($]IE1 M5C1']Y;U@T_+N!>P?$DH')1.8R@D'KEE#$R/9/"<,A)\"^:DO]16 MY#6=Z98F !U4]C[X*8 L>3(?3J(G;O[3C";SBY<523)347!%6R@R'KDF]"RC MHR&N1OGGA=E]+C+;I^51S :,A0R*D0_."AA'HWAS<9/^B >">782\O.5L!R3 MJ-X[QP(BOTT[:"B>H5:N:D=>Q@U;'P..]##.[WK0/&J%&UG5MTRL@IH5)F%=8:3 M\F\(ZZ%Y.-A!+=XIJC.4KTJ1KSCTR9P>;NO>^2!V0(]WRJB XU6IVR$71<<5 M;S2GG7=*IEW.W-P7>9H',6ITQ0C;0/,/96J6[#98FY/-''@8V%%8WNDS&+I] MXXGV47:XGV98.;""U.9,5MLSW89PGP_.Z+#CW$9Q(&$"C3D5/%_WP7>S!QX& M=E3?$:S[]IOFW\:Z?Y/F1&^VC+\<[7P?.Q[1][5; =;;ZKRY:RR9?PA>S-;* M",N+[MOH$9K>+<1FE-Z4N1+3P36XE]K^=J[&1M#5AU?E$[DA;M$-^WT(/138 M.P5MR/^(O72?TC1ZIG&L5Z5M"_2 XT%TH,WQL;KP:SX.MCC8/X@>_HRY2$#Q M&'2Q.)9XQ%N)WH+D- RV,V\G./''08,3)[_;^>1;L.(!N-TJ1CW>QN"RTW7C M7^ * =">_,@W-LCZX\X\?DT!Q4BO[44%S%1^0-I7J36;BII5_+*)BO&9-SQIS,VI;^Q(= M;=6HIO?=PCOZX4HF**BL1E& JS%2_00Q$GGR6L*TTRK>FUMDH, )]VBQC;5K M'#+*,1N?./W1=(K8=KISH"B[?7O8]'96>#LKO)T5O#0ZW\X*1PG;VUGA[:SP M=E8XEK/")4UH3D06NZAM?IZN/P?_2ME9''">C6N=4R=^3)V!UC\GSM%KJAE& MNQWK3;"TKI#.'?D!>@]EA^.M9GR4DDL.D#^P(")B0/KB&573;DOL!;>GNK8@ MTTD ?>GE/)$X)F%>!'&=;M1>V5!/@_V0=ABX[%)!!Z[.7'5'8BG<;$%7UNEE M),)^$3@,= "YH&-GX/032TTE4^R4Q^" OF MI$[/K$RO5W6[7Z_8VV,/O(<0HR=N\[DGI&)]L M>GMSD;^YR-]U33-_9@. ZUI&A[1'=R-$8F4$S=I$FQ_\\!_RKC-)#BU>6N<._(#7J.J MML^"KBR.N?+=YVGX[;9@H3CHGB%& 5@$S838ZV%/?>RNCA#YH"^49XQ$ M-+\,0EG:PKQ*JMKZ,8<&6B)5##8\\#X@9#/RU*W]0$FO:T8<1JY@S[7B-$B^ MW9R8*]5WFF&GG33IQ4[]#@V#XRP]&A)? M2C\X@&H5P$BU^>HCM?SF=':1<3:?M359!8F1 CL$RT7R5F9&%7SYJ<]!+BJL MK\^#7)<74M40^[CD*F8]LWZL/*=?W>&VS1,AZ,GMO\-Y;RP)CG MX$]N>0Z0G%Q0-:C^P===H^-.*!K/X49MO#X"'!UC[]!_;TU\MIF]/ M?P\,#=+3W]$%4V>#JK[S.<[@E^-MT3;+XZ*3\[:7YW4GU8EE^I/OUVLX!Y MLV!:'[L*<\,5\N&9Q$_D.?)& /S^E0 MBK'I#MO4/+Q"M"1YC'K O]SKC&'I$-L<1=*%IC2/4!LNT\+@%>K;'[9!BJ,+ M35D>HRHTDH<-H@JR/VPG/9(J-!.Q'9&=_7Y)EHB,KB=C!GF/SQA[;_H>Y9EG %^!70DT[^ECP,S26J&Y"J M9\Y&]PH\!##1>!=47,<.W,9!DG/^Q3/0E7C!8/(:_OC>Y#6LN_P?$]FIG,B; M;K']@5I^[3,40(H=4:P=(CB>V-:#'Q%J8!2U$<0V/O'CA[4C[%R..*CJM;^Q MPS#=;2<\ #"*'S>L'>7I6F2A,\<+@XA?-YA-3M&C@_6L\8_:(H)!Q'Z Z:"T M4!R;3&)'_%YSL\0:WM9H@WUIX:!V[7"V#J?H'H33@K-*D_G5DMNG3^4K6AL8 M)AILSW%_<.R20 ?K<\"93PA;-QFSH64DPH[C[0\70!;H>($QZHO+>P\7.5_! M$#D#BIPP,"A: B@XH[F_^X-C$0(Z2)<%2ZB,JTJB2_HB?K)N1R8:*%0_^P>5 M710H^4OO1+(-?<[2QI_],)[[GH1V>1DG1SQ$U%KMKP?H22[W77FI93E03O9> MPOQ,$[HLEB9QMII@I@M50-\0II(7E-7@<_!BE>IN$[2K1;M45;R@[XC:5I0ET:?B44TPX3\DX(1.RM&Z0W@AZ^$6J\9CDG7,(AE?+E/\=$ M"CK9>>6B91/!/YS-)X9M/C!I?&&R_<1$?F-2?<2?*7=. M'G.72#A=>^S@FOL%MP8>"%N* 8(#:E14?OBHS+AH(V=4#.%'R^R,JK/!J[(> MJ]O[ 0U$Z3IIBM4,X4>_B %=)5R["GM!4%7;HX5$Q0QZ^,KNH"!9[/04?B"C MUR\C'@.FG]/4;;@GJURZ]1Z>TX=%6F3<)N:VSL,S_[HT"(RUI,#4V"X9FT8U MJSLXB@3=$W.=)O.\GNK64#UU:S]F28_U2\T.>N'B]K!LZY>NO1^XF#3,@H7-D8>PDSJU0+!@.[Z.N5&/SKJ[\.7K$T_*#7$GZKM7YTM=:O M2)E]&,;#C)?UTG:' M>!F$1%LM4,E4DP+;0M@#FR[CZ,C(4K!E!$=!7$MET)2(Z=GL8)'R>1 M> !@69:ZNML\*YB01VG3AN4_3/ !B+%SSSB"!Q8'.G3;)9>?X\4.6ZI6N<\: M]B8;'?8;,K?5$"0$=*QV]\W2_*%A5=(4:D9TR+#+0^YA.FA$X!E0]7)PQP]_ M][F()>3C#H6(Y^"#L+D/((2CO6?: T*(<+S <[M&G),L9'1E"^?2DJ"787&& MR\@[.CJ- X08K&W/:C1$?U#;8Y?J\(DN_WH*UYGN\X6M]E>W-10)/UP1)HX] M"7=LW,X(@Z:J=7X2YO1)^"%-V)GN;5-U-ZOZPTX:)^-1\;8]=;+?# M"H:SE*RW5*R?%GF6!XG(2W%3F"^D1O@4LA=>#74GVFXD"?=^5[ JG95YP'+4 MER0#2N8KH?.%J.C#=R5NK5V\<,.-9D2Z[@ZBD>8!8%])'%I1(7"\#O5]M,OK MT5E>=T3$E/#?Q+Y8.O8JJ1?XZULT])'29LAF1B6>RJZ1TNXVGCLJ/85^O'401 M#6(^ZO?+5KED[H(9R?P=@PS#T75A)(7ZTXL7T^, M_57L6U"S*AU$!*_/R#NX"^<7^"EBM.M9'"_.+ZI30A^#[B+Q?#]])5X$AV4-+1;N!QC\EO:EE)J)JL(NIK[&U=\2GTP(*#:*%6QF^Z M5\L%9T\'#P ][.+0>GJ JQDOM'6CJ/OR$X%64PZ"$L![F9V0,G/P[M MP_"^:_\<1A4[WX1JG >7,Z-*??"E$R5@JU@N [:>SK[*5\ Y*%3KQTZH5MF+ MB-2J^GF+T=HWQZ\,[Q.ZR\B"JR]]XGK(82/7:999\LRY]>)',@#0I'9C##__ M''"\U_;,=.X]^0%K'X7N!_JU3]GMY)L"L:64:BV&G";B/LN<><5"]FH@M?") MG@ZO-2Q;+BE-UU(8RGO4 RGLZ+2A@S V(H!>BZG.WWM% M(_09 ?;JMJ_B'EQ@_BMO'Z\%1!(J5]DIFSZ8BJ,#^QHM MB4_"8")CQ 4#OHD=I^ZOV=""Q;>(2^6TJL:,O^?#!H(=F^[?UN\"X)@:N=]" MK^9"=]$UWJ;M.@[LD'-/]NE^\+W&K=FS0[Y#Q-QHL>S^;MC>ABV_G?/)>Q^" MY_W;[JTB\UU]#WD@].J$[W:R'RW(WA.+80\@_3U7_8-D@H\D$NF*0O[C0_H/ MF;S('JL\T$H!'P%V'+TG2ZLK9$>A?*!PV!&W^!Y#08^H]T\?W5#T]VP/8,DE M)XLTYL!EY4D15I[XCYW(T$9'__D??_KP M_J>_3,H._2E%?%PAHF=QD&73V0,C 9?Q6@K8$@]J(/$C1@D4_&G@ C_2LPKR M40RQL^IHX\?,Q'X@9=4^=229F34/XC7%TGY'5@4+Q6)XR](Y"Y:68$T#S7&" M9>((/293/3A;:*:9R@^8[,H'PFGDLL7*;YIK%1M)L&^+(/K4,1 M D"_Q+F- M@T346C:O7+NM_)@$KFO5+@_HY8?KX=C6HW8[/X2O4AN-O,==950%P,\I(R'O M(-L&4M?',S$HXQ*T1W_8-X5JC6JN2'L+:R0W26-<#R39C,@%+!T=]AV8$RAF MYD<2_LE2GO5WAV$5O94*^Z;&+G@@XP?1^?U6*FL'V-<5KK/ C[7H0GKB2%)6 M]$Q$M1_Z1%R L?> GHW!"1JH1 Z,32\X7!$8+2JR/P):H;M%+3P1]IAF!#^SJUV-7/J!E:ED0:XWL-L4VE%T>O6HY17>GC/K@ M^./(*9F\>W&)T]E5$M$G&A5!K-DK>%M-4S_6(/#^ MH&>D\7(#4?Y?:;ZX([$47[:@JX?T@AN(^5J[0Z@8LG6"C)D> SM6-M9&V4$L M()XM*)E=O)"P$*;\=#:C(6':]8M3& GPCC-]Y-U!#"",L2*%Q*3_6QGV8+XC M432$2GWXJY']I:[C:51I?V9_#Y9!/'U\#"*CM%4-H:^+AS\P#B-M/?/HYI., MCWK@'S"?^EK-CFP75S/1N+WT]#F7MK3*EI,D@EYKC?,U/S1!J<6#%;(Q\3_. M'=O9Q;0*6#2NE=UFZ(D_Q]3IYI*JD]!(VQ=?_8M0CK_\JARL$1LC!=Z&=F"8 M ')#WP(OEJLX71/2*(=M\R882*">A1$KQX\/K5T,GF![6F0T(5EV$OZ[H!F5 MDC :.EH"/S8Z5Y-'RTXC-,(?9,2/C%@M&0"I'VA9M ^ 58NM<:R-03APWXEM,?\ TD$'3@YFLZS MRTT>C>V>O6USLDR+)#=5Q]NC3T\"*WL OK\D\96A=TXAF;=J.H.;OB-\"OL- MU1ZJ,Y;CNJG[QBZ]W;]HS\X-.R) M1)&5U5V?V::^6A!X/^DG7/O04'O"-_M"F> 4L7S'G! M.)>W9:TKN0KOAN,\)X2)\&01R6,Y9_7I$#W2<,]35G\A^K'R[6&8R>H7V552 MLOV)I9DMA=K0'T-_ 8YG%1N$?]PKDU(N[4/EEX0#VP@7%/,JVTD0?"?D^&6U M(DS^=$V7U)#O<]ROXKWR&4E-AX7#TX6P)Y/7Z3."SG6^"M4Y#]W5AX###YWK M8[F>A"&)N8DJ[CU)ED.]4<-^"JI=/OK&QQ(\NDHIHE4E)W(RZ-7#0@:%VD-? M-D@@Z+#U5TCQ/Y4JWHG#J[B3%9F=^/%UC-7 ^#FHFOCJH!X+ #_4J\]!0R8' M2R,ZHZ$DN4I")@F"N-G369HY&SE#?QTS0 MGZ(J.^J11'7I96*@C(C?!FS=;%2&UNA9W[=? MY'<1/>!OK33#"-:3>DIE$:J'X(4 Y_R?VG.^[&$BN_!GEF_XO\DG!)![%X,U#P,:QW&KN"[=@Y]N.GH=2@ETR/0C_D4Q*^?UWS M$<2-17P_Q=#WBOV@:AR-L$D1714V8ZKBD$Y)PJT/R!;6)L!^2.4.H(5W3PRH M^W!!HD+DRBLK?!9,"..:!H]3=#:1'4ZJ'B>-+C=F M%I)Q)0?69-'!QH+0(@5+AB$K^ E^.[;+5%1L7=(L$_9#I8:BHHUYI77N"-GH M@L/9CIWL)S'T5;4:]VVPYD**Y=BJ668%54F#;2[M"Z!!$+Y@U> ."I6*!-N, M&7"J#0R4KFI3^=T[DA=,%5 I"QSMML&V--QEK&#"+^VOPS,K$P@\!;1TV*^S M]YT'%H&,.QFNDO*9QQVAR\>"9=)]:)X;&A+L-]9[316C&-!G3ILUZY31$F"_ MI.X]5RPBZ'U]E:=Y$'MP>;4]>EUD.5V*4*?R'=9GFM!EL9P^QG1>^OY,A[ _ M_F ZA&VZGI1]3ZK.)XW>L<]CTN3.Y24GM[5+W^><)*'CT<%]6SF$@\]+WD' 2Q2#UF$L#^?>-?;[FK0N>]XU B1M\%E*SP45\E M,AO=,XF?R&?>9F$XSKOT@7T2' U^H\P\AOE>^'NC'M.^0XU]=!P7VJZ#;;7 M<]HJELN K:>S_\U/_?P %91WJ[.4+4N4'M,BKZ(MDODUX1V8CUWO.\>N\@OB MU-7\QJ3QD8G\RF3SF4GYG3T/8!IWSW9PY5<,)RC17M\-5\/_NT*R9,BF,Y<[(P/)O=NW:6, MMWFS*B!S*,L(T>AFPR\(]Z_U[_&([)!]Q8:^'T(9$&?3A^=T?[@W':&9-B/" MW)+2<:$K:K@,A&_9%9J5-#;"34D=%<;"SS0,Q&5/:+;4R @WY71< #<>>.T) ML.P)S>TZ-L#-AW#' O#)+"=L.)1;W:&Y:D>$6BFQH\Y,!^5\?_5 C) :42-> MA;O#P.J7).*"$R^2273Q$HJ\0Y:'WSV[0ZM+,;1RV"3FKBD_EYJ2D+D(,$/5 M%0W/SI<$B,4DAKL=,&SX& ZP'1^7^7G^'S^VG5TM5]:^#_-?IU-K4QYVIRZO M*F_T;CODPK8]-+[-0;/L K+LK]L9?@SR;[3UH\BS6H-TPF\,OYGLRYM$C)I* MVQ6%EN"(H-#RT/ F^@.'LHH[#)@6J1\0650.@%6+K7&*<]_&P:_!9Q+14%KR M*1.4Z[.4K8R%NNUDV+?U8!UK/ON!2F.DQU=G:3(K0EID_-OF0NG*EM@W\;U$ M;N 9W1GUB8@R?:L%#;D)LDUR9=PY3#1^K$R@S[4#"KT:PIPPEB9:-SO^H.(];QLH/$#%9N> ? 9V=Q1>M I,2]* M5BKLBM1V;=HQ?6!"&.E@O/MU6=EA.ON2D9,L([D##!I*[%+.^T!A% ;Z)G+" M2#"=70>)H=I[LPUR:@&]H[Z=HZ?#%[JH=]6BON:'WFYNVV,[[L 8F!E&QT-< MM*=L=Y"B7NUT5C^B-,+G$+ Y[,B8.'S8SV +[G MSF**F3F^H$FC]0@%M4.&G4"N)[0:]E]!U2.^M69%+!@]F3,B17.21/-)];G)]GL3\<')]HN' M"]KJ)1!PC->>O;^%A/4."1L$U[<(,G\,N?1P18"YLH8>>-8=D\YVKVOJ!B[LV&C ;UWO^)6'EMV2N-OE! MH\/6T![;,Z77G>:)SLHP2I3 ':AD/M&#LK4[8 M\IP\Y@_\.V8;2-WZ&-89(P/C!"'M@8+-MM&U]P,)DTY9\!AU<7(YL94G4#$L M[?)4ZUVW*;:I8U:G]HE-QRJ.I2.JH1MLG.V?_=!UNW6S'?$X(4@0@1JWV&8# M#VR9M@*T95D/%<-^J:H+F,39:H)V:](65T>82EY0YOSGX,4JU=TFF &B%JFJ M>$&W\L0F,)V=,";&;CA%5NTUS8]AQ35ST)AM6!%5FQ&)--XW:1)L?]/T!=FL M#N>._ #/J(B=*"U'%L=Q@8E@%YJ4LCL\D!?[JZ2 M)U*>MNU'6E5;/^8*:*%3#;^Q^_D@_S/.QCQE]%"C ML05Z!8W-)V@-K!L/+%4?>))(0%,;=E3B)NEHB'P#(.J:H)8-MM@.1@ MA]YX:R! )SN/RQU$@[X@"O_C5<+'6 @&+X.0V-+]Z2F.Y1V*C6?,4%7M:2C+ M+PG)RFBL;5!CYPS4;H;M$X<%=.O80Y\>6W-F^IR0://F3)@V$&-:174T;U @ MS!]U6'>+P1.^%E#VCR V9;\UT1S->Q4[X^@SKW$_!KH$/(:W*ZI1>R+N6Y8^ MT8Q+ZC)EYVGQF,^*^"2466T-"YV9ZFB>KD"8?P7/&^[I/*$S&@9)?E9D.;=L MV5G*5_1$6JAI DPE^V.G;M*VWTG=\62WY\&>+.P?RTJS;\('^X4/C_$A)>(] MOKWVH84,9]+NR%B,T/(F0=?>CT,R")EN:54E1_B/#SHCZRQ" 'RN?7N,8-8X M&SC7/CU.Z(SN='U*DG"Q#-@WLS_03OD:P.HPA?X,H3O$>H V)Z&=TE/$-#II MQ:[-'K:_\#Z(Q>G^B22BE)T]N$_='/M\!57 MKUO8GZDG /+(@:;_?,-^?J MMM@74*[2-K RYB'+&F7UKY355G&F#[%4M?-T4=+%7*I80'E4 M+,GN:@.7PDBKO'8 #\]I/Q@:A&C^M,%@Z$CAX#"(0I\]@6B28H8S#P1%5Q*' M!D/4Y.R'19,2>J'F\>K4%02Z^UEQ\+''$!J)CLEV@O"#_EBNRPK@Q9R1R%.( MNJIG=3IZ](1.Z=D7@[2=N:V$WIV^K6_L@+) 7_TJWX Q"TK= CG(QN[6[B3- MV.4-7=@=#FX)$[\(YN2]PT*V0X4=9>.,"D0("J10;BW#!8F*F-L]]V0N;G.O MDEG*EF4@7GFIJ+ZG_&/GGK+J:9+.)E5?DT9GFSM*I)O):DAW9)4RF9K+>BFI MIT#R\K:AVHRL(>;3=?5'6P*U/IWY85+8D&S[A_MPBG_#:1AL9_FQZZZ:VA,\ M^^MU)_0'PC7^Y>@F=*8N3U<-7.? ;D?'9IF=M$O3*OAV YIK6:>H 31 M0/7L.K3KV]&IY$NZ$J5VF!U(ARKHF17\U';+TJ@(V*4.,G?PI(G^VCY M4/\FNWQ M4?3G66/JVMY@>*)P?.S58GM*$C*C5F51$*#7&=H7:*T0W.V[GTO[+B%S<2Q$ MM>]N2+[58SVLK6:>G+K[@*ED&'V>R2)6!OG7?\<.A]]#\+LL>G>O>QID-.2F MY3F-"SXI;T0]WRR[)4RF&C#>\?YDNN.5_^>@H/EK&3)R[+TIX[2Y?+-+G/T_#;@A_)"S\N@ 9FG;![8W9G"TVN)!7SEA.B;W>9$+:#H3"9ID MKB8J,I$8'2_[=8SMH'%<70<2)+I":':):L?O;!;.FZF^(VPGSC#;J4U0WCD: M3I*MPM4\V!?\4)EQ)ES;N3V8T/##[O?DY72M[L 8?""-:4IFG"<,#2_G;<%"83+7IW5+L+V5#MO-#U73 MW5!\H#C03ZP7RU6N*U9VCCR!:<^5Q%:!8Z#ND:]/ MAS:GA]V-M15!,#T9=_S?.8EN R9X@67K_KGMFJ@ZF52]>)29>\O=NED3$9"< MVTJ)[7 XKX+3A,X1/KYRCFU*0(IW*U=)1)]H5 3QYN5*:5=P->"LK>OBD;GZ0< ^G6V[X6W+5#;JSX.=&/Z.W0^[$:JW6@>)OP+&=[J, M+AN 6^:08_!#I8]!-Y63ZI!0C>0NLN2V[4I+FU)8T_1-Q?JIF%ZBXSAG7!5! M"$KN16+S6=#50WK!;>!\;4I][-P)?D)DXP0P865C;1Q?R_\*LC3Y>\"^%6;? MBJ(=FB^EC_2Z;A4MY^CG\_L@#IAPS271UV!N"NWHMD0^-1_>'NH6,U#*SI,C M\GWQF)%_%[S+BR>1' )R1O[IA\[U_::7B>S>-RBS_ X5A/@33Y=L=C.X8J M6WMBPEBP:,\<)2OX1ZS6N '(CV%E\ 84WAI6<&_#6ZS84V(K24X=E@Z:; 1 MB=9IA/Z ;4Z5WHM4T D)?2JT"T/%?L?-)1MQ=);>$T33ZQ(Q9<4;Y&'8N M5(LCQG56]Y?W$>='E2P_VJ7RJ)R%_R"9R*US)]Z[9=N:*!8]'/YSGAU!0:HX MEM"/.HEK_UU!.4M;+S$O7KBT:$9N&0UM2GJH06!G AEZ%1T>H"->7<_%\8\D M4<8%(8X;99AL'31K"*&RT&&'HCLJ#4P,Z!99>YAG!1.RX&:FR'U9_@..F9H: M.\O(GLB91(*.GWIMJK(M%/DB9?17$GU)N(0;CR'$$2+;67CNQ%KV9;4B3/YT M39>F/*+C?A7]F#;$]C L!*_0P.DIH.OT&4%'.U_%SL>"J:,:" ;647UH4/47 M\3_BM,!_\_\#4$L! A0#% @ "H2M5"J;@U>(" Z4H H M ( ! &5X,S$M,2YH=&U02P$"% ,4 " *A*U4'F?Z 9$( !6 M2P "@ @ &P" 97@S,2TR+FAT;5!+ 0(4 Q0 ( J$ MK52WB;>M"04 )0> * " 6D1 !E>#,R+3$N:'1M4$L! M A0#% @ "H2M5 =4&Q_V! Z!T H ( !FA8 &5X M,S(M,BYH=&U02P$"% ,4 " *A*U4RW2_*%.[ 0"3!18 # M @ &X&P 9F]R;3$P+7$N:'1M4$L! A0#% @ "H2M5.@"B"#/$P M*N !$ ( !-='-D4$L! A0# M% @ "H2M5&[7QH_I&P IH4! !4 ( !,^L! '!R<&@M M,C R,C S,S%?8V%L+GAM;%!+ 0(4 Q0 ( J$K51*7XOPLC4 %]@ P 5 M " 4\' @!P6! "3>P< %0 @ $T/0( <')P:"TR M,#(R,#,S,5]L86(N>&UL4$L! A0#% @ "H2M5*3QR" 56 OKT% !4 M ( !3+\" '!R<&@M,C R,C S,S%?<')E+GAM;%!+!08 .."@ * &4" "4%P, ! end